,nct_id,primaryOutcomes,secondaryOutcomes,startDate,status,study_type,phases,otherOutcomes
0,NCT01674309,Tumor control rate of the primary tumor and metastasis,metastasis response rate,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1,NCT03979131,Pathological complete response (pCR) rate,Surgical complete resection rate (R0),2019-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2,NCT00890188,Overall response(CR+PR) and Clinical benefit (CR+PR+SD),"To determine the progression free survival, overall survival (OS)and assess the safety profile",2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3,NCT00003046,Maximum Tolerated Dose (MTD) of Intraperitoneal Interleukin-12,,1997-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
4,NCT05201885,The positive rate of oncological contamination of peritoneal washings,Disease free survival,2022-01-15,RECRUITING,OBSERVATIONAL,['NA'],
5,NCT03982641,Cost relate to HCRU,Rate of preoperative chemo-radiation therapy in patients with rectal cancer,2019-04-16,UNKNOWN,OBSERVATIONAL,['NA'],
6,NCT04556344,Change in patient emotional skills from baseline to 15 days after the end of intervention,Patient satisfaction,2020-10-26,RECRUITING,INTERVENTIONAL,['NA'],
7,NCT03418584,radical rate,operation time,2017-12-05,UNKNOWN,INTERVENTIONAL,['NA'],
8,NCT03730558,Evaluate the efficacy of aflibercept in terms of progression-free survival (PFS) in association with FOLFIRI in patients treated in common practice for metastatic colorectal cancer (CCRM) after failure of oxaliplatin + anti-EGFR-based treatment,,2017-11-08,UNKNOWN,OBSERVATIONAL,['NA'],
9,NCT02324023,T-stage in left sided colonic cancer determined by endoscopic ultrasound compared to histological stage,Perfusion in left sided colonic cancer determined by contrast enhanced endoscopic ultrasound compared to histological vascular immunostaining,2014-11,COMPLETED,INTERVENTIONAL,['NA'],
10,NCT05999162,Onset time,Re-admission,2023-08-04,COMPLETED,OBSERVATIONAL,['NA'],
11,NCT04695782,1-year local control,Patient reported outcomes,2020-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],
12,NCT02901600,Determination of the histological localisation of DMBT1,,2013-06,COMPLETED,OBSERVATIONAL,['NA'],
13,NCT02504983,Complete remission,Safety and tolerability of TACE plus sorafenib therapy recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
14,NCT00576498,Proportion of patients with biopsy confirmed intestinal metaplasia,Inter observer variability in reading of mucosal and vascular patterns,2005-10,COMPLETED,INTERVENTIONAL,['NA'],
15,NCT05609370,Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and C,"Number of Participants with anti-drug antibodies (ADAs) to Tislelizumab, and Bevacizumab in Arm A, Arm B and Arm D",2023-01-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
16,NCT05000554,pCR rate,operative mortality,2021-07-02,RECRUITING,INTERVENTIONAL,['PHASE2'],
17,NCT00527891,,,2004-06,COMPLETED,OBSERVATIONAL,['NA'],
18,NCT01791322,Correct identification of tumor mutant genes,,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
19,NCT00493402,Overall survival,Time to progression,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
20,NCT05570279,Complete clinical response,Incidence of pelvis fractures,2016-04-01,RECRUITING,OBSERVATIONAL,['NA'],
21,NCT01871363,Pathological complete remission rate (pCR),Acute and late toxicity,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease-free survival
22,NCT05868317,Pathologic complete response,objective response rate to induction chemotherapy,2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
23,NCT01759238,Progression free survival rate,Toxicity,2013-05,TERMINATED,INTERVENTIONAL,['PHASE2'],
24,NCT00201747,Most efficacious of two combination regimens of sequential CPT-11 and MMC in patients with advanced and previously untreated esophageal and GE junction adenocarcinomas,"Evaluate if pre- and/or post-treatment Topo I-, CE and NQ01-gene expression in fresh tumor specimens and adjacent tissue, are associated with antitumor efficacy or toxicity.",2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
25,NCT01265979,WB-DWI as early predictor for regorafenib treatment response,Evaluation WB-DWI parameters in correlation with progression free survival (PFS),2011-01,COMPLETED,OBSERVATIONAL,['NA'],
26,NCT05484908,Mortality rate,Model for end-stage liver disease (MELD) score variation,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
27,NCT04550663,The occurrence of AEs and SAEs during the study treatment,Overall survival (OS),2020-09-25,UNKNOWN,INTERVENTIONAL,['PHASE1'],
28,NCT01970748,Bleeding,Complication survival,2009-08,RECRUITING,INTERVENTIONAL,['PHASE4'],
29,NCT02588781,overall response rate,Number of subjects with Adverse Events as a measure of safety and Tolerability,2015-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
30,NCT05035914,Objective response rate,Score of quality of Life,2021-07-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
31,NCT06017661,IL-8 level,Patients' quality of life,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],
32,NCT04857684,Proportion of patients with grade 3-4 treatment-related adverse events as assessed by CTCAE v5.0,Recurrence-free survival (RFS) after resection,2021-06-18,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
33,NCT00700258,"Efficacy: best response, progression-free survival, overall survival",Safety: absolute and relative incidence of therapy interruption,2008-02-13,COMPLETED,OBSERVATIONAL,['NA'],
34,NCT03167112,Time to Progression (TTP).,Overall survival (OS),2017-07-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
35,NCT06015022,Change in Prognostic Liver Secretome signature (PLSec) score,Change in quality of life measured by the chronic liver disease questionnaire,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],HCC incidence
36,NCT03175146,Response rate within the treated liver lesion,Overall survival,2017-09,UNKNOWN,INTERVENTIONAL,['NA'],
37,NCT00072033,Feasibility of successful study therapy completion and survival after surgery,Feasibility in Switzerland after surgery,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
38,NCT00564694,Reliability and clinical and psychometric validity of the European Organization of Research for the Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-CR29),,2007-05,COMPLETED,OBSERVATIONAL,['NA'],
39,NCT02112240,Evaluating the sensitivity of identifying the sentinel lymph node using a unique mobile gamma camera intraoperatively.,Feasibility,2013-05,WITHDRAWN,INTERVENTIONAL,['NA'],
40,NCT05911789,Response rate after surgery,Margins for clinical target volume(CTV) and gross tumor volume (GTV),2023-08-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
41,NCT04208724,Intention to get screened for cancer (type of cancer will be determined by the community-based organization) pre- and post-intervention,,2020-11-18,COMPLETED,INTERVENTIONAL,['NA'],
42,NCT00017212,,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
43,NCT05084859,Part 2 - Objective response rate,Part 2 - Blood samples for measurement of the plasma levels of SM08502 and its metabolite,2021-11-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
44,NCT00622674,Maximum tolerated dose (MTD) of bortezomib,Disease response as measured by RECIST criteria,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
45,NCT01403402,Congenital Muscle Disease Patient and Proxy Reported Outcomes,,2009-09,RECRUITING,OBSERVATIONAL,['NA'],
46,NCT04422249,Survival rate,intraoperative parameters,2019-12-23,RECRUITING,INTERVENTIONAL,['NA'],Incidence of postoperative complications
47,NCT02324127,Hsp90α Concentration of plasma,,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],
48,NCT02663427,detection rate of gastric cancer among all group,,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],
49,NCT04602299,focal lesion detection rate,rate of procedures reaching the minimal time,2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],
50,NCT03569488,validation of the French version of the LARS score,,2020-01-24,RECRUITING,OBSERVATIONAL,['NA'],
51,NCT00394433,10-month Progression-Free Survival Rate,Progression-Free Survival,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
52,NCT05280210,pathological complete response rate(pCR),prediction accuracy of PTC,2022-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
53,NCT05286086,Comprehension Complication Index (CCI),Hospital Anxiety and Depression Scale (HADS) test : anxious and depresion scale,2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
54,NCT00500188,Disease-free survival (DFS) time,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
55,NCT04380480,Percentage of Recent Weight Loss,"Changes of participants' intestinal flora assessed by blood, urine and stool test",2020-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
56,NCT04427527,CRC screening - clinic level,CRC screening - community level,2020-08-19,RECRUITING,INTERVENTIONAL,['NA'],
57,NCT02534961,Infection after radiofrequency ablation,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
58,NCT02143115,"Compare the test characteristics (sensitivity, specificity, positive and negative predictive value) of Computed Tomography colonography (CT-C) in the post Colorectal cancer resection using optical colonoscopy as the reference standard",Compare the costs and outcomes of Computed Tomography Colonography versus independent Optical Colonoscopy plus Computed Tomography for post Colorectal Cancer resection surveillance.,2011-08,COMPLETED,OBSERVATIONAL,['NA'],
59,NCT01336049,Objective response rate,adverse events,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
60,NCT03158610,Progression Free Survival 2 (PFS2),Number of participants with quality of life (QoL) as assessed by CTCAE v4.0,2018-01-29,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
61,NCT01927146,Overall survival,,2013-07,UNKNOWN,OBSERVATIONAL,['NA'],
62,NCT02014025,survival rate,intraoperative parameters,2013-03,COMPLETED,INTERVENTIONAL,['NA'],postoperative complications
63,NCT06226857,progression-free survival,progression-free survival based (per protocol),2024-01-17,RECRUITING,INTERVENTIONAL,['PHASE3'],
64,NCT01071941,Characterize rRp450 pharmacokinetics and viral shedding.,Correlate radiographic and pathologic assessments of tumor response.,2010-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
65,NCT04576572,Tumor recurrence,The Best Criteria,2020-06-15,COMPLETED,OBSERVATIONAL,['NA'],
66,NCT03250273,Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1),Progression Free Survival (PFS) at 24 Months,2017-11-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
67,NCT06144853,The number of patients with metabolic response according to FDG-PET/CT evaluated by PERCIST 1.0 one lesion after PIPAC 3,The number of patients where FDG-PET/CT evaluated by PERCIST one lesion agrees with histological response according to PRGS after PIPAC 1 and 3,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
68,NCT00380055,"Proportion of individuals receiving recommended screening for prostate, breast, colorectal, and cervical cancer.",Cost-effectiveness of using community navigators to improve cancer care among rural Native Americans.,2006-10,COMPLETED,INTERVENTIONAL,['NA'],
69,NCT00376909,"Screening rates as measured by mammography, Pap test, hfoBT, sigmoidoscopy, barium enema and colonoscopy",,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
70,NCT04401709,Two-year disease free survival (DFS),Overall Survival (OS),2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
71,NCT04638036,Feasibility of molecular fluorescence-guided surgery using Cetuximab-800CW,Evaluation of the distribution of Cetuximab-IRDye800CW,2020-11-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
72,NCT03403101,progression free survival (PFS),Toxicity evaluated according to the Common Terminology Criteria Adverse Events,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
73,NCT02119676,Overall Survival (OS),Percentage of Participants With Treatment-emergent Adverse Events (TEAEs),2014-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
74,NCT00923897,To determine the change in index symptom(s) using an 11 point numerical rating scale for patients with locally advanced hepatocellular cancer or hepatic metastases treated with 8Gy,To determine serum marker and radiographic response with 8Gy,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
75,NCT04980287,metastasis rate,3-year DFS,2021-01-12,RECRUITING,OBSERVATIONAL,['NA'],
76,NCT02150447,Time-to-bleeding event,Overall survival,2009-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
77,NCT01580631,Determine the inter-observer agreement of a consensus driven NBI classification system in Barrett's esophagus.,Negative predictive value of the newer NBI classification in identifying dysplasia in Barrett's esophagus.,2012-10,SUSPENDED,OBSERVATIONAL,['NA'],
78,NCT04246710,Reliability of PDAC molecular subtyping on biopsy samples,Overall survival,2018-01-28,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
79,NCT00409994,Phase II: Tumour blood flow assessed CT-PET + CTp,"Phase II:Incidence of acute side effects of rapamycin, assessed according to CTCv 4.0",2006-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
80,NCT04796818,Absolute change in the true diffusion coefficient (D),Diffusion related parameters in intravoxel incoherent motion diffusion weighted imaging,2020-08-12,RECRUITING,INTERVENTIONAL,['NA'],
81,NCT00898781,"Correlation of the number of CTCs with extent of tumor burden as measured by tumor markers, imaging, and the number of metastatic sites and proliferation and apoptotic markers",,2007-11,TERMINATED,OBSERVATIONAL,['NA'],
82,NCT03152565,Progression Free Survival,Immunophenotype signature in tumor biopsies before and during treatment.,2018-03-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
83,NCT00728078,morbility,recurrence rate,2008-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
84,NCT05741255,Montreal Cognitive Assessment,,2022-01-05,COMPLETED,INTERVENTIONAL,['NA'],
85,NCT04540081,Overall Adherence to CLOVER Metrics,Hepatitis C screening,2020-10-05,COMPLETED,INTERVENTIONAL,['NA'],
86,NCT00593060,To determine the pharmacokinetics of combined treatment with cetuximab and temsirolimus.,To document objective response rate and progression-free survival in patients treated with the combination.,2007-11-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
87,NCT01829035,The overall survival (OS) of oral sorafenib given as monotherapy daily compared to sorafenib with combination cTACE in subjects,Evaluation of adverse events,2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
88,NCT04609176,Objective Response Rate (ORR) According to RECIST 1.1 based on investigator assessment,Number of Participants Experiencing an Adverse Event (AE),2020-11-18,RECRUITING,INTERVENTIONAL,['PHASE2'],
89,NCT03638141,Objective response rate (ORR) using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.,Number of participants experiencing study drug-related toxicities,2019-10-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
90,NCT03613389,Clinical assessment of Oral Mucositis,,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
91,NCT04813913,Difference in carotid stiffness between baseline and at 4 months of bevacizumab treatment.,Progression-free survival at 12 months.,2019-05-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
92,NCT00554892,Overall morbidity including infectious and non infectious complications,Evaluate the postoperative complications classified according to the DINDO classification.,2007-09,COMPLETED,INTERVENTIONAL,['NA'],
93,NCT06222619,Overall survival,Recurrence free survival,2020-01-30,COMPLETED,OBSERVATIONAL,['NA'],
94,NCT01253837,Phase II: Investigation of the anti-cancer activity of L19TNFα as measured by Objective Response Rate (ORR),Investigation of early signs of anti-tumor activity of L19TNFα,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
95,NCT05934643,Average daily energy expenditure in MET.h,30-day complication rate,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
96,NCT05339984,Estimation of the intraoperative portocaval post-procedural gradient.,Prediction of the evolution of hepatic artery and portal vein flows after surgery,2023-01-03,RECRUITING,INTERVENTIONAL,['NA'],
97,NCT02926716,Accuracy for identifying the status of resection margin,Microvessel density,2015-12-14,COMPLETED,OBSERVATIONAL,['NA'],
98,NCT00033241,,,2001-07-23,COMPLETED,INTERVENTIONAL,['PHASE1'],
99,NCT01015118,"PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).",Change in Global Health Status/ Quality of Life (QoL) Scale Over Time.,2009-11-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
100,NCT05656326,Successful implementation,Satisfaction of the patient-led home-based follow-up,2021-08-23,RECRUITING,OBSERVATIONAL,['NA'],
101,NCT04588025,Measure change in blood flow within the pancreatic cancer as measured by the P4.,,2020-10-14,RECRUITING,INTERVENTIONAL,['NA'],
102,NCT05168527,ORR,DOR,2021-09-03,RECRUITING,INTERVENTIONAL,['PHASE2'],
103,NCT02751086,Rate of patients alive,Rate of complications after discharge,2016-04,RECRUITING,OBSERVATIONAL,['NA'],
104,NCT03344614,PFS,DCR,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
105,NCT06111872,To evaluate the efficacy of Ketamine- Midazolam as a sedative agent in ERCP in terms of sedation failure rate.,To compare the depth of sedation,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2'],
106,NCT04074447,The proportion of ctDNA content decreased in patients with good therapeutic effect,,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],
107,NCT01718808,Progression free survival in week 12,"Overall treatment utility (OTU) (predefined composite endpoint including clinical benefit, tolerability and acceptability of the treatment)",2012-11,TERMINATED,INTERVENTIONAL,['PHASE2'],
108,NCT04868149,Amount of future liver remnant volume increment by percentage after stage I ALPPS,Inflammatory markers associated with inflammation and regeneration after stage 1 ALPPS,2020-09-02,RECRUITING,INTERVENTIONAL,['NA'],
109,NCT03377842,Progression-free survival (PFS),Overall survival (OS),2018-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],
110,NCT05895942,Degree of tumor regression,,2021-09-10,RECRUITING,OBSERVATIONAL,['NA'],
111,NCT04351880,Anxiety and Depression measured through the Hospital Anxiety and Depression Scale,Re-hospitalization and Emergency Department Visits,2020-04-16,COMPLETED,INTERVENTIONAL,['NA'],
112,NCT02646514,Patency of metal stent,Complication rate,2015-09,UNKNOWN,INTERVENTIONAL,['NA'],
113,NCT05052801,Overall Survival,Number of Participants with an Anti-bemarituzumab Antibody Formation,2022-03-07,RECRUITING,INTERVENTIONAL,['PHASE3'],
114,NCT00134069,Pharmacodynamics of the combination of irinotecan when given in combination with sorafenib and cetuximab in tumor tissues,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
115,NCT06143722,Progression-Free Survival (PFS),Adverse events,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
116,NCT01733628,Progression Free Survival (PFS),"Number of Participants With ""White Coat"" AHT With 24 Hours Ambulatory BP Measure",2012-10-23,COMPLETED,OBSERVATIONAL,['NA'],
117,NCT00005616,,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
118,NCT05214820,Tumor uptake of 68Ga-PSMA,Radiation dose (mGy),2022-01-17,RECRUITING,INTERVENTIONAL,['PHASE2'],
119,NCT05407584,Confirmed ORR,second objective disease progression,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE2'],
120,NCT04510935,mean percentage change from post- to pre-operative values of invasion of HepG2 cells cultured in patients' serum,serum IL-2 level,2020-08-20,COMPLETED,INTERVENTIONAL,['NA'],
121,NCT02893982,maximum tolerated dose,local control,2017-11-09,TERMINATED,INTERVENTIONAL,['PHASE1'],
122,NCT05304481,Relapse-free survival rate,Changes in respiratory rate,2022-05-14,RECRUITING,INTERVENTIONAL,['PHASE2'],
123,NCT05585437,patient complication rate,,2021-11-11,COMPLETED,OBSERVATIONAL,['NA'],
124,NCT00584597,The specific aim will be to determine the safety of TRAUMEEL S for mucositis in head and neck cancer patients undergoing radiation therapy,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
125,NCT02976142,Overall 2-year survival,Quality of life,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
126,NCT05032027,grade 3 entiritis,Changes in intestinal flora,2021-08-27,RECRUITING,INTERVENTIONAL,['NA'],
127,NCT00352638,Colorectal cancer screening compliance,Cost,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
128,NCT01762293,Progression Free Survival(PFS),Number of Participants with Adverse Events as a Measure of Safety,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"body vitals, laboratory parameters"
129,NCT04418739,Overall Complications,Ease of surgery,2020-01-27,RECRUITING,INTERVENTIONAL,['PHASE2'],
130,NCT04493632,Resection Rates,,2022-04-12,RECRUITING,OBSERVATIONAL,['NA'],
131,NCT05999396,Safety 3-Hematology-White Blood Cells,,2024-01-12,RECRUITING,INTERVENTIONAL,['PHASE1'],
132,NCT02908204,Overall survival,Long-term complications incidence rate,2016-10,UNKNOWN,OBSERVATIONAL,['NA'],
133,NCT01278537,Quality of life,Stress,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
134,NCT00288444,Determine the molecular interaction,Determine safety and efficacy,2006-01,TERMINATED,INTERVENTIONAL,['PHASE1'],
135,NCT04794465,Time to treatment,Time to symptoms,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA'],
136,NCT00060502,"Change in Lean Body Mass (LBM) from baseline to the end of first cycle, as measured by bioelectrical impedance analysis (BIA).","Change in 6-minute walk test distance from baseline to the end of the first cycle; Safety, Karnofsky performance status; Survival.",2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
137,NCT00066846,,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
138,NCT04108494,3 years relapse-free survival,5 years overall survival,2019-01-01,RECRUITING,INTERVENTIONAL,['NA'],Postoperative morbidity
139,NCT04624217,ORR,OS,2020-11-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
140,NCT02154737,Rate of dose limiting toxicities of each subject,Adverse events related to pulse dose erlotinib and gemcitabine,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
141,NCT03833700,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),Overall Survival (OS),2019-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
142,NCT01127425,primary: Length of stay,"secondary: Nursing hours, pain and recovery",2006-07,TERMINATED,INTERVENTIONAL,['NA'],
143,NCT03579836,DCR(Disease Control Rate) in combination therapy of BEY1107 and Gemcitabine (Phase II),Number of subjects with Adverse events in BEY1107 and Gemcitabine combination (Phase II),2018-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
144,NCT02092519,diagnostic accuracy,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
145,NCT01808417,Feasibility of real-time intraoperative NIR lymphatic mapping,Identification of sentinel lymph nodes,2013-06-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
146,NCT04567069,Health-related quality of life (QoL): 36-Item Short Form (SF-36),Health-related quality of life (QoL): 36-Item Short Form (SF-36),2020-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
147,NCT05694949,All-cause mortality at 30 days after operation,Major Adverse Cardiovascular Events (MACE),2023-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
148,NCT03172403,Correlation between skeletal muscle and degree myostatin,Analysis level of myostatin muscular expression and blood samples results,2018-08-02,TERMINATED,INTERVENTIONAL,['NA'],
149,NCT00814086,Number of patients who have at least 1 dose-limiting toxicity or delay in therapy for more than 2 weeks,Objective tumor response (partial or complete) assessed by Response Evaluation Criteria for Solid Tumors (RECIST),2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
150,NCT00954174,Overall Survival,Patient-reported Peripheral Neuropathy Symptoms - Post Baseline,2009-08-17,UNKNOWN,INTERVENTIONAL,['PHASE3'],
151,NCT00689364,The recurrence and metastasis rates for 1、2、3、4 and 5-year.,Survival index: the survival rate for1、2、3、4 and 5-year.,2007-04,UNKNOWN,OBSERVATIONAL,['NA'],
152,NCT00002470,,,1990-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
153,NCT04281784,Proportion of Patients With EHR Documentation of Goals of Care Discussions,All-cause Mortality at 1 Year (Safety Outcome),2020-04-23,COMPLETED,INTERVENTIONAL,['NA'],
154,NCT01564810,the rate of patients converted to resection for liver metastases,tumor response,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
155,NCT06205706,"identification of dose/dose range fulfilling favorable PK and pharmacodynamic profile, with acceptable safety",Duration of response (DoR).,2023-12-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
156,NCT02699047,Serum albumin,,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],
157,NCT05734105,Progression-free Survival (PFS),Overall Survival (OS),2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE3'],
158,NCT03958890,OS,Duration of response,2019-06-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
159,NCT04840056,Gastric cancer and gastric dysplasia,Area under the receiver operating characteristic curve of machine learning model,2021-04-15,RECRUITING,OBSERVATIONAL,['NA'],
160,NCT04251403,Correlation of pathologic diagnosis from gastric aspirate compared with diagnosis from standard endoscopic inspection and biopsies.,,2020-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
161,NCT04357158,Diagnostic accuracy in distinguishing colorectal carcinoma from healthy controls,Acceptance rate,2020-05-25,COMPLETED,INTERVENTIONAL,['NA'],
162,NCT05298020,PFS,AEs,2022-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
163,NCT05156463,Use of Actigraph to measure changes in activity and sedentary behavior,Exercise Self-Efficacy Scale This scale assesses an individual's beliefs in their ability to continue exercising on a 3 time/week basis at moderate intensities for 40+ min. per session in the future.,2022-04-12,WITHDRAWN,INTERVENTIONAL,['NA'],
164,NCT05911243,Acceptability (feasibility),Change in body weight (kg),2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
165,NCT03774680,Measurement of pharmacokinetics parameters of Cetuximab for targeted colon cancer,,2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
166,NCT03750786,Overall Response Rate,Duration of Response,2018-12-18,COMPLETED,INTERVENTIONAL,['PHASE3'],
167,NCT04827485,Left colon distension score,Left colon sessile serrated lesion detection rate,2022-01-13,TERMINATED,INTERVENTIONAL,['NA'],
168,NCT03784417,Tumor necrosis induction by EUS-guided laser ablation (LA) - Number of patients with necrosis of the tumor,Overall survival,2019-10-15,TERMINATED,INTERVENTIONAL,['NA'],
169,NCT00252564,Progression-free Survival (PFS) Rate at 1 Year.,Objective Response Rate,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
170,NCT02042430,Number of participants with an increase in CD8+ T cells,Changes in IDO1 expression by IHC,2014-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
171,NCT00142038,Response Rate,Quality of Life,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
172,NCT04548765,Colonoscopy Ordered at 6 months,Colonoscopy Result,2020-07-24,COMPLETED,INTERVENTIONAL,['NA'],
173,NCT05639972,Feasibility of administering E7 TCR-T cell therapy as induction treatment for LAHPVC,2-year and 5-year disease free survival (DFS),2024-06-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
174,NCT04902352,SMA margin status,Disease free survival,2021-04-06,RECRUITING,INTERVENTIONAL,['NA'],
175,NCT04593407,Percentage of surgical referral after treatment,Cumulative complications rate after treatment,2020-11-03,RECRUITING,INTERVENTIONAL,['NA'],
176,NCT01801085,"Composite preparation, dispensing and administration time",Capital item utilization (hospital bed and infusion pump),2011-10,TERMINATED,OBSERVATIONAL,['NA'],
177,NCT05252390,Phase 1b Food Effect Substudy: Effect of Food on the Pharmacokinetics (PK) of NUV-868,,2022-03-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
178,NCT00008047,,,1999-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
179,NCT02729948,Incidence of adverse events associated with TCE use,,2016-07-28,COMPLETED,INTERVENTIONAL,['NA'],
180,NCT01497964,Objective Response Rate,Pharmacokinetic parameter Vss,2011-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
181,NCT00047112,overal survival,recurrence free survival,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
182,NCT02527967,Hospital length of stay (days),Readmission rate (%),2013-01,COMPLETED,OBSERVATIONAL,['NA'],
183,NCT02330536,Respiratory change,,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
184,NCT03776370,The five-year survival rates of rectal cancer between the two groups were compared.,,2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],
185,NCT03387774,Incidence of Severe Acute Oral Mucositis (Grade of CTC-AE ≥ 3),The Adverse events Related to Ulinastatin,2018-01-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
186,NCT00293462,Comparison of the Mean Number of Days for Mucositis to Heal Across by Group,Comparison of Combined Mean Score on the Pain Questionnaire by Group,2005-06-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
187,NCT04004650,Perineal wound healing rate 30 days,Female sexual distress,2019-06-28,UNKNOWN,INTERVENTIONAL,['NA'],
188,NCT04172402,Overall response rate (ORR),,2019-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
189,NCT00836303,Completion of Colorectal cancer screening,Patient adherence to physician recommended colorectal cancer screening test,2005-12,COMPLETED,INTERVENTIONAL,['NA'],
190,NCT06090656,progression free survival，PFS,"Patient-reported outcomes, PRO",2023-10-24,RECRUITING,INTERVENTIONAL,['PHASE2'],
191,NCT04718402,adverse events (AEs),overall survival (OS),2021-03-30,TERMINATED,INTERVENTIONAL,['PHASE1'],
192,NCT01514110,to determine the Maximum tolerated dose and dose limiting toxicity of RAD001 in combination with paclitaxel and carboplatin,Toxicity of combination Paclitaxel/carboplatin/RAD001 in advanced adenocarcinoma of the stomach and gastroesophageal junction,2008-01-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
193,NCT06184841,Adverse Events,The overall survival (OS),2020-06-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
194,NCT05959356,Progression free survival,Quality-adjusted time without symptoms or toxicity,2023-11-09,RECRUITING,INTERVENTIONAL,['PHASE2'],"Treatment-emergent genetic mutations (e.g., KRAS, NRAS, BRAF, SMAD4, HER2, Etc.)"
195,NCT03404661,Methylated DNA markers as measured by mean percentage of total human DNA per pancreatic juice volume,,2018-01-11,COMPLETED,OBSERVATIONAL,['NA'],
196,NCT02738359,"Prevalence of advanced colorectal neoplasia or cancer identified by each screening strategy (OC, CC and FIT)",Rate of colorectal cancer identified by each screening strategy,2017-11-03,RECRUITING,OBSERVATIONAL,['NA'],Quality assessment of colonoscopy and capsule endoscopy
197,NCT04548752,Progression-free survival (PFS),Duration of response (DoR),2021-02-22,RECRUITING,INTERVENTIONAL,['PHASE2'],
198,NCT01836653,Progression-free survival,Response rate,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free survival among the RAS wild type subpopulation
199,NCT02202317,Number of Subjects Whose Y-90 Based PET/CT (Positron Emission Tomography/Computed Tomography)Scans Detected Extrahepatic Non-target Embolization.,Comparison of Y-90 PET/CT to Y90 SPECT,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
200,NCT03712943,Maximum Tolerated Dose,Frequency and Severity of Adverse Events,2018-10-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
201,NCT04458740,Assess how the patients and their family members face the disease,,2018-10-29,COMPLETED,OBSERVATIONAL,['NA'],
202,NCT01739894,Overall survival (OS) rate,Number of participants with adverse events,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
203,NCT04739696,Caregiver: Change in Center for Epidemiological Studies Depression Scale (CESD),Caregiver: Job Satisfaction,2021-02-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
204,NCT01386502,To determine the safety and tolerability of escalating doses of anti PD1 antibody (CT-011) in combination with subcutaneous p53 vaccine.,To determine the clinical efficacy of this combination.,2011-06-15,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
205,NCT04605731,Overall response,Overall survival,2021-08-03,RECRUITING,INTERVENTIONAL,['PHASE1'],Gene expression signatures
206,NCT05512260,Feasibility regarding iDA format,Self-reported lifestyle behaviors,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],Satisfaction with the iDA and the decision
207,NCT00747097,Progression-free survival,"overall survival, objective response, safety",2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
208,NCT04930315,1-year tumor recurrence-free rate,Adverse events,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE2'],
209,NCT01984580,Changes in zinc-regulated cellular proteins within Barrett's tissue,Changes in cellular microRNA profile; changes in protein cancer biomarkers,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],
210,NCT00675194,response rate,Analysis of the dose and efficacy of Epoetin beta weekly in anaemic patients,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
211,NCT01408407,Maximum skin toxicity,,2011-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
212,NCT01238965,To assess the safety of this regimen,Overall survival,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1'],
213,NCT04466696,Postoperative length of stay,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],
214,NCT01287130,"To assess for evidence of anti-tumor activity with this combination, per tumor measurements",To evaluate the safety and tolerability of the combination of AZD6244 and cetuximab in patients with K-RAS mutated metastatic colorectal cancer,2011-01-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
215,NCT01143922,,,2009-08,UNKNOWN,OBSERVATIONAL,['NA'],
216,NCT05775419,5-years overall survival (OS),5-year progression-free survival (PFS),2021-06-30,RECRUITING,INTERVENTIONAL,['NA'],
217,NCT00332865,Objective swallowing using videofluoroscopy and endoscopic evaluation of swallowing,Swallowing scale of EORTC HN 35,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
218,NCT00234416,Incidence of DLT,"Nature, incidence and severity of adverse events (AEs) and serious adverse events (SAEs)",2002-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
219,NCT02032485,fluorescence intensity of tumoral and healthy tissues after IV injection of ICG to patients with peritoneal carcinomatosis from colorectal origin.,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
220,NCT02628093,Versatility Score,Operative Procedure Time,2016-02-17,COMPLETED,INTERVENTIONAL,['NA'],
221,NCT06209970,Numerical Rating Scale,,2023-12-20,COMPLETED,INTERVENTIONAL,['NA'],
222,NCT06216405,"Comparing the percentage of patients with at least one right colon polyp detected according to the randomization group, and adjusted for Boston Bowel preparation scale, for the operator, for the endoscope and for stratification factors.",,2022-01-20,COMPLETED,INTERVENTIONAL,['NA'],
223,NCT05367687,"Recurrence-Free Survival (RFS), as Determined by the investigator",The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
224,NCT03053167,Progression Free Survival [PFS],Disease Control Rate [DCR],2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of Life [WHO-QOL]
225,NCT04287400,K-RAS Mutation,Radiomics - MR image findings,2019-03-05,RECRUITING,OBSERVATIONAL,['NA'],
226,NCT01721785,Diagnostic performance of the techniques under investigation,To determine the inter-observer agreement for the imaging techniques under investigation,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
227,NCT04621370,Complete response,Euro Qol-5 dimensions 3 levels (EQ5D-3L),2020-12-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
228,NCT05603065,Pathological complete response rate (pCR),Quality of life measurement and evaluation 2,2022-10-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
229,NCT03329534,Ratio of non-acidic to acidic reflux events,Gastroesophageal reflux disease-health related quality of life instrument,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
230,NCT04107324,Liver Function,Resection rate,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
231,NCT00996333,To Determine Response Rate to the GTX Regimen in Patients With Pancreatic Cancer,Toxicity Assessment,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
232,NCT01297998,Maximum tolerated dose,Number of Participants with dose limiting toxicity,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
233,NCT05230771,2-year overall survival rate,,2022-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
234,NCT01171482,Progression free survival (PFS),Overall survival,2015-11,TERMINATED,INTERVENTIONAL,['PHASE2'],
235,NCT00591123,"Overall Response Rate of Previously-untreated Patients With Unresectable or Metastatic Adenocarcinomas of the Upper Gastrointestinal Tract When Treated With the Combination of 5-fluorouracil, Leucovorin, Oxaliplatin, and Erlotinib.","Toxicity of the Combination of FOLFOX, 5-FU, and Erlotinib",2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
236,NCT06304545,Pathological Complete Response rate,3-years Overall Survival rate,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
237,NCT06069960,Overall survival（OS）,Disease-free survival，DFS,2023-10-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
238,NCT03882866,Objective Response Rate (ORR),Quality of life of two treatment regimens in patients,2019-03-28,UNKNOWN,INTERVENTIONAL,['NA'],
239,NCT03428321,Thermal ablations,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],
240,NCT05360420,Time benefits based on US and immediate CEUS with current routine,The economic benefit based on US and immediate CEUS with current routine,2022-10-26,RECRUITING,INTERVENTIONAL,['NA'],
241,NCT00733850,Progression-free survival,Survival,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
242,NCT05631041,The change between groups in response rate (RECIST),Changes in serum levels of the measured biological marker serum permeability glycoprotein in ng/ml,2022-12-31,RECRUITING,INTERVENTIONAL,['PHASE3'],
243,NCT04906733,Correlation of ex vivo sensitivity test on patient-derived organoid models with clinical outcomes,,2021-04-15,UNKNOWN,OBSERVATIONAL,['NA'],
244,NCT02029326,To explore biomarkers predictive of clinical response to cetuximab-based treatment in metastatic colorectal cancer using the Prometheus Platform,3. To analyze correlation between the quantity of circulating tumor cells and treatment response to cetuximab,2010-02-01,COMPLETED,OBSERVATIONAL,['NA'],
245,NCT00388700,"Primary Outcomes: Assess the efficacy and safety of GM-CT-01 administered with 5-FU, LV, and Avastin® in the first-line treatment of unresectable, locally advanced, and/or metastatic CRC.",Explore progression-free survival (PFS) and survival,2006-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
246,NCT04098796,Objective response rate (ORR),"Exploration of biomarkers (PD-L1 expression, TMB at the baseline, changes of AFP and T lymphocyte in peripheral blood)",2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
247,NCT05926726,RP2D of JWATM214 in HCC patients,overall survival (OS),2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],
248,NCT01438385,Establishing a database that contains all Interventional Endoscopies,,2011-07,UNKNOWN,OBSERVATIONAL,['NA'],
249,NCT01949870,The Number of Dose-limiting Toxicities,,2013-10,TERMINATED,INTERVENTIONAL,['PHASE1'],
250,NCT04457297,Disease-free survival 1 (DFS1),Treatment Completion Rate,2020-07-08,RECRUITING,INTERVENTIONAL,['PHASE3'],
251,NCT06084689,Disease control rate (DCR),Safety and tolerability of the combination,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
252,NCT04094675,Change in colon polyp burden by staging,Change in well-being assessment,2019-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
253,NCT05185947,"Evaluate efficacy of bidirectional chemotherapy using intraperitoneal and intravenous paclitaxel and oral nilotinib by calculating the rate of downstaging of peritoneal disease burden to become resectable, based on Peritoneal Carcinomatosis Inde...",Assess clinicopathologic response to therapy,2022-10-13,RECRUITING,INTERVENTIONAL,['PHASE2'],
254,NCT05669807,Objective Response Rate,Quality of life assessment,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
255,NCT00216788,Urine sucrose level falls below 90 mg after 8 weeks of therapy,Reduction of patient symptoms consistent with GERD,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
256,NCT00152087,- Adverse experience,,2002-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
257,NCT04534543,Change in PME/PDE (ΔPME/PDE): predictive,Response to treatment,2021-12-15,RECRUITING,INTERVENTIONAL,['NA'],
258,NCT06111105,Collection of clinical plasma samples at relevant time points,Prognostic value of ctDNA analysis at relevant time points,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],
259,NCT03642561,overall survival,objective response rate,2019-09-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
260,NCT03829098,90 day mortality,Hospital based costs,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],
261,NCT04557969,Assess disease-free intervals (DFIs) between surgical resection of disease for at least 5 years,Characterize genomic and clinicopathologic features of GISTs,2020-12-18,RECRUITING,OBSERVATIONAL,['NA'],
262,NCT01885702,Safety and feasibility of vaccination with frameshift-derived neoantigen-loaded DC of CRC patients,"Clinical responses, e.g. disease-free survival, determined according to the standard protocol.",2010-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
263,NCT00532909,"Maximum tolerated dose of vandetanib in combination with capecitabine, oxaliplatin and bevacizumab",Dose limiting toxicities associated with the combination,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
264,NCT04426669,Safety of tumor reactive autologous lymphocytes with knockout of the CISH gene - Incidence of Adverse Events,Toxicity profiles resulting from treatment using these engineered tumor-infiltrating lymphocytes,2020-05-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
265,NCT03546660,Feasibility of imaging of the Esophagus using a SECM Capsule,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],
266,NCT01770132,Evaluate the number of subjects with adverse events which occur when up to 3 sites within the pancreas are treated with PDT using a total dose of 50 or 100 J per site,Overall survival,2013-04-19,COMPLETED,INTERVENTIONAL,['PHASE1'],
267,NCT02653521,Toxicity of treatment,Overall Survival（OS）,2015-12-30,UNKNOWN,INTERVENTIONAL,['NA'],Dosimetric Parameters
268,NCT04539769,Diabetes remission rate,,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
269,NCT01108107,The frequency of patients requiring adjuvant chemotherapy based on the histological evaluation of the preparation from the operation.,Overall survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
270,NCT05896787,pCR,AE,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
271,NCT05359393,NED rate,Acute toxicity associated with immunotherapy,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
272,NCT01926769,Disease Control Rate,Progression Free Survival,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2'],
273,NCT04940546,Adverse events,Overall Survival,2021-06-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
274,NCT03887702,"Time until adverse liver outcome, assessed by incidence of adverse liver outcome",Death due to any cause,2020-01-17,TERMINATED,INTERVENTIONAL,['PHASE3'],
275,NCT00019747,Time to Progression,,1999-08,TERMINATED,INTERVENTIONAL,['PHASE2'],
276,NCT03804203,Efficacy of palliation using the short course scheme compared with the standard scheme: Likert scale,Quality of Life (QoL): EORTC questionnaire C15-PAL,2017-11-08,UNKNOWN,INTERVENTIONAL,['NA'],
277,NCT01028495,Survival,"Karnofsky Performance Scale, Clinical Laboratory Assessment, and Molecular Markers",2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
278,NCT05980221,Metabolome,Response of the fed and fasted metabolome to PERT,2020-08-24,RECRUITING,INTERVENTIONAL,['NA'],
279,NCT02390947,Overall Survival(OS),The severity of Adverse Events,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
280,NCT00277303,Safety and tolerability,Pharmacokinetic (PK) and Pharmacodynamic (PD) parameters,2005-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
281,NCT00069108,Progression Free Survival,Number of Participants With Marked Post-baseline Laboratory Abnormalities by Trial Treatment,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
282,NCT01043835,Disease free survival,"Complications, recurrence, quality of life measured by EORTC QLQ-C30 V 3.0 and EORTC QLQ-STO22",2010-02,UNKNOWN,INTERVENTIONAL,['NA'],
283,NCT01032850,Number of Participants Experiencing Adverse Events,Progression Free Survival (PFS),2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
284,NCT06152783,Histopathology was used as the diagnostic gold standard to evaluate the diagnostic performance of CellTouch in the diagnosis of early gastric cancer.,"Using histopathology as the diagnostic gold standard, the diagnostic performance of CellTouch and ME-NBI in the differential diagnosis of low-grade intraepithelial neoplasia and high-grade intraepithelial neoplasia was evaluated.",2023-11-21,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
285,NCT05253716,3-year disease free survival after discharge,"toxicity of chemotherapy graded according to the CTCAE, version 5.0",2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],
286,NCT05245786,Number of patients with impactful finding using 64Cu-M5A positron emission tomography (PET) imaging.,Count of Adverse Events.,2022-08-31,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
287,NCT04745988,Major pathological response (MPR) rate,The incidence of adverse events,2021-11-11,RECRUITING,INTERVENTIONAL,['PHASE2'],
288,NCT03944421,Genotoxic potential of Faecal extracts from volunteers consuming intervention diets rich in red and processed meat versus diets containing Quorn,Changes in MicroRNA Expression,2019-07-03,COMPLETED,INTERVENTIONAL,['NA'],Blood Glucose
289,NCT01252628,"The evaluation of antitumor effects of PX-866 in combination with cetuximab versus cetuximab in patients with incurable metastatic colorectal cancer and/or patients with incurable progressive, recurrent or metastatic SCC of the head and neck.",,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
290,NCT00467129,Progressive disease-free survival,,2002-07,UNKNOWN,OBSERVATIONAL,['NA'],
291,NCT05453851,Proportion of patients that are free of metastatic disease to the liver from a pancreatic primary,Time to overall survival (OS),2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of adverse events (AEs)
292,NCT05606081,Rates of colorectal neoplasia per number of colonoscopies performed,,2022-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],
293,NCT00767234,Identify Biomarkers,,2008-08,TERMINATED,OBSERVATIONAL,['NA'],
294,NCT04510064,margin-free-(R0) resection rate,overall survival (OS),2020-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
295,NCT03290937,Objective response rate (Dose expansion),Duration of response,2017-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
296,NCT00436501,Median Progression-Free Survival (PFS) (Phase II),Number of Participants With PFS (Phase II),2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
297,NCT00844454,Local treatment responses,Disease-free survivals and overall survivals,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
298,NCT02017704,Number of Patients With Pathologic Complete Response,Time to Local Disease Recurrence,2014-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
299,NCT01928290,Number of Participants With an Objective Response,Toxicity and Tolerability (Arm A and Arm B) as Measured by the Number of Participants With Grade 3 or Higher Adverse Events,2013-11-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
300,NCT02387138,Dose limiting toxicities,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
301,NCT05671809,ARP,MASCP and Wexner,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
302,NCT05903885,Fecal Immunochemical Test (FIT) kite return rate,Fecal Immunochemical Test (FIT) kit positive rate,2023-10-02,RECRUITING,INTERVENTIONAL,['NA'],
303,NCT00839332,Phase 2: Overall Survival (OS),Phase 2: Electrocardiogram QTc Prolongation,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Deaths During the Phase 1 Post-study Period
304,NCT01208194,Evaluation of median progression-free survival (PFS) in both treatment groups,Assessment of the safety profile of MGN1703,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
305,NCT06225609,Calculation postoperative of the Comprehensive Complication Index (CCI) for each patient,Total hospitalization costs,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The number of patients with complications after total mesorectal excision for rectal cancer
306,NCT01662739,"Collection of life-style, familiar, clinical, histological and biomolecular data",Collection of biological samples (blood and cancer tissue samples),2010-01,UNKNOWN,OBSERVATIONAL,['NA'],"Analysis of epidemiology, risk factors, family history and unidentified susceptibility genes and proteins"
307,NCT02851004,ORR,Pharmacokinetic,2016-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",safety according to immune status
308,NCT01634126,FIT Kit adherence,,2012-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
309,NCT05573776,Comparison of muscle variation between exercise therapy alone and high protein supplement combination groups,Overall Survival (OS),2020-08-01,RECRUITING,INTERVENTIONAL,['NA'],
310,NCT01357486,Time to radiologic progression,Quality of life,2011-11-14,COMPLETED,INTERVENTIONAL,['PHASE2'],
311,NCT04389502,Correct Answers (60% group),Correct Answers (80% group),2020-05-15,UNKNOWN,INTERVENTIONAL,['NA'],
312,NCT02182687,Freedom From Progression Over Time,Quality of Life - Questionnaires Include PIQ-6 and SF-36v2 Health Survey,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
313,NCT00857545,Progression-free Survival (PFS),Overall Survival,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
314,NCT00027833,,,2001-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
315,NCT00903396,Complete Response (no Episodes of Nausea or Vomiting),Average Level of Nausea Reported and the Proportion of Patients Experiencing a Complete Response Independent of Treatment Arm,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
316,NCT00555295,,,2007-12,UNKNOWN,OBSERVATIONAL,['NA'],
317,NCT00003296,,,1998-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
318,NCT00026104,Overall survival,Progression-free survival,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
319,NCT03906565,Tumor response to utidelone treatment,Safety profile associated with utidelone injection,2019-04-12,SUSPENDED,INTERVENTIONAL,['PHASE2'],
320,NCT04110977,Rate of radiation dermatitis grade ≥2,Rate of radiation-induced oral mucositis grade ≥3,2020-10-10,UNKNOWN,INTERVENTIONAL,['NA'],
321,NCT04541173,Progression free survival (PFS) by RECIST 1.1,Subject function,2020-11-30,TERMINATED,INTERVENTIONAL,['PHASE2'],
322,NCT05007145,Pathologic complete response (pCR) rate,Disease Free Survival (DFS),2021-08-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],
323,NCT04530981,AUC from time 0 and extrapolated to infinity (AUC0-∞),Incidence of Adverse Events,2021-09-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
324,NCT06010901,Objective response rate (ORR),Neutralizing antibodies (NaB),2024-01-13,RECRUITING,INTERVENTIONAL,['PHASE1'],
325,NCT03401957,Percentage of detected circulating DNA RAS mutations during 1st line cetuximab exposure.,Overall survival from the start of 1st line treatment with cetuximab.,2018-01,UNKNOWN,OBSERVATIONAL,['NA'],
326,NCT06169202,Progression-free Survival (PFS),Disease Control Rate (DCR),2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],
327,NCT03211416,Overall response rate defined as partial or complete response per immune-related Response Evaluation Criteria in Solid Tumors,Time to tumor progression,2017-12-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in levels of immunosuppressive cells
328,NCT02921256,Neoadjuvant Rectal Cancer (NAR) Score,Rate of Sphincter Preservation,2017-01-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Relationship Between Radiographic Findings and Pathologic Outcomes
329,NCT01549418,Clinically significant bleeding after colorectal polypectomy,Proportion of clinically significant delayed bleeding in both groups,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
330,NCT05913570,Pathological complete response (pCR) rates,Number of participants with any treatment-related delays in the planned surgery of no more than 28 days after the last preoperative Cadonilimab dose,2023-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
331,NCT01256203,Skin erythema responses of control (unprotected) and Solar Protection Formula® SPF 60-protected sites to light exposure,Proportion of subjects with adverse events as a measure of safety,2013-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
332,NCT06332274,Efficacy of tislelizumab compared to placebo as measured by DFS (Disease-free survival),Cost effectiveness analysis: ICER,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
333,NCT04512729,Colonic Adenoma,Risk factors for Colonic adenoma,2020-08-04,UNKNOWN,OBSERVATIONAL,['NA'],
334,NCT03635619,MRI TN staging in Esophageal Cancer,MRI prediction of prognosis in esophageal cancer,2018-09-02,UNKNOWN,OBSERVATIONAL,['NA'],
335,NCT06128798,Physiology Return of Bowel Function,Length of Hospital Stay,2023-09-26,RECRUITING,INTERVENTIONAL,['NA'],
336,NCT03469479,Overall survival,Adverse Events,2018-03-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],
337,NCT01121562,Clinical Benefit Response Rate (CBR),"Dose-corrected Trough Plasma Concentrations of Sunitinib, SU012662 and Total Drug (Sunitinib + SU012662).",2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
338,NCT00003524,,,1996-10-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
339,NCT02315625,Median Amount of Time Subject Survives Without Disease Progression After Treatment,Number of Participants With Serious and Non-Serious Adverse Events,2015-04-08,TERMINATED,INTERVENTIONAL,['PHASE2'],
340,NCT00058487,Toxic effects,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
341,NCT00455091,Primary endpoint: Primary endpoint: the 3-years recurrence rate (excluding those recur within first year).,"Secondary endpoints: the first 2 year tumor recurrence rates,the recurrence-free survival,the overall survival.anti-viral efficacy.",2007-05,TERMINATED,OBSERVATIONAL,['NA'],
342,NCT05756725,Number of open orders for mammography screening,Appropriateness of Implementation Strategies,2023-07-25,COMPLETED,INTERVENTIONAL,['NA'],
343,NCT03642652,Follow-up colonoscopy 120 days after a positive fecal occult blood test,,2016-04-01,COMPLETED,INTERVENTIONAL,['NA'],
344,NCT06010303,Overall Response Rate (ORR),Number of Participants with Adverse Events (AEs),2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],
345,NCT05838768,Frequency of dose reductions as a measure of tolerability,Number of participants with anti tislelizumab antibodies,2023-06-27,RECRUITING,INTERVENTIONAL,['PHASE1'],
346,NCT00836407,Percent of Patients Experiencing an Unacceptable Toxicity,Progression Free Survival (PFS),2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
347,NCT02427269,Collaboration with other investigators,,2015-04-28,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
348,NCT05871892,Metabolic function of the liver evaluated by the PET tracer 18F-FDGal,,2023-09-11,RECRUITING,INTERVENTIONAL,['NA'],
349,NCT01126112,Progression-free survival rate at 6 months,Evaluation of molecular predictive markers for response.,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
350,NCT05595811,overall survival,adjuvant oncologic treatment,1999-01-01,COMPLETED,OBSERVATIONAL,['NA'],
351,NCT05570942,Changes of irritable bowel symptoms,The presence of bacteremia,2021-12-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],
352,NCT03110939,local recurrent rate,mortality rate after treatment,2017-03-21,WITHDRAWN,INTERVENTIONAL,['NA'],
353,NCT01439724,Incidence and / or Severity of Oral Mucositis,"Oral Mucositis Survival Free, Pain, Opioid Treatment, Hospitalization, Treatment Interruption, Treatment Delay, Patient Weight Loss, Nasogastric Tube or of a Gastrostomy.",2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
354,NCT02168426,ileus rate,adverse effect rate,2013-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
355,NCT01298011,Grade III/IV histological response in tumor specimen rate after induction therapy.,Overall Survival,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
356,NCT03209336,The basic information and medical history achieved (questionnaire),The short-term complications,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
357,NCT01100372,Remission rates (complete response and partial response),Toxicity,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],
358,NCT02709213,Determination of the aetiologies of colitis using microbiological examination of the stools +/- colonoscopy,"Identification of anamnestic, clinical and biological predicting factors for patients requiring diagnostic colonoscopy",2016-11,COMPLETED,OBSERVATIONAL,['NA'],
359,NCT00294203,"Post-operative hemoglobin, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte fraction measured on post-operative days 1, 4, 8, and between days 20 and 30",Post-operative quality of life related to anemia measured by Functional Assessment of Cancer Therapy - Anemia (FACT-An) between post-operative day 20 and 30 and post-operative transfusion requirement,2006-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
360,NCT01129310,Overall Response Rate and dose limiting toxicity,"Progression Free Survival, overall survival, death, alterations in quality of life outcomes",2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
361,NCT00897754,VEGF165b protein expression as measured by ELISA,,2007-07-24,COMPLETED,OBSERVATIONAL,['NA'],
362,NCT02489838,Lung dose measured with actual lung mass vs Lung dose measured with conventional method.,,2012-02-03,COMPLETED,OBSERVATIONAL,['NA'],
363,NCT05767697,Number of subjects who still survive at 1 year,,2020-04-15,RECRUITING,OBSERVATIONAL,['NA'],
364,NCT06324825,Recovery rate of Low-grade Intraepithelial Neoplasia,Adverse event rate,2022-10-24,RECRUITING,INTERVENTIONAL,['NA'],
365,NCT02641691,Complete Response Rate,Quality of Anorectal Function as Measured by the FACT-C Questionnaire,2016-05-27,COMPLETED,INTERVENTIONAL,['PHASE2'],
366,NCT05733000,Overall response rate (ORR),Incidence of adverse events,2023-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],
367,NCT01103479,Colorectal Cancer (CRC) Screening Completion,Provider Recommendation of CRC Screening,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
368,NCT00006387,,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
369,NCT05327582,Object response rate (ORR),Number of participants with laboratory test abnormalities,2022-04-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
370,NCT00089362,"MTD, defined as the dose level where the observed DLT incidence in no more than one out of six patients treated at a particular dose level",,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
371,NCT01012362,Number of Participants Who Experienced a Dose Limiting Toxicity (DLT),Number of Participants With Treatment-Related Adverse Events,2009-12,TERMINATED,INTERVENTIONAL,['PHASE1'],
372,NCT01649271,Dose Limiting Toxicities During cycle1,Clinical Benefit,2012-07-23,COMPLETED,INTERVENTIONAL,['PHASE1'],
373,NCT03504618,Prognostic factor of progression free survival,Overall survival after 24 months,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],
374,NCT03799731,Progression Free Survival (PFS) at 6 months,AMHRII (Anti-Mullerian Hormone type II receptor) expression,2018-07-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
375,NCT00660582,,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
376,NCT00152607,"The primary outcome for recipients will be the assessment of patient and graft survival. Comparison to results of contemporaneous, non-randomized cadaver donor transplants will be made.",,2000-04,TERMINATED,INTERVENTIONAL,['PHASE4'],
377,NCT01336881,Biomarkers associated with hepatoblastoma subtypes and cancer stages,Exome sequencing,2011-04,COMPLETED,OBSERVATIONAL,['NA'],
378,NCT03426397,2-year non-regrowth disease-free survival,Quality of life,2017-05-10,RECRUITING,OBSERVATIONAL,['NA'],
379,NCT01129167,Frequency of local invasion modalities in surgical population,,2009-09-15,COMPLETED,OBSERVATIONAL,['NA'],
380,NCT00829413,Specificity: Percentage of True Negative Lesions Among All Benign Lesions Per Truth Standard',Inter-reader Agreement,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
381,NCT03923309,3-year overall survival,,2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],
382,NCT04927780,Overall survival,Patient reported Quality of Life as assessed using Exocrine Pancreatic Insufficiency (EPI) questionnaire,2021-09-07,RECRUITING,INTERVENTIONAL,['PHASE3'],
383,NCT03718624,Conversion to negative rate,Adverse events,2018-10-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],
384,NCT00202774,Determine time to disease progression,"Determine safety of combination, objetive response rate, time to onset of response , duration of response, time to treatment failure, one year survival time, overall survival time",2002-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
385,NCT02571725,Phase 2: Objective response rate (ORR),Phase 2: Progression free survival (PFS),2016-02-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
386,NCT06304350,Pathological complete remission (pCR),Safety (incidence of adverse drug reactions),2024-02-17,RECRUITING,INTERVENTIONAL,['PHASE2'],
387,NCT01084460,,,1997-01,COMPLETED,OBSERVATIONAL,['NA'],
388,NCT05060770,IBD associated CRC oncogenesis,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],
389,NCT01048320,The primary outcome measure for the study is to establish the Maximum Tolerated Dose of the drug regimen based on the endpoint of dose-limiting toxicity,Characterise safety profile of Gemcitabine Plus Oxaliplatin in Combination with imatinib mesylate (Glivec) in Patients with Gemcitabine-Refractory Advanced Adenocarcinoma of the Pancreas,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
390,NCT04886193,TRG grade,the incidence and severity of adverse events,2021-04-16,UNKNOWN,INTERVENTIONAL,['NA'],
391,NCT05725200,"Main Study: To evaluate the anti-tumor activity, measured as objective response rate (ORR) of MTB-nominated therapies with drugs not approved or implemented in standard of care (SOC) for treatment of mCRC.",Main study: Patient-reported outcome measures.,2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE2'],
392,NCT04496765,Local recurrence,,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],
393,NCT02138981,overall survival time,Number of Adverse Events,2014-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
394,NCT05019534,Evaluate tolerability and safety and identify the recommended Phase 2 dose(RP2D),Preliminary efficacy,2021-08-15,RECRUITING,INTERVENTIONAL,['PHASE1'],
395,NCT04795661,Rate of complete pathological response (pCR) after surgery,The prognostic value of lung immune prognostic index (LIPI),2021-10-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
396,NCT05224596,Sensitivity and specificity of the cfDNA methylation-based model in detecting gastric cancer.,"Sensitivity and specificity of a ctDNA mutation-based model and a serum protein-based model in detecting gastric cancer, respectively.",2021-01-18,UNKNOWN,OBSERVATIONAL,['NA'],Sensitivity and specificity of a blood miRNA-based model in detecting gastric cancer.
397,NCT04539808,Proportion of participants with R0 resection,Incidence of grade >= 3 toxicities,2021-05-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Proportion of LAPC participants who die within 30 days of surgery
398,NCT03124498,Phase II: Disease Control Rate,,2017-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
399,NCT03166436,Survival,Augmentation of antitumor immunity,2017-06-08,UNKNOWN,INTERVENTIONAL,['NA'],
400,NCT06320080,Progression-free survival (PFS),Immunogenicity,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
401,NCT05983133,Number of participants with DLTs by dose level,Overall survival (OS),2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE1'],
402,NCT02572141,Disease-free survival,Postoperative complications,2015-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
403,NCT01135056,Overall Survival,Disease control rate,2010-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],
404,NCT02343835,Characterization of the intra-tumoral and systemic immune response to IRE in unresectable pancreatic cancers,Comparison immune response between non-ablated and ablated pancreatic cancer and pre-ablated and post ablated serum,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Overall survival and (local and distant) progression-free survival.
405,NCT02637596,Quality of life after RFA of pancreatic cancer,3- months perioperative morbidity and mortality,2013-02,COMPLETED,INTERVENTIONAL,['NA'],Overall Survival
406,NCT03165344,Esophageal stenosis rate,Side effect of drugs,2017-02-10,COMPLETED,INTERVENTIONAL,['NA'],
407,NCT03273647,Disease-free survival time,overall survival time,2017-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
408,NCT02715492,Number of patients with portal vein thrombosis,,2018-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
409,NCT02602249,Reduced size of the tumor.,"Safety, as measured by the rate of adverse events and serious adverse events",2017-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],
410,NCT02805829,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Number of Participants with tumor recurrence metastasis as a Measure of effectiveness,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",T cell subsets figures
411,NCT00313794,"To assess the best overall response rate per RECIST (BRR) in patients with metastatic adenocarcinoma of the colon or rectum treated with CP-675,206 .","To obtain pharmacokinetic (PK) data to be evaluated in a future meta analysis of CP-675,206 pharmacokinetics.",2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
412,NCT06313801,Complications from polychemotherapy.,Аssessment of the quality of life,2023-01-19,RECRUITING,INTERVENTIONAL,['PHASE2'],
413,NCT05445245,Self-report Questionnaire,,2022-04-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
414,NCT06061328,Maintenance as assessed by maintenance of other measures,Feasibility of Intervention Measure (FIM),2024-02-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
415,NCT06173310,To measure the reproducibility of qDCE-MRI measurement of BRPC.,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
416,NCT03082833,Objective response rate (ORR) by RECIST 1.1,,2017-02-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
417,NCT00450424,Impact of Standard Informed Consent vs CD-ROM Educational Intervention on Knowledge About Microsatellite Instability (MSI) Testing,Patient Satisfaction With the Preparation to Make a Decision,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
418,NCT02162641,The proportion of nodes detected will be expressed per inguinal nodal basin and per number of patients,Delays in receiving radiotherapy treatment,2014-09,WITHDRAWN,OBSERVATIONAL,['NA'],
419,NCT06320990,"Feasibility, by retention rate",Objective response rate (ORR) of pancreatic MCN,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
420,NCT05482529,disease free survival rate,R0 resection rate,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],
421,NCT03587532,An ICGA based cutoff point to predict anastomotic leakage and graft necrosis after esophageal reconstructive surgery.,pulse pressure,2021-12-13,RECRUITING,INTERVENTIONAL,['NA'],
422,NCT05210283,To validate the association of circulating tumor DNA (ctDNA) with recurrence-free interval (RFI).,To assess time from positive ctDNA to clinical recurrence,2021-12-15,RECRUITING,OBSERVATIONAL,['NA'],
423,NCT03396029,A questionnaire-based lifestyle score,Body weight,2014-11-01,COMPLETED,INTERVENTIONAL,['NA'],
424,NCT02494791,Cost-effectiveness of universal enhanced screening strategy to identify women with Lynch Syndrome and their family members via cascade testing,Discovery of novel genetic mutations and molecular events in unexplained MMR loss (Lynch-like Syndrome),2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
425,NCT03109886,Overall Safety Profile,Duration of overall Response (DoR),2017-07-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
426,NCT06177496,overall survival,Progression-free survival,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
427,NCT05721885,Degree of radiation-induced oral mucositis (RTOG criteria),,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
428,NCT00507143,SLCO1B1 and PXR genotypes and pharmacokinetics of SN-38,"SLCO1B1 and PXR genotypes and response duration, time to progression and overall survival",2006-08,UNKNOWN,INTERVENTIONAL,['NA'],
429,NCT03825328,OS,,2019-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],
430,NCT05099848,Surgical conversion rate,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2021-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
431,NCT05554367,ORR (Cohort 4),Incidence of adverse events (AE) (All Cohorts),2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Plasma RAS allelic burden in in relation to response (Cohorts 3 and 4)
432,NCT01111838,To Determine Overall Objective Response.,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
433,NCT01147380,Side Effect of Cadaveric Donor Liver NK Cell Infusion,Anti-HCV Effect of This Treatment (If Applicable),2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
434,NCT02448056,Patient survival,,2015-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
435,NCT01523639,Reduction in the chemotherapy-associated steatosis,Reduction in chemo-therapy associated steatohepatitis (CASH),2012-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
436,NCT00191568,"To evaluate recurrence free one year survival, time to disease progression and local recurrence rate, analyzed at the end of the study",To assess overall survival at the end of the 24 months follow up period;To assess acute and late toxicity (every month for the first 3 months and then every three months for 24 months after treatment discontinuation),2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
437,NCT04698915,Median Overall Survival after SBRT completion,Median Progression Free Survival after SBRT Completion per RESIST 1.1,2021-05-07,TERMINATED,INTERVENTIONAL,['PHASE2'],
438,NCT05284864,Determine and compare morbidity and mortality rates in patients with early and late stoma closure,Determine and analyze quality of life assisted by the SF36 scale in early vs late ileostomy closure,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],"Determine the patient's percentage with anterior resection syndrome, after early and late ileostomy closure assisted by the LARS scale."
439,NCT00120939,"Determine the Dose Limiting Toxicity at 8 weeks (2 cycles), and the Maximum Tolerated Dose at 24 weeks.","Tumor response rate 8, 16 and 24 weeks, and common PK parameters at 24 weeks",na,COMPLETED,INTERVENTIONAL,['PHASE1'],
440,NCT00844168,Dose-limiting toxicity (DLT) as defined by the Common Terminology for Adverse Events (CTAE) version 3,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
441,NCT03125980,3-year disease free survival,Relapse-free survival (RFS),2017-05,RECRUITING,INTERVENTIONAL,['PHASE3'],
442,NCT04046133,Safety and tolerability- 12 months post CRT,Patient reported outcome - 12 months follow up,2020-10-19,UNKNOWN,INTERVENTIONAL,['PHASE1'],
443,NCT05356585,Detectable ctDNA at the Completion of TNT,Correlation of Complete Response TNT,2023-12-30,WITHDRAWN,OBSERVATIONAL,['NA'],The correlation of ctDNA at end of TNT with relapse-free survival
444,NCT03493152,,,na,TEMPORARILY_NOT_AVAILABLE,EXPANDED_ACCESS,['NA'],
445,NCT02845973,differences in abundance of gut microbiota,evidence of colorectal neoplasia,2012-01,COMPLETED,OBSERVATIONAL,['NA'],diet difference in patients with different clinical outcomes
446,NCT03111368,Diagnostic yield,,2015-04-27,COMPLETED,INTERVENTIONAL,['NA'],
447,NCT00063427,,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],
448,NCT05669521,Mucositis,Secondary efficacy/outcome mucositis,2022-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
449,NCT01563133,Descriptive criteria in nCLE sequences for the characterization of pancreatic masses and lymph nodes,Feasibility and safety data on nCLE during EUS-FNA procedure,2012-06,UNKNOWN,INTERVENTIONAL,['NA'],
450,NCT04885283,Time to Start Postoperative Chemotherapy,,2021-01-20,COMPLETED,OBSERVATIONAL,['NA'],
451,NCT03631173,Total hospital stay,Risk factors of postoperative pancreatic fistula at 90 days after surgery,2019-04-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Number of patients expired at an average of 10 days
452,NCT03908788,Proportion of patients with mCRC (metastatic colorectal cancer) who develop a RAS (rat sarcoma viral oncogene homolog) mutation under anti-EGFR (epidermal growth factor receptor) therapy,Evaluation of the following criterion: frequency of mutated alleles,2018-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
453,NCT00423293,Percentage of Subjects With Acute Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for Adverse Events),Five-Year Rate of Colostomy-free Survival,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
454,NCT00262990,To show superiority of patupilone in overall survival compared to doxorubicin in taxane/platinum resistant patients with ovarian cancer,To explore relationships between Cmin (pre-dose patupilone blood concentration) and efficacy/adverse events,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
455,NCT03647839,Objective response per iRECIST,Overall survival,2018-09-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
456,NCT05214339,Objective response rate (ORR) by RECIST 1.1,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE2'],
457,NCT00005077,,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
458,NCT03396614,The cardiopulmonary (dys)function in EC survivors treated with neo-CRT followed by surgical resection will be compared to cardiopulmonary (dys)function in EC survivors treated with surgical resection alone.,,2017-10-21,COMPLETED,OBSERVATIONAL,['NA'],
459,NCT03301454,Estimate the overall survival for patients suffering from Esophageal cancer,Estimate the consequences of pursuing chemotherapy,2018-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],
460,NCT00005640,Number of Procedures Resulting in Improved Detection,,1999-06,COMPLETED,INTERVENTIONAL,['NA'],
461,NCT06060990,Serum copper (Cu) as a predictive biomarker of the response to systemic treatment of biliary tract cancer patients,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],
462,NCT01194206,Rate of downstaging of stage B and C Hepatocellular Carcinoma using Stereotactic Body Radiotherapy,Survival rate,2010-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
463,NCT05664178,Participant Treatment Outcome,,2023-02-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
464,NCT05378867,AUCtau，Area under the curve over the dosing interval,DOR，Duration of response,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
465,NCT03198546,Number of Patients with Dose Limiting Toxicity,Median CAR-T cell persistence,2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE1'],
466,NCT03679910,Diagnostic value of cell migration inducing protein (CEMIP) in serum of pancreatic cancer as non invasive marker.,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
467,NCT01425996,Adverse Event/Serious Adverse Event,Change from baseline in tumor marker/biomarkers,2011-10-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
468,NCT04157140,Time To Progression(TTP),Incidence of Treatment-Emergent Adverse Events,2019-11-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],
469,NCT05720676,To use PDX and PDO to evaluate the efficacy of various treatments.,,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
470,NCT06257030,LPFS,Post-treatment dosimetry analysis,2024-02-05,RECRUITING,OBSERVATIONAL,['NA'],
471,NCT00367861,Progression free survival,Toxicity,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
472,NCT05688020,Postprocedural bleeding,Side effects,2023-02-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
473,NCT02944188,incidence of postoperative complications,operative mortality,2014-12-01,COMPLETED,INTERVENTIONAL,['NA'],postoperative hospital stay
474,NCT02610218,Correlation of HER2 status on CTCs and cfDNA with clinical outcomes,Gene variations associated with resistance in HER2-targeted therapy,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],
475,NCT02435953,Overall survival rate,Adverse event rate,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
476,NCT00001254,To determine an approach to the localization and management of tumor in patients with ZES.,,1991-10-29,COMPLETED,OBSERVATIONAL,['NA'],
477,NCT04638868,Number of circulating tumor cells,,2020-11-17,UNKNOWN,INTERVENTIONAL,['NA'],
478,NCT03400592,Objective response rate,Potential predictive biomarkers of nimotuzumab,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
479,NCT03825705,Overall Response Rate(ORR),,2019-04-23,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
480,NCT00004187,,,1999-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
481,NCT00005060,Event-free survival,Rate of complete resection (RO) and postoperative mortality as measured after surgery,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
482,NCT04229355,Progression-free survival,Overall survival,2021-02-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],
483,NCT03566797,Incidence of SC-CIP in patients at risk,NOD2 polymorphisms,2018-07-20,RECRUITING,OBSERVATIONAL,['NA'],
484,NCT05984589,To compare the difference in WCRF/AICR score between the intervention (RISE-PSMT) and control (SSMT) groups.,To assess percent change across the various component scores on the WCRF/AICR (e.g. grams of fiber) to better understand what might be driving any changes in the overall WCRF/AICR composite score.,2024-01-29,RECRUITING,INTERVENTIONAL,['PHASE2'],
485,NCT02705105,Number of Subjects Experiencing Dose-limiting Toxicity,Objective Tumor Response Rate According to RECIST,2016-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
486,NCT00062374,Histological Response Determined by FDG Uptake Correlates,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Free Survival (DFS)
487,NCT01220999,Mean 111^In-CS-1008 Serum Maximum Concentration by Gamma Counting Following the Day 36 Infusion of 111^In-CS-1008,Number of Subjects With Best Overall Metabolic Response,2010-10-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
488,NCT02936856,Detection of numbers of confirmatory diagnosis of malignant lesions before and after hepatic arteriography,Detection of distribution of confirmatory diagnosis of malignant lesions before and after hepatic arteriography,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],
489,NCT03104283,Progression-free survival (PFS),Overall survival (OS),2017-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
490,NCT05650151,Infection rate,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
491,NCT04575922,Overall response rate for unirradiated lesions (ORR),Overall survival (OS),2020-10-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
492,NCT00625651,Progression-free survival,The incidence of anti-AMG 655 antibody formation,2007-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
493,NCT00808145,Safety of the combination of gemcitabine/cisplatin/sorafenib,Effectiveness of gemcitabine/cisplatin/sorafenib in shrinking tumors extending time to progression of disease,2009-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
494,NCT03200691,Pathologic Complete Response Rate,Numbers of adverse events and the degree of each adverse events according to the NCI CTCAE 4.0 criteria.,2017-08-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
495,NCT05897268,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
496,NCT02034968,Progression free survival(PFS),Objective Response Rate,2014-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Adverse events
497,NCT00560560,Estimate of the 6 Month Survival Probability,Counts of Circulating Tumor Cells (CTCs),2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
498,NCT04993846,Quantitative analysis of the dental plaque microbiome in patients with pancreatic cancer vs. healthy controls and IPMN patients,Qualitative analysis of OM and periodontal status between the various stages of PC,2021-07-26,UNKNOWN,OBSERVATIONAL,['NA'],
499,NCT01924624,disease-free survival,Overall survival,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],
500,NCT05213637,Recurrence-free survival (RFS),Adverse events (AE),2018-04-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],
501,NCT01832467,overall response of re-treatment with cetuximab-based chemotherapy,progression-free survival,2013-04-24,COMPLETED,INTERVENTIONAL,['PHASE2'],
502,NCT00361309,Progression free survival of hepatocellular carcinoma (HCC) patients treated with SU011248.,Overall Survival,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
503,NCT03146637,OS,SRR,2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
504,NCT02781285,The influences of traditional Chinese medicine standardized treatment on the overall survival (OS) of patients with advanced gastric cancer by the method of Propensity Score.,The influences of Western Medicine treatment mainly by chemotherapy on the overall survival (OS) of patients with advanced gastric cancer by the method of Propensity Score.,2014-12,RECRUITING,OBSERVATIONAL,['NA'],
505,NCT02008656,disease-free survival (DFS),major adverse events,2013-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
506,NCT04862793,Feedback from CoPS results in change in patient discomfort.,Make an immediate measure to assess the quality of individual colonoscopy performance.,2021-06,UNKNOWN,INTERVENTIONAL,['NA'],
507,NCT01751763,"Treatment pattern of Sorafenib: duration and doses of Sorafenib, dose modification/discontinuation of Sorafenib, concomitant anti-cancer therapy, treatment after observed radiological recurrence.",Time to recurrence (TTR),2013-07-09,COMPLETED,OBSERVATIONAL,['NA'],
508,NCT00094965,Adverse events.,Tumor evaluations for response or progressive disease.,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
509,NCT04354246,Evaluation of the PK profile of the Triplet combination (COM902 + COM701 + Pembrolizumab).,To characterize the immunogenicity of the Triplet combination (COM902 + COM701 + Pembrolizumab).,2020-03-31,RECRUITING,INTERVENTIONAL,['PHASE1'],Preliminary antitumor activity of the triplet combination (COM902 + COM701 + Pembrolizumab).
510,NCT02437136,Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 3 Stage 2 (Melanoma pre-treated),Time to Response (TTR),2015-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
511,NCT05114148,Rate of unacceptable toxicity.,Assessment of regional liver function,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],
512,NCT01575990,Appropriate colorectal cancer screening,Appropriate screening for stool cards,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
513,NCT01707121,Length of hospital stay,Health economic analysis,2012-12,COMPLETED,OBSERVATIONAL,['NA'],
514,NCT03407716,Change in general subscale of the Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF),Perceived treatment efficacy as measured by the Subject Global Impression of Change,2019-03-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],"Change in inflammation biomarkers (adiponectin, cortisol, IL-6)"
515,NCT00639314,delayed gastric empty after pancreaticoduodenectomy,"evaluation of quality of life, early and late complications after pancreaticoduodenectomy",2005-10,COMPLETED,INTERVENTIONAL,['NA'],
516,NCT02178956,Overall Survival,Number of Patients With Adverse Events,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
517,NCT01630239,MR Images,,2012-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
518,NCT01586611,The difference Progression Free Survival (PFS) between Gemcitabine and FOLFOX treated patients in hENT1 high and hENT1 low pancreatic adenocarcinoma.,Health-related quality of life (HRQL) parameters in patients with metastatic pancreas adenocarcinoma treated in both treatment arms.,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],
519,NCT00679913,Survival,Morbidity,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
520,NCT01322152,Rate of Diarrhea,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
521,NCT03614910,Tumor response,Cancer related pain,2018-05-15,COMPLETED,OBSERVATIONAL,['NA'],
522,NCT01860222,overall survival,local tumor progression,2011-01,UNKNOWN,INTERVENTIONAL,['NA'],
523,NCT03790059,Tumor-free survival,Overall survival,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],
524,NCT01131689,MTD,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
525,NCT05183776,Safety of a fractional administration device for holmium radioembolization,Accurate dosimetry based on MRI and SPECT imaging of holmium-166.,2022-07-12,COMPLETED,INTERVENTIONAL,['NA'],
526,NCT00683358,PhaseⅠ; safety (NCI CTCAE v.3) PhaseⅡ；time to progression (RECIST),"Tumor regression(Imaging study, tumor marker, etc.)",2008-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
527,NCT01668381,"variation of serum IL-10,TGF-β1,IFN-γ concentration of HCC patients before and 1,4 weeks after radiofrequency ablation therapy","variation of suppression ability of CD4+CD25+ T cells of HCC patients on cytokine secretion before and 1,4 weeks after radiofrequency ablation therapy",2012-08,UNKNOWN,OBSERVATIONAL,['NA'],
528,NCT03383367,participation rate at future colonoscopy,Cost-utility analysis of the reminder letter for surveillance colonoscopy,2017-08-24,UNKNOWN,INTERVENTIONAL,['NA'],
529,NCT06135558,DFS,,2016-01-30,COMPLETED,OBSERVATIONAL,['NA'],
530,NCT00126256,"Progression-free survival after two lines of chemotherapy, defined as the time duration from randomization until progression after two lines of chemotherapy or death whatever the cause in the absence of progression or last-follow-up",Costs,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
531,NCT01398449,Overall survival,Failure pattern,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],
532,NCT04780802,The change in the perfusion pattern of HCC tumors,Tumor response,2022-05-01,COMPLETED,INTERVENTIONAL,['NA'],
533,NCT03988556,Rate of discontinuation due to AEs,Oral mucosa lesions assessment - Time until resolution,2019-07-04,COMPLETED,INTERVENTIONAL,['NA'],Use of the device - Cumulative dose
534,NCT01943786,To estimate the proportion of patients with advanced colorectal cancer in whom KRAS mutation can be detected in circulating extracellular DNA,Number of each adverse event per cycle,2013-04,UNKNOWN,OBSERVATIONAL,['NA'],
535,NCT00589030,,,2007-04,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],
536,NCT02449135,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],
537,NCT00154531,,,2004-08,UNKNOWN,OBSERVATIONAL,['NA'],
538,NCT05352165,Pathologic Complete Response,anus-saving rate,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
539,NCT05672524,Clinical complete response of study participants,,2022-12-30,RECRUITING,INTERVENTIONAL,['PHASE2'],
540,NCT00602602,Progression-free survival,Percentage of potentially resectable patients who are able to proceed to successful resection,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
541,NCT04104074,Incidence of treatment-emergent adverse events,Overall Survival (OS),2019-11-25,UNKNOWN,INTERVENTIONAL,['PHASE1'],
542,NCT05727852,Indicators of arterial stiffness,Composite of clinical records,2023-01-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
543,NCT03255343,size of tumor,HPFS,2017-03-13,UNKNOWN,INTERVENTIONAL,['NA'],
544,NCT04992143,1-year survival rate,Disease control rate,2021-08-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
545,NCT01444495,local and systemic recurrence rate,downstaging of rectal cancer,1999-01,COMPLETED,INTERVENTIONAL,['NA'],
546,NCT03192618,Disease-free survival (DFS),Overall survival (OS),2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
547,NCT01217060,Pathologic Complete Response (PCR) Rate,Disease-free Survival (DFS) Time,2010-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
548,NCT01192971,TTP (Time to Progression),QoL (quality of life): EORTC QLQ-C30,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
549,NCT03577535,Oral mucositis grade in patients during chemotherapy and radiotherapy treatments,Nutritional status of the patients during Chemotherapy and radiotherapy treatments,2017-11-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
550,NCT00158886,To determine the MTD of oral topotecan in combination with pelvic radiation,To evaluate the toxicity and potential efficacy of oral topotecan and concurrent pelvic radiation for the treatment of rectal cancer. To determine pathologic response to treatment and assessment of sphincter preservation.,2001-11-08,TERMINATED,INTERVENTIONAL,['PHASE1'],
551,NCT01141478,Overall Survival Rate Between Time of Consent and Time of Death,,2010-09-08,TERMINATED,INTERVENTIONAL,['NA'],
552,NCT02426034,"Safety, which was assessed by recording the incidence and severity of adverse events","Quality of life, measured by the questionnaire of EORTC QLQ-C30",2015-05-15,COMPLETED,INTERVENTIONAL,['PHASE4'],
553,NCT04280640,Correlation between treatment response in CTCs and in vivo,"Sensitivity, specificity, and predictive values of CTC cultures' treatment response",2021-06,WITHDRAWN,OBSERVATIONAL,['NA'],
554,NCT03753789,Percentage of Lesions Where Re-ablation is Suggested,Hospital Resource Utilization,2019-11-05,TERMINATED,INTERVENTIONAL,['NA'],
555,NCT01868139,Response Rate to Therapy,Safety of Spray Cryotherapy in This Setting;,2013-06,TERMINATED,INTERVENTIONAL,['NA'],
556,NCT05109130,Change of circulating tumor cells during laparoscopic or transanal endoscopic surgery,Disease free survival,2021-10-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
557,NCT00003307,,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
558,NCT01313416,"Toxicity Evaluation: From Time of First Treatment With CT-011 (Pidilizumab, MDV9300)",Disease Response: Evaluated Using the Revised Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines (v1.1),2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
559,NCT00453323,To evaluate the response rate,To estimate the overall survival,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
560,NCT05964543,Objective response rate (ORR),Progression-free survival (PFS),2023-06-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
561,NCT02514525,percentage of all treated patients who have complete eradication of all dysplasia (CE-D),Number of CryoBalloon ablation treatments required to achieve CE-D or CE-IM,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],
562,NCT02325232,Identification of celiac patients at higher risk of developing small bowel neoplasia and evaluation of the the usefulness of VCE and DBE,The diagnostic yeld of DBE and VCE in this setting of patients,2012-02,UNKNOWN,INTERVENTIONAL,['NA'],A flowchart for early diagnosis of small bowel tumors in CD patients
563,NCT01763125,Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.,,2003-11,RECRUITING,OBSERVATIONAL,['NA'],
564,NCT05568316,Biochemical Measurements,Lenght of Hospital Stay of Participants,2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],
565,NCT03116152,Overall Survival,Duration of Response,2017-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
566,NCT02316028,toxicity of escalating doses of decitabine administered by HAI,measuring Global DNA methylation of cell free DNA,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
567,NCT05035381,Objective response rate,Adverse Events,2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
568,NCT04178759,Volume of regenerated liver after liver resection,Evaluation of short term surgical outcomes,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],
569,NCT05634525,Overall survival (OS),,2023-05-03,RECRUITING,INTERVENTIONAL,['PHASE1'],
570,NCT01054274,Overall survival and Median Survival,Successful rate of stent placement,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],
571,NCT04523493,Overall survival (OS),Immunogenicity,2020-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Tumor mutation burden (TMB)
572,NCT03093870,Progression-free Survival (PFS) - Part 1,ECOG Performance Status - Part 1,2017-07-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
573,NCT00087074,"Proportion of confirmed tumor responses, defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart",Time to treatment failure,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
574,NCT00183885,Tumor Response,Number of participants with grade 3 or higher toxicity,2004-10-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],
575,NCT03015675,Progression Free Survival,Response Rate,2017-03-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],
576,NCT06193356,Performance of detecting a recurrence at an endoscopic resection scar.,Performance of a learning tool in improving detection of recurrence at an endoscopic resection scar compared between endoscopists with different experience level,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
577,NCT03804255,"Factors influencing heterogeneity of capacity for biomarker testing, from among modifiable testing practice-related factors, e.g. cost, complexity, technologic complexity, lack of familiarity, physician and patient demand",Proportion of pathology practices testing for novel biomarkers using a standard reflexive testing protocol,2019-01-08,WITHDRAWN,OBSERVATIONAL,['NA'],
578,NCT04387903,Tumor recurrence,Risk factors for surgical reoperation,2000-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
579,NCT05103631,Number of Patients with Dose Limiting Toxicity,Median T cell persistence,2021-06-17,RECRUITING,INTERVENTIONAL,['PHASE1'],
580,NCT04288999,Locally recurrent free survival,QOL,2019-10-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
581,NCT00002575,Overall survival,Compare the differences in quality of life of patients treated with these regimens,1994-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
582,NCT04546802,Viral eradication,Adverse events,2019-09,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Overall survival
583,NCT03193216,Percentage of Patients With Successful Eradication,Number of Treatments (Mean),2017-08-25,COMPLETED,INTERVENTIONAL,['PHASE2'],
584,NCT02729493,Disease control rates,,2015-11-14,UNKNOWN,INTERVENTIONAL,['NA'],
585,NCT02298959,Recommended combination dose of ziv-aflibercept and pembrolizumab,Time-to-progression,2015-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Effects on tumor vasculature and vascular active molecules
586,NCT01675258,,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],
587,NCT03896646,Tumor objective response rate (ORR),Development of a model correlating normal liver radiation dose to liver function using single-photon emission computed tomography computed tomography hepatobiliary iminodiacetic acid (SPECT CT HIDA) imaging,2019-10-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
588,NCT05962723,"sensitivity, specificity and accuracy",,2023-08-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
589,NCT02293811,Analysis of expression of P2RX7,Five isoforms of the P2RX7 protein,2015-02-09,TERMINATED,INTERVENTIONAL,['NA'],
590,NCT06155383,Pathological complete response (pCR) rate,Adverse events,2023-11-27,RECRUITING,INTERVENTIONAL,['PHASE2'],
591,NCT00147134,Overall survival,The proportion of completion of LAP,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
592,NCT00897403,Collection of blood and tissue,,2006-12,COMPLETED,OBSERVATIONAL,['NA'],
593,NCT03400072,M6 Health-Related quality of life (HRQoL),,2018-08-03,RECRUITING,INTERVENTIONAL,['NA'],
594,NCT05564338,Recurrence-free survival (RFS) as assessed by the investigator between Arm B and Arm D,Participants Reported Outcome as measured at Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and its hepatocellular carcinoma cancer module QLQ-HCC18,2023-06-30,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
595,NCT06045975,local recurrence-free survival,Safety of Durvalumab/Tremelimumab infusions,2024-03-28,RECRUITING,INTERVENTIONAL,['PHASE2'],"Consittution of a sequential biobank comprising peripheral samples (serum, plasma)"
596,NCT00041808,,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
597,NCT01373164,Phase 2: Overall Survival (OS),Phase 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA19-9) Level at First Study Completion Follow-up,2011-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
598,NCT05668910,The performance of each single feature and the ensemble model with integrated features for early GC detection in each clinical stage,"The performance of the ensemble model in combination of possible GC related biomarkers such as PG, G17, and/or Hp levels for early GC detection",2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],
599,NCT01630174,,,2009-10,UNKNOWN,OBSERVATIONAL,['NA'],
600,NCT04988945,Downstaging for hepatectomy,Pathological response,2020-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
601,NCT00695201,Determine the MTD of hepatic arterial floxuridine (FUDR) & dexamethasone (Dex) given via implanted pump in combination w biweekly intravenous Oxaliplatin + systemic irinotecan (CPT-11) in patients w unresectable hepatic metastases from colorectal cancer.,"To procure normal and disease liver tissue for evaluation of TS, p53, p21, TOPO 1, DPD, and ERCC levels.",2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
602,NCT05208047,Part 2 - Progression Free Survival (PFS),Part 2 Only - European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30),2022-04-14,RECRUITING,INTERVENTIONAL,['PHASE3'],
603,NCT03663062,Risk model of colorectal adenomas and CRC,The incidence of colorectal adenomas or CRC in patients who are smokers or who have high alcohol intake,2017-12-27,COMPLETED,OBSERVATIONAL,['NA'],
604,NCT01529827,Transplant Related Mortality (TRM),Median Time to Neutrophil Engraftment,2012-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],
605,NCT03730675,Overall survival,"Treatment Safety in terms of type, incidence, severity timing, seriousness, and relatedness of adverse events and laboratory abnormalities",2018-11-10,UNKNOWN,INTERVENTIONAL,['NA'],
606,NCT04724239,The progression-free survival (PFS) rates at 18 weeks,Duration of response (DoR),2021-03-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
607,NCT05630937,Objective Response Rate (ORR) (Phase II),Overall survival (OS),2020-11-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
608,NCT05578820,Pharmacokinetics (Quantitative content of plasmid DNA (pTKhGM) in patients' urine),,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE1'],
609,NCT04844385,progression-free survival rate,Quality of life assessed by QLQ-C30,2021-02-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
610,NCT03841110,The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort.,Duration of FT500 persistence,2019-02-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
611,NCT03974542,rescreening of CRC,,2019-10,UNKNOWN,INTERVENTIONAL,['NA'],
612,NCT03492151,Accuracy of risk-stratification of IPMNs,Imaging quality,2018-10-01,RECRUITING,OBSERVATIONAL,['NA'],
613,NCT06239155,Progress free survival (PFS),,2019-09-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
614,NCT02465112,relapse-free survival (RFS),Impact of the therapy on 5-year RFS in treatment and control group,2015-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
615,NCT00632333,Safety(toxicities as assessed by NCI CTCAE version3),survival,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],
616,NCT05281783,The efficacy,Incidence of Treatment-Emergent Adverse Events [Safety],2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
617,NCT00005870,,,1999-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],
618,NCT05622357,Sphincter saving surgery,Disease free survival,2018-03-18,COMPLETED,INTERVENTIONAL,['PHASE2'],
619,NCT00563316,Number of Participants With Clinically Significant Adverse Events (AEs),,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
620,NCT03717519,Overall survival,Clinic-pathological variables,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],
621,NCT04050345,TRACC Part C (Randomised ctDNA guided adjuvant chemotherapy versus SoC study):,"Relationship between ctDNA detection before, during and after treatment",2016-12-05,RECRUITING,OBSERVATIONAL,['NA'],
622,NCT02526134,Patients rate in which a significant variation in the area to be irradiated will be observed between before evaluation and evaluation after laying the trustees.,Number of trustees (2 up 6 maximum) and set up their positions estimated success rate of implementation and the evaluation of the safety and toxicity (complications) associated with the establishment trustees (composite measure),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
623,NCT04936750,overall survival,,2021-06-17,RECRUITING,OBSERVATIONAL,['NA'],
624,NCT01661829,Incidence of anterior resection syndrome after stoma closure,,2012-03,COMPLETED,OBSERVATIONAL,['NA'],
625,NCT03693248,Progression free survival,days of management in intensive care unit,2018-12-19,UNKNOWN,INTERVENTIONAL,['PHASE3'],
626,NCT01617876,Diagnostic accuracy of enhanced ME (combining ME-NBI and ME-AIM),The relationships between the microsurface patterns and the histopathological findings,2010-03,COMPLETED,OBSERVATIONAL,['NA'],
627,NCT04110769,The rate of genetic mutation,oncologic outcome,2019-07-17,RECRUITING,INTERVENTIONAL,['NA'],
628,NCT05401045,Fatigue state using the Revised Piper Fatigue Scale (RPFS),Quality of life using the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC-C30),2023-01-20,COMPLETED,INTERVENTIONAL,['NA'],
629,NCT03055130,The different incidence of cervical neoplasm between controls and patients by performing Thinprep Cytology Test,Find drugs relating to HPV infection of IBD patients,2015-07,UNKNOWN,OBSERVATIONAL,['NA'],
630,NCT02508883,mortality,"Finding the cut-off value of highest sensitivity and specificity of Rockall, Glasgow-Blatchford and AIMS65 scores employing the receiver operating curve (ROC).",2015-04,COMPLETED,OBSERVATIONAL,['NA'],
631,NCT02839109,Tumor response,Disease free survival (DFS),2015-02,COMPLETED,OBSERVATIONAL,['NA'],
632,NCT01064999,toxicity,overall survival,2010-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
633,NCT00582296,"To assess adherence to comprehensive, multi-organ screening and risk-reducing behavior recommendations in patients with Lynch Syndrome.","To evaluate predictive factors for adherence to comprehensive, multi-organ screening and risk-reducing behavior recommendations.",2004-12,RECRUITING,OBSERVATIONAL,['NA'],
634,NCT00397384,MTD defined as the dose level at which fewer than 2 out of 6 patients experience DLT graded using CTCAE-v3,Antitumor effect observed,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
635,NCT00844064,To determine the maximum tolerated dose (MTD) as well as the dose-limiting toxicity (DLT) of two cycles of AP 12009 administered intravenously at weekly intervals and for four days every other week.,"To determine the potential antitumor activity of AP 12009 administered intravenously at weekly intervals and for four days every other week, as assessed by the effect on tumor size and tumor markers.",2005-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
636,NCT01369329,Number of Participants With Clinical Response at Week 6,Number of Participants With CDAI 70-point Response at Week 3,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
637,NCT00343239,"To determine the R0 resection rate for the treatment of locally advanced gastric carcinoma with Docetaxel, Cisplatin, Fluorouracil combination.",,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
638,NCT02219529,Number of gastric focal lesions founded by MCE Versus Standard Gastroscopy,Adverse events of both procedures,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
639,NCT01941173,"Feasibility of a shorter infusion time, determined by rate of greater or equal to grade 2 hypersensitivity reactions as graded according to CTCAE version 4.0","Incidence of grade 3 and above toxicities, graded according to CTCAE version 4.0",2014-01,WITHDRAWN,INTERVENTIONAL,['NA'],Time on protocol therapy
640,NCT03276091,Participation to the colonoscopy,cancer and adenoma detected,2017-05-23,COMPLETED,INTERVENTIONAL,['NA'],
641,NCT03277235,Self-report Questionnaire,Self-report Questionnaire,2017-09,UNKNOWN,INTERVENTIONAL,['NA'],Self-report Questionnaire
642,NCT01023412,Rate of post-operative complications,Rate of post-operative infectious complications,2006-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
643,NCT02649790,Part H: 2- Year Progression-free Survival (PFS),Part H: Overall Survival (OS),2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
644,NCT02510001,Maximal Tolerated Dose (MTD) of Binimetinib and PF-02341066,Pharmacokinetic Plasma t1/2 Etc for PF-02341066 and Binimetinib,2014-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
645,NCT00075218,Time to Tumor Progression (TTP) as Assessed in the Double-blind Treatment Phase at End of Study,Change From Baseline in EQ-5D Health State Profile Index,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
646,NCT05636085,Specificity,Positive predictive value and negative predictive value,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
647,NCT06194786,Dietary target-red meat,Disease free survival,2023-05-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
648,NCT05493956,Overall survival,Hepatobiliary symptom index,2019-04-01,RECRUITING,INTERVENTIONAL,['NA'],
649,NCT03292289,"Quality of life 1 year after the second intervention, using LARS score","Quality of life of patients with a second stoma placement, using LARS score",2018-01-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
650,NCT02062749,Maximum Tolerate Dose (MTD) of Oxaliplatin in Hyperthermic Intraperitoneal Chemotherapy,Differences in Genetic Aberrations in Pediatric Colon Cancer Patients and Adult Patients,2014-05-19,COMPLETED,INTERVENTIONAL,['PHASE1'],"Time to Recurrence After HIPEC in Pediatric, Adolescent and Young Adult Age Colon Cancer Patients"
651,NCT04233866,Overall survival (OS),Instrumental Activities of Daily Living (IADL),2020-08-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Geriatric assessment scores and biomarkers of aging (CRP and IL-6)
652,NCT00020579,Pharmacology and pharmacokinetics,Tumor response by CT scan every 12 weeks,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
653,NCT02673177,Incidence of sexual and urinary dysfunction,Anus preservation rate,2016-02,UNKNOWN,INTERVENTIONAL,['NA'],
654,NCT04400357,Percentage of patients with pancreatic adenocarcinoma who achieve administration of adjuvant chemotherapy at 8 weeks postoperatively,Comparison of perioperative inflammatory response (Interleukin-6),2020-06-15,UNKNOWN,INTERVENTIONAL,['NA'],
655,NCT05903456,Objective Response Rate,adverse event,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
656,NCT01215838,Accuracy of a new MR protocol in diagnosing HCC and other liver lesions.,,2010-08,TERMINATED,OBSERVATIONAL,['NA'],
657,NCT02419677,Recurrence-free survival,Adverse events,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
658,NCT01825824,Local control rate,Treatment related toxicity,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
659,NCT03472365,Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,Number of Subjects With Treatment-related Adverse Events (AEs),2018-04-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
660,NCT01942083,To investigate the maximum tolerated dose (MTD) of OPB-111077,Biomarker of OPB-111077,2013-05-29,TERMINATED,INTERVENTIONAL,['PHASE1'],
661,NCT05111314,Intraindividual intralesional difference in maximum standardized uptake value (SUVmax),Incidence of adverse events,2022-02-11,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],
662,NCT05517343,Proportion of definite depression cases,Depression score,2022-08-20,RECRUITING,INTERVENTIONAL,['NA'],
663,NCT00977613,Number of Participants Who Maintained an Exercise Regimen Average of 18 Metabolic Units (MET) Per Week or Greater,Overall Survival,2007-04,COMPLETED,INTERVENTIONAL,['NA'],
664,NCT02199912,biological and radiological markers,loss of fat body mass and/or lean body mass,2013-10-07,COMPLETED,INTERVENTIONAL,['NA'],
665,NCT02100696,"Maintenance Phase: Percentage of Participants With Remission at Week 66 Among Participants Who Had Achieved a Clinical Response at Week 14, as Determined by the MCS",Etrolizumab Serum Trough Concentration (for Arms/Timepoints Below LLOQ),2014-05-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
666,NCT05873829,Chemotherapy Induced Peripheral Neuropathy Symptoms Assessment,,2022-04-25,COMPLETED,INTERVENTIONAL,['NA'],
667,NCT03421912,Overall patient satisfaction after 30 days treatment,Use rate of dermocorticoids,2018-02-16,COMPLETED,INTERVENTIONAL,['NA'],
668,NCT01882868,Percentage of Participants With Overall Response,Volume of Distribution at the Steady State (Vss) for Irinotecan: Participants With Additional Blood Sampling for Detailed PK Analysis,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
669,NCT05064059,Overall Survival (OS),TTD in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score,2021-11-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
670,NCT04768660,Length of hospital stay,,2021-02-14,UNKNOWN,INTERVENTIONAL,['NA'],
671,NCT02079623,Tumor response,Overall survival,2013-11,COMPLETED,OBSERVATIONAL,['NA'],Pain registration
672,NCT05198609,Overall survival,Disease control rate,2022-01-17,RECRUITING,INTERVENTIONAL,['PHASE3'],
673,NCT05245331,LARS score,Adverse effects related to both treatments.,2022-08-04,RECRUITING,INTERVENTIONAL,['NA'],
674,NCT05797883,Objective response rate (ORR),Disease control rate (DCR),2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
675,NCT00900016,Independence of tumor fibroblast activation protein (FAP) activity and Met-α2-antiplasmin expression,Potential plasma surrogates of plasma dipeptidyl peptidase activity and plasma antiplasmin converting enzyme,2007-08,COMPLETED,OBSERVATIONAL,['NA'],
676,NCT04521153,The rate of subjects of major pathological response (MPR),Safety and toleraty,2021-03-25,RECRUITING,INTERVENTIONAL,['NA'],
677,NCT00233623,Time to progression (6 months after Last patient in),"Objective Response Rate, Duration of Response, Disease control rate, Overall Survival, (6 months after Last patient in)",2004-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
678,NCT03546985,Area under the curve (AUC) of pain score of oral mucositis,Incidence of adverse events,2017-12-26,COMPLETED,INTERVENTIONAL,['NA'],
679,NCT00510354,Tumor assessments should be performed by a CT or MRI scan after 4 months. Response to treatment with RAD001 plus Imatinib mesylate at 4 months (defined as progression-free survival (PFS) at 4 months).,Tolerability and safety assessed by AEs and SAEs. Objective tumor response rate (complete response [CR] and partial response [PR]) assessed by CT or MRI PFS at month 12 for patients with data available from follow up observation (optional),2006-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
680,NCT00466505,Progression-free Survival (PFS),Serum TGF-alpha: Treatment Cycle 2,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
681,NCT00541021,Progression-free survival,Biomarkers of response,2006-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],
682,NCT00538954,Recovery of gastrointestinal function: Time to pass flatus/stool (hours following the end of surgery),Patient activity level: measured by activPAL® activity meter,2006-08,COMPLETED,INTERVENTIONAL,['NA'],
683,NCT03045952,overall survival,disease free survival,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
684,NCT01472601,disease-free survival,,2011-05-24,UNKNOWN,OBSERVATIONAL,['NA'],
685,NCT03481296,Colorectal cancer screening test-specific adherence at 12 months (Colonoscopy),Change in knowledge about colorectal cancer and colorectal cancer screening between baseline and 6 months,2018-08-20,COMPLETED,INTERVENTIONAL,['NA'],
686,NCT06206278,Overall survival (OS),,2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE2'],
687,NCT00052897,,,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
688,NCT05488522,Primary Objective,Progression Free survival,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE1'],
689,NCT03287453,Self-reported intentions to engage in behavior change to reduce risk of colorectal cancer,,2017-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
690,NCT02581423,Incidence of treatment discontinuation due to AEs,Incidence of toxocity-related dose reductions,2005-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
691,NCT00005842,,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
692,NCT03862885,,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],
693,NCT05617378,Risk factor,,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],
694,NCT06189664,Detection of adenocarcinoma,,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],
695,NCT01797224,Major malformations,Infant follow-up,2012-03,RECRUITING,OBSERVATIONAL,['NA'],
696,NCT04266548,surgical benefit rate of fluorescent image,Post operative Mortality,2018-07-09,COMPLETED,INTERVENTIONAL,['NA'],
697,NCT02934529,Overall Survival,Safety and tolerance as measured by the NCI-CTCAE version 4.03 criteria,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
698,NCT03331406,Number of participants that adhered to physical activity program,Number of participants with adverse events,2017-12-01,COMPLETED,INTERVENTIONAL,['NA'],
699,NCT01912586,Changes in sexual function based on the (IIEF)-5 score and NPT,Compliance and overall patient satisfaction based on the self reported compliance diary and IIEF-5 score and NPT,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
700,NCT05710406,Disease free survival (DFS) (Phase III),Alternative disease free survival,2023-05-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']","• Patient Reported Outcomes Version of Common Terminology Criteria for Adverse Events for symptoms of rash, diarrhea, and fatigue"
701,NCT03231176,Objective Response Rate (ORR),Safety and tolerability of varlitinib when combined with capecitabine,2017-12-19,COMPLETED,INTERVENTIONAL,['PHASE2'],
702,NCT01782690,Overall Survival Stratified by Rash,Score in Participant Questionnaire: Quality of Life,2012-03-31,COMPLETED,OBSERVATIONAL,['NA'],
703,NCT02507882,"Specific miRNA levels and their association with degree of fibrosis, cirrhosis and HCC",,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],
704,NCT02323776,Postoperative complications,,2014-12,TERMINATED,OBSERVATIONAL,['NA'],
705,NCT00036400,Number of red blood cell transfusions,"Hemoglobin levels during preoperative chemoradiation; effect on quality of life measured by patient self-reported Linear Analog Scale Assessment, Functional Assessment of Cancer Therapy-Anemia, and Brief Fatigue Inventory; tumor response; safety",2001-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
706,NCT03217773,Short-term morbidity,Local recurrence,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
707,NCT01760356,Change in the Percentage of expression of IL-2 in CD4 and CD8 subsets of T lymphocytes.,Post transplant surgical complications,2011-05-01,TERMINATED,OBSERVATIONAL,['NA'],
708,NCT02545309,bile acid transporter genes,upper gastrointestinal bleeding episodes,2015-12-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
709,NCT03516994,Proportion of Whites who complete advance care planning,Patient Quality of Life,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
710,NCT00651742,Overall Tumor Response Rate (ORR),Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE),2006-01-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
711,NCT00548236,"To evaluate the ability of a multi-center, telephone-based physical activity intervention to increase weekly physical activity levels in sedentary patients treated with adjuvant chemotherapy for Stage I-III breast or colorectal cancer.","To evaluate the impact of a physical activity intervention upon fitness, exercise self-efficacy, anthropometric measures, and quality of life in a group of patients with stage I-III breast or colorectal cancer.",2007-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
712,NCT01095523,To compare the overall survival of patients at high risk for developing peritoneal carcinomatosis from colorectal cancer who undergo mandatory second look surgery + HIPEC and CRS (if applicable) vs. similar patients who receive standard of care.,To determine recurrence-free survival in both arms. To investigate selection criteria for patients who might benefit from a strategy of MSLS with CRS + HIPEC.,2010-01-14,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
713,NCT04666090,Pathological Complete Response (PCR),The changes in the peripheral blood immunoprofile among non-PCR (NPCR) and PCR patients,2020-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
714,NCT00103324,Confirmed response probability (complete and partial),Overall survival,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
715,NCT00416494,Response Rate (Percentage of Participants With Partial or Complete Response),Safety and Tolerability,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Effect on Wound Angiogenesis
716,NCT02284529,To evaluate the incidence of grade 0-3 neurosensory symptoms (paresthesia) in the end of study,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
717,NCT02991638,Adverse events and severe adverse events,,2016-11-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
718,NCT01972490,the rate of patients converted to resection for liver metastases,tumor response,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
719,NCT02041897,Rate of change of diagnosis,Number of Participants with Adverse Events,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],
720,NCT05996276,Overall survival (OS),Progression-free survival (PFS).,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],
721,NCT00388037,Objective Response (Partial Response or Complete Response) as Per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
722,NCT02817425,Overall Survial (OS),Dose intensity,2013-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
723,NCT05944237,Number AEs Related to Atezolizumab (Dose Escalation and Expansion Phase),Assess change in tumour T cell infiltration in baseline and on-treatment biopsies,2023-07-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
724,NCT04127734,1-year stomafree survival,1 year mortality,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA'],Hospital related costs
725,NCT05982184,Patient reported anxiety measured by the 6-item Spielberger State-trait Anxiety (STAI-6) inventory at admission.,Quality of recovery is a comprehensive 40-item questionnaire (QoR-40) used to assess the rate of recovery after surgery.,2023-10-03,RECRUITING,INTERVENTIONAL,['NA'],Rate and type of complications during surgery as recorded in the EHR
726,NCT04519138,Proportion of patients with pre-specified adverse events,Amount of visible biopsy material over or under 5 mm at endoscopy examination,2020-09-30,COMPLETED,INTERVENTIONAL,['NA'],
727,NCT04624555,Participant acceptance of mt-sDNA as a follow up strategy compared to colonoscopy as measured by the Stool Test Satisfaction Survey.,,2024-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
728,NCT03792854,Qol (EORTC QLQCR29) absolute values and change over time,late toxicity,2018-12-01,RECRUITING,OBSERVATIONAL,['NA'],
729,NCT03957902,Assessment of changes in acetylation levels of COX enzymes in platelets and non-neoplastic and neoplastic colonic tissues,Assessment of changes in major urinary metabolite of PGE2 (PEG-M) levels depending on drug dosis,2019-05-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
730,NCT06137170,Overall Survival (OS),"Proportion of patients in the sequential treatment groups who received myelopoiesis supporting therapy, differentiating between prophylactic and for therapeutic purpose",2024-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
731,NCT00416858,,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],
732,NCT00020345,,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
733,NCT03550625,Assessment of the computer- made optical diagnosis of each colorectal polyp,,2018-07-15,UNKNOWN,OBSERVATIONAL,['NA'],
734,NCT03811431,Number of patients in whom contrast enhanced ultrasound guided liver biopsy leads to the final diagnosis as compared to conventional ultrasound guided liver biopsy. The final diagnosis will be assessed based on histological examination.,,2011-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
735,NCT01569282,Morbidity,"The numbers of Surgical, Radiological or Endoscopical therapeutic re-interventions",2011-10,WITHDRAWN,INTERVENTIONAL,['NA'],
736,NCT03516695,Effectiveness of TheraSphere® treatment in participants with liver cancers in a real-life setting,TheraSphere® Dosimetry in the subgroup of HCC participants,2018-02-23,TERMINATED,OBSERVATIONAL,['NA'],
737,NCT02145013,Mortality,Survival outcomes,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],Impact of PET CT on overall survival following liver resection
738,NCT05608200,Overall survival (OS),Adverse Events (AEs),2022-11-02,RECRUITING,INTERVENTIONAL,['PHASE3'],
739,NCT04359732,Imaging parameters as potential predictors of tumor response,Early regression model (ERI),2020-05-08,RECRUITING,INTERVENTIONAL,['NA'],
740,NCT05956990,Fear of Progression Questionaire-Short Form (FoP-Q-SF),Platelet count,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
741,NCT05732623,Diet and the risk of eoCRC,,2022-12-05,RECRUITING,OBSERVATIONAL,['NA'],
742,NCT02057471,Hemoglobin levels,C Reactive Protein levels,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of adverse events associated with intravenous iron infusion
743,NCT05239741,Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) For RAS Wild-type Participants,Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE),2022-04-02,RECRUITING,INTERVENTIONAL,['PHASE3'],
744,NCT03382327,Comparison of the intra-operative modifications rates,Preoperative images independent analysis,2017-10-16,COMPLETED,INTERVENTIONAL,['NA'],
745,NCT04013841,Intestinal microbiome composition,Intestinal microbiome composition,2021-04-08,COMPLETED,INTERVENTIONAL,['NA'],
746,NCT00838656,Percentage of patients completing 12 courses of chemotherapy,Rates of optimal and suboptimal interval debulking,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
747,NCT02437656,The efficacy will be assessed on the operative specimen by the complete histological response rate (absence of tumor cells : pCR).,Sphincter preservation rate and downstaging rate,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
748,NCT00826410,number of surgical site infections according to CDC guidelines after laparotomy in general surgery,risk factors for surgical site infections,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
749,NCT01572987,Complete histological eradication of Barrett's esophagus,Complication rates,2011-09,TERMINATED,INTERVENTIONAL,['NA'],
750,NCT01905384,Rate of Long-term Stent Failure,Rates of Adverse Stent-related or Intervention-related Outcomes,2017-11-08,COMPLETED,INTERVENTIONAL,['NA'],
751,NCT00140036,Correlation of genotype with safety and efficacy measures.,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
752,NCT02890355,Overall Survival (OS),Duration of Response (DoR),2016-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Genomic Alterations Identified by the BROCA-homologous Recombinant (HR) Assay
753,NCT06215651,Conversion success rate,Overall survival,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE2'],
754,NCT00049400,dose defining,Symptomatic deterioration,2003-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
755,NCT00637091,Response rate,"Progression free survival, overall survival",2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
756,NCT05366816,Number of Participants Achieving Overall Response,Incidence of Treatment-Related Toxicity and Adverse Events,2023-10-17,RECRUITING,INTERVENTIONAL,['PHASE2'],
757,NCT05018208,Quantification of false alerts and downstream clinical actions (Arm 2),Point-in-time assessment of physiological signals from standard of care devices (Arm 1),2021-12-15,RECRUITING,OBSERVATIONAL,['NA'],
758,NCT06149481,Phase II: Overall response rate (ORR) defined as the CR+PR of the IO regimen in mCRC,Overall survival,2024-03-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
759,NCT05643105,Anastomotic leak,Local recurrence,2022-12-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Intraoperative complications
760,NCT05265663,Overall survival,Progression of disease (local and distant),2020-10-13,RECRUITING,INTERVENTIONAL,['NA'],
761,NCT02644148,Quality of life,Complications,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],
762,NCT01384240,to determine whether tissue in nepoplastic or non-neoplastic,,2010-04,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],
763,NCT03076216,Safety / Tolerability of Device as determined by the number of treatment emergent adverse events (TEAEs) evaluated according to CTCAE V4.0,Pain Scores,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],Tumor Response
764,NCT01375738,Blood sugar stabilization after gastrectomy,,2011-07,UNKNOWN,INTERVENTIONAL,['NA'],
765,NCT03242369,Quality of bowel cleansing according to Boston Bowel Preparation Scale (BBPS),Detection of colorectal neoplasia,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],
766,NCT05415475,Obtain the maximum tolerated dose of CEA-CAR-T cells[Safety and Tolerability],Pharmacodynamics of CEA-CAR-T cells[Cell dynamics],2021-09-10,RECRUITING,INTERVENTIONAL,['PHASE1'],Changes in the number of tumor-infiltrating immune cells of CEA- CAR-T treatment in patients with CEA-positive
767,NCT06202781,Single-cell profiling,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],
768,NCT01941641,Objective tumour response rate,Number of response to neoadjuvant therapy,2013-10-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
769,NCT01464593,Determine the Local Tumor Control at 1 Year Post Randomization,Overall Survival,2011-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
770,NCT05311319,Disease Free Survival (DFS),Safety: adverse events,2022-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],
771,NCT00973440,To determine the feasibility and added clinical utility of a self-administered computer-based version of an abbreviated comprehensive geriatric assessment tool.,,2009-03,COMPLETED,OBSERVATIONAL,['NA'],
772,NCT05584540,Enrollment Rate,CSQ-I Score,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Ratings
773,NCT04833387,Pathological complete response,Clinical complete response (CCR),2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
774,NCT00103168,Overall survival,Adverse events,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
775,NCT04479527,PFS,Incidence of AE and SAE,2021-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],
776,NCT01955096,food intake time,readmission,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
777,NCT02141295,"Progression-free Survival (PFS), Time to Event",Cmax Accumulation Ratio (AR) of Vanucizumab,2014-06-30,TERMINATED,INTERVENTIONAL,['PHASE2'],
778,NCT06065059,Measure anti-tumor activity using RECIST 1.1 (Phase 2 only),Assess changes in levels of ubPCNA in response to TNG348 as single agent or in combination,2023-12-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
779,NCT00077519,,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
780,NCT00727831,Incidence and severity of CNS toxicity and neurocognitive changes taken from patients' medical records and measured using the Mini-Mental State questionnaire and MRI data,Incidence of antibodies to glucarpidase measured serologically at the start of each methotrexate course and at follow-up visits if present during therapy,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
781,NCT05291988,Demographic information,COVID-19 impact assessment,2022-10-08,TERMINATED,INTERVENTIONAL,['NA'],
782,NCT00707681,To evaluate Quality of Life (QoL) score of MS-20 versus placebo in advanced HCC patients,"Overall survival, Overall survival rate, Change from baseline of the highest weight observed, Change from baseline of body weight",2008-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
783,NCT03563248,Proportion of participants with R0 resection,Number of participants with treatment related serious adverse events,2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
784,NCT02630420,Safety and tolerability based on regular clinical assessment and NCI Common Terminology Criteria for Adverse Events,Progression free survival,2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],"Changes in genetic aberrations over the course of the disease by comparing archival, baseline and progression samples."
785,NCT04947826,Objective response rate,Overall survival rate at 12-month time point,2021-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Discontinuation rate due to any adverse events
786,NCT02112747,Successfully following screening guidelines appropriate to the participant's risk profile,Cost effectiveness of the interventions,2013-09,COMPLETED,INTERVENTIONAL,['NA'],
787,NCT06017323,Proglumide Recommended Phase II dose and schedule (RP2D),Change in tumor marker (CA19-9),2023-10,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
788,NCT05727787,Maximum tolerated dose (MTD) of Single Fraction GRID SBRT,Molecular correlatives: TCR repertoire analysis.,2023-02-23,RECRUITING,INTERVENTIONAL,['NA'],
789,NCT00321100,Objective Response Rate (ORR),Overall Survival,2006-04-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
790,NCT05510895,Tumor regression grade (TRG),Translational research 3,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
791,NCT03532204,Progression Free Survival,Quality of life EORTC QLQ CR29,2019-04-15,WITHDRAWN,INTERVENTIONAL,['NA'],
792,NCT01658878,ORR for Nivolumab plus Ipilimumab plus Cabozantinib Combination Cohort,Effective T-Half of nivolumab,2012-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
793,NCT04861987,Maximum Plasma Concentration (Cmax) of capecitabine,Number of participants with Adverse Events of Special Interest (AESI),2021-06-18,RECRUITING,INTERVENTIONAL,['PHASE1'],
794,NCT04873895,Serious adverse event (SAE) rate,axitinib treatment intensity,2022-01-24,RECRUITING,INTERVENTIONAL,['PHASE1'],
795,NCT05158374,"Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel",Change in the proportions of bacterium the colorectal microbiome after aspirin and/or metformin medication,2022-08,UNKNOWN,INTERVENTIONAL,['NA'],
796,NCT00199797,"Safety as Measured by the Number of Patients With Treatment Emergent Adverse Events (TEAEs), Grade 3 TEAEs, TEAEs Resulting in Death, TEAEs Related to Treatment and Serious TEAEs in Patients With Metastatic Colorectal Cancer.","Tumor Response in Patients With Metastatic Colorectal Cancer Receiving huA33, Oxaliplatin and 5-FU Plus Leucovorin.",2005-04-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
797,NCT04640103,Adverse event rate,Incidence of second tumor in patients with Lynch syndrome,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
798,NCT02062515,Number of Participants with Adverse Events,,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],
799,NCT02195011,The Number of Participants With Treatment-Related Adverse Events and Serious Adverse Events as a Measure of Safety,Median Overall Survival,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
800,NCT00683085,Number of Participants Without Grade 4 Hematological or Grade 3 to 4 Non-hematological Adverse Events,Number of Participants With Tumor Regression,2008-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
801,NCT05162118,RP2D (phase 1),CEA,2022-03-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
802,NCT05682794,disease-free survival ratev,DRM status,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
803,NCT01341132,,,2011-05,UNKNOWN,OBSERVATIONAL,['NA'],
804,NCT04615013,Maximum tolerated dose and recommended phase 2 dose (RP2D),Overall survival,2020-11-23,RECRUITING,INTERVENTIONAL,['PHASE1'],Concordance of cell free deoxyribonucleic acid (DNA)
805,NCT05890742,"Event Free Survival, EFS(EFS), defined as the time from randomization to the first determination using RECIST v1.1 of inoperable disease progression, local recurrence or distant metastasis after surgery, or death from any cause, whichever occurs first.","Overall-survival(OS), defined as the time from randomization to death from any cause",2023-05-25,RECRUITING,INTERVENTIONAL,['PHASE3'],
806,NCT06246630,Objective Response Rate,Concordance between drug sensitivity test results and patients' treatment response,2024-02-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
807,NCT05395780,Objective response rate (ORR),Correlation between expression level and mutation of FGFR1OP2-related proteins and efficacy,2022-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
808,NCT03702491,PFS,,2018-08-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
809,NCT05709197,Delayed gastric emptying (DGE),Functional outcome at 12 months,2023-04-17,RECRUITING,INTERVENTIONAL,['NA'],
810,NCT01325883,The relative decrease in exercise capacity (LT) associated with NAC prior to upper gastrointestinal cancer resection will predict outcome (1 year mortality) following surgery.,Patients whose LT changes following NAC so that they move into a higher risk category will have a worse outcome (1 year mortality) when compared with those who do not increase risk category.,2011-04,COMPLETED,OBSERVATIONAL,['NA'],
811,NCT06236464,Primary Endpoint,Secondary Endpoint,2023-09-25,RECRUITING,OBSERVATIONAL,['NA'],
812,NCT05502198,MELD-score,Quality of life (Questionnaire),2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],
813,NCT00980382,"*phase I study:the maximum tolerated doses (MTD)of S-1 and docetaxel,recommended dose for subsequent phase II study *phase II study: evaluation of efficacy and toxicities of this new combination regimen in metastatic",To investigate the time to progression and overall survival,2004-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
814,NCT00832637,Tumor Control Rate,Toxicity,2007-08,TERMINATED,INTERVENTIONAL,['PHASE2'],
815,NCT05178576,Recurrence-free survival (RFS) at one year,Immunogenicity,2022-06-24,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
816,NCT03487523,Number of participants taking part in the Scottish national bowel cancer screening programme,,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA'],
817,NCT03542214,Safety of the calcium electroporation procedure in colorectal cancer (registration of adverse events; CTCAE v4 will be used),Tumorregression,2018-04-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
818,NCT02724358,Time to progression,,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
819,NCT00075686,Overall survival comparison between treatment groups,"Pain and quality of life comparison between treatment groups as measured by patient questionnaire at baseline, before each course, and then completion of study treatment",2004-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
820,NCT00220051,Acute toxicity has been evaluated in previous phase I studies and should occur to a similar extent.,Bowel function and quality of life,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
821,NCT01192763,Frequency and severity of adverse events as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE),"Proportion of cancer stem cells (CD44+, CD24+, ESA+ population of cells) self-renewal and tumorigenesis as measured by FACS",2010-08,TERMINATED,INTERVENTIONAL,['PHASE1'],
822,NCT02558868,Overall Survival,Progression Free Survival,2015-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
823,NCT05138159,Overall Survival,Incidence of Adverse Events,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
824,NCT01993472,Progression free survival (PFS),Quality of Life,2013-11,TERMINATED,INTERVENTIONAL,['PHASE2'],
825,NCT02948426,Overall Maximum Tolerated Dose of Actimmune (Interferon Gamma-1b),Time to Disease Progression,2017-02-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Participants With a Grade 3 or Higher Dose-Limiting Toxicity (DLT)
826,NCT01334710,Comparison of MRI/CT Scans to Pre-treatment Scan,Toxicity Assessment,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
827,NCT05113459,"pathologic Complete Response, PCR","Overall survival , OS",2021-12-18,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
828,NCT06270017,Tumour growth,response evaluation,2022-01-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
829,NCT06269978,Half-life,Overall response rate,2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE1'],
830,NCT05679583,R0 rate,Tumor recurrence,2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],
831,NCT01265576,failure free survival,clinical benefit response,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
832,NCT06181318,Predicting the posthepatectomy hemorrhage after major liver resection,Correlation between remnant liver function after major liver resection and postoperative mortality,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
833,NCT03254121,"Characterisation of genomic mutations of HCC, developed in HCV patients with SVR",,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],
834,NCT00251186,To measure the response (CR/PR) for a novel chemotherapy/biologic combination-capecitabine/cetuximab for patients with metastatic colorectal cancer who are too fragile for more intensive chemotherapy doublet regimens.,To describe the baseline quality of life and functional characteristics of elderly patients or those with multiple comorbidities enrolled in this study and assess the impact of disease and its treatment on such functional characteristics.,2006-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
835,NCT04111029,Serial Quantification of ctDNA in plasma samples by means of real-time PCR post treatment,Mortality,2020-01-16,RECRUITING,OBSERVATIONAL,['NA'],
836,NCT04118933,objective response rate,,2019-07-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],
837,NCT03478488,Overall Survival (OS),Time to progression (TTP),2018-04-16,RECRUITING,INTERVENTIONAL,['PHASE3'],
838,NCT00515853,Cleveland Clinic Incontinence (CCI) Score,,2006-11-27,COMPLETED,INTERVENTIONAL,['NA'],
839,NCT00238394,Time to disease progression,Laboratory measures,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
840,NCT04757311,Progression Free Survival (PFS),Advers events,2020-08-01,COMPLETED,OBSERVATIONAL,['NA'],Percentage of use biologics in right side tumors.
841,NCT00899002,Identification of proteomic profiles and molecular pathways involved in tumor progression,Association between fibrolamellar carcinoma and hepatocellular carcinoma in terms of molecular aberrations and clinicopathologic features,2007-07,WITHDRAWN,OBSERVATIONAL,['NA'],
842,NCT01954732,"Pancreatic tumor cell proliferation and apoptosis as measured by the percentage of cells Ki-67+, percentage of cells TUNEL+, and mitotic counts in tissue samples",Percentage of pancreatic cancer stem cells in tissue samples,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
843,NCT05982197,Change in severity of radiation induced mucositis,,2023-01-03,COMPLETED,INTERVENTIONAL,['NA'],
844,NCT02892305,Overall Survival,Intraoperative estimated blood loss,2018-05-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
845,NCT06078709,Pathologic complete response,Toxicity of chemoradiation between groups receiving proton based versus photon-based radiotherapy,2023-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
846,NCT03149978,TRG,Number of participants with chemoradiation-related adverse events as assessed by CTCAE v4.0,2014-07-01,UNKNOWN,OBSERVATIONAL,['NA'],
847,NCT01576380,disease control rate (DCR),progression free survival (PFS) per independent central review,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
848,NCT05759923,Occurence of DLTs,PK parameter: AUCO-24,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE1'],
849,NCT05891028,Standardized uptake value,Adverse events collection,2023-05-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
850,NCT03433092,Gastrointestinal Tract Cancer Incident Measure,,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],
851,NCT05824403,Diagnostic tools,Clinical data access,2023-11-28,RECRUITING,OBSERVATIONAL,['NA'],
852,NCT01744340,"If Eribulin Mesylate, up to a Maximum Dose of 1.4 mg/m2 Day 1 and 8 of a 21 Day Cycle, Can be Safely Combined With Full Dose Cetuximab for Patients With Advanced Head and Neck Cancer and Colon Cancer.",Response Rate (Whether Patient's Disease is Progressing or Being Controlled) of Patients With Head and Neck Cancer Treated With Eribulin Mesylate and Cetuximab.,2012-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
853,NCT05804799,Measurement of standard deviation of CT attenuation values at the liver,Sensitivity to detect malignant liver tumor,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],
854,NCT02494388,Accuracy of EUS-guided nCLE in a cohort of cystic pancreatic tumors,Number of participants with adverse events as a measure of safety,2015-06,TERMINATED,OBSERVATIONAL,['NA'],
855,NCT05802056,Incidence of adverse events,Overall survival,2023-11-29,RECRUITING,INTERVENTIONAL,['PHASE1'],
856,NCT05160168,"Expansion (Phase 2): Efficacy Assessment - For each expansion phase cohort (Cohorts 1, 2, and 3), confirmed objective response rate (ORR), according to modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",Expansion (Phase 2): Plasma PK parameters of THE-630 and its active metabolite - AUC 0-t (area under the concentration-time curve from time zero to time t),2022-01-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
857,NCT01839604,Number of Participants With Dose Limiting Toxicities During Cycle 1,"Evaluation of Pharmacokinetics (PK) of AZD9150 (Following Single Administrations in Patients With HCC) by Determining Tmax, Using the Plasma Concentration Data.",2013-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
858,NCT04309747,Effectiveness analysis,Secondary validity analysis,2020-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
859,NCT03402607,Change in Quality of Life (QOL) Using EORTC C-30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30),The Total Healthcare System Costs Associated With PLA vs HIGRT,2018-08-08,TERMINATED,INTERVENTIONAL,['NA'],
860,NCT04145388,Number of patients identified at high risk of cancer,,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
861,NCT04656249,Progression free survival (PFS),The Rate of Treatment Related Adverse Events,2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Clinical benefit rate (CBR)
862,NCT05099549,Phase 2a/Expansion,Phase 2a/Expansion,2021-11-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
863,NCT02859155,Survival,Recurrence,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
864,NCT02885727,Improvement in median Progression Free Survival using the combination of RT and durvalumab.,,2017-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
865,NCT03587818,The Longitudinal Preparedness for Colorectal Cancer Surgery Questionnaire (PCSQ),Behaviour pertaining when and how to seek health care for recovery support: Visits at outpatients clinics,2012-11-01,COMPLETED,INTERVENTIONAL,['NA'],
866,NCT02420509,Progression-Free Survival,Quality of Life,2015-08-27,TERMINATED,OBSERVATIONAL,['NA'],
867,NCT05802394,Resection rate,Major pathological response,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],The prognostic role of targeted therapy selected based on MRD
868,NCT02133079,electrocardiogram,changes in antigen specific T cells,2012-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change from baseline in subpopulation of CD8+ T cells at the end of vaccination
869,NCT03030404,Characterization of the natural and clinical histories of hereditary gastric cancer syndromes,,2017-01-27,RECRUITING,OBSERVATIONAL,['NA'],
870,NCT03542799,Safety: Occurrence of study related adverse events,Effectiveness: duration of in vivo survival of EGFR CART,2018-05-22,UNKNOWN,INTERVENTIONAL,['PHASE1'],
871,NCT05600335,incidence of various postoperative complications,radicality of surgery,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],
872,NCT03883919,Tolerability between two different dose levels of paricalcitol added to the combo regimen of liposomal irinotecan plus 5-FU / LV as measured by the occurrence of grade 3 and 4 toxicities,Duration of stable disease,2019-07-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
873,NCT02100254,Change in likelihood of CRC screening in previously unscreened subjects,"Influential factors in behavior changes, assessed using qualitative analyses of text from participant interviews, including affective associations with the program, participants' cognitive-affective influences, and predisposing influences",2009-10-01,COMPLETED,INTERVENTIONAL,['NA'],
874,NCT00950144,"Relationship among characteristics (i.e., sociodemographic, disease, health status) associated with illness perceptions, overall symptom distress, and QOL)",,2008-12,COMPLETED,OBSERVATIONAL,['NA'],
875,NCT00004873,,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
876,NCT00394615,To learn whether new medical imaging technology can help predict the response of rectal cancer to preoperative chemotherapy and radiation therapy.,,2003-10,TERMINATED,INTERVENTIONAL,['NA'],
877,NCT02413437,diagnostic accuracy,,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],
878,NCT02831179,Maximum tolerated dose determined by dose limiting toxicities defined as any toxicity in the first course evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,Poly-adenosine diphosphate (ADP)-ribosylated (PAR) level,2017-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
879,NCT05031975,"To assess the activity in terms of seroreversion of TEMIRI consolidation regimen administered to patients with high-risk stage II (pT4) or III MSS, MGMT silenced CRC and positive post-adjuvant ctDNA after standard oxaliplatin-based adjuvant chemotherapy.",Quality of life as assessed using the Euro Quality of Life 5 Dimensions Questionnaire (EQ-5D-5L),2022-05-02,RECRUITING,INTERVENTIONAL,['PHASE2'],To assess the accuracy of ctDNA as disease recurrence biomarker
880,NCT01009593,Overall Survival,Overall Response Rate (ORR),2010-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
881,NCT06192862,CRC screening uptake rate,qualitative factors checklist associated with CRC screening,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
882,NCT04417764,Incidence of Adverse Events,Overall Survival,2019-06-20,RECRUITING,INTERVENTIONAL,['PHASE1'],
883,NCT01927978,"The effectiveness of 18F-FDG PET in the initial staging, therapy planning, and therapeutic response monitoring for esophageal cancer patients.",,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],
884,NCT05954871,Number of Participants with Dose-Limiting Toxicities (DLTs),Progression-Free Survival (PFS) After Enrollment as Determined by Investigator According to RECIST v1.1,2024-01-08,RECRUITING,INTERVENTIONAL,['PHASE1'],
885,NCT00064181,,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
886,NCT02827786,"EMA (colour scale) images will be compared to baseline US grey-scale images for a specific target lesion, as determined by standard of care imaging (US, CT, MRI or PET) and/or histologically proven lesion in a given subject.",US grey-scale and EMA colour maps will be obtained from both target liver lesions and background liver tissue from the same subject and compared.,2016-09,UNKNOWN,INTERVENTIONAL,['NA'],
887,NCT05136326,To evaluate the rate of complete pathologic response (pCR),"To assess the incidence, nature, and severity of adverse events",2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
888,NCT02353936,response rate,Progression free survival,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
889,NCT02409199,Progression-free survival (PFS),Safety (incidence of adverse events),2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
890,NCT05775939,Change in mean standardized uptake value (SUV) changes in the heart,Cardiac related death,2023-01-20,RECRUITING,INTERVENTIONAL,['NA'],
891,NCT03924466,Feasibility and added value of 68GaNOTA-Anti-HER2 in neoadjuvant setting of breast carcinoma,Influence image-guide biopsy on patient management,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
892,NCT03693846,Number of Participants With Progression-Free Survival at 6 Months,Duration of Response,2019-02-15,TERMINATED,INTERVENTIONAL,['PHASE2'],
893,NCT00587314,Response to treatment,,2004-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
894,NCT04918459,Death adjusted cumulative incidence of rebleeding at 30-day,Mortality rate at 6 months,2021-08-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
895,NCT00360971,Duration of Oral Mucositis as Measured in Terms of Days,Time to Second Primary Tumor,2006-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
896,NCT00889343,To compare the PFS between patients receiving chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo,Safety,2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
897,NCT04264260,survival,serious adverse effect,2019-12-24,RECRUITING,INTERVENTIONAL,['PHASE2'],
898,NCT03708783,the incidence of postoperative complications within 30 days,3-year disease free survival,2018-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
899,NCT00914537,High resolution anoscopy,,2009-06-02,COMPLETED,OBSERVATIONAL,['NA'],
900,NCT06327386,Evaluation efficacy of tumor regression level,SUV,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],
901,NCT04742959,Dose limiting toxicity (DLT),Volume of Distribution (Vd),2021-03-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Genetic Alteration Status
902,NCT06324032,Evaluation of EUS-E accuracy quantitative,"Complication rate (perforations, bleeding) of the procedure",2020-12-17,RECRUITING,OBSERVATIONAL,['NA'],
903,NCT05052671,Progression free survival (PFS),Overall survival (OS) in ctDNA positive versus ctDNA negative.,2022-05-25,RECRUITING,OBSERVATIONAL,['NA'],
904,NCT03023436,2-year Median survival time,Morbidity and mortality,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Molecular biomarker alteration
905,NCT00515216,Overall Response Rate (ORR),Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease),2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
906,NCT00003531,Number of Participants With Objective Response and Stable Disease,,1996-04-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
907,NCT05821361,Overall response rate ( ORR) per RECIST 1.1,Disease Control Rate (DCR) per RECIST 1.1,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
908,NCT02565017,Acceptability of IBM Watson Oncology,,2015-09-15,COMPLETED,OBSERVATIONAL,['NA'],
909,NCT02314052,Phase 2: Preliminary Antitumor Activity,AUClast (hr*ng/mL) - DCR-MYC Levels in Blood (Phase 1b Only): Dosing Day 1 and Day 8,2015-01-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
910,NCT02173353,Evaluate the use of ultrasound to detect motion of pancrease and surrounding structures,Quality of ultrasound imaging for Pancreas,2014-02,COMPLETED,OBSERVATIONAL,['NA'],Assess organ motion and compare in conjunction with magnetic resonance imaging or CT
911,NCT03666442,tumor area in endoscopy,tumor thickness in TRUS,2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
912,NCT01987726,Proportion of patients who have multiple options recommended,Presence of any oncogene or tumor suppressor gene mutations or amplifications identified by NGS on tumor tissue in each cohort,2013-09-03,COMPLETED,OBSERVATIONAL,['NA'],
913,NCT01225523,Progression-free survival,Rate of local recurrences and metastasis,1997-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
914,NCT02238613,Tumor Response rate,Adverse events,2014-08,UNKNOWN,INTERVENTIONAL,['NA'],
915,NCT00242788,Objective tumour response (CR and PR) at study closure based on the RECIST,"Incidence of controlled disease (CR, PR and SD) at study closure",2004-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
916,NCT02456285,Adherence to an evidence-informed common pathway assessed using guidelines suggested by the European Society of Medical Oncology (ESMO),,2015-05-20,COMPLETED,OBSERVATIONAL,['NA'],
917,NCT01113736,If there is a decrease on adhesion formation of AlloMEM™ used in formation of a temporary loop ileostomy.,Decrease in operative time and a promotion of peritoneal remodeling,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
918,NCT04443816,Loss of health related quality of life (HRQL),Disability,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],
919,NCT04281511,progressive-free survival,,2019-04-03,COMPLETED,OBSERVATIONAL,['NA'],
920,NCT01384227,To determine whether tissue is neoplastic or non-neoplastic,,2009-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
921,NCT06148298,Level of c-ERBB1 in blood using Chromatin immunoprecipitation and Reverse transcription-quantitative polymerase chain reaction,,2023-05-24,RECRUITING,OBSERVATIONAL,['NA'],
922,NCT01905969,Relapse free survival,,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],
923,NCT03566056,"Hypotension, defined as mean arterial bloodpressure <65 mmHg, measured by invasive arterial blood-pressure, the first morning after surgery at 06.00 (AM)",,2018-01-18,COMPLETED,OBSERVATIONAL,['NA'],
924,NCT04625543,Major Pathological Response (MPR) rate,The incidence of adverse events,2020-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
925,NCT01077739,Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression,Geometric Mean Values of Pro-Angiogenic Cytokine Concentrations at Baseline and Prior to Progression,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
926,NCT03857815,PFS,ORR,2019-03-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],
927,NCT03117023,sleep time,side effects,2017-04-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],
928,NCT02454790,Late toxicity,Loco-regional tumor control,2014-09,RECRUITING,OBSERVATIONAL,['NA'],Patient-rated symptoms and Quality-of-Life
929,NCT00719641,Number of Participants Without Re-looping Among Those With Looping,,2008-08-05,COMPLETED,OBSERVATIONAL,['NA'],
930,NCT05377034,Best Overall Response Rate (BORR) at 12-months post-randomization.,Quality-adjusted life years at 18 months.,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Occurrence of adverse events leading to death.
931,NCT03435536,Kinetic of circulating tumor DNA evaluation in resected pancreatic cancer.,Correlation between circulating tumor DNA rate and Ca19.9 dosage,2018-02-26,COMPLETED,INTERVENTIONAL,['NA'],
932,NCT01978808,the overall diagnostic accuracy rate of both needles,,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],
933,NCT03090139,Time-to-first Indicator of Sub-optimal Therapy,Physician Survey Questionnaire,2017-03-28,COMPLETED,OBSERVATIONAL,['NA'],
934,NCT00801320,To gain experience in appropriate clinical processing of tumor samples and determining cell yield.,"Based on feasibility of collection of blood samples of subjects, quantification of T cell subsets, regulatory T cells, activated memory effector cells, and DC phenotype at pre-surgery and post-surgery time points.",2008-09,COMPLETED,INTERVENTIONAL,['NA'],
935,NCT02319187,progression free survival,quality of life,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],
936,NCT06165380,Objective Response Rate,Safety,2023-10-23,RECRUITING,INTERVENTIONAL,['PHASE2'],
937,NCT00585221,Time to Progression (TTP).,,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2'],
938,NCT02246049,Progression-free survival (PFS) at 10 months,Treatment duration,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
939,NCT00660205,,,2008-02,COMPLETED,OBSERVATIONAL,['NA'],
940,NCT03385577,Program Acceptability - Plan to continue intervention exercises after completion of the study,Depressive Symptoms,2018-02-05,COMPLETED,INTERVENTIONAL,['NA'],
941,NCT00003704,overall survival,,1999-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
942,NCT03829969,OS,Patient-Reported Outcomes collected via the EORTC QLQ-OES18,2019-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
943,NCT02385630,Post-prandial satiety gut hormone area under the curve,Fasting ghrelin concentration,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
944,NCT03221127,Death,Infectious disease,1984-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
945,NCT00630084,"Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.",Safety - adverse event rate and profile,2006-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
946,NCT05699655,Pathological complete response,Objective Response Rate (ORR),2023-05-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
947,NCT05595122,Stentdysfunction after technical successful EUS-CDS,Costs,2022-12-02,RECRUITING,INTERVENTIONAL,['NA'],
948,NCT05447715,Sequential treatment of PFS with furoquitinib in second-line (F-C group) versus third-line (C-F group),,2022-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
949,NCT00718354,Event Free Survival (EFS) - Composite endpoint of overall survival plus free of symptomatic VTE .,"Incidence of SVTE Overall survival Major and minor haemorrhages during chemotherapy and / or up to 30 days after last dose is provided. Serious adverse events, All reported adverse events HIT",2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
950,NCT03477019,difference in measured response between treated and untreated lesions,Occurrence of adverse effects,2018-11-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
951,NCT01172028,Maximum-tolerated dose (MTD) of combination ALIMTA and Taxotere,Antitumor activity,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
952,NCT01248637,correlation of intratumoral hypoxia with patient survival rate,to assess utility of circulating osteopontin and miR-210 for identifying hypoxia,2010-10,COMPLETED,OBSERVATIONAL,['NA'],
953,NCT05142033,Percent of patients referred for molecularly targeted clinical trials,Percent of patient participating in microbiome collection and analysis,2021-11-01,RECRUITING,OBSERVATIONAL,['NA'],
954,NCT04982276,Objective response rate (ORR),Number of subjects who develop detectable anti-drug antibodies (ADAs),2021-07-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
955,NCT03946917,Objective response rate (ORR),Intestinal microorganism,2019-03-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
956,NCT05138302,OS,,2021-04-19,UNKNOWN,OBSERVATIONAL,['NA'],
957,NCT02345746,Determine response rate,,2012-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
958,NCT05103020,curative-intent resection rate,Overall response rate (ORR),2021-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
959,NCT04599777,Overall survival (OS),DOR assessed by investigators according to mRECIST.,2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
960,NCT06152263,"Microvascular density differences between the atrophic and non-atrophic mucosa, as well as cancerous and non-cancerous mucosa",,2023-09-30,RECRUITING,OBSERVATIONAL,['NA'],
961,NCT06072287,Illness-related distress,Cognitive and Behavioural Responses to Symptoms,2023-06-28,RECRUITING,OBSERVATIONAL,['NA'],
962,NCT02845999,number of patients with clinical or biological grade 3 or 4 treatment-related adverse events as assessed by CTCAE v4.0,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
963,NCT03360695,Disruptions in Cancer Care,PHQ-9,2017-12-11,COMPLETED,INTERVENTIONAL,['NA'],
964,NCT00842257,Response Rate of Single Agent Panitumumab Among Patients With KRAS Wild-type Colorectal Cancer Previously Treated With Cetuximab.,Disease Control Rate as Defined by RECIST Criteria,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
965,NCT03200821,Survival,Gastrin-17 Antibodies,2000-08-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
966,NCT00789841,Gastrointestinal transit time in NET patients,Changes in carcinoid symptoms and biomarkers,2008-09,COMPLETED,OBSERVATIONAL,['NA'],
967,NCT00262769,Overall Survival,Toxicity,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
968,NCT03813381,Body weight change,Waist circumference reduction,2015-11,COMPLETED,INTERVENTIONAL,['NA'],
969,NCT01257360,Rate of pathological complete remissions,Correlative biomarker analyses,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
970,NCT05427383,Overall Survival (OS) according to RECIST 1.1 by IRC,Incidence of neutralizing Antibody，Nab,2022-04-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Change from baseline in CA72-4 (carbohydrate antigen 724)
971,NCT01924260,"Dose-limiting toxicity (DLT) defined as any related (possibly, probably, or definitely) grade 3 non-hematological toxicity or any attributable grade 4 toxicity graded according to the National Cancer Institute (NCI) CTCAE version 4.0",Maximum-tolerated dose (MTD) defined as the maximum dose level at which less than 2 patients experience DLT graded according to NCI CTCAE version 4.0,2013-08-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
972,NCT02503969,Individual attended colorectal cancer screening,Individual accepted colorectal cancer screening after refusing the initial invitation for colorectal cancer screening,2015-09,COMPLETED,OBSERVATIONAL,['NA'],
973,NCT00477880,Response,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
974,NCT05052099,Overall response rate (ORR),Incidence and severity of adverse events (AEs) (with severity determined according to NCI CTCAE v5.0),2021-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
975,NCT05152147,Overall survival,Incidence of anti-drug antibodies (ADAs),2021-12-02,RECRUITING,INTERVENTIONAL,['PHASE3'],
976,NCT04352894,Best modality of ICG injection,Sensitivity of ICG fluorescence,2020-09,UNKNOWN,INTERVENTIONAL,['NA'],
977,NCT03998033,The recommended phase 2 dose (RP2D) regimen of ET140202 T-cell therapy,Assess the persistence of ET140202 T cells circulating in blood over time.,2019-05-30,TERMINATED,INTERVENTIONAL,['PHASE1'],
978,NCT06232759,Progression-free survival,Overall survival,2022-04-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
979,NCT01926444,"Measurements of Visceral Pain, Using a 100-mm Visual Analog Scale (VAS)",Subject Satisfaction and Acceptability of the Colonic Analgesia - Patient's Global Impression of Abdominal Pain,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
980,NCT02551991,Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT),Median Duration of Response (DoR),2015-10-19,COMPLETED,INTERVENTIONAL,['PHASE2'],
981,NCT05640791,Incidence of adverse events,Overall survival (OS),2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
982,NCT01565811,complication rate,To evaluate prognostic significance of perihepatic LN involvement with overall survival and disease free survival,2010-08,COMPLETED,OBSERVATIONAL,['NA'],
983,NCT06133023,Clinical success within 180 days of randomisation,Incidence of new pancreatic cancer,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
984,NCT01910610,Duration of Disease Control (DDC),Safety profile of each treatment sequence,2013-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
985,NCT00966667,Normative influences of family and friends,,2009-11,COMPLETED,OBSERVATIONAL,['NA'],
986,NCT02681601,Anthropometric measurement: Body Composition,Quality of life: Appetite,2016-07-19,TERMINATED,INTERVENTIONAL,['NA'],
987,NCT05781581,All-cause mortality at 30 days after operation,Major Adverse Cardiovascular Events (MACE),2023-03-19,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
988,NCT02202928,Progress-free survival,Phenotypic analysis of T cells,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],
989,NCT01114035,gene identification,mutation identification,2010-04,COMPLETED,INTERVENTIONAL,['NA'],
990,NCT00215722,Determine the Efficacy of the combination treatment (cetuximab plus capecitabine and oxaliplatin) as first-line therapy based on the overall response rate (ORR) according to the RECIST criteria.,Evaluate the Quality of Life,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],
991,NCT04014478,Visual Analog Scale Changes over the time,Quality of Life Score Changes over the time,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],
992,NCT00398398,Overall Response Rate,Toxicity Profile,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
993,NCT06208046,5-year overall survival,,2023-07-01,COMPLETED,OBSERVATIONAL,['NA'],
994,NCT00264446,,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],
995,NCT00427375,"Compare the proportion of patients presenting at least 1 component of the composite outcome (4 components: death, recurrence, major morbidity and severe after effects) at 2 years after",Quality of life (QLQ C30 - CR38),2007-03-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
996,NCT05922930,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",,2023-10-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
997,NCT06275204,Healthcare workers' assessment of feasibility and acceptability of the proposed practical implementation of a screening program,Participation rate of subjects selected for the program,2024-03-04,RECRUITING,OBSERVATIONAL,['NA'],
998,NCT02284802,accuracy of confocal endomicroscopy,,2014-09-10,COMPLETED,INTERVENTIONAL,['NA'],
999,NCT02227914,Time To Progression (TTP) - Phase 2,Overall Survival (OS) - Phase 2,2014-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1000,NCT00236249,"Readiness for discharge, checked twice a day",Clinical side effects twice a day,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1001,NCT01648465,15 month PFS (Progression-Free Survival) rate,Association of biologic markers with disease progression,2012-08-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
1002,NCT06060704,ORR（Objective response rate）,Quality of life: EORTC QLQ-C30,2023-11,RECRUITING,INTERVENTIONAL,['PHASE2'],
1003,NCT04646187,cumulative incidence of out-of-range fecal calprotectin results at 48 weeks follow-up,Identification of predictors of successful de-escalation.,2021-03-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4'],Patients' attitudes towards deprescribing anti-TNF agents
1004,NCT01929915,Perioperative immunoprofile,survival rate,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
1005,NCT03251417,Disease control rate,Median overall survival time,2017-09-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
1006,NCT05192018,Feasibility of early reversal of adefunctioning ileostomy,,2021-12-25,UNKNOWN,INTERVENTIONAL,['NA'],
1007,NCT00845884,response rate,"Safety, PFS, overall survival",2009-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1008,NCT04512209,Biophysical properties of the tumor tissue - measurement of hydraulic conductivity,Measurement of Pt penetration,2019-10-11,RECRUITING,INTERVENTIONAL,['NA'],
1009,NCT02130752,Surgical duration,Postoperative Mortality and Morbidity,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],
1010,NCT00903136,Comparison of participants' satisfaction with the TCE vs esophagogastroduodenoscopy (Phase II),Results of the histologic analysis of any biopsy specimens (Phase II),2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1011,NCT01715233,Response,Overall Survival,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
1012,NCT05809869,Rate of abscopal effect,Distant control rate,2023-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],
1013,NCT00405873,Best overall tumour response according to RECIST; within 20 weeks after registration; confirmation 6 +/- weeks later,Safety and Tolerability,2007-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
1014,NCT05956847,Changes in ecDNA content in different gastric precancerous lesions,,2023-08-10,RECRUITING,OBSERVATIONAL,['NA'],
1015,NCT03531632,Number of Participants With Adverse Events,The Number of Participants With Response Based on the Change in Tumor Volume,2018-06-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1016,NCT04684355,Quality of life degree,Anxiety and depression degree,2020-12-22,UNKNOWN,INTERVENTIONAL,['NA'],
1017,NCT03337087,Best response rate (Phase II),Incidence of adverse events (Phase II),2018-11-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1018,NCT06154785,To assess the impact of the stable low-pressure approach (using Airseal Insufflator) and its associated parameters into the the early rehabilitation program after colorectal surgery on length of stay.,The Surgical and Medical morbidity at 30 days,2023-12-15,RECRUITING,OBSERVATIONAL,['NA'],
1019,NCT00423254,To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP,to describe any objective tumor responses to the treatment with MKC1106-PP,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1020,NCT01177007,Progression-free Survival (PFS) of the Treated Lesion(s) According to RECIST and EASL Criteria,Mean Radiation Dose Delivered to Total Liver,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1021,NCT00544011,Objective response (complete and partial) rate,Biomarkers predictive of efficacy,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1022,NCT05138887,acute radiation-induced proctitis (ARP) incidence,cancer remission rate assessed by imaging,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events
1023,NCT01982487,PFS (Phase IIb),"Toxicity rate, graded according to NCI CTCAE version 4.0",2013-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1024,NCT05225207,Number of Participants With Non-serious ADRs,Percentage of Participants With Overall Response,2019-05-28,COMPLETED,OBSERVATIONAL,['NA'],
1025,NCT02436018,Low pulse oximetry incidence,Other adverse events,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],
1026,NCT05374122,Cholangiocarcinoma diagnosis confirmation after biopsy and six-month follow-up,Insufficient biopsy sample rate,2022-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1027,NCT01027221,Principal purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumoral activity,"quality of life according to the EORTC QoL questionnaire after 6, 12, 18 and 24 months",2009-11,COMPLETED,INTERVENTIONAL,['NA'],
1028,NCT01754272,Primary colorectal cancer tumor blocks,Metastatic tumor blocks,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],Residual blood samples
1029,NCT05517681,The number of positive lymph nodes,The incidence of postoperative complications,2020-09-07,COMPLETED,INTERVENTIONAL,['NA'],
1030,NCT03308552,Overall survival（OS）,Adverse events,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1031,NCT03615599,Incident cases of breast cancer among subjects with documented dietary habits.,Incident cases of prostate cancer among subjects with documented dietary intakes.,2002-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Incident cases of colorectal cancer among subjects with documented dietary habits.
1032,NCT05462496,Achievement of overall immune response,Overall survival rate (OS),2023-03-13,RECRUITING,INTERVENTIONAL,['PHASE2'],
1033,NCT03657914,Number of lymph nodes dissected,Postoperative drainage tube indwelling time,2017-07-12,UNKNOWN,INTERVENTIONAL,['NA'],Local recurrence rate of tumor within 3 years
1034,NCT04046575,Maximum tolerated dose (MTD) of hypofractionated IMRT with chemotherapy,Number and type of adverse events experienced by patient,2019-11-07,RECRUITING,INTERVENTIONAL,['PHASE1'],
1035,NCT05163236,sensitivity of the fecal immunochemical test for the detection of colorectal cancers,Treatment,2021-04-20,COMPLETED,OBSERVATIONAL,['NA'],
1036,NCT04644250,Pathologic complete response rate,R0 resection rate,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1037,NCT03355391,colorectal cancer rate,,2018-01-30,UNKNOWN,OBSERVATIONAL,['NA'],
1038,NCT03071094,Overall Response Rate (ORR) According to RECIST 1.1.,,2017-07-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1039,NCT05583890,Health inequalities,,2022-08-25,RECRUITING,OBSERVATIONAL,['NA'],
1040,NCT04950166,Clinically Significant Events (CSE),Pegsitacianine fluorescence and imaging performance,2021-11-30,COMPLETED,INTERVENTIONAL,['PHASE2'],
1041,NCT05848739,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,ST316 Assessment Objective Response Rate (ORR),2023-06-05,RECRUITING,INTERVENTIONAL,['PHASE1'],
1042,NCT03313700,3-year disease free survival rate,operation time,2017-09-25,COMPLETED,INTERVENTIONAL,['NA'],
1043,NCT04371224,Progression-free survival,QOL: eortc qlq-c30,2020-06-23,RECRUITING,INTERVENTIONAL,['PHASE2'],
1044,NCT00091195,Survival,,2004-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
1045,NCT00188266,Phase II: Comparison of acute toxicity rates with those observed in their previous study of 20 patients treated similarly to the SWOG INT 0116 protocol.,Survival and disease-specific survival,2002-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1046,NCT03076567,Relation of DNA methylation marakers to gastric cancer status,,2017-03-09,COMPLETED,OBSERVATIONAL,['NA'],
1047,NCT04761783,Examine the impact of SIGNATERA on treatment decisions on tumor assessment timepoints after initiation of immunotherapy,Determine the impact of SIGNATERA on patient reported outcomes,2021-05-28,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1048,NCT04048278,Upregulation or Downregulation of Gene Expression.,Specimen outcome measure,2018-11-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
1049,NCT01287585,Overall survival,Safety and tolerability - number of participants with adverse events.,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
1050,NCT03121807,Overall survival,Cycles of salvage chemotherapy completed,2014-09-01,COMPLETED,INTERVENTIONAL,['NA'],
1051,NCT01002287,"The Incidence of Adhesions, Defined as the Proportion of Subjects Presenting at the Follow-up Surgery (10-12 Weeks) With One or More Adhesions to the Midline Incision, Regardless of Extent and/or Severity.",Mobilization Time,2009-10,TERMINATED,INTERVENTIONAL,['NA'],
1052,NCT06003998,Overall survival,Peritoneum/plasma ratio of intraperitoneal irinotecan,2022-12-27,RECRUITING,INTERVENTIONAL,['PHASE2'],
1053,NCT05845450,major pathological response rate,microbiota,2023-05-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival
1054,NCT04045496,Find Recommended Phase 2 Dose (RP2D) of JAB-3312,Duration of response ( DOR ),2019-09-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1055,NCT01849588,Decline in HCV-RNA Level,Overall Survival,2013-05,TERMINATED,INTERVENTIONAL,['PHASE4'],Decrease Alpha-fetoprotein(AFP) Level > 20% From the Baseline
1056,NCT06281379,Postoperative outcome,,2023-04-01,COMPLETED,INTERVENTIONAL,['NA'],
1057,NCT05043857,Local Recurrence Rate,Overall Survival,2021-07-06,RECRUITING,INTERVENTIONAL,['NA'],
1058,NCT00681421,Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),To evaluate immunological responses,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1059,NCT03465722,"Efficacy of Avapritinib Based on Progression-free Survival (PFS) Determined by Central Radiological Assessment Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST), Version 1.1",European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30). Change in Individual Scores in Patients With Advanced GIST Treated With Avapritinib Compared to Patients Treated With Regorafenib,2018-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],
1060,NCT05969847,Organ preservation,Anorectal function,2023-08-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1061,NCT02930902,Incidence of toxicities as defined by Common Terminology Criteria for Adverse Events version 4.0,Resection rate,2017-02-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival (OS)
1062,NCT05453760,Area under the curve (AUC) of the Lung ultrasound score,Complications according to the Dindo-Clavien classification,2022-08-21,RECRUITING,OBSERVATIONAL,['NA'],
1063,NCT02507414,"Relative changes in plasma-hormone concentrations (pro-ANP, PGF2, GLP-1, ACTH, cortisone, adrenaline, IL-1, IL-6, TNF-alfa and CRP (stress hormones)) from baseline.",Relative changes in systemic vascular resistance from baseline measured in dyn.s/cm5,2014-08,COMPLETED,INTERVENTIONAL,['NA'],
1064,NCT02550613,The recurrence rate at 3 months after treatment,The overall survival after treatment,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],
1065,NCT02784470,Gastric Outlet Obstruction Scoring System (GOOSS) score,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1066,NCT03028584,EHR-based SCPs and care planning,Impact of providing EHR-based care planning,2017-09-11,COMPLETED,OBSERVATIONAL,['NA'],
1067,NCT02599662,Maximum Tolerated Dose,QOL surveys,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1068,NCT06067438,"Development of atrial fibrillation (AF), or completion of seven-day course of amiodarone","Serum amiodarone level, classified as therapeutic or subtherapeutic",2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1069,NCT04069468,QoL Measurements Using FACT-HEP Questionnaire Before and After Treatment,"Determination of a correlation between Dose volume histogram (DVH) for total perfused tumour, Index lesion and whole normal liver tissue, using 99mTc-MAA (SPECT or SPECT/CT) and Y-90 (PET/CT or PET/MRI).",2019-03-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1070,NCT05411679,Overall Response Rate (ORR) as measured using RECIST v1.1,Incidence of treatment-emergent AEs leading to dose reduction of trial treatment,2023-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Magnitude of response to first-line chemotherapy
1071,NCT01786980,Overall survival,,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
1072,NCT02358070,Lifestyle factors,,2015-04,COMPLETED,OBSERVATIONAL,['NA'],
1073,NCT01572974,Health State Utility as measured by the Time Trade-off (TTO) method/Standard Gamble (SG) method,SF-36 general health (GH) subscale,2010-01,TERMINATED,OBSERVATIONAL,['NA'],
1074,NCT00161460,Colorectal cancer screening test utilization,Cancer worry score,2005-06,COMPLETED,INTERVENTIONAL,['NA'],
1075,NCT00003753,,,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1076,NCT06151262,Incidence of CIM,Safety and Tolerability,2024-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
1077,NCT01016860,Maximum tolerated dose (MTD) and the recommend phase II dose (RP2D) for the combination of irinotecan and OSI-906 in patients with advanced cancer.,,2009-12,TERMINATED,INTERVENTIONAL,['PHASE1'],
1078,NCT01977066,"Physical functioning score, as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) EORTC QLQ-C30",Overall quality of life from EORTC QLQ-C30 and the specific module for pancreatic cancer(QLQ-PAN26),2013-11,COMPLETED,INTERVENTIONAL,['NA'],Fatigue (Multidimensional Fatigue Inventory (MFI))
1079,NCT00354978,Median Progression-free Survival (PFS),,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
1080,NCT05524012,Tumor regression grading (TRG),Surrogate marker: Carcinoembryonic Antigen (CEA),2022-11-30,RECRUITING,OBSERVATIONAL,['NA'],
1081,NCT03465982,pathologic complete response (pCR),OS,2018-06-05,RECRUITING,INTERVENTIONAL,['NA'],
1082,NCT03228147,A tea product with the highest total average nutrition supplement scores as assessed by questionnaires,,2017-07-25,COMPLETED,INTERVENTIONAL,['NA'],
1083,NCT02842580,The primary objective is the percentage of patients without failure of the strategy 16 months after the randomization.,Progression free survival (PFS) at 2 years and at 3 years,2016-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
1084,NCT01963429,local progression-free survival(LPES),disease-free survival (DFS),2013-09-30,COMPLETED,INTERVENTIONAL,['NA'],overall survival (OS)
1085,NCT02513784,Difference in Esophageal F. Nucleatum Between Experimental Group and no Intervention Group,,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
1086,NCT00964457,response rate,,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1087,NCT05689138,microbial features by 16s rRNA sequencing,,2020-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1088,NCT02233595,tumor volume,,2014-10-15,TERMINATED,OBSERVATIONAL,['NA'],
1089,NCT04508387,respiratory parameters: tidal volume,morphine consumption,2019-04-22,COMPLETED,INTERVENTIONAL,['NA'],
1090,NCT03223818,Length of post-operative hospital Stay,,2018-07-01,RECRUITING,INTERVENTIONAL,['NA'],
1091,NCT02395523,local progression - free survival,overall survival,2015-03-05,COMPLETED,INTERVENTIONAL,['NA'],
1092,NCT05935579,Objective response rate,overall survival rate,2022-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],
1093,NCT02734004,Second Stage Cohorts: DCR at Week 24,Initial and Second Stage Cohorts: Number of Participants With Anti-Drug Antibody (ADA) Response to MEDI4736,2016-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1094,NCT02021500,Overall Survival,Disease progression,2014-01-02,COMPLETED,OBSERVATIONAL,['NA'],
1095,NCT04656041,Pathologic Complete Response Rate,Overall Survival,2021-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],
1096,NCT05559775,ORR,,2022-08-10,RECRUITING,INTERVENTIONAL,['PHASE2'],
1097,NCT03379844,"Safety, expressed as the rate of unacceptable toxicity.",Changes in hepatic function as determined by hepatobiliary scintigraphy,2017-08-21,COMPLETED,INTERVENTIONAL,['PHASE2'],
1098,NCT04899492,Testing the feasibility of smoking cessation interventions evaluated in French cancer patients undergoing surgery,Evaluate the efficacy of interventions on patient quality of life,2021-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1099,NCT00227773,,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1100,NCT00062426,,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1101,NCT01312389,Number of Participants With Adverse Events,Clinical Response,2011-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1102,NCT03124212,Establishing the CASCADE Cohort,Cancer Surveillance,2017-04-01,RECRUITING,OBSERVATIONAL,['NA'],
1103,NCT03958812,Discrimination between Malignant and Benign Gastric/Breast Lesions and normal group with each diagnostic method (Na-nose/GC-MS/CTC),Comprehensive diagnostic model of VOCs and CTCs,2019-06-15,UNKNOWN,OBSERVATIONAL,['NA'],
1104,NCT03450889,Incidence of colorectal cancer during protocolled endoscopic surveillance,Incidence of post-colonoscopy complications,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],
1105,NCT05718284,POST-OPERATIVE PULMONARY COMPLICATIONS,CARDIO-VASCULAR COMPLICATIONS,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],
1106,NCT00636948,Symptomatic anastomotic leakage following low anterior resection of the rectum for cancer with and without a defunctioning stoma. Anorectal function after one and five years without defunctioning stoma.,Reoperation within 30 days of initial surgery.,1999-12,COMPLETED,OBSERVATIONAL,['NA'],
1107,NCT01520779,Recurrence of hepatocellular carcinoma,,2012-01,COMPLETED,OBSERVATIONAL,['NA'],
1108,NCT03812289,Proportion of participants who are transplanted or with localized disease control per Milan criteria,Incidence of liver toxicity assessed per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0,2019-02-07,TERMINATED,INTERVENTIONAL,['NA'],Proportion of histopathologic changes in irradiated tumor sites relative to uninvolved liver tissue
1109,NCT06018896,Quality of life (QOL),Overall survival (OS),2023-08-25,RECRUITING,INTERVENTIONAL,['PHASE3'],
1110,NCT03415815,Numbers of lymph nodes and percentages of patients with surgeries,Impact factors of lymph metastases,2017-12-12,UNKNOWN,OBSERVATIONAL,['NA'],Effects of surgeries on the extents of the patients with esophageal cancer who received surgeries
1111,NCT00040859,Objective tumor response rate,Quality of life,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1112,NCT01738620,items SL (sleep disorder) and QL2 of the QLQ C30,PSQI score,2013-01,TERMINATED,INTERVENTIONAL,['NA'],
1113,NCT00550563,"Relationship between serum cholecalciferol pharmacokinetic parameters and CYP24 SNPs, splicing variants, and enzyme activity",,2007-08,COMPLETED,INTERVENTIONAL,['NA'],
1114,NCT04908176,area under the plasma concentration-time curve (AUC) of midazolam,"area under the plasma concentration-time curve at steady state (AUC,ss) of metabolite",2022-08-24,RECRUITING,INTERVENTIONAL,['PHASE1'],
1115,NCT01469598,Response rate,Number of Adverse Events,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
1116,NCT03159585,treatment-related adverse events as assessed by CTCAE v4.03,assess the expression of tumor markers,2017-04-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
1117,NCT01344538,"Evaluate Whether 2.0g of Ginger Taken Daily, Standardized to 5%-Gingerols for Four Weeks Will Result in Bioactive Levels in Colonic Tissue Sufficient to Reduce Mucosal Prostaglandin E2 (PGE2), a Marker of Cyclooxygenase Function Versus Placebo.",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1118,NCT04594863,SIRT-6 expression,,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
1119,NCT01092078,Colon Cancer Screening Behavior,Social Influence relating to colon cancer screening,2010-05,COMPLETED,INTERVENTIONAL,['NA'],
1120,NCT00019110,,,1995-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1121,NCT03519074,Efficacy Evaluation: Timing,,2016-07-22,RECRUITING,INTERVENTIONAL,['PHASE2'],
1122,NCT01786850,,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],
1123,NCT00001693,,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
1124,NCT03120104,Change of The Wexner Score,Change of Functional assessment of Cancer Therapy - Colorectal (FACT-C),2017-06,UNKNOWN,INTERVENTIONAL,['NA'],
1125,NCT05551416,New strategies for gastric cancer (GC) early diagnosis,Characterization of the microbiome: 16S rRNA studies,2021-09-09,RECRUITING,OBSERVATIONAL,['NA'],
1126,NCT00622622,Safety(toxicities as assessed by NCI CTCAE version 3),survival,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1127,NCT03529669,Completion Rate,Number of Patients Who Would be Prepared to Repeat the Procedure,2018-04-18,COMPLETED,INTERVENTIONAL,['NA'],
1128,NCT04798612,T-cell infiltration in tumor,Immunological and inflammatory cytokines and interleukins,2023-08-14,RECRUITING,INTERVENTIONAL,['PHASE2'],
1129,NCT02215070,Percentage of GI Toxicity From the Preparatory Regimen and the GVHD Prophylaxis in Stem Cell Transplantation (SCT) Patients Who Are Treated With Pasireotide,Disease Free Survival Compared to Historical Controls,2015-01-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluate GI Toxicity Assessment by Video Capsule Endoscopy.
1130,NCT04103697,3-year disease-free survival,Preoperative tumor-associated complications rate,2019-08-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],
1131,NCT01008566,Toxicities and tolerability of this regimen as assessed by NCI CTCAE version 4.0,Progression-free rate according to the Response Evaluation Criteria in Solid Tumors (RECIST),2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1132,NCT01819766,Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC.,Determine Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC and HGD.,2013-03,COMPLETED,OBSERVATIONAL,['NA'],
1133,NCT00296114,,,2004-02,COMPLETED,OBSERVATIONAL,['NA'],
1134,NCT00107861,- Evaluate the safety of a single IV administration of Ad.hIFN-β.,Explore preliminary clinical activity.,2005-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1135,NCT06178848,frontal spectral power,Riker sedation-agitation score,2023-06-26,COMPLETED,INTERVENTIONAL,['NA'],
1136,NCT05993923,Change in functional status after colorectal cancer surgery between groups,The rate of early unscheduled re-hospitalizations or admissions to the emergency department between groups,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1137,NCT00622557,,,2007-05-01,COMPLETED,OBSERVATIONAL,['NA'],
1138,NCT02613156,Perioperative complications,relapse-free survival,2014-06,COMPLETED,OBSERVATIONAL,['NA'],
1139,NCT02706184,Common toxicity criteria for diarrhea Version 4.0,ECM/BCM-Index,2015-07,COMPLETED,INTERVENTIONAL,['PHASE3'],stool microbiome analyses
1140,NCT05523778,Rate of POPF within 3 months after EN.,Total cost of hospitalization,2023-02-06,RECRUITING,INTERVENTIONAL,['NA'],
1141,NCT05464875,Duration Of Response,Vd（volume of distribution）,2022-07-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Assessment of dose effect of antineoplastic agents
1142,NCT03317119,"Maximum tolerated dose defined for the combination of trametinib, and Trifluridine and Tipiracil Hydrochloride (TAS?102) as the highest dose level at which 0-1 out of 6 patients experience dose limiting toxicities",Overall survival,2018-04-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1143,NCT02818530,Changes in anterior chamber depth measured by ultrasound.,Time dependent changes in anterior chamber depth during prolonged trendelenberg position.,2017-06-21,TERMINATED,INTERVENTIONAL,['NA'],
1144,NCT06135571,Metastatic rate of No.253 lymph node,5-year overall survival rate,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],
1145,NCT03848182,Change in CD4 T Cell Responses After TT Booster,Change in CD8 T Cell Responses After TT Booster,2017-07-21,TERMINATED,INTERVENTIONAL,['PHASE2'],Change in Myeloid-derived Suppressor Cells
1146,NCT00973193,Pathological Complete Response (pCR),"Safety, pathologic R0 resection, negative Circumferential Resection Margin, pathologic downstaging, tumor regression grade, quality of mesorectal excision, rate of sphincter-preservation, Disease-Free Survival, local control rate, translational research",2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
1147,NCT02210039,Number of Participants With Tolerability of the Procedure,,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
1148,NCT03231462,Pulmonary complications,The change of symptom,2015-03-06,RECRUITING,OBSERVATIONAL,['NA'],
1149,NCT03039608,the time when stricture occurs,the frequency of complications,2017-02-10,COMPLETED,INTERVENTIONAL,['NA'],
1150,NCT01023529,Effect on patient's target symptom.,Time to improvement in patient's symptoms and QoL.,2009-11,COMPLETED,OBSERVATIONAL,['NA'],
1151,NCT01937104,ONSD and PaCO2,ONSD and PaCO2,2013-09,COMPLETED,INTERVENTIONAL,['NA'],ONSD and PaCO2
1152,NCT01962376,progression-free survival(PFS),Objective response rate (ORR),2013-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],Adverse events
1153,NCT00201318,"We expect to enter 33 patients per year. Taking into account 10﹪dropout rate, we may finish accrual of patients within 3 years.",,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1154,NCT01740375,2-year disease-free survival (DFS) rate,treatment-related mortality,2012-11,TERMINATED,INTERVENTIONAL,['PHASE3'],
1155,NCT04653181,postoperative complications,Need for red blood cell transfusion,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],
1156,NCT05555888,complete response (CR) rate,10 year Quality of Life,2022-12-12,RECRUITING,INTERVENTIONAL,['PHASE2'],
1157,NCT04969107,disease-specific survival,recurrence-free survival,2012-01-01,RECRUITING,INTERVENTIONAL,['NA'],
1158,NCT05854394,6-minute-walking-distance (6MWD),Quality of Life Scale,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],
1159,NCT00075595,Time to death from progression,Incidence of grade 3 or 4 toxicity,2002-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1160,NCT05655494,Proportion of patients who self-refer to cancer clinical trials,Mediators of intervention effectiveness,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1161,NCT05113290,Objective response rate (ORR) according to mRECIST criteria,Number of participants with adverse events,2021-12-28,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1162,NCT00009893,survival at 6 months,tumor response rate,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
1163,NCT04677088,Safety evaluation of the TCR-T treatment,Overall survival (OS),2018-03-29,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1164,NCT01544452,Synchronous colon cancers and liver metastasis,sensitivity/specificity of CT versus MR versus Peroperative ultrasonography of the liver,2010-08,TERMINATED,INTERVENTIONAL,['NA'],
1165,NCT03006926,DLT+Expansion Part: Duration of Response (DOR) Based on RECIST v1.1 Assessed by IIR,DLT+Expansion Part: Number of Participants Positive for Serum Anti-drug Antibodies (ADA) Status,2017-02-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
1166,NCT06307314,Different grades radiotherapy-induced oral mucositis,Tumor response,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],
1167,NCT06046846,To investigate the usability in terms of user satisfaction of the asensei app to deliver a mHealth prehabilitation programme.,To collect preliminary data and assess for change on a participants quality of life by using the EORTC QLQ-OG25 questionnaire in order to inform the sample size for a fully powered RCT as part of the feasibility study.,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Semi structured interviews
1168,NCT03126071,PFS,AEs,2017-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1169,NCT05205187,Response of target organ,,2022-02-28,RECRUITING,OBSERVATIONAL,['NA'],
1170,NCT04192071,Information seeking behavior,,2020-01-06,RECRUITING,INTERVENTIONAL,['NA'],
1171,NCT01082224,Sensitivity of contrast-enhanced CT scan vs contrast-enhanced MRI for diagnosing hepatocellular carcinoma (HCC),Diagnostic value of sensitivity and PPV when patients are stratified by AFP level (elevated vs normal),2010-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1172,NCT00385203,"Tumour Metabolic Activity as Assessed by Change in Central Review of Standardised Uptake Value (SUVMax) at Day 29, in Patients With GIST Tumours. SUVmax at Day 29 Minus SUVmax at Baseline.",Anti-tumour Activity as Measured by Total Lesion Volume at Week 16 in GIST Patients by Central Review of CT Images.,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1173,NCT00507273,Current patterns of medical practice in management of patients with GIS,,2005-08,COMPLETED,OBSERVATIONAL,['NA'],
1174,NCT01071824,Pouch function 4 month after closure of protective ileostomy.,Pouch function 2 and 12 month respectively after closure of protective ileostomy.,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],
1175,NCT01211561,Reduction in ACF biomarkers,,2010-12,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
1176,NCT06164769,blood loss,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],
1177,NCT00867724,Ability to screen the entire length of the colon to the cecum.,"Safety endpoints to include incidence of bowel perforation, Colonic bleeding, Damage to colon, rectum and anus mucosa or any other Adverse events",2009-09,COMPLETED,INTERVENTIONAL,['NA'],
1178,NCT00451022,To facilitate the continuous usage of stored research specimens collected from subjects under completed and ongoing protocols.,,2004-09-13,RECRUITING,OBSERVATIONAL,['NA'],
1179,NCT00613743,difference of pain alleviation in the two branches one hour after mouthwash and as well as the duration of pain relief.,the requirement of supplementary systemic analgesics,2007-12,COMPLETED,INTERVENTIONAL,['NA'],
1180,NCT04622098,Estimating the prevalence and types of sub-epithelial lesions among patients undergoing EGDs in Egypt.,characterization of SEL in Egypt,2020-11-18,UNKNOWN,OBSERVATIONAL,['NA'],
1181,NCT04555265,Early tumor recurrence,Other tutor recurrence,2020-09-01,COMPLETED,INTERVENTIONAL,['NA'],
1182,NCT01838317,Glucose to Insulin Ratio,Changes in Serum and MRI End Points,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
1183,NCT02988635,Functional Assessment of Cancer Therapy-General (FACT-G) (Quality of life measure),Resource utilization at the end of life (EOL): emergency room admissions,2014-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
1184,NCT00758381,Progression Free Survival,- overall Response Rate (RECIST Criteria) - duration of response - overall survival time,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1185,NCT02845986,overall postoperative morbidity rates,The variation of prealbumin,2016-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1186,NCT02526043,Overall survival,Incidence of postoperative complications,2015-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1187,NCT01697072,Overall Survival,Immunogenicity,2012-10,TERMINATED,INTERVENTIONAL,['PHASE3'],
1188,NCT00983801,Percentage of Participants With Overall Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (RECIST),Number of Participants With Serum Chemistry Abnormalities,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Best Response as Assessed With Modified RECIST
1189,NCT02961998,Incidence of participants with clinically definite Sorafenib-related Hand Foot Syndrome,Overall survival,2015-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
1190,NCT01601808,Overall survival,Patient pain assessment,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1191,NCT03274427,Progression-free Survival,quality of life,2017-07-18,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1192,NCT01984658,Safety and tolerability,Efficacy; Tumor change,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Safety & efficacy; Quality of life
1193,NCT02451384,the changes of CTCs countings between the pre and post-operation among the arms,,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],
1194,NCT00436514,,,2007-04,COMPLETED,INTERVENTIONAL,['NA'],
1195,NCT05022030,Progression free survival (PFS) rate at 9 months,Adverse event rate,2021-07-21,RECRUITING,INTERVENTIONAL,['PHASE2'],
1196,NCT06181201,histological response according to Ryan classification,,2024-01-19,RECRUITING,OBSERVATIONAL,['NA'],
1197,NCT01583699,Qualitative MALT-features on Endomicroscopy,Sensitivity and Specificity of Endomicroscopy to diagnose GI-MALT-Lymphoma,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
1198,NCT04292496,Anastomotic leakage,Postoperative surgical complications,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],
1199,NCT00002655,,,1995-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
1200,NCT01196494,,,na,TERMINATED,INTERVENTIONAL,['NA'],
1201,NCT03422601,disease-free survival (DFS),,2017-07-13,UNKNOWN,OBSERVATIONAL,['NA'],
1202,NCT03890354,Post operative compliction,Surgical outcome,2019-02-21,COMPLETED,OBSERVATIONAL,['NA'],
1203,NCT00621036,Safety and tolerability,Kinetics of humoral immune response development,2007-10-19,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1204,NCT01669668,"Local recurrence, defined as the recurrence at the size of original tumor",Ability of patients who develop recurrence to undergo salvage transplantation,2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1205,NCT03089268,Risk of developing metachronous advanced lesions or cancers,Prevalence of serrated lesions in FOBT screening population,2017-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1206,NCT01422928,Changes in immune biomarker levels,Changes in Symptom Scores,2010-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
1207,NCT02276300,Safety and tolerability of HER2-derived peptide vaccination measured by clinical and chemical parameters.,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
1208,NCT00003652,,,1999-01-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1209,NCT04915599,Change in Feasability Questionnaire (regarding Patient reported tolerance of cryotherapy with Cooral ®),Change in degree of acute OM up to 6 weeks after EOT,2021-06-22,COMPLETED,INTERVENTIONAL,['NA'],
1210,NCT05801666,Arts' Dumping Questionnaire,Medical charts and drug use.,2023-02-10,RECRUITING,INTERVENTIONAL,['NA'],
1211,NCT03655223,Incidence Rates: Number of newborns who screen positive comparative to the whole sample,Impact of Screening: Semi-structured parent interviews.,2018-10-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
1212,NCT05822752,Best Overall Response (BOR) per Investigator,Overall Survival (OS),2023-09-21,RECRUITING,INTERVENTIONAL,['PHASE2'],
1213,NCT04718038,Progression-free survival(PFS),Safety,2016-07-01,COMPLETED,OBSERVATIONAL,['NA'],
1214,NCT00225745,To evaluate plasma ghrelin levels in patients with pancreatic cancer and compare with age matched controls,To generate hypotheses for future studies and treatment based on the findings,2004-04,COMPLETED,OBSERVATIONAL,['NA'],
1215,NCT03895359,Time to Intrahepatic Progression,Cost-benefit,2019-05-27,RECRUITING,INTERVENTIONAL,['PHASE3'],
1216,NCT06325267,Clinical characteristics of overall cohort by liver disease etiology,Risk factors of prognosis in overall cohort and different etiologies,2010-01-01,RECRUITING,OBSERVATIONAL,['NA'],
1217,NCT00711412,Determine Pathologic Complete Response,Correlate Proteomic and Pharmacologic Characteristics With Prognosis and Response to Therapy.,2006-05-31,COMPLETED,INTERVENTIONAL,['PHASE2'],
1218,NCT05174286,CRC Screening Uptake,Change in Life's Simple 7 Score (CVD Risk Screening Measure),2023-03-19,RECRUITING,INTERVENTIONAL,['NA'],
1219,NCT02164448,gas passing,sips of water time,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],soft diet time
1220,NCT01514045,Collect detailed clinical and epidemiological information on patients with gastric cancer; with a family history of gastric cancer in a first or second degree relative; or persons with a known germline mutation in their CDH1 (E-Cadherin) gene,,2011-04,RECRUITING,OBSERVATIONAL,['NA'],
1221,NCT04554771,Efficacy defined as pathological response to chemoradiotherapy according to the Mandard criteria,Feasibility delay,2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Predictive biomarkers using oa RNA sequencing
1222,NCT01595217,"EHCC performance on DWI, ADC map and MRCP","ADC, SNR, CNR and SIR for EHCC lesion under different b values",2012-03,COMPLETED,INTERVENTIONAL,['NA'],
1223,NCT05496270,3-year diseases free survival,Local recurrence rate,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
1224,NCT01492907,Pharmacokinetic Metabolite Profile of Radiolabeled MeIQx in Urine,Quantify ambient adducts in the human pancreas,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
1225,NCT04981665,2-year Recurrence Free Survival Rate (2-year RFS rate),Adverse Events (AEs),2021-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],
1226,NCT02157363,operating time,,2014-06-16,TERMINATED,INTERVENTIONAL,['NA'],
1227,NCT05788874,SUVmax,,2023-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1228,NCT01383707,Objective Response Rate (ORR) in the Per-protocol Analysis Set (PPAS),Overall Survival (OS),2011-08-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
1229,NCT02063230,"Dose Normalized Cmax, Unbound Selumetinib",,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
1230,NCT00868569,overall survival,resection rate of liver metastasis progression-free survival,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1231,NCT05051475,Level of late post-procedural pain (at day 30 after treatment),The rate of complications,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],
1232,NCT00681876,Time To Progression,"Quality of life, Symptoms improvement",2008-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
1233,NCT04751591,Early operative mortality rate,En bloc resection rate,2021-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1234,NCT05461430,BOR,PFS,2022-07-15,RECRUITING,OBSERVATIONAL,['NA'],
1235,NCT01415089,Quality of life,Satisfaction with intervention,2009-05,COMPLETED,INTERVENTIONAL,['NA'],
1236,NCT06245356,Treatment specific safety,Quality of life questionnaire - Colorectal (QLQ-CR29),2024-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1237,NCT05181488,3-year local recurrence rate,Overall survival,2020-04-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1238,NCT06315101,Survival analysis,Adverse Events assessment,2023-09-01,COMPLETED,OBSERVATIONAL,['NA'],
1239,NCT05939687,hernia rate,Quality of life indicators by HerQLes scale,2023-06-05,RECRUITING,INTERVENTIONAL,['PHASE3'],
1240,NCT06166589,ORR,OS,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1241,NCT01798134,Freedom From Tumor Progression at 6 Months,12 Month Survival,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
1242,NCT01765673,Change in Swallowing Frequency 70 & 110 Hz,Change in Swallow Initiation Time,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],
1243,NCT00477711,Tumor response rate,"Time to progression Disease control rate Overall survival K-ras, b-raf, p53 gene mutation and EGFR gene copy number vs. tumor response safety",2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
1244,NCT01381822,To determine the MTD and DLT(s) of TH-302 when used in combination with sunitinib.,To make a preliminary assessment of the efficacy of TH-302 in combination with sunitinib as determined by the response rate and the progression-free survival in subjects with advanced RCC treated at the RP2D.,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1245,NCT02748772,PFS,RR,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1246,NCT01845675,overall response rate,toxicities,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1247,NCT06205836,Complete Response Rate,Number of participants experiencing grade 3 or above drug-related toxicities requiring treatment discontinuation,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1248,NCT01493336,Relative bioavailability: Area under the concentration-time curve (AUC),Safety: Incidence of adverse events,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
1249,NCT05171166,Progression-free survival,Number of paitents with treatment-related adverse events,2021-12-24,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1250,NCT02788526,Overall survival,Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1251,NCT06214988,textbook outcome; stoma-free survival at two years without major LARS,Quality of life by European Organization for Research and Treatment of Cancer- Cancer30 (EORTC-C30),2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1252,NCT03792932,Recurrence Free Survival,Detected lymph node number,2019-02-02,RECRUITING,INTERVENTIONAL,['NA'],
1253,NCT06220058,Incidence of incisional hernia.,Morbidity and mortality rates,2024-01-15,RECRUITING,INTERVENTIONAL,['NA'],
1254,NCT01075893,Number of stem cells in the colonic crypt,Stem cell position in colonic crypt,2010-02,COMPLETED,OBSERVATIONAL,['NA'],
1255,NCT01242605,"To investigate the safety and tolerability of the combination of cisplatin, gemcitabine and selumetinib, and to establish the recommended phase II dose of selumetinib when given in this combination.",Response rate,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1256,NCT02646462,Ratio of malignant/total number of lymph nodes,Number of N1 patients,2015-06,UNKNOWN,OBSERVATIONAL,['NA'],
1257,NCT01766661,post-operative morbidity,local and/or distant recurrence of neoplasm,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],
1258,NCT00601198,"Test Drug in 28 Patients and Assess PSN. If 5 or More Have Grade 3 & 4 PSN, Trial Will be Terminated.","Assess PSN in 69 Patients. If Total Number of Cumulative PSN is > or Equal to 14, Drug Will be Rejected.",2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
1259,NCT02889679,Incomplete resection rate (histologic),,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
1260,NCT04888403,Pathologic Complete Response(pCR),postoperative complications rate,2021-12-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1261,NCT01286883,Primary endpoint: correlation of stem cell markers on CTCs with response to therapy,Secondary Outcome: Correlation of stem cell markers in primary tumors with stem cell markers in CTCs,2011-02,TERMINATED,OBSERVATIONAL,['NA'],
1262,NCT03692429,Occurence of Dose Limiting Toxicities,,2018-11-28,RECRUITING,INTERVENTIONAL,['PHASE1'],
1263,NCT00534001,Prequit Change in Cigarettes Per Day,Abstinence,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
1264,NCT05147168,Quality of Life(SF-36),,2021-11-22,RECRUITING,OBSERVATIONAL,['NA'],
1265,NCT02565641,Overall objective response rate,Incidence of adverse events,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
1266,NCT05571098,Psychosocial Adjustment to Illness Scale (PAIS-SR) scores should be lower in the NNP applied group than in the non-applied group.,,2021-07-08,COMPLETED,INTERVENTIONAL,['NA'],
1267,NCT03203525,Incidence of adverse events,Biomarker analysis,2020-06-23,RECRUITING,INTERVENTIONAL,['PHASE1'],
1268,NCT03601923,Progression Free Survival,Evaluation of the safety and tolerability of niraparib as assessed by the Common Terminology Criteria for Adverse Events (CTCAE),2018-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1269,NCT05943444,Low Anterior Resection Syndrome (LARS) score 1 year after surgery,The incidence of postoperative anastomotic complications,2023-08-08,RECRUITING,INTERVENTIONAL,['NA'],
1270,NCT01911988,Disease Free Survival,5 years overall survival,2013-06,UNKNOWN,OBSERVATIONAL,['NA'],
1271,NCT01749956,Pathologic Complete Response Rate,The Number of Participants Who Experienced Serious or Non-Serious Adverse Events as a Measure of Safety.,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
1272,NCT04517643,Number of Patients That Met the Criterion That the Dose Estimated With Tc-99m MAA SPECT Was Within 15% of the Dose Estimated From Y-90 SPECT,,2020-11-12,COMPLETED,INTERVENTIONAL,['NA'],
1273,NCT00066716,Pathological response rate at time of surgical resection,Toxicities and safety,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
1274,NCT01923987,R0 resection rate,Toxicity,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1275,NCT04919824,Procedure time,Delayed post-procedural adverse event,2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1276,NCT04797923,Rate of R0 resection,,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1277,NCT03392571,To evaluate 2 year survival from date of entry into study,Time to Recurrence,2018-08-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1278,NCT05718349,Microbial composition,,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],
1279,NCT02508389,Duration (in Days) of Radiation Induced Severe Oral Mucositis (OM) Per World Health Organization (WHO) Criteria,"Number of Participants With Tumor Outcomes Defined as Locoregional Failure, Distant Metastases, Disease Progression and Deaths",2015-10-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
1280,NCT01750619,Technical success.,Endoscopic en bloc resection rate,2011-07,RECRUITING,OBSERVATIONAL,['NA'],
1281,NCT02765620,Evaluate treatment response by PERCIST to RECIST 1.1 criteria after the whole treatment process,PFS,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],
1282,NCT01688232,relapse in relation with the immunoscore determined on a tumor section.,relapse in relation with the immunological events and psychological status of the patient during the monitoring,2012-09-27,UNKNOWN,OBSERVATIONAL,['NA'],
1283,NCT06267703,Chronic atrophic gastritis,,2024-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1284,NCT02169765,Overall survivals,Recurrence rates,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],morbidity
1285,NCT05689775,Perineal wound healing,Abdominal wall strength,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],
1286,NCT00190515,Disease-free survival,Rate of adverse event,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
1287,NCT02860429,neural electrophysiological test,"stress hormone,in blood.",2016-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1288,NCT00339183,Overall Survival,Number of Participants With Adverse Events (AEs),2006-06-30,COMPLETED,INTERVENTIONAL,['PHASE3'],
1289,NCT03722056,rates of intraoperative tumour rupture,,2005-01,COMPLETED,OBSERVATIONAL,['NA'],
1290,NCT00568646,Objective tumor response rate based on tumor measurements according to the RECIST,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
1291,NCT05029882,Objective Response Rate (ORR),Overall survival (OS),2021-10-13,RECRUITING,INTERVENTIONAL,['PHASE1'],
1292,NCT04813523,Major pathologic response (MPR),Pathologic complete response (pCR),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1293,NCT05876026,Difference in T1 relaxation time (ms) in the rectal cancer tumor measured in IntelliSpace-software before and after neoadjuvant radiochemotherapy.,,2023-05-08,RECRUITING,OBSERVATIONAL,['NA'],
1294,NCT01589328,Reduction in depression score,Overall survival,2012-03-15,COMPLETED,INTERVENTIONAL,['NA'],
1295,NCT03925870,Duration of response (DOR),Overall survival (OS) rates,2019-06-21,COMPLETED,INTERVENTIONAL,['PHASE2'],
1296,NCT00985192,Overall Disease-control Rate in Patients With Previously Treated Unresectable or Metastatic Adenocarcinoma of the Upper Gastrointestinal Tract Treated With Everolimus.,Biomarker Correlations: Time to Progression,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1297,NCT03215264,Maximum Tolerated Dose (MTD) of Hydroxychloroquine and Entinostat in Combination With Regorafenib,,2017-10-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1298,NCT05527301,Change in Low Anterior Resection Syndrome score from Baseline to 8 weeks,Change of fecal metabolites assessed by fecal analysis,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1299,NCT00176800,Median Recurrence Free Survival Time,Percentage of Patients That Require Dose Modification Due to Toxicity,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
1300,NCT01282502,To determine Maximum Tolerated Dose (MTD) of midostaurin in combination with standard 5-FU chemoradiation,To evaluate proteomic markers of response and resistance to midostaurin-based chemoradiation,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1301,NCT01657383,Surgical Outcome,,2012-04,COMPLETED,OBSERVATIONAL,['NA'],
1302,NCT03118349,Occurrence of graded adverse events (AEs) in each subject,Cl,2017-06-01,TERMINATED,INTERVENTIONAL,['PHASE1'],Evaluate the relationship between circulating CA19-9 levels and MVT-1075 pharmacokinetics
1303,NCT04596384,Maximum CCI,Change in Sleep,2021-02-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1304,NCT02730104,Time to disease progression,Patient satisfaction with treatment,2015-11-23,COMPLETED,OBSERVATIONAL,['NA'],
1305,NCT03520257,overall survival,,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1306,NCT00928161,Frequency of acid reflux episode (during each 24 hour pH probe),,2012-11,WITHDRAWN,INTERVENTIONAL,['NA'],
1307,NCT05193292,Objective Response Rate,Duration of Response,2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1308,NCT03152435,Occurrence of study related adverse events as assessed by CTCAE v4.0,Determine duration of in vivo survival of EGFR CART .,2017-06-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1309,NCT03401229,Change From Baseline in NBS at Week 40,Change From Baseline in SF-36v2 Mental Health at Week 56,2018-01-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
1310,NCT02555813,Number of participants with adverse events,Best Overall Response,2015-05-08,COMPLETED,OBSERVATIONAL,['NA'],
1311,NCT03295006,Alternative two-compartment TheraSphere dosimetry methodology,Dose reproducibility,2016-10-31,COMPLETED,OBSERVATIONAL,['NA'],Normal tissue dose and tumor dose using post-procedural PET/CT Imaging
1312,NCT06001476,Incidence of complications in the application of cold snare polypectomy for 5-9mm small bowel polypectomy in patients with PJS,Incidence of complications within 28 days after enteroscopy,2023-08-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
1313,NCT05351931,"Incidence of diarrhoea, fecal urgency, anal skin toxicity/mucositis and anal pain CTCAEv5.0 ≥ grade 2 during and up to 6 months after RCT. Anal skin toxicity/mucositis is to be verified by photos.",Disease free and overall survival at 3 and 6 months after stop of RCT.,2022-06,UNKNOWN,INTERVENTIONAL,['NA'],Incidence of AEs CTCAEv5.0 grade ≥ 2 considered probably related to investigational products/placebo.
1314,NCT05587452,Specificity,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],
1315,NCT04380012,Objective Response Rate,The Incidence of Adverse Events,2019-12-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1316,NCT00011960,,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
1317,NCT05356117,Protein Supplementation (PS) Rate,Psychosocial function - Physical Function,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],
1318,NCT00524069,Margin status after pancreatic resection,Toxicity,2007-01,WITHDRAWN,INTERVENTIONAL,['NA'],
1319,NCT02402062,Objective Response Rate,Biomarkers in Serum and Tumor Tissue,2015-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
1320,NCT05875870,Sleep-wake rhythm,Survival rate,2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],
1321,NCT04323917,Assessments of diagnosis of PC by EMT-TF mRNA levels in blood,Prediction of prognosis of PC by EMT-TF mRNA levels in blood,2017-11-02,UNKNOWN,OBSERVATIONAL,['NA'],
1322,NCT00867477,Comparison Patient's PMRR + Mean Exhaled NO Measurement,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
1323,NCT00119912,1. Evaluate the effect on CRC mortality and morbidity by screen detection of CRC and removal of precursor lesions (polypectomy of adenomatous polyps).First evaluation after 5 years.,2. Clarify possible psychosocial effects of endoscopic screening and how it may influence lifestyle and lifestyle related morbidity and overall mortality. Evaluation in 2005.,1999-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1324,NCT01121848,Progression-Free Survival (PFS),Median Overall Survival (OS),2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
1325,NCT01416714,create a database for the collected tissue,To create tissue microarrays for each gastrointestinal cancer subtype,2008-07-02,SUSPENDED,OBSERVATIONAL,['NA'],
1326,NCT02466906,Disease-free survival（DFS）,Adverse effects (AE),2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1327,NCT04389086,Proportion of patients with a clear resection margin,Colorectal cancer specific quality of life,2020-11-13,RECRUITING,INTERVENTIONAL,['PHASE3'],
1328,NCT02965417,Best overall response (OR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,,2016-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1329,NCT06022887,Acceptability of the study,Microbial Deoxyribonucleic acid (DNA) isolation: 16S on V4 region,2023-10-18,RECRUITING,INTERVENTIONAL,['NA'],
1330,NCT00291785,"Phase I: determine the Maximum Tolerated Dose, dose limiting toxicities, safety profile and antitumor activity",,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1331,NCT00058474,Loco-regional disease control as assessed by evidence of tumor at 3 years,Convenience of care as assessed by NSABP C-06 convenience of care scale adapted from ECOG after definitive analysis,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1332,NCT06259058,R0 resection rate,Incidence of adverse events,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1333,NCT04673448,Best objective response,Overall survival,2021-10-18,RECRUITING,INTERVENTIONAL,['PHASE1'],
1334,NCT03956056,Safety of Neoantigen Peptide Vaccine as Measured by the Number of Serious Adverse Events,Immunogenicity of the Neoantigen Peptide Vaccine as Measured by Multiparametric Flow Cytometry,2020-02-13,TERMINATED,INTERVENTIONAL,['PHASE1'],
1335,NCT00789763,TO DETERMINE MTD,RESPONSE (ACCORDING TO RECIST),2007-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
1336,NCT04821778,Overall survival,Distant metastasis free survival,2002-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Radiomics analysis
1337,NCT00516165,Progression-free Survival Rate at 24 Weeks,Overall Survival,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1338,NCT03677050,Boston Bowel Preparation Score,Adenoma detection rate,2018-09-14,COMPLETED,INTERVENTIONAL,['NA'],
1339,NCT04425122,Microbiological culture from biopsy specimens,Overall survival,2020-07-01,RECRUITING,OBSERVATIONAL,['NA'],
1340,NCT00116935,Recurrence-free survival,GIST-specific survival,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
1341,NCT04985604,Phase 2: Evaluate the efficacy of tovorafenib monotherapy or in combination with other therapies,"Phase 2: Assess the safety and tolerability of tovorafenib as monotherapy, or in combination with other therapies",2021-07-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1342,NCT05375708,Progression-free survival,Depth of response,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1343,NCT03125343,3-year disease free survival.,Health economic evaluation,2017-01,RECRUITING,INTERVENTIONAL,['NA'],
1344,NCT04848753,To compare IRC-assessed events-free survival (EFS) in 2 arms,5- year OS rate,2021-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
1345,NCT00005076,Determine the complete and partial response rates and time to progression in patients with refractory advanced colorectal carcinoma treated with cetuximab and irinotecan.,Determine the tumor epidermal growth factor receptor levels in patients treated with this regimen,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
1346,NCT02896803,Response rate,Toxicities according CTCAE v4.03,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1347,NCT04188990,Mortality rate,Patient's functional status,2020-06-15,COMPLETED,INTERVENTIONAL,['NA'],
1348,NCT04214990,The incidence of gastric cancer between the intervention and placebo groups,Improvement of atrophy and intestinal metaplasia,2020-02-15,RECRUITING,INTERVENTIONAL,['PHASE3'],
1349,NCT05485077,Negative predictive value and positive predictive value of polygene methylation in colorectal cancer,,2022-07-09,RECRUITING,OBSERVATIONAL,['NA'],
1350,NCT02089763,Time to progression (TTP),Safety profile of PEG-BCT-100 treatment,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"Biomarker study - to explore the predictive and prognostic functions of tissue biomarkers, ornithine transcarbamylase (OTC) and arginine succinate synthetase (ASS)"
1351,NCT02373020,"virulence genes: eaeA, bfpA and stx. PCR",Strains: OF E COLI,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
1352,NCT03418948,Adenoma miss rate (%),To compare patient reported outcomes e.g. pain,2017-12-08,UNKNOWN,INTERVENTIONAL,['NA'],
1353,NCT01294202,Rate of reduction/stabilisation of tumour size at 4 months according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria,"Treatment emergent adverse events, classified by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.",2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
1354,NCT05313906,ORR,DCR,2022-05-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1355,NCT02370498,Overall Survival (OS) in PD-L1 Positive Participants,Percentage of All Participants That Discontinued Study Treatment Due to AE,2015-05-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
1356,NCT00737802,Pressure at the gastric sling and clasp fibers,,2013-04-12,TERMINATED,OBSERVATIONAL,['NA'],
1357,NCT03030937,Adverse Event（AE）,Quality of Life (QoL),2017-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1358,NCT00093782,Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria),Time to Progression,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
1359,NCT00006366,,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
1360,NCT04150874,Number of Participants with Early Tumor Response,Number of Participants with Early Signs of Radiation Induced Liver Disease (RILD),2020-02-19,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],
1361,NCT00021047,,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1362,NCT04821258,Rate of complications.,Quality of life assessment.,2021-04,UNKNOWN,INTERVENTIONAL,['NA'],
1363,NCT01642797,number of participant with gastric IM/IN/CA,number of biopsies needed per patient,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],
1364,NCT05692024,Change in hepatic fat fraction.,Change in liver fibrosis assessment and plasma levels of liver enzymes,2024-03-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in stool metabolomics
1365,NCT05155124,Incidence of DLT（Dose-limited toxicity）,Adverse Eevents,2022-09,RECRUITING,INTERVENTIONAL,['PHASE1'],
1366,NCT05536102,Pathological complete remission rate,3-year PFS rate,2022-09-05,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events (AEs)
1367,NCT03148093,Reasons for dose adjustments and/or discontinuation of treatments,Burden for caregivers providing support to patients enrolled in the registry per Modified Caregiver Strain Index (MCSI),2017-06-30,TERMINATED,OBSERVATIONAL,['NA'],Progression free survival
1368,NCT03732768,Maximum Tolerated Dose (MTD),,2020-06-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
1369,NCT04923646,Return proportion,Return proportion,2021-06-30,COMPLETED,INTERVENTIONAL,['NA'],
1370,NCT06012734,The RP2D of LB-100 when given in combination with standard doses of atezolizumab,The incidence of dose-limiting toxicity,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Concentration of LB-100 and endothall in tumor tissue
1371,NCT05907642,Low Anterior Resection Syndrome Questionnaire Score,The European Organization for Research and Treatment of Cancer quality of life questionnaire c-30,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],
1372,NCT03843957,Percent of Patients Who Complete the mPATH-CRC Program,mPATH-CheckIn Feasibility,2019-10-31,COMPLETED,INTERVENTIONAL,['NA'],
1373,NCT01063192,The primary end point is to evaluate the time to progression after gemcitabine alone versus Gemcitabine-based combination induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer.,"The secondary end points are to evaluate the disease control rate, overall survival time, toxicity profile and compliance after induction chemotherapy and concurrent chemoradiotherapy .",2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1374,NCT02611024,Response Rate,Overall Survival,2016-05-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1375,NCT00290316,To compare the accuracy of the EUS and CT scan for detection of the primary and metastatic carcinoma of the liver.,2.2.5 To study characteristic echoendoscopic findings of the primary and secondary liver tumor.,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1376,NCT02567942,natural killer cell activity,helper T cell activity,2016-02,COMPLETED,INTERVENTIONAL,['NA'],change of percentage of CD39 and CD73
1377,NCT00059891,Determine the risk of complications and feasibility of total anorectal reconstruction using the Acticon Neosphincter prosthesis after abdominoperineal resection in patients with anal or rectal cancer.,"Determine continence, bowel function, and quality of life of patients treated with this surgery.",2003-01,COMPLETED,INTERVENTIONAL,['NA'],
1378,NCT00557024,Overall survivals,Recurrence rates,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1379,NCT01683357,feasibility on an intention-to-treat basis,safety of the procedure,2001-09,COMPLETED,OBSERVATIONAL,['NA'],reliability of the procedure from an oncological standpoint
1380,NCT02632006,Overall survival,Quality of life,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1381,NCT00566644,Rate of atypical endometrial hyperplasia or endometrial cancer during the active follow-up period of the study,,2007-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
1382,NCT05902533,Assess patient reported GI toxicity using PRO-CTCAE Diarrhea,Proportion of patients requiring a treatment break due to toxicity; measured by more than 3 consecutive fractions missed.,2023-08-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1383,NCT04857203,The Role of Vitamin D in response to neoadjuvant therapy for the patients with locally advanced rectal cancer,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],
1384,NCT00681577,safety (Phase I: toxicities as assessed by NCI CTCAE version 3) and efficacy (Phase II: Feasibility as evaluated by RECIST),To evaluate immunological responses,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1385,NCT00026234,Survival rate,Adverse events as assessed by NCI CTC version 2.0,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
1386,NCT00445497,Incidence of serious adverse events (randomized and registered patients),Health service costs (randomized patients),2007-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1387,NCT01910974,SAFETY THAT IS TO SAY PERFORATION RATE AND delayed BLEEDING ONE,,2012-07,COMPLETED,INTERVENTIONAL,['NA'],
1388,NCT05280665,30-day mortality,Hospital stay,2022-02-14,COMPLETED,OBSERVATIONAL,['NA'],Neoadjuvant treatment usage
1389,NCT06117891,Overall survival (OS),Treatment sequences post first-line AB or other IO combinations,2023-11-27,RECRUITING,OBSERVATIONAL,['NA'],
1390,NCT01547845,PRO symptom measurement,,2012-02-10,COMPLETED,OBSERVATIONAL,['NA'],
1391,NCT03660449,Progression-Free Survival,rate of grade 3-4 radiation pneumonitis,2017-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
1392,NCT00416767,,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
1393,NCT01519817,Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine,Changes in Soluble Cluster of Differentiation 40L (sCD40L),2012-01-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
1394,NCT04191421,Maximal tolerated dose (MTD) of siltuximab that can be combined with spartalizumab,Overall survival time,2020-01-17,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1395,NCT02843802,Relief degree,Overall survival（OS）,2016-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1396,NCT03113604,"Rate of expression of SLAM3 and MDR transcripts, correlation with the responder status or not with Sorafenib",,2015-11-20,WITHDRAWN,OBSERVATIONAL,['NA'],
1397,NCT03743428,Identify biomarkers specific to apatinib or bevacizumab by proteomic analysis,Overall Survival (OS),2020-10-22,SUSPENDED,INTERVENTIONAL,['NA'],
1398,NCT02016274,progression free survival,overall survival,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],quality of life
1399,NCT03260179,AE,PFS,2017-08-31,UNKNOWN,INTERVENTIONAL,['PHASE1'],Exosomes
1400,NCT05418387,Acceptability of the intervention,Proportion of patients who attend a scheduled appointment after their surgery with hepatologists or urologists in control vs. intervention group,2022-09-30,WITHDRAWN,INTERVENTIONAL,['NA'],
1401,NCT03077685,Incidence of Treatment Emergent Adverse Events (safety and tolerability),Change in tumor markers,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
1402,NCT04798560,Development of Postoperative pancreatic fistula after pancreaticoduodenectomy,Overall survival,2018-10-10,UNKNOWN,OBSERVATIONAL,['NA'],
1403,NCT00876551,Closure of postsurgical leak,C reactive protein,2008-01,UNKNOWN,INTERVENTIONAL,['NA'],
1404,NCT02756455,% of patients without leaks after gastric surgery correctly identified by PCT and CRP,PCT cut-off that gives good negative predictive value for leak after gastric surgery in 5th POD,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],
1405,NCT02236884,Composite mesure of prioperative feasibility and safety,Composite mesure of oncological outcome,2014-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1406,NCT01668680,"Length of progression free survival (PFS), measured in months.","Quality of life, as expressed by FACT-C.",2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
1407,NCT00278876,2-year Relapse Free Survival Rate,Toxicity Profile,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1408,NCT05504265,Postoperative pain score,Rate of pulmonary infection,2022-08-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1409,NCT05709249,Two-year disease-free survival (DFS),Changes in total score on the MD Anderson Symptom Inventory for Traditional Chinese Medicine (MDASI-TCM),2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
1410,NCT04599140,Incidence of adverse events (AEs),Overall survival (OS),2020-10-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Biomarker analysis
1411,NCT00568529,Response Rate,time to progression and overall survival,2007-10,SUSPENDED,INTERVENTIONAL,['PHASE2'],
1412,NCT06033482,The lymph node metastasis rates in No.12aa and No.12av groups.,,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],
1413,NCT01293448,Treatment effect,Post procedure pain,2010-12,COMPLETED,INTERVENTIONAL,['NA'],
1414,NCT03523312,The proportion of patients who undergo definitive surgery,,2018-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1415,NCT03309722,distant recurrence,,2008-10-10,RECRUITING,OBSERVATIONAL,['NA'],
1416,NCT03655002,Incidence of adverse events,Overall survival,2019-02-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Circulating immune cell profiles circulating tumor deoxyribonucleic acid (DNA)
1417,NCT02633020,Percent Change From Baseline in the Percentage of Aberrant Intestinal Intraepithelial Lymphocytes With Respect to All Intraepithelial Lymphocytes,Change From Baseline in Total Celiac Disease GSRS (CeD-GSRS) Score at Week 12,2016-04-13,COMPLETED,INTERVENTIONAL,['PHASE2'],
1418,NCT06161909,disease-free survival (DFS),recurrent metastasis pattern,2024-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
1419,NCT05625737,Objective Response Rate (ORR),Adverse Event (AEs),2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory endpoint
1420,NCT03895723,disease-free survival (DFS),Sugical complications,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],
1421,NCT02454075,A Reduction of 25% in the Gastric ECL Cell Density.,"Acid Control Study 3, Control of Gastric Acid Secretion Assess by Changes in Drug-controlled Gastric Acid Analysis: Acid Output",2011-04-11,TERMINATED,INTERVENTIONAL,['PHASE2'],
1422,NCT01828918,postoperative early recurrence,,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1423,NCT00642733,Overall survival; time to progression,"AEs, lab parameters",2007-08,TERMINATED,INTERVENTIONAL,['PHASE4'],
1424,NCT04143191,Recurrence-free survival,Quality of life,2019-09-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1425,NCT01302613,The primary study endpoint for the phase I portion of this study is to assess surgical complications through the Clavien grading system.,The primary endpoint of the phase II portion of the study is complete pathologic response.,2011-03,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1426,NCT03252808,Dose Limiting Toxicity (DLT),Progression-free survival (PFS) by irRECIST,2017-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],1 year survival rate
1427,NCT04304209,complete response rate,Tumor response,2019-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1428,NCT00611858,Pathological Complete Response Rate,1-Year Overall Survival Rate,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],1-Year Disease-Free Survival Rate
1429,NCT05951842,Postoperative immune function (NK cell count),,2018-04-16,WITHDRAWN,INTERVENTIONAL,['NA'],
1430,NCT04792892,Toxicity related to treatment,Sexual function,2021-08-01,RECRUITING,OBSERVATIONAL,['NA'],
1431,NCT01425879,Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1,Progression-free Survival,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1432,NCT00911092,Initial complete clinical response,Prolonged clinical response at one year,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
1433,NCT01472250,chemotherapy regimen,treatment expense,2011-11,COMPLETED,OBSERVATIONAL,['NA'],
1434,NCT01330186,Tumor response,,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],
1435,NCT00447967,Objective Response Rates,Symptoms improvement,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
1436,NCT02761408,Number of participants with treatment-related adverse events assessed by CTCAEv5.0,,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],
1437,NCT00152243,Overall survival and relapse-free survival,Adverse events,1997-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1438,NCT02175992,Health-related quality of life,,2012-03,COMPLETED,OBSERVATIONAL,['NA'],
1439,NCT02975141,MTD of afatinib in combination with gemcitabine/nab-paclitaxel,Incidence of Treatment-Emergent Adverse Events,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1440,NCT01239355,Progression-free Survival,Overall Survival,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
1441,NCT05290480,'Patient Mobility and Observer Mobility Scale,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
1442,NCT01523808,Number of Patients With Dose-limiting Toxicities up to Week 4 After Treatment,Summary of CA 19.9 Over Time,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1443,NCT02636738,Technique success,,2016-06-06,TERMINATED,INTERVENTIONAL,['NA'],
1444,NCT00210106,Complete Hepatic Response Rate at 3 Months,Event-free Survival,2003-06,COMPLETED,INTERVENTIONAL,['NA'],
1445,NCT00601705,Feasibility of Induction Chemoradiotherapy as Measured by Resectability Rate,Postoperative Adjuvant Chemoradiotherapy Feasibility,2008-01-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
1446,NCT01625351,Feasibility of haploidentical HSCT,event-free survival,2012-08-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
1447,NCT02975661,Disease free survival (DFS),Concomitant medication,2017-02-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1448,NCT03006705,Relapse-free survival (RFS),Safety will be analyzed through the incidence of laboratory abnormalities,2017-01-31,COMPLETED,INTERVENTIONAL,['PHASE3'],
1449,NCT01053104,"Toxicities (frequency at each of grades 2, 3 and 4, over all cycles)",Dose intensity in mg/m2/week and toxicities as for stage 1,2009-11,COMPLETED,OBSERVATIONAL,['NA'],
1450,NCT04791644,This study will compare fecal microbiota richness and composition differences between LS patients with no previous adenoma at inclusion in AAS-Lynch study and LS patients with history of adenoma or adenoma at inclusion in AAS-Lynch study.,Gut microbiota composition description,2021-04-20,RECRUITING,OBSERVATIONAL,['NA'],
1451,NCT03748927,"Characterize the natural history of Fibrolamellar hepatocellular carcinoma (FL- HCC), including clinical presentation, family history, patterns of disease progression, response or lack of response to therapeutic interventions, disease recurre...",,2019-04-08,WITHDRAWN,OBSERVATIONAL,['NA'],
1452,NCT00438906,To determine the diagnostic yield of screening high risk patients,,2006-12,COMPLETED,OBSERVATIONAL,['NA'],
1453,NCT05019794,Objective Response Rate (ORR),Accumulation ratio (Racc),2020-05-13,RECRUITING,INTERVENTIONAL,['PHASE2'],
1454,NCT03410914,Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF),Average Length of Stay in Hospital,2018-08-13,COMPLETED,INTERVENTIONAL,['PHASE2'],
1455,NCT04766502,Peritoneal Regression Grading Score (PRGS),Quality of life mesure,2022-01-11,RECRUITING,INTERVENTIONAL,['NA'],
1456,NCT05674773,Metachronous (advanced) neoplasia,Associations with treatment choice,2019-05-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1457,NCT06251050,The incidence of Severe Oral mucositis (WHO grade ≥3),Taste function,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1458,NCT04574245,5-year overall survival,The prognostic predictive value for patients with different C-GCLM classification,2010-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1459,NCT00402025,Number of Participants Positive for Anti-herpes Simplex Virus-1 (HSV-1) Antibodies,Change From Baseline in Pain Intensity,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1460,NCT02792023,The number of patients with colorectal cancer among those with a positive immunochemical fecal test (Positive predictive value),The number of patients without a significant lesion among those with a negative immunochemical fecal test (negative predictive value) after the colonoscopy and after the upper endoscopy,2016-06-30,UNKNOWN,INTERVENTIONAL,['NA'],
1461,NCT03547999,Overall Survival (OS),Progression Free Survival (PFS),2018-06-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1462,NCT03975049,Disease-free survival,Treatment related quality of life,2019-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Tumor regression grade after neoadjuvant therapy
1463,NCT00489697,evaluation of the response to bevacizumab based chemotherapy by RECIST criteria,survival time,2007-01,COMPLETED,INTERVENTIONAL,['NA'],
1464,NCT00084591,Acute toxicity by CTCAE at 6 weeks following study completion,Quality of life as assessed by Quality of Life Questionnaire Core 30 Items (QLQ-C30) before and after radiotherapy and then every 6 months after surgery,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
1465,NCT00362102,Response according to the RECIST criteria accessed every 6 weeks,"Time to progression, duration of achieved response, and the disease control rate will be accessed in all patients who received Cetuximab. The worst toxicity grades per patients will be tabulated for adverse events and laboratory measurements.",2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
1466,NCT04711473,Colorectal Cancer Screening Completion,Choice of Colorectal Cancer Screening Test,2021-10-27,COMPLETED,INTERVENTIONAL,['NA'],
1467,NCT03124394,Overall Survival,Cost-effectiveness,2015-06-01,UNKNOWN,OBSERVATIONAL,['NA'],
1468,NCT04843956,Quality of the sample in relation to the technique,Sample contamination relative to technique,2020-01-08,UNKNOWN,INTERVENTIONAL,['NA'],
1469,NCT05720598,The primary endpoint of this study is the identification rate of ICG-guided SN in advanced GC patients.,Pathological status and regression grade of the retrieved sentinel node after neoadjuvant chemotherapy,2022-11-04,RECRUITING,INTERVENTIONAL,['NA'],
1470,NCT00597311,recurrence rate,Impact on quality of surgical resection,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1471,NCT01860846,Total Activity Impairment (TAI),Number of Participants With Serious Adverse Events,2013-05,COMPLETED,OBSERVATIONAL,['NA'],
1472,NCT03516916,"Impact of demographic, socioeconomic and religious factors on HRQoL in rectal cancer survivors with a colostomy",,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],
1473,NCT02253602,Ferumoxytol dose response,,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
1474,NCT03671369,Number of Participants With Serious Adverse Events (SAEs) and Fatal SAEs,,2018-10-02,COMPLETED,OBSERVATIONAL,['NA'],
1475,NCT00004248,,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
1476,NCT06236568,Survival,Graft survival,2024-02-06,RECRUITING,INTERVENTIONAL,['NA'],
1477,NCT05292443,PFS: Progression-free survival,TTD: Time to Treatment Discontinuation,2021-12-20,WITHDRAWN,OBSERVATIONAL,['NA'],
1478,NCT02745639,Pathological response rate,Acute Toxicity,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
1479,NCT03703063,Treatment safety as assessed by CTCAE v4.03,Response rate,2018-09-17,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1480,NCT05178745,Assessment of resection rate (R0/R1),Safety (serious and non-serious adverse events occurring during treatment,2016-09-07,COMPLETED,OBSERVATIONAL,['NA'],
1481,NCT05991947,Differences in ctDNA gene and tumor-specific proteins expression,,2021-12-01,RECRUITING,OBSERVATIONAL,['NA'],
1482,NCT00428285,High grade dysplasia (AIN 2/3),Tolerability and safety of the treatment,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
1483,NCT02612077,Progression-free Survival,Quality of Life - Global Health Status,2008-05,COMPLETED,OBSERVATIONAL,['NA'],
1484,NCT03832621,"Evaluate the efficacy, measured as 8-month PFS rate, of the combination of temozolomide, nivolumab and ipilimumab in patients achieving disease control following 2-month lead-in treatment with single agent TMZ",Assess quality of life,2019-03-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluate the tumor mutational load
1485,NCT00423306,Response Rate,toxicities,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1486,NCT04383210,Objective Response Rate,,2020-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1487,NCT01666145,Successful Insertion of Ablation Antenna Into Target Lesion,Percentage of Participants With Significant Ease of Lesion Targeting Using Advanced Image Guidance (AIM),2012-02,COMPLETED,INTERVENTIONAL,['NA'],
1488,NCT02000089,Evaluate pancreatic juice for early cancer markers.,Compare pancreas juice with pancreas cyst fluid,2014-01-06,RECRUITING,INTERVENTIONAL,['PHASE3'],Diagnostic performance of a tumor marker gene test for CA19-9 interpretation
1489,NCT01673607,,,2012-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1490,NCT01466504,p63 expression levels,Tumor response,2011-05,TERMINATED,OBSERVATIONAL,['NA'],
1491,NCT00889187,Grade 3-5 Toxicity Rate [Phase II],Surgical Mortality Rate [Phase II],2009-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1492,NCT01395563,muscle mass and strength,quality of life,2009-01,WITHDRAWN,INTERVENTIONAL,['NA'],
1493,NCT02837029,Phase IB: Objective Response Rate (ORR),Disease Control Rate (DCR),2016-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Circulating Free DNA (cfDNA) Mutation Analyses
1494,NCT01946139,Incidence of HSIL Among Women Who Were HRA Negative for HSIL at Study Entry,Acceptability of Anal Cancer Screening,2013-12-04,COMPLETED,INTERVENTIONAL,['NA'],
1495,NCT02909530,Correct histological diagnosis of the mass assessed by each needle,Adverse events,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
1496,NCT02564146,Overall survival (OS),Neurotoxicity Assessment FACT taxane score,2016-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
1497,NCT01956812,overall survival,Clinical benefit,2013-12,TERMINATED,INTERVENTIONAL,['PHASE3'],
1498,NCT05133102,Intra-class correlation coefficients (ICC) by BE status,,2021-03-19,RECRUITING,OBSERVATIONAL,['NA'],
1499,NCT02550743,Maximum Tolerated Dose of BYL719,Pathologic Complete Response for Patients With Rectal Cancer,2016-06-03,TERMINATED,INTERVENTIONAL,['PHASE1'],
1500,NCT01558947,the relapse-free survival time/rate,,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1501,NCT04611035,Efficacy of second-line therapy,Haematologic and non-haematologic toxicities,2020-01-20,UNKNOWN,OBSERVATIONAL,['NA'],
1502,NCT02850874,Peritoneal disease-free survival,Postoperative mortality,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1503,NCT05794048,Theranostic metabolic signatures of TNEP.,Comparison of metabolic profiles on surgical specimen,2022-06-08,RECRUITING,INTERVENTIONAL,['NA'],
1504,NCT05945082,Presence of F.nucleatum in a colon cancer biopsy,,2017-11-29,RECRUITING,INTERVENTIONAL,['NA'],
1505,NCT02291614,Number of Participants With Treatment Emergent Adverse Events (TEAEs),Progression Free Survival (PFS) at 6 Months in Participants Treated at the MTD,2014-11-27,TERMINATED,INTERVENTIONAL,['PHASE1'],
1506,NCT05914766,Self-Efficacy (CASE-Cancer),Quality of Life (FACT-C),2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],
1507,NCT04911647,Re-intervention rate,"Procedure related complication, Postoperative complication",2021-06,UNKNOWN,INTERVENTIONAL,['NA'],
1508,NCT04119622,Major pathological response rate,Overall Survival (OS),2019-10-08,RECRUITING,INTERVENTIONAL,['PHASE2'],
1509,NCT01579591,The impact of the probiotic preparation on increasing the TRG1-2 rate.,Determine whether VSL#3® can have an impact on reduction of late toxicity at 12 and 36 months.,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1510,NCT00954525,"Safety, assessed by toxicity (graded by NCI CTC), urinalysis, ECG, basic metabolic panel, CBC, and osmolality.",Progression-free survival,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
1511,NCT04483076,pCR rate,Five-year overall survival,2021-01-13,RECRUITING,INTERVENTIONAL,['PHASE3'],
1512,NCT03993353,Overall Survival (OS),Adverse event rates,2020-04-07,RECRUITING,INTERVENTIONAL,['PHASE2'],
1513,NCT02489201,Number of participants with Adverse Events,Progression-free survival,2015-07-21,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1514,NCT01453452,"Increase in fruit and vegetable consumption by 1 full serving per day (not including iceberg lettuce, potatoes, or fruit juices) OR reduce caloric intake by 100 kcal/day",DNA methylation patterns,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
1515,NCT04329429,Objective Response Rate (ORR),Adverse Events,2020-08-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1516,NCT02422095,Natural history and disease progression in pancreatic cysts,Evaluate the role of plastic stents in patients undergoing EUS-guided drainage of pancreatic fluid collections.,2015-02,WITHDRAWN,OBSERVATIONAL,['NA'],
1517,NCT04169399,Progression free survival (PFS),Adverse Events,2019-11-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1518,NCT05679050,Disease-free Survival(DFS),Treatment-Emergent Adverse Event Rate,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
1519,NCT02748551,"""Major"" Surgical Morbidity",Extent of lymph node dissection,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1520,NCT04607057,Body weight change for 2 months after surgery,Mortality rate,2020-12-22,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1521,NCT00819559,Disease-free survival,Overall survival Local recurrence Early or late complication associated with preoperative radiotherapy Quality of life Accuracy of clinical staging Difference of surgical outcome between laparoscopic and open surgery,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],
1522,NCT00613080,"The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0, Occurring Preoperatively",Number of Patients Who Underwent Abdominoperineal Resection,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1523,NCT02064803,Change from baseline Gastric Outlet Obstruction Score System - GOOSS,Overall survival,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
1524,NCT00310050,Quantitative Toxicity of Pemetrexed When Administered With Concomitant Radiation Therapy,Number of Participants That Survived,2005-10,TERMINATED,INTERVENTIONAL,['PHASE1'],
1525,NCT04310709,Response rate,Overall survival,2020-06-16,COMPLETED,INTERVENTIONAL,['PHASE2'],
1526,NCT00966706,Progression-free survival at 6-months,Toxicity,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
1527,NCT01102335,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Overall survival,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1528,NCT01522677,Safety,Sustained immunity,2012-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1529,NCT02605265,Pathologic Complete Response,Surgical complications,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1530,NCT02048943,Incidence of adverse events graded by NCI CTCAE version 4.0,Biomarker expression levels in tumor specimens,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
1531,NCT01936233,recurrence free survival,adverse events,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1532,NCT03139058,"Determine the prevalence, by registry data analysis, of cirrhosis in patients with VADS cancer",,2018-08-20,UNKNOWN,INTERVENTIONAL,['NA'],
1533,NCT04072679,Incicende of Adverse Events (AEs),Anti-drug antibody (ADA),2018-10-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1534,NCT00689715,recurrence during follow up,predictive factors for complete resolution,2006-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1535,NCT02910843,Pathological near complete or complete tumor response (npCR or pCR),Postoperative complications,2017-02-22,TERMINATED,INTERVENTIONAL,['PHASE1'],
1536,NCT04062721,Incidence of treatment-emergent adverse events,Potential predictive biomarkers,2021-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
1537,NCT02131441,abdominal adhesion,time to disease recurrence,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],
1538,NCT00062023,"Percentage Change in Colorectal ACF Patients Treated with Sulindac, Aspirin or Ursodiol",,2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
1539,NCT01928524,Median Overall Survival,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
1540,NCT05761717,Overall survival (OS) after initial administration.,,2023-04-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1541,NCT04066543,PFS,,2019-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1542,NCT05078515,Specificity of PREDICT score,,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],
1543,NCT01298401,Dose-limiting toxicity of ganitumab and capecitabine given concurrently with radiotherapy,Overall survival (for patients treated at maximum-tolerated dose of ganitumab),2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1544,NCT01225757,Fluid administration decrease,Cardiac complications,2010-11,WITHDRAWN,INTERVENTIONAL,['NA'],
1545,NCT03563144,Progression-Free Survival,Evaluation of safety as determined by incidence or treatment-emergent adverse events,2018-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1546,NCT02256800,Progression-free survival,overall survival,2014-08-13,COMPLETED,INTERVENTIONAL,['NA'],
1547,NCT02093104,Liver Tumour Perfusion using CT & C-arm systems in 40 patients at VGH over a 3 month period,,2014-02,COMPLETED,OBSERVATIONAL,['NA'],
1548,NCT03109457,Hep C cAg by Immunohistochemistry,,2017-09-06,COMPLETED,OBSERVATIONAL,['NA'],
1549,NCT03910387,Weight stability,Duration of response,2019-04-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1550,NCT04400292,The number of lymph nodes visualized to be fluorescent and nonfluorescent.,,2020-05-20,RECRUITING,INTERVENTIONAL,['NA'],
1551,NCT06070636,Objective response rate (ORR),Overall survival (OS),2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1552,NCT05123209,Incidence of adverse events (AEs) and abnormal laboratory test results as assessed by CTCAE V5.0,Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood),2021-08-24,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1553,NCT03716518,Completion Rate of 8-cycle Adjuvant Chemotherapy,Incidence of SAEs,2018-12-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1554,NCT02855944,Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (ITT Population),Overall Survival (ITT Population),2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1555,NCT03322280,Overall survival (OS),Duration of portal patency,2018-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
1556,NCT03007212,changes in Radiological Response in the (CT/ MRI) after the intervention,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
1557,NCT02369757,Participation rates,Qualitative analysis,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
1558,NCT02242409,4 month progression free survival,Overall Survival,2014-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
1559,NCT03485196,Disease Free Survival,Overall survival(OS),2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],
1560,NCT06050200,Successful resection,Overall morbidity,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1561,NCT00601549,Oncologic Results,Functional recovery of patients,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1562,NCT05411133,Incidence and severity of adverse events,Effect of Cabotamig (ARB202) on tumour as determined by changes in RECIST evaluation from baseline,2022-05-30,RECRUITING,INTERVENTIONAL,['PHASE1'],
1563,NCT04230018,Mutation Consistency of metastatic and primary sites of colorectal cancer patients with postoperative metastasis,Mutation Consistency of tissue and blood sample,2018-12-28,UNKNOWN,OBSERVATIONAL,['NA'],prediction accuracy of survival rate
1564,NCT05869474,Overall survival (OS),Visual analog scale (VAS),2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],
1565,NCT05165602,the relationship between 68Ga SUVmax before treatment and the therapeutic effect will be assessed by SPSS26.0,the relationship between the dynamic change of 68Ga SUVmax and the therapeutic effect will be assessed by SPSS26.0,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
1566,NCT05528783,The diagnostic sensitivity and specificity of FIT-DNA detection for local recurrence and advanced colorectal neoplasm of CRC.,3.The time interval between CRC recurrence and advanced colorectal neogenesis after the first positive appearance was detected by FIT-DNA detection.,2022-04-25,RECRUITING,OBSERVATIONAL,['NA'],
1567,NCT03722498,Progression-free survival,Objective response rate,2018-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1568,NCT03417765,Incidence of treatment-emergent adverse events,Assessment of quality of life,2018-09-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1569,NCT02475889,PD-L1 expression in primary tumor,,2007-11,COMPLETED,OBSERVATIONAL,['NA'],
1570,NCT05755672,"Follow-up examination of tumour remission, progression or recurrence",Quality of life changes,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],
1571,NCT01828762,Vital signs，physical examinations and adverse events,,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
1572,NCT05495152,Disease-free Survival (DFS),,2022-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
1573,NCT02693236,objective rate response (CR+PR) as measured by RECIST criteria,number of participants with adverse events,2014-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1574,NCT06201585,The rate of postoperative complications,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Intraoperative instrument operation error rate
1575,NCT06246448,Time to functional recovery,Abdominal wall complaints,2024-01-23,RECRUITING,INTERVENTIONAL,['NA'],
1576,NCT00164918,Bowel function and related symptoms early post-op,,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1577,NCT03578445,Clinical impact of EUS-guided microbiopsies in patients with pancreatic cystic lesions,Diagnostic values of gene mutations (NGS analyses) in microbiopsy material in the surgical subcohort,2018-02-01,COMPLETED,INTERVENTIONAL,['NA'],
1578,NCT04642547,Progression free survival,Safety endpoint,2020-12-02,COMPLETED,INTERVENTIONAL,['NA'],
1579,NCT03417843,Incidence of adverse and serious adverse events,Technical efficiency of the method,2018-02,UNKNOWN,INTERVENTIONAL,['NA'],
1580,NCT03421327,Qualitative analysis of how parents and children with either Huntington's Disease or hereditary cancer communicate about genetic risk information,,2017-09-01,COMPLETED,OBSERVATIONAL,['NA'],
1581,NCT00017082,,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1582,NCT00208546,toxicity,translational research,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1583,NCT00327093,"Elaboration of a predictive model, based on biological and functional imaging parameters, for the response to monoclonal antibodies as assessed through RECIST criteria 2 months after the beginning of treatment",Correlation between the response at 2 months and that at 6 months of treatment (taking into account the therapeutic adjustments during the 6-month follow-up),2006-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
1584,NCT04683744,"Identify patient knowledge, attitudes, and beliefs that influence decisions to engage in cancer screening and prevention during the COVID-19 pandemic, and barriers to uptake",,2021-01-11,UNKNOWN,OBSERVATIONAL,['NA'],
1585,NCT04634448,The Prevalence of Appendiceal Tumours in Periappendicular Abscess,Surgery after follow-up MRI,2020-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1586,NCT05845502,Overall survival (OS),,2023-05-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1587,NCT03850769,R0 resection rate,,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1588,NCT00172159,Response rate and resectability after neoadjuvant therapy.,Survival of the patients.,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1589,NCT05442632,The proportion of patients who require blood product infusion or intervention with platelet raising drugs due to bleeding during the perioperative period,Incidence of liver failure,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],
1590,NCT05924997,Adverse events (AEs) and serious adverse events (SAEs),Overall Survival,2023-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1591,NCT00958841,Percentage of Responders at Month 6 - Pooled Pancreatic NETs (PNETs),Nelson's Syndrome: Number of Patients Attaining Normalization or a More Than 50% Reduction in Primary Biochemical Tumor Marker,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
1592,NCT02486198,The relief of neurotoxicity in patients with grade 2 or higher neurotoxicity by means of CTC 4.03 and EORTC QLQ-CIPN20,quality of life,2015-05-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1593,NCT01905202,Number of patients with adverse events,Number of participants who develop C. difficile induced diarrhea,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],48 hour gastroesophageal pH measurement
1594,NCT04256707,Combination Therapy Period: Arm C: Number of Patients With Adverse Events (AEs),Combination Therapy Period: Arm C: Overall Response Rate (ORR) as Assessed by RECIST 1.1,2020-01-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1595,NCT05187481,Overall survival,the United States Eastern Oncology Collaboration Group (ECOG) score scale,2021-11-15,RECRUITING,INTERVENTIONAL,['PHASE3'],
1596,NCT05877573,pCR rate,SAE,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],
1597,NCT03388190,Primary - progression-free survival (PFS),Secondary 8 - Quality-of-life (QoL),2018-05-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory 5 - Histologic and molecular tumor biomarkers
1598,NCT03350945,Tumor localization time,Blood loss,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
1599,NCT02162758,Percentage of Participants With Recurrence of Intestinal Metaplasia (IM),Change From Baseline in the Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) Total Score,2014-07,TERMINATED,INTERVENTIONAL,['PHASE2'],
1600,NCT05236972,Disease Free survival [ Time Frame: 3 years ],Overall Survival [ Time Frame: 5 years ],2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
1601,NCT04821895,genetic profiles in gastrointestinal stromal tumor (GIST) patients,To help for search the potential targeted agents for the treatment of these wild type GIST patients,2021-08-28,RECRUITING,OBSERVATIONAL,['NA'],
1602,NCT03528785,"Number of patients achieving R0 resection after preoperative nanoliposomal irinotecan (nal-IRI), Oxaliplatin, Leucovorin (LV), 5-FluoroUracil (5-FU)",assess surgical morbidity,2018-03-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1603,NCT02425930,Disease-Free Survival,Expenditure of hospitalization,2013-08,COMPLETED,OBSERVATIONAL,['NA'],
1604,NCT03914170,Median Progression free survival (PFS),Liver metastases resection rate,2017-04-01,COMPLETED,OBSERVATIONAL,['NA'],
1605,NCT00165490,"To determine the response to the combination of cetuximab, cisplatin, irinotecan, and radiation therapy in resectable esophageal carcinoma.",To determine the progression-free survival of patients treated with combination chemotherapy and radiation therapy.,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
1606,NCT02172651,VDR Binding Sites,Number of Participants with Serious and Non-Serious Adverse Events,2014-07-14,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
1607,NCT05632328,Objective Response Rate,Grade 3-5 Treatment-related Toxicity Rate,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1608,NCT04269746,Evaluate the diagnostic value of long noncoding RNA (CCAT1) expression,,2020-12,UNKNOWN,OBSERVATIONAL,['NA'],
1609,NCT06308445,Evaluation of the safety profile of two doses of rapamycin in adolescents with Familial Adenomatous Polyposis.,"Evaluation of the effect of rapamycin on the size of the largest polyp in each segment (rectum, left colon, transverse colon and right colon) in adolescents with Familial Adenomatous Polyposis",2024-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1610,NCT03097666,Efficacy: Percent Eradication by therapeutic dose,Efficacy: Treatment,2017-03-20,COMPLETED,INTERVENTIONAL,['NA'],
1611,NCT01342705,Cumulative incidence of HepatoCellular Carcinoma during follow-up,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2011-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
1612,NCT03488537,sensitivity/specificity for CRC,Sensitivity/specificity for detection of CRC and/or polyps before and after bowel preparation,2018-02-28,COMPLETED,INTERVENTIONAL,['NA'],
1613,NCT02812628,3-year local recurrence,3-year disease-free survival,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],Perforation rate
1614,NCT03426904,Relapse free survival after randomization,Pathological tumor stage,2018-10-24,RECRUITING,INTERVENTIONAL,['PHASE3'],
1615,NCT00379743,Difference between the two intervention groups in the proportion of participants who complete at least one of the recommended screenings.,Stage at diagnosis.,2006-10,COMPLETED,INTERVENTIONAL,['NA'],
1616,NCT05415345,evaluate the concentration of IgG antibodies to HEV,Serious adverse events occurred throughout the study,2021-10-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
1617,NCT03619668,Changes in position and shape of the tumour during RT.,Change in functional imaging parameter: Ktrans.,2018-06-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1618,NCT03727763,Objective Response Rate(ORR),adverse events,2018-10-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1619,NCT04670445,"Change in participant knowledge, using the Immunotherapy Knowledge Assessment",Patient questions asked in visit with oncologist,2021-01-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1620,NCT03667911,Boston bowel preparation score,cecal intubation rate,2018-09-15,UNKNOWN,INTERVENTIONAL,['NA'],
1621,NCT00003864,,,1999-09-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
1622,NCT03069664,Change in experienced quality of life,Change in need for pancreatic enzyme supplements,2017-11-17,RECRUITING,INTERVENTIONAL,['NA'],
1623,NCT01477814,colorectal cancer screening,cost-effectiveness of various strategies for screening,2008-07,COMPLETED,INTERVENTIONAL,['NA'],
1624,NCT04406831,Analysis of miRNA profile,miRNA PCR expression,2015-04,RECRUITING,OBSERVATIONAL,['NA'],
1625,NCT02375880,"Composite Safety parameters as assessed by new or changing physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratories, concomitant medication reviews, and assessment of adverse events.",Efficacy - Response to treatment evaluated using the Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1),2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
1626,NCT06152419,Patient questionnaire on radiotherapy-related anxiety,,2023-10-17,RECRUITING,INTERVENTIONAL,['NA'],
1627,NCT05252078,DFS,3-year OS rate,2022-06-02,RECRUITING,INTERVENTIONAL,['PHASE2'],
1628,NCT02863770,"The yield of EUS versus contrast EUS to diagnose pancreas cystic lesions, mass lesion, and origin of pancreatitis.",Quantitative Parameters of Pancreas Lesions,2016-07,RECRUITING,INTERVENTIONAL,['NA'],
1629,NCT00949273,postoperative complications,3-years overall survival,2009-07,UNKNOWN,OBSERVATIONAL,['NA'],
1630,NCT00389935,Blood Transfusion requirements,Hemoglobin overall complication rate Constipation Neuropathy,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
1631,NCT03217643,Evaluate the 2-year progression-free survival,,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1632,NCT02017015,Overall Response Rate (ORR) Based on Independent Radiological Review (IRR),Kaplan-Meier Estimate of Overall Survival (OS),2013-12-24,COMPLETED,INTERVENTIONAL,['PHASE2'],
1633,NCT03448341,To assess the changes of deglutition function by means of Videofluoroscopy (VFS) from before to after radiochemotherapy,"To correlate radiation dose features received by the different swallowing related structures (SWOARs) to the changes of MDADI, FEES and VFS scores from before to after treatment by using a Machine Learning Methodology",2016-07-16,COMPLETED,OBSERVATIONAL,['NA'],
1634,NCT02460198,Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor,Duration of Response (DOR) Per RECIST 1.1 as Assessed by the Central Imaging Vendor,2015-08-25,COMPLETED,INTERVENTIONAL,['PHASE2'],
1635,NCT00898768,"The main outcome measure will be the number of neoplastic small bowel lesions, with determination of size, location and histological characteristics at baseline and at follow-up after 2 years.",The secondary endpoint will be the number of complications following endoscopic procedures: rates of capsule retention and postpolypectomy bleeding and perforation.,2009-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
1636,NCT02870010,Tolerance: toxicities will be defined according to the scale: National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTC AE v3.0) to determine the limiting dose,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1637,NCT03310632,tumor assessment in millimeters,Eastern Cooperative Oncology Group (ECOG) status,2017-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1638,NCT03038100,Overall Survival - PD-L1-Positive Subpopulation,Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab,2017-03-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
1639,NCT02839954,Phase I: Adverse events attributed to the administration of the anti-MUC1 CAR-pNK cells,Phase II: Objective Response Rate,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1640,NCT06037343,Hypervascular capsule,Infiltrative nature Classification of the hepatic lesion by LI-RADS in MRI,2023-02-23,RECRUITING,OBSERVATIONAL,['NA'],
1641,NCT00696696,4-month Progression Free Survival (PFS) Rate,Median Overall Survival (mOS),2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1642,NCT01130142,Overall survival comparison,"Comparison of PFS, TTP and ORR",2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1643,NCT04547725,6-month disease control rate,Safety evaluation,2020-09-16,RECRUITING,INTERVENTIONAL,['NA'],
1644,NCT05053191,Frequency of nurses' use of family centered care practices,,2021-09-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1645,NCT00813696,overall survival,time to progression,2002-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1646,NCT04674228,Number of participants who required endoscopic resection of advanced upper gastrointestinal (GI) neoplasms,Number of participants with evidence of progression of upper GI disease,2021-05-07,COMPLETED,OBSERVATIONAL,['NA'],
1647,NCT04224480,Number of CD8+ Ki67+ T cells found in resected tumour from subjects,,2019-12-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
1648,NCT02301091,Overall survival rates,Number of participants with adverse events,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1649,NCT03502317,Global Health Score,Health care utilization,2018-08-14,UNKNOWN,INTERVENTIONAL,['NA'],
1650,NCT03653377,HPV vaccination,,2018-12-17,COMPLETED,OBSERVATIONAL,['NA'],
1651,NCT04696757,DFS,,2018-02-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
1652,NCT06168084,Helicobacter pylori eradication,adverse events,2023-06-06,RECRUITING,INTERVENTIONAL,['PHASE4'],
1653,NCT04331184,Local tumor progression,technical success rate,2020-01-28,UNKNOWN,INTERVENTIONAL,['NA'],
1654,NCT05322499,Objective response rate (ORR),Overall survival (OS),2022-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1655,NCT02848638,Degree and distribution of Y90 particle uptake,,2012-07,COMPLETED,OBSERVATIONAL,['NA'],
1656,NCT00166465,Proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated using the exact binomial distribution.,,2003-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1657,NCT03316053,Cell Markers,,2017-11-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1658,NCT02997956,Median Progression Free Survival,Number of patients alive at two years post treatment,2017-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1659,NCT02018107,"Number and Percentage of Tumors With Complete, Circumferential Ablation Margin Visibility During FDG PET/CT-guided Liver Ablations (AP-PET-1 v. Contrast-enhanced MRI)",Does an Inadequate Ablation Margin on PET Predict Local Progression? Compare to MRI?,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
1660,NCT01032057,Progression-free survival at 39 weeks (from registration) according to RECIST criteria,Radiotherapy quality assurance (adherence to protocol),2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
1661,NCT00875615,Number of Subjects Experiencing Adverse Events,Number of Patients Achieving Clinical Benefit,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
1662,NCT04569331,Quality of life related to health (European Organization for the Research and treatment of Cancer Quality of Life Questionnaire (QLQ-CR29).,Low anterior resection syndrome (LARS),2020-05-15,COMPLETED,INTERVENTIONAL,['NA'],Percentatge of patients with postoperative paralytic ileus
1663,NCT04892927,Improved information sharing,,2021-05-03,UNKNOWN,OBSERVATIONAL,['NA'],
1664,NCT00897494,Analysis of serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis,,2005-02,COMPLETED,OBSERVATIONAL,['NA'],
1665,NCT03599362,Number of Participants Who Proceeded to Surgical Resection,,2018-07-31,TERMINATED,INTERVENTIONAL,['PHASE2'],
1666,NCT00732745,Progression-free survival (Phase II) at 5 months,Correlation of tumor characteristics and tumoral expression with response and outcome (Phase II),2008-10,TERMINATED,INTERVENTIONAL,['PHASE1'],
1667,NCT01264952,"Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms)","Treatment Evaluation of Tumor Response - Measurements of Tumor Lesions by Contrast Enhanced Ultrasonography (US-Doppler), Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Histology",2008-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1668,NCT05314101,progression free survival,Objective Response Rate (ORR),2022-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS)
1669,NCT06121089,Disease-free survival.,Number of days of inpatient treatment.,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],Quality of life in patients after ICR and RHC using questionnaire.
1670,NCT06231524,Overall survival,Progression-free survival,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],
1671,NCT01049620,To assess the maximum tolerated dose (MTD),Response rate,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1672,NCT04006301,Part 2: Overall Response Rate (ORR),Change From Baseline in QTc Interval Based on the Fridericia Correction (QTcF) Method,2019-07-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
1673,NCT01704664,Phagocytic activity of blood platelets in gastric cancer patients.,,2007-03,UNKNOWN,INTERVENTIONAL,['NA'],
1674,NCT03109639,Tissue adequacy rate will be measured by assessing for the presence of histological core tissue representative of the lesion in the samples obtained using the two needles,Qualification of the sample obtained using the two needles will be performed by spectroscopic analysis.The ratio of absorbance at 260 nm and 280nm; the ratio of absorbance at 260nm and 230nm will be measured,2017-04-13,COMPLETED,INTERVENTIONAL,['NA'],
1675,NCT00113360,Progression Free Survival (PFS),,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
1676,NCT01042028,Phase II: Progression-free survival as measured from inclusion to either documentation of disease progression or death,Survival All events grade 1-5 according to NCI-CTCAE in fase I All Adverse events grade 1-5 according to NCI-CTCAEW in Fase II Correlation between effect of treatment and tumourmarkers Quality of life - EORTC QLQ Time to failure of Strategy,2010-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1677,NCT06075836,Reader speed with vs without AI assistance.,,2023-10-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1678,NCT00898495,Comparison of pretreatment clinical tumor staging vs post-treatment pathologic staging (at resection),,2007-05-11,COMPLETED,OBSERVATIONAL,['NA'],
1679,NCT04110093,Progress Free Survival,Adverse Effect,2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1680,NCT04030624,The Feasibility of Remote Electronic Patient Monitoring Intervention,Health Care Utilization,2020-09,WITHDRAWN,INTERVENTIONAL,['NA'],
1681,NCT06242457,Complete resection of adenocarcinomas located in the jejunum or ileum is associated with 5-year survival rates of 20% to 30%.,,2023-07-15,COMPLETED,OBSERVATIONAL,['NA'],
1682,NCT00039793,,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
1683,NCT04348084,impact of clinically relevant (CR-) POPF,identifying positive and negative prognostic factors,2009-01-30,COMPLETED,OBSERVATIONAL,['NA'],
1684,NCT05628038,Local objective response rate,Safety and tolerability of the treatment,2022-08-18,RECRUITING,INTERVENTIONAL,['PHASE2'],
1685,NCT00209651,objective tumor response,"Response duration, time to progression, overall survival, and safety will also be assessed.",2004-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1686,NCT01346917,Prevalence of postoperative nausea and vomiting.,Duration of postoperative hospital stay.,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
1687,NCT01099631,Number of Participants With Dose Limiting Events to Determine the Maximum Tolerated Dose (MTD) of Salmonella Typhimurium,Peripheral Blood T Cells Count,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
1688,NCT00177242,Ascertain the median survival of advanced pancreatic cancer patients treated with Gefitinib and docetaxel.,Determine the time course of serial CA19-9 measurements during treatment.,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1689,NCT01363739,Progression-Free Survival,Overal survival,2009-04,UNKNOWN,OBSERVATIONAL,['NA'],
1690,NCT05920863,Major pathological response,Recurrence-free survival (RFS),2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
1691,NCT03944447,Treatment of Symptoms,Monitoring Adverse Events,2018-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
1692,NCT05350501,Response to treatment at 6 months,Immunogenicity and cross-reactivity,2023-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
1693,NCT02195141,• Pathological complete remission rate (pCR),Number of participants with adverse events (according to the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events v3.0 (CTCAE),2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],• Disease-free survival
1694,NCT01125020,tumor recurrence and metastasis,Postoperative survival,2008-12,UNKNOWN,INTERVENTIONAL,['NA'],
1695,NCT03844620,"Treatment-related adverse events (TRAEs) of interest (grade 3/4 toxicity, intolerable grade 2 toxicity, or any toxicity requiring dose reduction) between arms",Proportion of patients referred to clinical trial,2019-01-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1696,NCT04965597,Graft-Versus Host-Disease (GVHD)-Free Event-Free Survival (EFS),Incidence of cytomegalovirus (CMV) reactivation requiring therapy by day 180 post-HCT,2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE2'],
1697,NCT02013492,Effect of beta-adrenergic blockade on the host immune system,Overall survival,2014-01-21,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
1698,NCT05188573,Clinical performance of test: Specificity,Stage Shift,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1699,NCT00416507,,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
1700,NCT03824899,pathological response rate,,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA'],
1701,NCT04937738,Histopathological regression rate (Becker regression criteria),Median overall survival,2021-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1702,NCT01222208,Whole body protein balance,Synthesis rates of hepatic secretory proteins,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
1703,NCT02557061,Number of alive patients,Rate of preoperative blood T-lymphocytes,2009-04,COMPLETED,INTERVENTIONAL,['NA'],
1704,NCT04906174,Incidence of complications after liver resection,,2021-04-10,RECRUITING,OBSERVATIONAL,['NA'],
1705,NCT01744054,Evaluate y90-PET/MRI and PET/CT for potential on reporting technical success of radioembolization,,2012-10-25,TERMINATED,INTERVENTIONAL,['PHASE1'],
1706,NCT03126435,Overall Survival,Serum Carcinoma Antigen 19-9 (CA 19-9) Response Rate,2018-10-16,COMPLETED,INTERVENTIONAL,['PHASE3'],"Change From Baseline in European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score"
1707,NCT02290574,Adverse Event of Laparoscopic TME and Hyperthermia With CCRT,Pathologic Complete Response of Hyperthermia With CCRT,2014-11,TERMINATED,INTERVENTIONAL,['NA'],
1708,NCT02368977,Device usability factors,Patient safety assessed by number of subjects with adverse events as a measure of safety and tolerability,2013-11-12,UNKNOWN,INTERVENTIONAL,['NA'],
1709,NCT05540951,objective response rate,,2018-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
1710,NCT04290806,Course of treatment (treatment reality),,2019-12-04,RECRUITING,OBSERVATIONAL,['NA'],
1711,NCT01436721,the size of any subphrenic collection or pleural effusion,incidence of postoperative morbidity,2011-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1712,NCT04970498,Changes of ADC map of MRI,,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA'],
1713,NCT01456598,3 year relapse free survival,3 years overall survival,2011-11-21,COMPLETED,INTERVENTIONAL,['NA'],
1714,NCT03352349,Change of Portal vein pressure,Adverse effect of Terlipressurinum,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1715,NCT05141656,OS,PFS,2019-08-31,UNKNOWN,OBSERVATIONAL,['NA'],
1716,NCT05451901,Time to clinical success from randomization,Morphological change of pancreas,2022-07-29,RECRUITING,INTERVENTIONAL,['NA'],
1717,NCT03856255,Mean Score Indicating Ease of Use in Taking a Picture That Included the Measuring Device and Polyp in Order to Photo-document the Measurement Reading,Mean Difference in Size of Polyp,2019-06-24,TERMINATED,INTERVENTIONAL,['NA'],
1718,NCT00588900,The Percentage of Patients Who Are Progression-free at 12 Weeks From the Start of Second-line Therapy,Overall Survival,2008-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
1719,NCT00306137,Percent of patients requiring a blood transfusion anytime in the intra-operative or post-operative period,Health related quality of life measurements,2005-12,TERMINATED,INTERVENTIONAL,['PHASE3'],
1720,NCT03838796,Disease free survival,Overall survival,2019-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1721,NCT03419663,the relationship between overall cereal consumption and gastric cancer occurance,the relationship between other grain and gastric cancer occurance,2017-09-12,COMPLETED,OBSERVATIONAL,['NA'],
1722,NCT00123825,To determine the response rate of the combination gemcitabine and cisplatin in patients with advanced biliary tract and gallbladder cancers,To assess the biomarker CA 19-9 response to the regimen and to correlate the CA 19-9 response with radiologic response and survival,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
1723,NCT06198400,Evaluation of the blood flow in pancreatic remnant with use of ICG,Correlation between ICG perfusion and development of pancreatic fistula,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1724,NCT04640792,Comparison of the Adenoma Per Extraction (APE) between the two arms,Comparison of the Adenoma Detection Rate (ADR) between the two arms,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],
1725,NCT05970705,PFS,DOR,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],AE
1726,NCT01831310,neutrophil functions,Length of stay,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1727,NCT01568151,Number of participants who undergo colorectal screening because of interventions,Number of problems associated with intervention program,2009-04,COMPLETED,INTERVENTIONAL,['NA'],
1728,NCT05652894,Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Independent Review Committee(IRC),Adverse events,2022-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
1729,NCT06206096,ORR,"Safety and tolerability by incidence, severity and outcome of adverse events",2021-05-26,RECRUITING,INTERVENTIONAL,['PHASE2'],
1730,NCT00019006,,,1995-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
1731,NCT05062889,ct-DNA clearance rate after the end of target-driven adjuvant treatment (ERASE-CRC part 1 target-driven),Overall survival TD1 (OS-TD1),2023-05-17,RECRUITING,INTERVENTIONAL,['PHASE2'],
1732,NCT02900664,Frequency of dose reductions,Presence and/or concentration of anti-CJM112 antibodies.,2016-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],
1733,NCT02150135,ECOG score change,Progression free survival rate,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
1734,NCT00506207,Blood level of irinotecan and S-1 and their metabolites,"Maximal response rate, progression-free survival, survival",2006-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1735,NCT03246438,CRC screening completion,Choice of screening test,2017-11-14,COMPLETED,INTERVENTIONAL,['NA'],
1736,NCT04796454,Progression-free survival (PFS),Jaundice scale,2022-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1737,NCT00303758,Overall survival,Duration of hospitalization,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1738,NCT00602147,Association between SNPs in genes that influence melphalan metabolism and development and/or severity of mucositis,,2007-07,TERMINATED,OBSERVATIONAL,['NA'],
1739,NCT03428477,Progression Free Survival (PFS),New Primary Cancers,2018-05-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Change in lean body mass (exploratory endpoint)
1740,NCT01893294,"MTD of gemcitabine hydrochloride defined as the dose at which no more than 3 of 6 patients experience grade 3 or greater adverse events, as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0","Incidence of delayed adverse events associated with this treatment, graded according to the NCI CTCAE v3.0",2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
1741,NCT02395705,Overall survival rate,predictive factors,2015-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1742,NCT01333917,Apoptosis,Number of Participants with Adverse Events,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1743,NCT02720926,Determine the recommended phase 2 dose of TKI258 in combination with XELOX (Capecitabine and Oxaliplatin),Measure the Area under the plasma concentration versus time curve (AUC) of TKI258 at specific timepoints,2011-09,TERMINATED,INTERVENTIONAL,['PHASE1'],
1744,NCT05481476,objective response rate (ORR),adverse events (AE),2023-09,RECRUITING,INTERVENTIONAL,['PHASE2'],
1745,NCT00462553,Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events,Overall survival,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
1746,NCT03781193,Correlation between psychological predictors questionnaires outcome and quality of life,,2018-03-06,UNKNOWN,OBSERVATIONAL,['NA'],
1747,NCT06109207,Feasibility of combination camrelizumab and dalpiciclib as assessed by number of participants who experience adverse events,Overall survival (OS),2023-10-31,RECRUITING,INTERVENTIONAL,['PHASE1'],
1748,NCT02081469,To compare the HBV relapse rate during the follow-up period in HBV carriers with malignant tumor receiving tenofovir for 24 and 48 weeks after the end of chemotherapy.,"To estimate the efficacy of TDF during chemotherapy with after chemotherapy and post-chemotherapy,as measure by the HBV reactivation, clinical relapse and adverse events in all patients.",2014-03-17,COMPLETED,INTERVENTIONAL,['PHASE4'],
1749,NCT03779009,Tumor status of the sentinel lymph node (SLN) and other lymph nodes (LN's),Immunological markers,2018-03-01,RECRUITING,INTERVENTIONAL,['NA'],
1750,NCT00229567,passage of stool.,time to readiness for discharge from hospital,2005-09,TERMINATED,INTERVENTIONAL,['NA'],
1751,NCT01668498,Percentage of patients developing no skin toxicity ≥ grade 2,Skin-toxicity related dose reductions of panitumumab,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
1752,NCT03452501,Incidence of adverse events (AEs) to Remsima®,Proportion of switched patients with UC achieving disease control.,2018-08-26,COMPLETED,OBSERVATIONAL,['NA'],
1753,NCT04633382,Reduction of bed-days,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
1754,NCT04449874,Percentage of Participants With Dose-Limiting Toxicities (DLTs),Relationship Between Tumor Pharmacodynamic Effects of GDC-6036,2020-07-29,RECRUITING,INTERVENTIONAL,['PHASE1'],
1755,NCT03515252,Incidence of Treatment-Emergent Adverse Events [Safety],Quality of Life (QOL),2005-04-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
1756,NCT00048139,Tumor measurement (RECIST criteria),"Efficacy: Time to progression, time to response, duration of response, time to treatment failure, survival.",2001-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
1757,NCT01127698,"Fractures, hip fractures",,1987-03,COMPLETED,OBSERVATIONAL,['NA'],
1758,NCT04114591,Life,,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],
1759,NCT06031285,"RFS, recurrence-free survival",,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
1760,NCT00637728,Average Daily Caloric Intake Over the Course of the 8-week Double-blind Phase,Change in Appetite Over the 8-week Double-blind Phase as Measured by a VAS Appetite Scale,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
1761,NCT05789485,proportion of patients achieving (ratio of delivered to planned treatment) RDI ≥ 90%,,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2'],
1762,NCT01114087,Average difference of the concentration of spermatozoa in the ejaculate measured before treatment and after 6 months of treatment.,Plasmatic concentration of the inhibitors of tyrosine kinase,2008-10,COMPLETED,INTERVENTIONAL,['NA'],
1763,NCT04663789,Clinically relevant postoperative pancreatic fistula (CR-POPF),Length of postoperative hospital stay,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
1764,NCT01325909,Maintain or improve physical fitness (anaerobic threshold measured by CPET)after treatment with neoadjuvant chemoradiotherapy in colorectal cancer patients.,Activity levels before during and after neoadjuvant chemoradiotherapy,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
1765,NCT02454673,Disease Free Survival,Estimate of TN Change From Baseline to Surgery,2013-09,COMPLETED,OBSERVATIONAL,['NA'],
1766,NCT04341337,qualitative analysis of the interviews,,2019-03-02,COMPLETED,OBSERVATIONAL,['NA'],
1767,NCT05954702,Mortality,Drain use time,2023-07-21,RECRUITING,INTERVENTIONAL,['NA'],
1768,NCT04138212,overall survival,postoperative complications,2019-10-22,RECRUITING,INTERVENTIONAL,['PHASE3'],
1769,NCT06221657,Proportion of subjects maintained at HBV DNA <29 IU/mL,blood Phosphorus levels,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
1770,NCT06236282,Operation time,TME quality (Operative outcome),2012-05-01,COMPLETED,OBSERVATIONAL,['NA'],
1771,NCT03706157,Histological analysis of biopsy samples for the evaluation of the kinetics of distribution of doxorubicine in tumor compartments depending on the solvent used for drug reconstitution,"In vivo evaluation of the kinetics of distribution of doxorubicine in tumoral tissue with confocal laser endomicroscopy, depending on the solvent used for drug reconstitution",2018-11-26,COMPLETED,INTERVENTIONAL,['PHASE4'],
1772,NCT00602082,Objective response rate,Quality of life,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
1773,NCT04737213,Ability of SGM-101 and a near-infrared camera system to detect colorectal lung metastases.,,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1774,NCT05226572,Diagnostic yield (%) of repeated EUS-fine needle biopsy of pancreatic masses after previous non-diagnostic or inconclusive results,"Sensitivity (%), specificity(%), positive predictive value(%), negative predictive value(%), specimen adequacy(%), Bethesda classification, adverse events incidence (%) and factors that influenced repeated EUS-fine needle biopsy performance.",2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],
1775,NCT02628067,Objective Response Rate (ORR),Percentage of Participants who Discontinue Study Intervention due to AEs,2015-12-18,RECRUITING,INTERVENTIONAL,['PHASE2'],
1776,NCT02981641,Overal survival,Local control rate,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],
1777,NCT00280618,Time to Tumor Progression (TTP) and Response Rate: evaluated by RECIST,Adverse Events collections and evaluation,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
1778,NCT03927898,1 year Progression-Free-Survival (PFS),Expression of PD-L1 on circulation tumor cell,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1779,NCT04738188,Downstaging success rate,Recurrence rate of Hepatocellular carcinoma,2020-03-18,RECRUITING,INTERVENTIONAL,['NA'],
1780,NCT03145558,Progression Free Survival,Duration of CR,2017-12-05,SUSPENDED,INTERVENTIONAL,['PHASE2'],Time to local recurrence
1781,NCT02128100,Grade 3 or Higher Adverse Event(s) as a Measure of Safety and Tolerability,Overall Response Rate for Participants as Assessed by Contrast-enhanced CT Scan of the Abdomen at 12 Months.,2014-09-19,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life Assessment at 12 Months Post-treatment
1782,NCT05027711,Treatment related Toxicity,Evaluation of potential prognostic biomarkers,2021-08-12,RECRUITING,INTERVENTIONAL,['PHASE2'],
1783,NCT06326502,Dose-limiting Toxicity (DLT),,2024-02-07,RECRUITING,INTERVENTIONAL,['PHASE1'],
1784,NCT02941861,Recurrence rate of Liver Carcinoma after surgery,,2016-08,COMPLETED,OBSERVATIONAL,['NA'],
1785,NCT03694977,Identification of potential biomarkers of MCS110 in combination with PDR001,Safety as measured by number and grade of toxicity events,2019-01-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1786,NCT02745509,Overall survival,Post-operative quality of life,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
1787,NCT04317599,First-line Systemic anticancer therapy (SACT) treatment patterns in BRAFV600E mutant mCRC patients,Time to treatment cessation,2020-04-12,COMPLETED,OBSERVATIONAL,['NA'],
1788,NCT02608229,Maximum Tolerated Dose (MTD) of BVD-523,Overall Survival (OS),2016-06-06,TERMINATED,INTERVENTIONAL,['PHASE1'],
1789,NCT00237172,To study the antineoplastic effect of the investigational drug.,To study the safety and pharmacokinetics of the investigational drug.,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1790,NCT02632448,Maximum Tolerated Dose(s),Overall survival,2016-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1791,NCT04853043,Progression free survival (PFS),Overall survival (OS).,2021-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],
1792,NCT01218880,Maximum tolerant dose,objective response rate,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1793,NCT00447330,Median Progression-Free Survival (PFS),Median Survival,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
1794,NCT00189657,,,na,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1795,NCT04534075,Intensity of the urgency syndrome,Acute side-effects,2020-09-02,RECRUITING,INTERVENTIONAL,['PHASE3'],Composition of microbiota
1796,NCT05043987,Number of participants with dose-limiting toxicities (DLTs) during the DLT evaluation period.,CPO102 immunogenicity: Number of participants with anti-drug-antibody (ADA),2022-11-16,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
1797,NCT02617134,Adverse events attributed to the administration of the anti-MUC1 CAR-T cells,Objective Response Rate,2015-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1798,NCT02053805,"Prevalence, stage and pathology of screen-detected prostate cancer in BRCA1/BRCA2 founder mutation carriers and Lynch mutation carriers","Accuracy of different screening tests (PSA, free to total PSA, prostate MRI) in detecting prostate cancer among men with genetic predispositions.",2014-02,UNKNOWN,INTERVENTIONAL,['NA'],Genomic and biological profiles in samples from BRCA and Lynch mutation carriers and characterize changes related to prostate cancer.
1799,NCT01743300,The feasibility of midazolam as a phenotyping probe for sunitinib exposure (area under concentration time curve)in cancer patients,The influence of sunitinib on CYP3A4 activity,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
1800,NCT03688230,Progression Free Survival (PFS),Number of participants with treatment-related adverse events summarized by CTCAE severity grade (v5.0).,2019-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1801,NCT04297280,Objective Response Rate (ORR),Adverse Events,2020-04-29,RECRUITING,INTERVENTIONAL,['PHASE2'],
1802,NCT01390194,image quality outcome,,2011-07-01,COMPLETED,OBSERVATIONAL,['NA'],
1803,NCT05267275,incidence of complications related to rectal anastomosis,,2021-11-30,RECRUITING,INTERVENTIONAL,['NA'],
1804,NCT00728650,Survival,Efficacy,2003-10,COMPLETED,OBSERVATIONAL,['NA'],
1805,NCT02318095,Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen,Number of Participants Who Received an R0 Resection,2015-02-17,COMPLETED,INTERVENTIONAL,['NA'],
1806,NCT00629863,Overall survival at 12 months of patients last randomized and at 48 months of patients first randomized,"Health resource utilization, including the selection of treatments and subsequent use of health service resources",2004-09,COMPLETED,INTERVENTIONAL,['NA'],
1807,NCT02940496,Incidence of dose limiting toxicity (DLT),Overall survival (OS),2016-12-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1808,NCT05419479,Switch Maintenance-Progression Free Survival,Number of Participants With Treatment-Related Adverse Events,2022-11-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1809,NCT00611507,Response rate - RECIST criteria (unidimensional),Progression-free Survival (PFS),2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
1810,NCT01964027,PFS and OS,,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1811,NCT04783831,POPF,Position and degradation of biodegradable stents,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
1812,NCT03734068,Tumor response,number of treatment required to achieve objective response in HCC patients,2018-06-13,UNKNOWN,OBSERVATIONAL,['NA'],
1813,NCT02984566,Difference in accumulated patient dose distribution with and without KIM,Patient-reported quality of life as measured by the European Organization for Research and Treatment of Cancer Quality-of-Life-Questionnaire-Hepatocellular Carcinoma 18 Module (EORTC QLQ-HCC18),2020-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1814,NCT06265844,Serum prealbumin,Feeding amount,2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],
1815,NCT04677192,OS,Complete ablation rate,2021-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1816,NCT05128890,Hospital charges,,2016-04-16,RECRUITING,OBSERVATIONAL,['NA'],
1817,NCT00900432,Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1),,2004-07,COMPLETED,OBSERVATIONAL,['NA'],
1818,NCT00293436,Disease-free survival (phase II),Overall survival (phase II),2005-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1819,NCT02575807,Phase 2: Progression Free Survival (PFS),Overall Survival (OS),2016-03-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1820,NCT05727163,Objective Remission Rate (ORR),"Safety (including chemotherapy-related adverse events, catheterization-related adverse events, surgical complications, etc.)",2022-07-29,RECRUITING,INTERVENTIONAL,['PHASE2'],
1821,NCT03982121,Recommanded phase 2 dose (RP2D),,2019-06-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
1822,NCT04230772,Incidence of surgical complications,Number of retrieved lymph nodes,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA'],
1823,NCT05509751,Acceptability of the intervention and the study,Effect of the intervention on unplanned healthcare utilization,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],
1824,NCT02005809,Post-ESD bleeding rate according to second look endoscopy,Post ESD bleeding rate according to bleeding degree during endoscopic submucosal dissection,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1825,NCT00478140,Objective Response (Complete and Partial Response),Overall Survival,2007-05,TERMINATED,INTERVENTIONAL,['PHASE2'],
1826,NCT02261844,Improved metabolic profile of liver cells,Decreased hepatic inflammation,2015-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1827,NCT00511264,,,2007-05,COMPLETED,OBSERVATIONAL,['NA'],
1828,NCT00915382,progression-free survival,overall survival,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1829,NCT03099031,Venous thromboembolism recurrence,Heparin induced thrombocytopenia,2015-05,COMPLETED,OBSERVATIONAL,['NA'],Premature treatment discontinuation
1830,NCT02401971,time to progression(TTP),overall survival (OS),2014-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1831,NCT05839002,Five-year survival of patients,,2010-05-21,COMPLETED,OBSERVATIONAL,['NA'],
1832,NCT01158274,Incidence of adverse events graded according to NCI CTCAE version 4.0 (Parts 2a and 2b),Overall response rate (Parts 2a and 2b),2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
1833,NCT01954745,Median Progression Free Survival (PFS),Median Overall Survival (OS),2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1834,NCT00193167,overall response rate,toxicity,2004-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
1835,NCT03966209,Acute Graft Rejection Rate,Over all survival Rate,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1836,NCT00560365,Overall survival by intention-to-treat analysis,NHS cost per life-year saved,2004-03,UNKNOWN,OBSERVATIONAL,['NA'],
1837,NCT06011473,feasibility of CGM system,SSI rate,2023-08-27,RECRUITING,INTERVENTIONAL,['NA'],
1838,NCT04718701,Progression-free survival (PFS),The incidence and severity of adverse events (AEs) and severe adverse events (SAEs),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1839,NCT04246125,Maximum absorbed skin dose and dose distribution,,2020-10-13,COMPLETED,OBSERVATIONAL,['NA'],
1840,NCT03346005,The ability of AeonoseTM to distinguish between patients with and without colorectal cancer in a FIT-positive population in terms of sensitivity and specificity.,Acceptance rate of AeonoseTM.,2017-11-09,COMPLETED,INTERVENTIONAL,['NA'],
1841,NCT00145860,,,2002-04,TERMINATED,OBSERVATIONAL,['NA'],
1842,NCT03365765,disease-free survival,incidence of adverse reactions after chemotherapy,2018-02-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
1843,NCT05507632,Objective response rate (ORR),Overall survival rate,2022-08-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1844,NCT00494299,Time to Progression (TTP),Overall Survival (OS),2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1845,NCT02061956,Efficacy,Safety,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
1846,NCT00363051,Objective Response Rate: Percentage of Participants With Best Over All Response of Complete Response or Partial Response by Central Radiology Review (Stratum 1) Based on Response Evaluation Criteria in Solid Tumors (RECIST),Effect of Octreotide Depot on the Trough Concentrations of Everolimus,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
1847,NCT04141995,Number of patients able to undergo resection surgery,Percentage of subjects with grade 4 thrombocytopenia and grade 3-4 diarrhea,2021-02-12,RECRUITING,INTERVENTIONAL,['PHASE2'],
1848,NCT06119906,Contrast of neoplastic vs non-neoplastic Barrett's,Image quality of Hyper-Spectral Endoscopy after post-hoc analysis,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1849,NCT05100446,Helicobacter pylori eradication,,2021-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
1850,NCT00732082,To determine the dose limiting toxicities of IMP321 in patients being treated with gemcitabine for advanced pancreas cancer.,To evaluate the clinical response and time to disease progression with computed tomography examinations at two month intervals (current standard of care in gemcitabine-treated patients).,2009-02,TERMINATED,INTERVENTIONAL,['PHASE1'],
1851,NCT05938322,Adherence to the ketogenic diet,Investigate indices of quality of life,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1852,NCT05181865,Phase 2a (Expansion): ORR (CR + PR) assessed centrally by RECIST v1.1,Phase 1: PK parameters - Half-life (t1/2),2022-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 1 (Exploratory): Explore the predictive potential of biomarkers measured in blood and/or tumor tissue in response to FL-301
1853,NCT00531245,"In a phase I study, to determine the maximum tolerated dose(MTD) In a phase II study, to evaluate the efficacy(response rates) and toxicities","To investigate the time to progression(TTP), overall survival and toxicity",2006-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1854,NCT01539993,Assess efficacy of percutaneous and transarterial treatments for liver cancer.,long term follow up,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
1855,NCT00438737,Safety (rate of perioperative safety findings),Overall survival,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1856,NCT06187961,Number of Patients Amendable to Curative Surgical Interventions,Quality of Life (QoL) after treatment,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
1857,NCT01786694,functional success of microdialysis,the quality of life after the surgery,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1858,NCT01555762,Progression-Free Survival,Percentage of Participants With Balducci Score,2012-03-05,COMPLETED,OBSERVATIONAL,['NA'],
1859,NCT00075465,Time to tumor progression,Tolerability,2001-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1860,NCT01993784,Objective response rate,adverse events,2013-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1861,NCT01362127,Pathological Complete Histological Response (pCR) After Resection Than Chemotherapy Alone in Patients With Resectable Carcinoma of the Esophagus and Cardia.,HRQOL and Swallowing Function,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
1862,NCT01013649,Overall survival (Phase III),Changes in fatigue,2010-04-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
1863,NCT01423734,reproducibility of diffusion weighted imaging for neuroendocrine liver metastases.,evaluate the reproducibility perfusion insensitive diffusion coefficients (ADC high) of liver metastases,2011-08-23,COMPLETED,OBSERVATIONAL,['NA'],
1864,NCT04924179,Progression-free survival (PFS),AEs,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1865,NCT00955097,identification of liver tumors,improved ablation of liver tumors,2008-05,TERMINATED,INTERVENTIONAL,['PHASE1'],
1866,NCT01429961,Time to progression (TTP),toxicity,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1867,NCT02213419,Rate of Subjects with Complete or Partial response of treatment,Incidence rate of adverse events after treatment,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1868,NCT03846726,PFS,OS,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],
1869,NCT03775525,Dose-limiting toxicity,Apparent Volume of Distribution (Vd/F),2019-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
1870,NCT02963207,Accuracy measures in comparison to the final histopathology in regards to polyps' subtype (SSA/P versus non-SSA/P),Agreement in predicting post-colonoscopy surveillance interval with final histopathology,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
1871,NCT00660140,To determine the response rate and time to failure for patients treated with this regimen,Survival times,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
1872,NCT04106024,PFS,,2018-10-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1873,NCT05044728,Immune Related Adverse Events (irAEs),2-year survival rate,2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1874,NCT02140034,Overall Survival,Peritoneal Recurrence Rate,2013-05,UNKNOWN,INTERVENTIONAL,['NA'],
1875,NCT04722133,Objective response rate (ORR),Incidence of treatment related adverse events (TRAE),2020-06-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
1876,NCT03977090,"Extended period recommended dose,RDE","Antidrug antibody, ADA",2019-04-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1877,NCT04334395,Complication rate,The survival time,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],
1878,NCT03281070,Anastomotic leakage,,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
1879,NCT03285230,Health outcomes,,1990-06-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1880,NCT04967482,Success rate of conversion to resection,Overall survival (OS),2021-07-09,RECRUITING,INTERVENTIONAL,['NA'],
1881,NCT04813406,Overall survival(OS),Disease Control Rate (DCR),2021-03,UNKNOWN,INTERVENTIONAL,['NA'],
1882,NCT02920944,single diagnostic yield of the histologic core,total diagnostic yield of the histologic core,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
1883,NCT02125409,Assessment of the degree of COX-1 acetylation by ASA administered for 1 week.,"Change from baseline in eicosanoid biosynthesis and protein expression of markers of growth and progression of colorectal cancer (such as COX-2, NF-Kb and PI3K/Akt/mTOR pathway).",2014-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1884,NCT02017002,Overall survival duration,Change of lung function after surgery,2014-03,UNKNOWN,INTERVENTIONAL,['NA'],
1885,NCT05687617,Number of patients with peritoneal metastases detected only with ICG.,,2022-12-15,TERMINATED,INTERVENTIONAL,['PHASE2'],
1886,NCT01766349,"Changes of respiratory muscle performance (MIP/MEP, PFT)from baseline",Total length of hospital stay,2011-09,COMPLETED,OBSERVATIONAL,['NA'],
1887,NCT04574050,Feasibility: the number of patients recruited into this study over a 12-month period,,2021-01-11,COMPLETED,INTERVENTIONAL,['NA'],
1888,NCT04151719,Overall Survival,,2020-02-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
1889,NCT06041490,EFFICACY: One-year recurrence-free survival rate (1-year RFS rate),SAFETY: Incidence of adverse events and serious adverse events,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1890,NCT03050879,Total Number of Retrieved Lymph Nodes,3-year overall survival rate,2017-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],
1891,NCT00662688,Thromboembolic events,Tolerance of regimens,2007-10,TERMINATED,INTERVENTIONAL,['PHASE3'],
1892,NCT05775120,"To assess the state of the gastric mucosa according to endoscopic and morphological studies using the OLGA system, and their correlation with serological markers of atrophy",To determine the prevalence of H. pylori in the Moscow population according to the serological method - level of IgG antibodies to H.pylori.,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],Develop recommendations for GC prevention and early detection strategy.
1893,NCT05759975,Oral Mucositis evaluation according NCI scale,Saliva analysis,2023-01-13,RECRUITING,INTERVENTIONAL,['NA'],
1894,NCT02144727,overall survival,Finding biomarkers predicting lymph node metastasis and recurrence,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1895,NCT03881111,OS in PD-L1 biomarker-positive participants,Change from baseline in the EORTC Quality Of Life Questionnaire Oesophageal Module (QLQ-OES18) Score,2019-01-21,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
1896,NCT03618758,Overall survival (Phase 2),Conversion surgery ratio,2018-12-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1897,NCT05629442,Rate of successful pathologic complete response,Overall Survival (OS),2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1898,NCT02040142,Evaluate the technical parameters,Progression-free survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Patient Reported Outcomes
1899,NCT02307500,"activity of regorafenib screening, in terms of 2-months progression free survival rate",safety profile of regorafenib according to NCI-CTC v.3,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
1900,NCT00094861,Number of Participants With Grade 2 or Higher Dysphagia,Maximal Body Weight Loss,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
1901,NCT02787954,Time to progression,1 year survival,2016-01,TERMINATED,OBSERVATIONAL,['NA'],
1902,NCT00501306,,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
1903,NCT00410579,"Comparison of patient-reported outcomes prior to randomization, 1 year after completion of study treatment, and in long-term follow up > 5 years after diagnosis in patients treated in NSABP C-06 or NSABP C-07 trials",,2006-11,COMPLETED,OBSERVATIONAL,['NA'],
1904,NCT04905082,Recall rates of personal genomic results,Operationalization of contextual guideline concordant care,2021-12-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],HOPE-Genomics tool usage
1905,NCT04075305,Toxicity in common toxicity criteria for adverse events (CTCAE).,,2019-02-01,RECRUITING,OBSERVATIONAL,['NA'],
1906,NCT02837159,Body Mass Index,Lower-body flexibility,2016-10,WITHDRAWN,INTERVENTIONAL,['NA'],
1907,NCT01673269,the frequency of bacteremia after ERCP with direct cholangioscopic examination of the CBD,To measure the frequency of fever or sepsis after ERCP with direct cholangioscopic examination of the CBD,2012-07,COMPLETED,INTERVENTIONAL,['NA'],
1908,NCT03033225,Tumor response,,2016-12-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
1909,NCT02560779,Overall Response Rate (ORR),TRC105 Immunogenicity as Assessed by Anti-Product Antibody (APA),2016-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1910,NCT01521780,Expression Levels of Beta-catenin Protein From Core Needle Biopsy (CNB) Equivalents of Resected HCC.,Expression Levels of Low Density Lipoprotein Receptor (LDL-R) in Resected HCC and Adjacent Liver From Whole Tissue Sections.,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1'],
1911,NCT03460080,PIVKA-II,Prothrombin Time (PT) (%),2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
1912,NCT01570452,,,2005-09,COMPLETED,OBSERVATIONAL,['NA'],
1913,NCT01696695,PFS by Therapeutic Regimens,Percentage of Participants With Dose Modification of Capecitabine,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
1914,NCT00909558,Is there any measurable effect upon the underlying cancer as assessed by an increase or decrease in the tumor as measured from baseline using established criteria?,"Are the dosages administered during the study safe, as measured by the number of unexpected and serious adverse events associated with the study drug, as defined by FDA regulations and as measured by established criteria?",2009-05,SUSPENDED,INTERVENTIONAL,['PHASE1'],
1915,NCT02726854,ORR (Objective response rate),Number of participants with treatment-related adverse events as assessed by NCI-CTC（V3.0）,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1916,NCT02532478,Stoma closure rate,,2007-02,COMPLETED,OBSERVATIONAL,['NA'],5-year overall survival
1917,NCT04188145,The Time-to-Treatment Failure (TTF),Quality of Life (QoL),2020-01-27,RECRUITING,INTERVENTIONAL,['PHASE3'],
1918,NCT04418895,complete pathologic response (pCR) rate,Median Neoadjuvant Rectal Score (NAR),2021-08-13,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
1919,NCT06282016,Asthma,Area deprivation,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1920,NCT03042000,3y-DFS,pCR,2017-02,UNKNOWN,INTERVENTIONAL,['NA'],
1921,NCT03935763,Overall survival,Quality of life using Patients Reported Outcomes,2019-03-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1922,NCT02951273,Changes in Internal Carotid Artery Blood Flow by Treatment of Anaesthesia-induced Hypotension,Changes in Stroke Volume From Baseline Before Induction of Anaesthesia.,2016-12-08,COMPLETED,OBSERVATIONAL,['NA'],
1923,NCT06129812,Overall survival,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
1924,NCT00975897,Efficacy of IrMdG with vs without bevacizumab in K-ras mutant tumors,Attitudes of patients about tests and treatment,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1925,NCT05126290,Number of CTNNA1 genotypes associated with a cancer phenotype,,2021-03-16,RECRUITING,OBSERVATIONAL,['NA'],
1926,NCT02862704,Number of patients with adverse event,Detection of transferred T cells in the circulation using quantitative -PCR,2016-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1927,NCT01534923,describe doctor-patient communication about CRC screening,examine the association between the quality of doctor-patient communication about CRC screening and low-income patients' screening outcomes,2012-02-07,COMPLETED,OBSERVATIONAL,['NA'],
1928,NCT02114359,comparison of overall survival,comparison of quality of life,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],comprehensive geriatric assessment
1929,NCT01517009,"The number of patients with (serious) adverse events receiving the combination of 4 courses of docetaxel, cisplatin and capecitabine as neoadjuvant chemotherapy and standardized surgery in resectable localized or locally advanced gastric cancer.",The number of patients receiving a D1-extra-resection as protocolized surgery in resectable gastric cancer,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
1930,NCT03531606,Anterior resection syndrome improvement change,Other biomarkers,2016-12-12,COMPLETED,INTERVENTIONAL,['NA'],
1931,NCT05637567,Hematogenous metastases-free survival,Number of resected lymph nodes,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
1932,NCT04411524,Pathologic Complete Response Rate,"Quality of Life Scale, range 0-60. It evaluates the quality of life from 12 aspects, including appetite, mental status, sleep quality, fatigue, etc. The higher scores mean a better quality of life.",2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1933,NCT04759846,Encorafenib AUC(0-inf),MRAUC,2021-01-21,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
1934,NCT00397878,Median Progression Free Survival (PFS),Time to Progression,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Pre- and Post-treatment Expression Values for Each Biological Correlate
1935,NCT00443196,"Complete Response, No Response",,2006-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1936,NCT04993378,EV-Score,Survival significance of EV-Score,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
1937,NCT03322995,Completion of all intended neoadjuvant therapy and surgical therapy,Progression-free survival,2018-06-21,RECRUITING,INTERVENTIONAL,['PHASE2'],
1938,NCT05970159,Postoperative complications,Mortality,2023-08,RECRUITING,OBSERVATIONAL,['NA'],Days of ICU stay
1939,NCT00273247,Recurrence Free Survival,Overall Patient Survival,1998-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1940,NCT01383538,The maximum tolerated dose (MTD) for FOLFIRINOX plus IPI-926 in patients with advanced pancreatic cancer.,Objective response rate (ORR) by RECIST criteria,2011-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],
1941,NCT03189576,ctDNA level,,2015-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1942,NCT02692365,Exploratory study for the determination of tissue changes of advanced hepatocellular carcinoma induced by electromagnetic waves amplitude modulated low energy specific frequencies during image MRIstudy.,,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
1943,NCT03806426,Total Number of Polypectomies (polyps > 5mm in the rectum) conducted during the 24 months study period,Change in score on the InSIGHT Polyposis Staging System (IPSS) at 24 months,2018-12-05,RECRUITING,INTERVENTIONAL,['PHASE3'],
1944,NCT02848443,Changes in ECOG (Eastern Cooperative Oncology Group) performance status as a measure of safety and tolerability for S95005-oxaliplatin,"PDL-1 expression, tumour-infiltrating CD8 T cell density, for S95005-oxaliplatin + nivolumab",2016-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Peripheral blood mononuclear cells
1945,NCT01861678,Anastomotic leakage rate,Amount of blood loss,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1946,NCT05995821,Biological specimens obtained from cancer patients,,2016-08-25,RECRUITING,OBSERVATIONAL,['NA'],
1947,NCT02488746,Rate of cases in which a complete macroscopic en bloc resection of the gastric subepithelial tumor could be achieved,Number of participants with needs of surgical therapy or endoscopic re-resection,2015-03,TERMINATED,OBSERVATIONAL,['NA'],
1948,NCT03248661,Primary endpoint is a received completed FIT kit within 15 months after the participant received results from the original FIT test,,2015-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1949,NCT01396707,Overall response rate,Overall survival,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
1950,NCT03644459,AUC(0-∞) of T1h after Each Subsequent Introduction (multiple dose),PGA after Each Subsequent Introduction (multiple dose),2019-04-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Half time (t1/2) of T1h after Each Subsequent Introduction (multiple dose)
1951,NCT06284226,To evaluate the safety and the efficacy,,2022-03-25,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],
1952,NCT05171335,Percent Tumor Necrosis,Explant Biomarkers,2022-06-20,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],
1953,NCT01963117,Time to Local Tumor Progression After Combined Hyperthermia and RT,Overall Survival Rate After Combined Hyperthermia and RT,2013-10,TERMINATED,INTERVENTIONAL,['NA'],
1954,NCT01529164,response rate,Number of participants with adverse events,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1955,NCT05838391,Time to plan and deliver treatment fractions.,Complete Clinical Response Rate,2023-05-18,RECRUITING,INTERVENTIONAL,['NA'],
1956,NCT00410774,Disease-free survival rate at 1 year,Median overall survival rate at 1 and 2 years,2006-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1957,NCT04258566,ICG Fluorescene,Exvivo fluorescence,2022-01-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1'],
1958,NCT04379999,Genome-wide expression analyses using RNA-Seq,Acceptability of the pilot study intervention and the willingness of the subject to participate in a similar larger study.,2018-09-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
1959,NCT02253511,Overall survival,Recurrence-free survival,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],Number of participants with adverse events
1960,NCT03177681,Percentage Change in Firmicutes in Stool from Baseline to Day 12,Adherence Rate of Dannon® Oikos® Yogurt Intake,2022-03-01,WITHDRAWN,INTERVENTIONAL,['NA'],
1961,NCT04161781,Feasibility of 18F-BMS-986229 PET in participants with Gastroesophageal Cancer,,2019-11-12,COMPLETED,OBSERVATIONAL,['NA'],
1962,NCT04827732,Maximum tolerated dose (MTD) of reirradiation using hypofractionated IMPT,Frequency of late adverse events as measured by CTCAE v 5.0,2021-05-04,RECRUITING,INTERVENTIONAL,['NA'],
1963,NCT04855448,learning curve of surgicla failure,Disease free survival,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],
1964,NCT05449860,Local tumor progression rate,Technical success rate,2020-01-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1965,NCT02457624,Detection rate for gastric premalignant lesion,Detection rate for gastric dysplasia,2008-03,UNKNOWN,OBSERVATIONAL,['NA'],
1966,NCT04673526,Quality of life associated to incontinence as assessed by Faecal incontinence quality of life scale (FIQL),Post-operative complications,2009-01-01,COMPLETED,INTERVENTIONAL,['NA'],
1967,NCT02934958,Colonoscopy Completion,,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],
1968,NCT01522209,Detection of Liver Metastasis during Operation,Comparison of Specicivity of all imaging modalities,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
1969,NCT04411537,Pathologic Complete Response Rate,"Quality of Life Scale, range 0-60. It evaluates the quality of life from 12 aspects, including appetite, mental status, sleep quality, fatigue, etc. The higher scores mean a better quality of life.",2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1970,NCT02165215,"Maintenance Phase: Percentage of Participants in Remission at Week 62 Among Randomized Participants With a Clinical Response at Week 10, as Determined by the Mayo Clinic Score (MCS)",Maintenance Phase: Etrolizumab Serum Trough Concentration (for Arms/Timepoints Below LLOQ),2014-08-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
1971,NCT03234465,Efficacy of AG013 Compared to Placebo for Reducing OM as Measured by Duration (in Days) of Severe Oral Mucositis (WHO Grades 3 or 4),,2017-07-18,TERMINATED,INTERVENTIONAL,['PHASE2'],
1972,NCT05419531,rate of young endurance athletes that have colorectal cancer on screening colonoscopies.,Comparison of the rate of young endurance athletes that have colorectal cancer on screening colonoscopies with that of the historical controls (those in the average risk group).,2022-10-18,RECRUITING,OBSERVATIONAL,['NA'],
1973,NCT02415829,The tumor regression grade of all the patients enrolled,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1974,NCT00354601,Objective Tumor Response,Quality of Life,2006-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
1975,NCT05318404,Percentage of body weight loss,Postoperative daily protein intake,2020-12-08,COMPLETED,INTERVENTIONAL,['NA'],
1976,NCT05108428,Feasibility of MRI guided dose adaptive chemoradiation therapy,Number of Participants with Pathological Complete Response (pCR),2021-12-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Number of Participants with Disease-Free Survival (DFS)
1977,NCT05670561,Pain Intensity at 12hours after the beginning of TACE operation,Analgesic Consumption,2023-01-05,RECRUITING,INTERVENTIONAL,['PHASE4'],Quality-of-Life Assessment at 24hours after the beginning of TACE operation
1978,NCT05043363,Clinician experience of LumenEye examination,"Diagnostic accuracy of the LumenEye for the detection of rectal pathology including tumour, polyps and inflammation",2020-11-14,COMPLETED,OBSERVATIONAL,['NA'],
1979,NCT04696055,Overall Response Rate (ORR) Per RECIST 1.1 by Central Assessment,Number of Participants With Dose Modification,2021-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1980,NCT00267046,Median Maximum Score for Patient Reported Outcomes in 2 Blinded Cycles,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
1981,NCT06157463,Change of FAPI SUV,Correlation of FAPI SUV,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1982,NCT05936931,CRC screeningintentions,,2024-02,WITHDRAWN,INTERVENTIONAL,['NA'],
1983,NCT04923672,Steps per day,Fitness level,2023-02-20,RECRUITING,INTERVENTIONAL,['NA'],
1984,NCT03649945,3 year disease-free survival rate,overall survival,2018-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1985,NCT03110328,overall survival,,2018-02-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
1986,NCT04246177,Overall Survival (OS),TTP per RECIST 1.1,2020-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
1987,NCT00918827,Relapse-free survival,,2009-04-01,COMPLETED,OBSERVATIONAL,['NA'],
1988,NCT05070598,ORR (Objective control rate),OS(Overall survival),2021-09-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1989,NCT02649348,The proportion of postoperative complications,,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
1990,NCT02186886,Clinical response,Calprotectin stool levels,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],molecular spectral range
1991,NCT04662346,correlation to post-operative complication,,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
1992,NCT00002935,,,1995-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
1993,NCT02138617,Progression Free Survival,Overall Survival,2014-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
1994,NCT03884868,Grade of distress experienced by patients,Grade of understanding of the information reported by patients,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],
1995,NCT04183218,Cardiac event rate at 12 months,Overall survival,2019-09-23,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Imaging changes
1996,NCT01313377,Quality of life,Toxicity of adjuvant chemotherapy,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
1997,NCT06217016,secondary catheterization owing to urinary retention,Postoperative complications,2024-03-21,RECRUITING,INTERVENTIONAL,['NA'],
1998,NCT02311803,Sexual function,5-year recurrence pattern,2015-02,UNKNOWN,INTERVENTIONAL,['NA'],
1999,NCT03168152,Time to local tumor progression,Incidence of intrahepatic failure,2017-05-11,WITHDRAWN,INTERVENTIONAL,['NA'],
2000,NCT02047500,Number of Subjects Experiencing Dose Limiting Toxicity (DLT),Number of Subjects With Treatment-emergent Adverse Events (TEAEs),2014-01,TERMINATED,INTERVENTIONAL,['PHASE1'],
2001,NCT01373320,Proportion of participants reporting the health behavior of interest (depending on which intervention component(s) were selected),"Retention (i.e., number of participants who complete all planned assessment timepoints)",2010-03,COMPLETED,INTERVENTIONAL,['NA'],
2002,NCT05476432,Overall survival,the predictive power of thymidylate synthase (TYMS),2022-07-26,RECRUITING,INTERVENTIONAL,['PHASE3'],
2003,NCT00609310,Recurrence rate of neoplasia,"Recurrence free survival, Overall survival, Serum-Flavonoid levels of patients",2015-05,SUSPENDED,INTERVENTIONAL,['PHASE2'],
2004,NCT01094600,Primary outcome: correlation between S-MRCP with ePFT,,2012-06,WITHDRAWN,INTERVENTIONAL,['NA'],
2005,NCT03909997,Number of patients with severe 30-day or in-hospital morbidity,Median and percentage of patients with long-term survival,2019-04-05,UNKNOWN,OBSERVATIONAL,['NA'],
2006,NCT00497497,Incidence and nature of dose-limiting toxicities,Incidence and severity of infusion reactions,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
2007,NCT03792269,Progression-free Survival (PFS),Adverse Events (AE),2016-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2008,NCT02170090,Disease free survival (DFS),locoregional control (assessed by the rate of patients with hepatic or locoregional recurrence),2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
2009,NCT04068896,Number of Patients with Clinically Significant Laboratory Abnormalities:,Skeletal muscle index during therapy with NGM120,2019-10-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2010,NCT02542436,Overall Survival (OS),Percentage of Participants with Adverse Events of Special Interest,2015-09-01,WITHDRAWN,OBSERVATIONAL,['NA'],
2011,NCT03458975,Objective response for liver metastases,Dosage of cytokines,2019-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2012,NCT03567629,"Progression-free Survival: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first.",The incidence of treatment related emergent adverse events（Safety and Tolerance）,2018-05-29,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2013,NCT02581215,Progression Free Survival (PFS),Characterize Adverse Events (AE),2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2014,NCT02543762,"Prevalence and incidence of dysplasia and colitis-associated colorectal cancer in patients with longstanding colonic inflammatory bowel disease (N-IBD), in Spain",Usefulness of advanced endoscopy in displasia characterization (chromoendoscopy ) for the diagnosis and endoscopic differential diagnosis of NIBD.,2012-02,COMPLETED,OBSERVATIONAL,['NA'],
2015,NCT04484909,Recommended phase II dose (RP2D),Overall survival (OS),2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Resection status
2016,NCT00910494,surgical complication rate,local control,2010-01,TERMINATED,INTERVENTIONAL,['NA'],
2017,NCT05552729,Cognitive function,Asthenia,2022-09-22,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2018,NCT01956864,Number of participants on high dose Vitamin D with adverse events,Changes in the expression of serum and imaging biomarkers,2013-09,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
2019,NCT06304597,Temperature,Evaluate targeted detection with nivolumab-800CW and durvalumab-680LT of the tumor by ex vivo visualization of the resection specimen with PEARL Trilogy,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
2020,NCT03722628,The level of Matrix metalloprotinease-1 genotypes polymorphism in the study population,,2018-12-15,UNKNOWN,OBSERVATIONAL,['NA'],
2021,NCT02660671,Colonoscopy participation,Scheduling of colonoscopy,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
2022,NCT03461341,Utilisation of routine surveillance imaging across European Centers,Health-related quality of life (HR-QL) as assessed by EORTC QLQ-C30 questionnaire,2009-06-01,COMPLETED,OBSERVATIONAL,['NA'],
2023,NCT05040425,Mucositis pain,Body mass index (BMI),2021-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],Electrical body conductivity
2024,NCT02246634,Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.,To describe the impact of MR screening on treatment received by patients who are diagnosed with liver metastases.,2014-08,RECRUITING,INTERVENTIONAL,['NA'],
2025,NCT01196000,Rate of conversion to open surgery as an indicator of surgical technical difficulty,Health economics,2011-12,WITHDRAWN,INTERVENTIONAL,['NA'],
2026,NCT02046174,Overall Survival,Pain Assessment,2014-04-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Necrosis Comparison of Tumors Using PET-CT Scan
2027,NCT00005053,,,1999-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
2028,NCT05500027,Differentiation expression of serum sCD58 and TGfbeta1 among pancreatic cancer and other conditions,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],
2029,NCT00848094,"Toxicity was graded using the CTCAE 3.0. Dose-limiting toxicity was defined as acute ≥ grade 3 hepatic or gastrointestinal toxicity, or any grade 5 treatment-related adverse event, or late complication of radiation-induced liver disease.","1,2 and 3 years survival",2005-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
2030,NCT01312467,"Change in Activated S6serine235 (i.e., the Ratio of pS6serine235/S6serine235)",Safety and Tolerability of Metformin Hydrochloride Treatment,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
2031,NCT02394769,Change in Urinary Prostaglandin Metabolites (PGE-M),Spectral Biomarkers of Colorectal Cancer,2015-07-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2032,NCT02781532,Evaluation of ingesta,,2014-04,COMPLETED,OBSERVATIONAL,['NA'],
2033,NCT00310882,,,2006-05,WITHDRAWN,OBSERVATIONAL,['NA'],
2034,NCT00617071,Screening utilization over the 6-month observation period,Identification of predictors of CRC screening use and screening preference,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2035,NCT02960282,"Best tumor response, defined as a complete response or a clear decrease in tumor burden",,2016-10-20,TERMINATED,OBSERVATIONAL,['NA'],
2036,NCT03762590,"Change of genetic testing among family members of mutation positive PDAC patients, among family members of mutation positive individuals with a family history of PDAC and among first-degree relatives of PDAC patients","Uptake of surveillance for pancreatic, other associated cancers and health behaviors",2019-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2037,NCT03945799,Disease free survival,Overall survival,2019-04-22,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2038,NCT02724397,Number of Proximal Serrated lesions and colorectal adenomas in proximal colon,Improvement of histological diagnosis for serrated lesions and colorectal adenomas using LCI/BLI by comparing with that under white endoscopy,2016-05-01,UNKNOWN,INTERVENTIONAL,['NA'],
2039,NCT01522820,"Incidence of adverse events in patients receiving the DEC-205/NY-ESO-1 fusion protein CDX-1401 with and without sirolimus, as evaluated according to the NCI CTCAE scale version 4.0",NY-ESO-1 specific humoral immunity,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Time to disease progression
2040,NCT03422120,Natural Killer Cell Activity (NKA) at baseline compared to POD1 in CRC surgery patients,Natural Killer Cell Activity (NKA) in healthy donors (HD) as compared to colorectal cancer (CRC) patients (at baseline),2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],
2041,NCT03662659,BICR-Assessed Objective Response Rate (ORR) in Randomized LAG-3 Positive (>=1 %) Participants,Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests,2018-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],
2042,NCT05961709,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",,2025-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2043,NCT02801500,Bilioenteric anastomotic leakage,Bilioenteric anastomotic stricture,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
2044,NCT00004002,,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
2045,NCT00033371,Number of Participants With Adverse Events Occurring at a Frequency of 5% or Grade 3 and Higher,Percent Change in the Area of Plaque-like Duodenal Polyps,2001-12-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Percent Change in Polyp Size in Focal Area(s) of the Colorectum
2046,NCT00155805,,,2004-02,UNKNOWN,OBSERVATIONAL,['NA'],
2047,NCT00568425,Evaluate the late effects of radiation treatment,,2005-09,TERMINATED,OBSERVATIONAL,['NA'],
2048,NCT03358095,Emerged complications related to surgery or preoperative endoscopy within 120 days of surgery,,2017-11-26,WITHDRAWN,INTERVENTIONAL,['NA'],
2049,NCT00508846,Patient Responses to Questionnaire,,2003-05,COMPLETED,OBSERVATIONAL,['NA'],
2050,NCT04222530,Diagnostic accuracy,Operating time,2020-01-28,UNKNOWN,INTERVENTIONAL,['NA'],
2051,NCT01901692,Progression-free survival (PFS) rate,Exploratory analysis for overall patient survival rate,2013-07-29,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2052,NCT04776590,Pathologic complete response rate,overall survival,2021-01-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2053,NCT04392050,Successful completion of the key contact interviews and focus groups leading to the development of the culturally tailored educational intervention,,2020-01-31,RECRUITING,OBSERVATIONAL,['NA'],
2054,NCT01260168,The primary endpoints are point estimates of the sensitivity of the diagnostic tests for detection of colorectal neoplasms.,To collect samples from patients diagnosed with colorectal cancers.,2010-10,COMPLETED,OBSERVATIONAL,['NA'],
2055,NCT01903694,determination of the tumor according to the evaluation criteria of Response Evaluation Criteria in Solid Tumors,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
2056,NCT04595864,OS,PFS,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
2057,NCT02779608,response rate of ascites,side effects of chemotherapy,2017-01-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2058,NCT06203327,early gastric neoplasm,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],
2059,NCT01082315,Safety,Clinical efficacy,2009-04,COMPLETED,OBSERVATIONAL,['NA'],
2060,NCT03645655,Change of PIVKA-II,Change of AFP,2018-10-01,COMPLETED,OBSERVATIONAL,['NA'],
2061,NCT02403544,Maximum Tolerated Dose (MTD) for capecitabine and oxaliplatin,Tumor response rate including complete response and partial response rates,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2062,NCT00335959,Pathologic Complete Response,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug,2006-05,TERMINATED,INTERVENTIONAL,['PHASE2'],
2063,NCT04572633,Primary Safety: Procedure-Related Major Complications,Secondary Safety: All Adverse Events,2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2064,NCT05637268,3-year DFS rate,5 years OS rate,2020-11-26,RECRUITING,INTERVENTIONAL,['PHASE2'],
2065,NCT00862524,Assess the efficacy of the study drug in combination with gemcitabine in terms of progression-free survival (PFS) at 16 weeks.,"Characterize the safety profile of study drug in combination with gemcitabine in terms of adverse events, clinical laboratory tests and electrocardiograms.",2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2066,NCT04440735,DSP107 Serum Concentration,Preliminary Efficacy (Part 2 only),2020-10-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2067,NCT00590278,"This study will evaluate the value of TOMUDEX in combination with a 'standard' course of pelvic radiotherapy for inoperable/recurrent rectal cancer, in terms of response rate and increasing the resectability rate",,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
2068,NCT04704960,correlation between circulating tumor DNA (ctDNA) before and after local treatment (surgery or radiation) and recurrence of lung metastases from colorectal cancer,mutations related to target drug,2021-02,UNKNOWN,OBSERVATIONAL,['NA'],
2069,NCT02919969,Overall Response Rate,Incidence of Adverse Events to Evaluate the Safety and Tolerability of Pembrolizumab,2016-10-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
2070,NCT03332576,Safety as measured by adverse event reporting (CTCAE),Impact on residual tumour,2013-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],
2071,NCT04422002,Survival,Surgical complications,2019-12-01,COMPLETED,OBSERVATIONAL,['NA'],
2072,NCT03592550,Difference in liver position after set-up,Number of available imaging positions,2018-09,UNKNOWN,OBSERVATIONAL,['NA'],
2073,NCT00500292,Number of Patients With an Objective Disease Progression Event,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
2074,NCT02077881,Overall Survival,Time to Progression of Disease,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2075,NCT02470559,Toxicity profile of IP and IV HER2Bi-aATC at the MTD or technically feasible dose graded using NCI CTCAE version 4.0,Progression free survival,2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
2076,NCT06061445,ORR,,2024-01-09,RECRUITING,INTERVENTIONAL,['NA'],
2077,NCT03844750,Proportion of patients with a >= 2-fold increase in the tumor-infiltrating cells per unit area (5 high power fields) in post- versus pre pembrolizumab treatment tumor specimens.,Median Relapse-free survival (RFS) per RECIST 1.1,2019-07-22,RECRUITING,INTERVENTIONAL,['PHASE2'],
2078,NCT03391843,Pelvic complete resection rate,The incidence of >=3 grade adverse events,2017-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2079,NCT01393249,Risk of pancreatitis,Course of pancreatitis,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
2080,NCT02851784,"Cumulative survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test.","disease free survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test",2009-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Local tumor progress rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test"
2081,NCT04678011,Advanced neoplasia,Complications,2020-11-24,RECRUITING,OBSERVATIONAL,['NA'],
2082,NCT01640522,Depression,Fatigue,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
2083,NCT02792881,Morbidity,The Surgery Task Load Index (SURG-TLX),2016-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
2084,NCT02008539,Safety and tolerability as indicated by Common Toxicity Criteria (CTC-AE) of the National Cancer Institute,,2013-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2085,NCT03775863,Incidence of recurrent hepatocellular carcinoma after liver transplantation.,Survival in patients with hepatocellular carcinoma after liver transplantation.,2017-11-11,COMPLETED,OBSERVATIONAL,['NA'],
2086,NCT00075439,Proportion of patients progression-free at 6 months,Time to treatment failure,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
2087,NCT01673334,Diagnostic Yield,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
2088,NCT01068769,"Clinical Benefit as Defined by the Composite of Complete Response, Partial Response and Stable Disease Lasting 16 Weeks or More Per RECIST 1.1 as a Measure of Disease Control",Progression-free Survival (PFS),2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2089,NCT03301805,Part II: Overall response rate (PR + CR),Part II: Incidence of grade 3/4 hematological toxicity,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2090,NCT04331743,Recommended Phase II Dose (RP2D),Duration of Response (DoR),2021-06-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2091,NCT06249321,"progression-free survival, PFS",disease control rate (DCR),2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2092,NCT01189929,To determine the maximum tolerated dose of demcizumab (OMP-21M18) when combined with gemcitabine +/- Abraxane®,To determine the exploratory biomarker changes of gemcitabine plus demcizumab (OMP-21M18),2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
2093,NCT01549327,Empowerment,Cost-effectiveness,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
2094,NCT05789433,Whole-Body Intermuscular Adipose Tissue,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],
2095,NCT03445585,Number of participants in the study.,Number of clinical phenotypes and/or endpoints observed (per category),2017-01,RECRUITING,OBSERVATIONAL,['NA'],
2096,NCT00504998,"Clinical toxicity (DLT and MTD) as defined by patient performance status, toxicity assessment score, hematologic, and metabolic profiles.",To identify an objective tumor response to Rexin-G,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2097,NCT00764595,Progression-free survival,Types and severities of adverse events,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2098,NCT05495776,Frequency of microsatellite instability and Lynch syndrome,Impact of the presence of microsatellite instability/deficiency,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],
2099,NCT05854498,Progression Free Survival (PFS),Efficacy of irinotecan measured by PFS for patients with and without irinotecan containing regimens,2023-10-13,RECRUITING,INTERVENTIONAL,['PHASE2'],
2100,NCT00920868,To determine the maximum tolerated dose(MTD)/recommended phase II dose (RPTD) of capecitabine/oxaliplatin/bevacizumab/dasatinib for patients with advanced solid tumors.,"To explore any correlation between blood, urine, and paraffin biomarkers and clinical outcomes",2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
2101,NCT02279134,Disease-free survival (DFS),Overall survival (OS),2014-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Adverse events
2102,NCT02675738,Number of cases with confirmed preoperative diagnosis,,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],
2103,NCT00009737,Disease-free Survival,Number of Participants With Any Adverse Events and Serious Adverse Events,1998-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
2104,NCT00576134,Respiratory evaluation,Nasofibroscopy,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
2105,NCT00356161,Safety of device and regional therapy,quality of life,2002-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2106,NCT02726399,Progression Free Survival,,2016-03-18,TERMINATED,INTERVENTIONAL,['PHASE2'],
2107,NCT03519997,Overall Response Rate,Safety and Tolerability: rates of adverse events according to the CTCAE,2018-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment response
2108,NCT00159471,"To see if patients with advanced pancreatic cancer treated with gemcitabine, docetaxel and capecitabine who bear more favorable genotypes of genes involved in drug metabolisms are more likely to have response and survive longer than those that do not.","To assess time to progression, toxicity and to identify other molecular correlates of response, toxicity, and survival.",2005-02,TERMINATED,INTERVENTIONAL,['NA'],
2109,NCT03442569,Overall Response Rate,Toxicity of Treatment,2018-03-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2110,NCT01152645,Antitumor effect,Adverse events,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2111,NCT01305993,Evaluating Tumor Response Rate,Determine duration of response rate by measuring time to progression,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2112,NCT00837031,"Six-Month Overall Survival (OS) Probability, the Percentage of Patients Estimated to be Alive Six Months After Beginning Protocol Treatment","Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death",2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2113,NCT03581773,CTCAE Mucositis,QOL MDASI,2017-12-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2114,NCT03447951,Objective Response Rate (ORR),EQ-5D-5L quality of life score,2018-06-19,RECRUITING,INTERVENTIONAL,['PHASE2'],
2115,NCT01185483,,,2009-11,UNKNOWN,OBSERVATIONAL,['NA'],
2116,NCT02858206,Adverse events,Recurrence rate,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2117,NCT01792934,Overall survival,Safety and efficacy of the additional local treatment measured by number of serious adverse events.,2013-05,RECRUITING,INTERVENTIONAL,['NA'],
2118,NCT02200250,Reviewing patients symptoms following resection,,2021-10-01,WITHDRAWN,OBSERVATIONAL,['NA'],
2119,NCT00524186,"Maximum tolerated dose of sunitinib malate when administered with FOLFIRI chemotherapy (i.e., irinotecan hydrochloride, fluorouracil, and leucovorin calcium)",Correlation of pre- and post-therapy changes in CEC number and VEGF expression with response rate and survival,2007-05,TERMINATED,INTERVENTIONAL,['PHASE1'],
2120,NCT01593475,feasibility and compliance,disease-free survival.,2011-09-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2121,NCT03993327,Percent of known liver lesions per standard staging scans identified on iodine I-124 (I-124) M5A imaging,Incidence of adverse events,2020-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
2122,NCT03165721,Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST),Change in Distress From Baseline,2017-08-16,TERMINATED,INTERVENTIONAL,['PHASE2'],
2123,NCT01607255,Number of Participants With Detected Proximal Diminutive (<10 mm) Adenoma Detection Rate,,2013-05-16,COMPLETED,INTERVENTIONAL,['PHASE4'],
2124,NCT02031536,Disease Free Survival (DFS),Overall Survival (OS),2014-04-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
2125,NCT04177797,Complete pathologic response rate,Incidence of adverse events,2020-03-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2126,NCT01686880,Peri-operative morbidity,Contra-lateral Lobe Hypertrophy,2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
2127,NCT03205176,Incidence of dose-limiting toxicity (DLT).,Clearance (CL).,2017-06-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
2128,NCT05002452,Tumor Response,Distant control,2021-12-20,RECRUITING,OBSERVATIONAL,['NA'],
2129,NCT04680104,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,economical impact,2015-11-03,COMPLETED,OBSERVATIONAL,['NA'],
2130,NCT02427841,R0 Resection Rate Defined as Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins by Pathologic Assessment,Response Rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Defined as the Percent of Subjects With Complete or Partial Disease Response as Confirmed Through Tumor Imaging With Computed Tomography (CT),2016-01-21,COMPLETED,INTERVENTIONAL,['PHASE2'],
2131,NCT05793554,Validation of tissue classification through fluorescence perfusion,Usability of video sharing and annotation technology in multiple sites,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2132,NCT05448157,"To evaluate the diagnostic efficacy and the safety of the combined approach with β-probe and 68Ga-DOTA-TOC PET/CT in the correct identification of primary tumor and lymph node metastases, in patients with GEP-NETs candidates to surgery",,2022-05-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
2133,NCT03357991,Determine the predictive value of HPV E6/E7 mRNA for the detection of HSIL and its ability to predict incident cases.,Cost-effectiveness analysis of an anal cancer screening strategy based on HPV E6/E7 mRNA analysis.,2015-01-11,UNKNOWN,OBSERVATIONAL,['NA'],
2134,NCT00578721,Rectal Tissue Putrescine Reduction,Safety/Toxicity,2008-09-24,COMPLETED,INTERVENTIONAL,['PHASE2'],
2135,NCT00002455,Survival rate,,1971-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2136,NCT05845294,Anxiety of patients was assessed by Hospital Anxiety and Depression Scale,,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],
2137,NCT05769959,Part 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs),"Part 1, 2, 3: Overall survival (OS)",2023-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2138,NCT04466267,The molecular mechanism of patients primary or secondary resistance to cetuximab,,2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],
2139,NCT05286814,Determine overall response rates,Determine hepatic progression-free survival (PFS),2022-10-24,RECRUITING,INTERVENTIONAL,['PHASE2'],
2140,NCT02229058,Progression-free survival,Disease control rate,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2141,NCT04652440,Measure Tolerability,Median Disease-free survival (mDFS),2020-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2142,NCT00578279,The Change in Mean Pain Scale Rating in Patients Following Treatment With 10mL or 20mL of Alcohol Injection,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
2143,NCT05372198,Progression-Free Survival (PFS),adverse events (AE),2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE2'],
2144,NCT03563157,"Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1","QoL for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component",2018-05-25,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2145,NCT05250895,To investigate the variability of hypoxia in HCC at baseline as quantified by immunohistochemistry,Treatment response,2022-04-28,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
2146,NCT03856658,Hepatic progression-free survival,EORTC Quality of Life Questionnaire,2019-02-05,RECRUITING,INTERVENTIONAL,['PHASE2'],
2147,NCT01138904,Response rate by RECIST,overall survival,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
2148,NCT00647530,Pathological down-staging as measured by depth of extramural spread among patients allocated to preoperative chemotherapy with or without panitumumab,Adverse events,2008-05-15,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2149,NCT05384184,Build the next generation biobank of liver-derived organoids,Evaluate the clinical relevance of the generated organoids,2019-06-06,RECRUITING,OBSERVATIONAL,['NA'],
2150,NCT01754623,Margin-negative (R0) Resection Rate,Overall Survival (OS) Rate,2013-02,TERMINATED,INTERVENTIONAL,['PHASE2'],
2151,NCT06290505,Progression free survival rate is the proportion of patients alive and progression free (the cancer has not worsened) assessed by CT Scan and clinical review.,Overall survival.,2021-12-08,RECRUITING,INTERVENTIONAL,['PHASE2'],
2152,NCT04903548,SPECT CT,,2021-04-20,RECRUITING,OBSERVATIONAL,['NA'],
2153,NCT03215017,"Bowel function, Low anterior resection syndrome (LARS)",Quality of Life (QoL),2017-05-15,COMPLETED,INTERVENTIONAL,['NA'],
2154,NCT03086993,Overall Survival,Objective response rate (CR + PR) as determined by the Investigator,2018-04-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Incidence of Treatment-Emergent Adverse Events (Safety)
2155,NCT03827044,Primary End point: Disease Free survival,Secondary End Points: Toxicity of Investigational Medicinal Product according to the NCI-CTCAE (Common Terminology Criteria for Adverse Events) version 4.0.,2018-08-31,TERMINATED,INTERVENTIONAL,['PHASE3'],
2156,NCT04164797,progression-free survival(PFS),overall survival (OS),2019-11-25,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2157,NCT04662853,Gut-microbiota-based color-rectal cancer diagnosis.,Dietary habits,2017-01-17,UNKNOWN,OBSERVATIONAL,['NA'],
2158,NCT01791374,Part 2: Dose-limiting toxicities (DLT) for each dose level of rilotumumab in combination with cisplatin and capecitabine (CX) chemotherapy tested,"Part 2: Evaluate efficacy based on the treatment effects of rilotumumab in combination with cisplatin and capecitabine as measured by the following: Objective Response Rate, duration of response, progression-free survival, overall survival.",2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
2159,NCT01686412,Autonomic response monitoring (blood pressure digital and manual monitoring),Baroreflex sensitivity (by the method of sequence),2012-07,COMPLETED,INTERVENTIONAL,['NA'],
2160,NCT05875558,ORR,OS,2022-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
2161,NCT05001321,Texture of nuclei,Recurrence/metastasis,2021-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
2162,NCT05217446,Progression-free Survival (PFS),Objective Response (OR),2022-07-11,RECRUITING,INTERVENTIONAL,['PHASE2'],
2163,NCT01358812,Response Rate,Analyses of Potential Predictive Factors,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
2164,NCT04669951,Tumor-to-background ratio,uPAR in patient groups,2019-11-18,COMPLETED,INTERVENTIONAL,['NA'],
2165,NCT05141643,Tumor drug uptake within PDAC tumors prior at pre-treatment baseline,changes in [18F]-FAC drug uptake during or following SOC chemo- and/or radiation therapy.,2021-11-18,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
2166,NCT00491140,Association of different biomarkers with Cetuximab sensitivity,Association of different biomarkers with time to progression and survival,2006-12,COMPLETED,OBSERVATIONAL,['NA'],
2167,NCT00867113,Kaplan-Meier Estimates for Recurrence-free Survival up to 60 Months,Kaplan-Meier Estimates for Overall Survival (OS) up to 60 Months,2009-07-22,COMPLETED,INTERVENTIONAL,['PHASE2'],
2168,NCT01739608,Participation rate to FS and CT Colonography,Type of false positive detections of Computer-aided detection for CTC in a CRC screening program,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
2169,NCT03487939,The ratio of tumor downstaging to stage 0 and stage I,Quality of life (QLQ C30),2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2170,NCT00643682,Boston Bowel Preparation Scale Score,Number of Repeat Procedures Recommended Due to Inadequate Bowel Preparation.,2006-02,COMPLETED,INTERVENTIONAL,['NA'],
2171,NCT05879172,success rate of anastomosis,time period of recovery,2021-07-01,COMPLETED,INTERVENTIONAL,['NA'],
2172,NCT04820179,Overall Response Rate or Stable Disease,T2 Signal,2021-10-12,RECRUITING,INTERVENTIONAL,['PHASE2'],
2173,NCT00006155,,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
2174,NCT04163627,Technical procedures evolutiveness,Regional disparities,2019-11-30,UNKNOWN,OBSERVATIONAL,['NA'],
2175,NCT05877352,Availability of potential primary outcome data,Resource use and cost,2022-05-18,RECRUITING,INTERVENTIONAL,['NA'],
2176,NCT03815461,PFS,Adverse reaction rate,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2177,NCT00096083,To determine the response rate and duration of response to intra-hepatic infusion of melphalan with subsequent venous hemofiltration in patients with primary and metastatic hepatic malignancies,To determine the progression free and overall survival in patients with hepatic malignancies following this therapy,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
2178,NCT00582829,Phone follow-up interview. Participants will be contacted by study assistant and the survey administered.,,2003-06,COMPLETED,OBSERVATIONAL,['NA'],
2179,NCT02032368,Change of circulating tumor cell(CTC) count at different timepoints,,2010-07,COMPLETED,INTERVENTIONAL,['NA'],
2180,NCT01262183,1-year overall survival,CTCs and CECs,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
2181,NCT00093652,Response (phase II),Immunohistochemistry,2003-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2182,NCT01605318,Percentage of Participants With Laboratory Abnormalities,Change from Baseline in Carcinoembryonic Antigen (CEA) Serum Levels,2013-02-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2183,NCT03335813,Percent Volume of the Tumor Receiving the Prescription Dose (V100),Number of Participants With the Need for Dilation,2018-03-06,COMPLETED,INTERVENTIONAL,['NA'],
2184,NCT00866957,HIF-1alpha bio-marker,Understand biological behavior of the tumors,2006-02,COMPLETED,OBSERVATIONAL,['NA'],
2185,NCT03387098,Objective response rate by RECIST,"Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.",2018-01-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2186,NCT02942238,Disease-free survival,The accuracy of preoperative staging with CT,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],
2187,NCT02514551,Progression Free Survival (PFS) in Ramucirumab 12mg/kg Arm I4T-MC-JVCZ,Number of Participants With Anti-Ramucirumab Antibodies,2015-10-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
2188,NCT03603756,objective response rate,treatment-related adverse events,2018-07-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2189,NCT01485744,Toxicity,Response Rate,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
2190,NCT03634982,Number of participants with dose limiting toxicities (DLTs),Duration of Response (DOR),2018-09-28,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2191,NCT05491616,Disease Free survival 18 months,overall survival at 2 years,2022-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],
2192,NCT02520154,Progression-free survival,Overall survival,2016-07-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in biomarker expression level
2193,NCT03960008,To compare the duration of disease control in treated lesions when utilizing SBRT versus TACE as a bridging strategy for patients with HCC eligible for liver transplantation,To assess 90 day Post-transplant mortality,2020-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
2194,NCT00839111,"Progression-Free Survival (PFS) ,defined as the time from treatment to disease progression or death due to any cause","Secondary endpoints are disease control rate, defined as a complete response, partial response, and stable disease; Response rate and overall survival; and safety are also evaluated.",2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2195,NCT04413526,The survival rates for one-year to five-year,The Child-Pugh score after therapy,2020-05-25,COMPLETED,OBSERVATIONAL,['NA'],
2196,NCT00576056,Determine Progression-free Survival in This Patient Population Treated With the Proposed Combination Treatment Modality,Determine the Overall Survival in Patients Treated With This Combination Regimen,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
2197,NCT02571374,Number of participants with colorectal cancer on symbiotic to prevent postoperative infection,,2013-10,UNKNOWN,INTERVENTIONAL,['NA'],
2198,NCT04795063,Morbidity rates,Time of digestive tract reconstruction,2021-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2199,NCT06195254,progression-free survival (PFS),Pain relief rate (PRR）,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],
2200,NCT04036643,Tumor response assessed by modified the Ryan tumor regression grading system obtained by quantification of the residual cancer cells compared to fibrosis on the surgical specimen,Calculation of the Net Reclassification Index (NRI) by comparing the sensitivity of [18F] -FDG-PET / MRI and the sensitivity of MRI alone for TRG1,2019-11-27,UNKNOWN,INTERVENTIONAL,['NA'],
2201,NCT04878783,Predictive performance of radiomics analysis on the pre-treatment CT scan.,Association between radiomics and molecular expression in regards to long-term outcomes,2019-12-20,UNKNOWN,OBSERVATIONAL,['NA'],
2202,NCT05595473,Number of participants with adverse events (AEs) in part 1 and 2 as graded by NCI-CTCAE,To determine safety and efficacy of RZ-001 by changes in overall survival (OS) of the partipants in Part 1 as graded by RECIST v1.1 and mRECIST,2022-07-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2203,NCT00926536,"Cumulative Dose (CD), a Measure of Radiation Dose",,2009-04,COMPLETED,INTERVENTIONAL,['NA'],
2204,NCT02221245,"Percentage of samples with identifiable Notch, Wnt and Hedghog pathways in the chemo naive esophageal tumor as well as in cancer stem cell populations (CSC).",,2013-04-05,TERMINATED,OBSERVATIONAL,['NA'],
2205,NCT02351765,Maximum Tolerated Dose (MTD) of Aclerain in combination with Cisplatin,Exploration of the pharmacokinetic profile for the combination of Acelarin with Cisplatin,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
2206,NCT01950442,Safety of gentle dilation,impact on staging,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
2207,NCT02559024,Immune Score,,2016-03-14,TERMINATED,INTERVENTIONAL,['PHASE1'],
2208,NCT04080414,Feasibility of home-based high-intensity interval training among colorectal cancer survivors,,2019-08-02,COMPLETED,INTERVENTIONAL,['NA'],
2209,NCT02101099,Peak push force is increased in patients receiving propofol as compared to conscious sedation.,,2014-03,COMPLETED,OBSERVATIONAL,['NA'],
2210,NCT03557216,Presence of ACN,Fecal calprotectin test predictive value for ANC detection,2018-06-15,COMPLETED,INTERVENTIONAL,['NA'],
2211,NCT01053923,Primary tumor apparent diffusion coefficient at simulation and during week 3 and last week of fractionated radiotherapy from MRI,Change with time from start of radiotherapy course in primary tumor apparent diffusion coefficient from MRI,2009-12,WITHDRAWN,OBSERVATIONAL,['NA'],
2212,NCT05990231,Objective response rate,Adverse events,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
2213,NCT03035136,Adenoma detection rate,Polyp detection rate,2017-01-15,COMPLETED,OBSERVATIONAL,['NA'],
2214,NCT02823691,incidence of SAEs and AEs,biochemical responses to Lanreotide ATG 120 mg in combination with Metformin,2016-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
2215,NCT04843397,Define the prevalence of pre-malignant upper GI tract lesions as measured by standardised endoscopy and biopsy protocol,Correlation between life-style factors and pathological outcomes,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],
2216,NCT00057876,Overall Survival Time,Overall Response,2003-08-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
2217,NCT05555901,Progression-Free Survival (PFS),Overall survival (OS),2023-06-18,RECRUITING,INTERVENTIONAL,['PHASE2'],
2218,NCT04677998,Advanced neoplasia,Surgery,2020-11-24,RECRUITING,OBSERVATIONAL,['NA'],
2219,NCT00954655,response,,2008-12,COMPLETED,OBSERVATIONAL,['NA'],
2220,NCT00521404,Progression-Free Survival Rate at 16 Weeks Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or Metastatic Pancreatic Cancer,Number of Participants With Treatment-Emergent Adverse Events Considered by the Investigator at Least Possibly Related to Gemcitabine Experienced by ≥5% of Participants by System Organ Class and Preferred Term,2007-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],
2221,NCT01356030,Direct comparison of tissue sampling techniques for patients with suspected pancreaticobiliary cancers.,,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
2222,NCT02215837,Progress-free survival,Severity of adverse events,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2223,NCT01806272,The incidence of grade II and less oral mucositis at the end of treatment,Tumor response to chemoradiotherapy,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2224,NCT02699073,Tumor response rate at 2 months according Choi Criteria,Correlation between Baseline cell free DNA and survival outcomes (PFS and OS),2016-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2225,NCT02480361,Remnant sitz markers in small intestine at postoperative day 7,hospital stay,2013-01,COMPLETED,INTERVENTIONAL,['NA'],serum albumin level in postoperative day 7
2226,NCT01365910,Overall Response Rate (Complete Response + Partial Response) With a Target of at Least 15%,Number of Patients With Each Worst-Grade Toxicity,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
2227,NCT03904121,Postoperative mortality,Functional performance,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],
2228,NCT00325611,Quality and cost of care,Lower total costs 6 months past hospitalization,2002-04,COMPLETED,INTERVENTIONAL,['NA'],
2229,NCT00403052,Occurrence of adverse events,Overall survival time,2006-11,TERMINATED,INTERVENTIONAL,['PHASE1'],
2230,NCT01219543,To investigate the safety and tolerability of AZD1480,To obtain a preliminary assessment of the anti-tumour activity of AZD1480,2010-11,TERMINATED,INTERVENTIONAL,['PHASE1'],
2231,NCT02955901,Score of mucosal visualization,Withdrawal time,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],Patients characteristics questionnaire
2232,NCT01362361,progression free survival,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2233,NCT01609660,Mucosal cytokine,Short chain fatty acids,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
2234,NCT00226941,Dose-limiting Toxicity (DLT) - Number of Participants Affected,Survival at 5 Years,2004-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2235,NCT01180959,Progression Free Survival (PFS),Overall Survival (OS),2011-04-14,COMPLETED,INTERVENTIONAL,['PHASE2'],
2236,NCT03161522,Overall survival (OS),Time to local or regional disease recurrence,2018-02-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Time to disease progression
2237,NCT01009801,Time to progression (Phase II),Time to treatment failure (Phase II),2010-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2238,NCT04608786,Recommended phase II dose (RP2D),the number of subjects presenting detectable anti drug antibodies (ADAs),2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2239,NCT00410618,Nature and long-term ramifications of CNS injury as a result of cancer treatment,Relationship between MRI measures and cognitive performance,2003-04,COMPLETED,OBSERVATIONAL,['NA'],
2240,NCT05732129,"Objective response rate of Metastatic Colorectal Cancer,inculdthe proportion of patients with complete response or partial response",The Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2241,NCT04601727,16s rRNA pyrosequencing analysis of microbial flora of rectal cancer patients,Categorisation of microbial flora against response to neoadjuvant chemoradiotherapy,2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],
2242,NCT04748744,Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases,,2019-11-06,COMPLETED,OBSERVATIONAL,['NA'],
2243,NCT04296851,Mean percentage change of the number and size of polyps in colon and/or duodenum.,A qualitative assessment of the total extent of colorectal polyposis,2020-02-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2244,NCT02296736,Review pre-operative imaging to distinguish the organ of origin of pancreatic head tumours,Resectabilty of the pancreatic tumour,2014-10,COMPLETED,OBSERVATIONAL,['NA'],
2245,NCT05981066,Clinically significant abnormal changes in laboratory tests,"Overall Survival, OS",2023-07-10,RECRUITING,INTERVENTIONAL,['NA'],
2246,NCT01134666,Safety and tolerability evaluated based on the incidence and severity of AEs.,Response rate,2009-11-30,TERMINATED,OBSERVATIONAL,['NA'],
2247,NCT00868114,Overall Survival,,2006-07,TERMINATED,INTERVENTIONAL,['PHASE2'],
2248,NCT02376478,"Number of anogenital warts, anogenital HPV DNA positivity and mucosal HPV seropositivity",,2009-12,COMPLETED,OBSERVATIONAL,['NA'],
2249,NCT04430231,Disease-free overall survival,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],
2250,NCT01103492,Number of Participants With Adverse Events,,2008-07,COMPLETED,INTERVENTIONAL,['NA'],
2251,NCT05163028,"To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), of HBI-2376 as an oral monotherapy for advanced solid tumors harboring KRAS or EGFR mutations.",Pharmacokinetic variables including volume of distribution,2021-12-13,RECRUITING,INTERVENTIONAL,['PHASE1'],
2252,NCT00314353,One-year Progression-free Survival (PFS),Duration of Response,2006-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
2253,NCT05887531,Post-surgical readmisions,Strength,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],
2254,NCT01255007,To establish superiority of Primovist-enhanced liver MRI and DWI to MDCT in the preoperative detection of colorectal liver metastases in patients who have received prior chemotherapy by comparison against pathology or Intra-operative ultrasound.,To compare accuracies of Primovist-enhanced MRI and DWI to MDCT in the characterization of non-metastatic liver lesions against histopathology or intra-operative ultrasound.,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
2255,NCT06085560,Anticipatory Racism,,2023-07-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
2256,NCT01887717,Overall Survival (OS) From Time of Randomization,Number of Participants With Treatment Emergent Adverse Events (TEAE),2014-02-27,TERMINATED,INTERVENTIONAL,['PHASE3'],
2257,NCT05264688,diagnose accordance rate,Total Glycolysis (TLG),2022-01-20,UNKNOWN,OBSERVATIONAL,['NA'],
2258,NCT04833699,time to the first passage of flatus after surgery,The time to the first bowel movement,2021-04-05,COMPLETED,INTERVENTIONAL,['NA'],
2259,NCT03951389,"The correlation between wild type PIK3CA, PIK3CA exon 9 and PIK3CA exon 20 mutations and developing of metastatic disease and overall colorectal patient survival",,2012-05-22,COMPLETED,OBSERVATIONAL,['NA'],
2260,NCT00191607,"- Progression free survival (PFS) in patients who have failed one, but no more than two, prior treatments",Quality of life,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
2261,NCT01290536,Number of Participants With Adverse Events,Radiographic Response,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2262,NCT05811195,Oral mucositis Children's International Mucositis Evaluation Scale (CHIMES),Analysis NET and TSE,2023-03-10,RECRUITING,INTERVENTIONAL,['NA'],
2263,NCT00006479,,,2000-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2264,NCT02619435,the rate of evaluable patients alive and not progressed at 6 months,overall survival,2015-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2265,NCT00095927,"Median duration of dependence on percutaneous endoscopic gastrectomy (PEG) for adequate nutrition at 8, 12, 24, and 52 weeks after completion of study treatment",Swallowing function,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2266,NCT05957822,CRT maximal amplitude,re-operation,2024-02-10,RECRUITING,INTERVENTIONAL,['PHASE4'],
2267,NCT00823290,Maximum tolerated dose of LBH589,Laboratory abnormalities (CTC grade 3 or grade 4 toxicities),2009-01,TERMINATED,INTERVENTIONAL,['PHASE1'],
2268,NCT06052202,Receipt of Colorectal Cancer Screening Test at Month 6,Change from Baseline in Colorectal Cancer Knowledge at Month 6,2023-12-08,RECRUITING,INTERVENTIONAL,['NA'],
2269,NCT02511756,CTP as predictive marker for efficacy measured by progression-free survival,Local and distant recurrences,2015-07,TERMINATED,INTERVENTIONAL,['NA'],
2270,NCT04850716,Progression-Free Survival (PFS),Disease Control Rate (DCR),2021-04-27,RECRUITING,OBSERVATIONAL,['NA'],
2271,NCT02758977,1 Year Disease-free Survival,Incidence of posthepatectomy renal failure,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],
2272,NCT05014776,Objective response rate (irORR) using immune Response Evaluation Criteria for Solid Tumors (iRECIST),Number of participants experiencing grade 3 or above drug-related toxicities,2022-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2273,NCT06136845,To characterize the microbiota of esophageal cancer patients differentiating it by: - demographic criteria - tumor characteristics,,2020-01-13,RECRUITING,OBSERVATIONAL,['NA'],
2274,NCT05292417,Progression-free survival (PFS),Safety:Percentage of Participants With Adverse Events (AEs),2022-03-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2275,NCT02870036,Adverse events (AE),accumulative excretion rate,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2276,NCT02785783,Number of polyps per patient,,2016-05-13,COMPLETED,INTERVENTIONAL,['NA'],
2277,NCT03852693,Frequency of distant metastases in aNET measuring 1-2 cm,Long-term survival after complete resection of aNET measuring 1 - 2 cm with or without oncological right-sided hemicolectomy,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],
2278,NCT01959087,Length of postoperative hospital stay,Post-operative quality of life,2014-01-27,COMPLETED,INTERVENTIONAL,['NA'],
2279,NCT03471052,Change in surface area of residual inlet patch post ablation,"Symptomatic response for cough, hoarseness and sore throat using Visual Analogue Scale (VAS)",2018-03-06,UNKNOWN,INTERVENTIONAL,['NA'],
2280,NCT01926743,To compare the number of retrieved lymph node in each nodal station after additional application of near infra-red fluorescence imaging,,2013-08-01,COMPLETED,INTERVENTIONAL,['NA'],
2281,NCT05030870,The incidence of hypoxia,The incidence of other adverse events,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],
2282,NCT01456923,,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],
2283,NCT02247336,Number of Patients With Provider Referral for Risk-appropriate Colorectal Cancer Screening,Number of Patients Who Received Referral for Genetic Consultation,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],
2284,NCT00003544,,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2285,NCT05927584,Success rate,Radical rescue surgery specimen quality,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2286,NCT01640405,Progression free survival (PFS),"Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)",2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
2287,NCT02806648,Activity of palbociclib (PD0332991) considering objective response rate,"Positive expression of tumor biomarkers (Cdk4, Cdk6, fosfo-Rb1, D1 cyclin, p53, Ki67)",2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2288,NCT03172884,Area Under the Concentration-time Curve of Copanlisib in Plasma Over the Time Interval From 0 to 168 h.,Number of Subjects With Treatment-emergent Adverse Events (TEAEs) in Different Severity.,2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
2289,NCT03823144,"4. Tumor blood flow (velocity, mm/sec)",Post-operative correlation of the microscopic observation of the tumor microvasculature tumor-specific and overall survival.,2019-02-28,COMPLETED,INTERVENTIONAL,['NA'],
2290,NCT02312284,Distant metastasis free survival,Surgery complication,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
2291,NCT05409482,Progression-free survival（PFS）,Occurence of AE and SAE,2022-08-20,RECRUITING,OBSERVATIONAL,['NA'],
2292,NCT02023593,Disease control rate,Progression free survival,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
2293,NCT00810719,Progression Free Survival,Overall Survival,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
2294,NCT01650766,,,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],
2295,NCT03370198,The occurrence of DLTs until 14 days after the last NKR-2 study treatment administration (Visit Day 43),The overall survival (OS).,2017-10-11,TERMINATED,INTERVENTIONAL,['PHASE1'],
2296,NCT04862260,Characterization of dose-limiting toxicities,CD36 (Cluster of Differentiation 36) changes in response to the multipathway cholesterol embargo,2021-10-04,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],To explore the feasibility of a larger multicenter trial
2297,NCT00602329,"Analysis of tumor blood flow, assessed by DCE-MRI as percentage change in Ktrans, after 2 courses of FOLFOX and bevacizumab or FOLFOX alone compared to baseline value","Correlation of markers of apoptosis in tumor cells with response to therapy, time to progression, and overall survival",2006-02,TERMINATED,INTERVENTIONAL,['PHASE2'],
2298,NCT04653701,Technical success,,2020-11-14,UNKNOWN,OBSERVATIONAL,['NA'],
2299,NCT00967291,Progression-free survival at 6 months,Overall survival,2006-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
2300,NCT00088894,Grade 3-4 neutropenia in terms of specific single-nucleotide polymorphisms (SNPs) and/or copy number variations that are associated with the prevalence of these events (Clinical endpoint),OS (Clinical endpoint),2004-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2301,NCT02545751,The proportion of patients with tumor responses after the initiation of treatment.,"The proportion of patients alive with tumor responses from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study.",2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2302,NCT04034355,Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN),Patients With Disease Free Survival,2019-01-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
2303,NCT05963087,Objective response rate (ORR),Overall survival time,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2304,NCT00575640,The study design calls for an initial phase of dose-escalation in cohorts of 3 patients. There are no intra-patient changes in dose.,"Subsequent to this Phase I scheme, the study will continue with the selected dose-level (on toxicity and tolerability grounds) to accrue patients in a phase II scheme.",2004-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2305,NCT04160962,EORTC Questionnaire QLQ-C30,,2020-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2306,NCT03193710,Cancer free survival,Colorectal cancer antibodies,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],Days of hospitalization
2307,NCT02048540,R0 resection rate,safety of peroperative treatment and surgery,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",circulating tumor cell number change
2308,NCT03917017,Postoperative survival,Disease-free survival,2019-01-01,RECRUITING,INTERVENTIONAL,['NA'],Intraoperative blood loss
2309,NCT05237921,Number of participants that adhere to a Combined Exercise and Dietary Intervention (CEDI),Number of participants that meet estimated dietary intake and exercise goals,2018-06-15,COMPLETED,INTERVENTIONAL,['NA'],
2310,NCT04842565,Progression-free survival time (mPFS) (mRECIST),Time to Progression (TTP),2021-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2311,NCT04506138,Major Pathologic Response (MPR),Event Free Survival（EFS）,2020-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",FACT-E questionnaire
2312,NCT00969046,To identifymaximum tolerated dose (MTD),"To evaluate the blood concentrations profile (pharmacokinetics [PK]) of patupilone by multiple blood sampling before, during and after drug administration",2003-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
2313,NCT02460991,Overall Survival,Frequency of Treatment Emergent Adverse Events,2015-11,TERMINATED,INTERVENTIONAL,['PHASE3'],FACT-Hep Quality of Life
2314,NCT00920192,Safety and tolerability of foretinib at the MTD as measured by number and severity of AEs,PK profile of foretinib,2009-08-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
2315,NCT02272699,Disease-free survival,Numbers of adverse events and the degree of each adverse events according to the NCI CTCAE 4.0 criteria.,2014-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2316,NCT03747588,Intra-abdominal infection,Length of hospital stay (day),2018-12-01,RECRUITING,INTERVENTIONAL,['NA'],progression-free survival
2317,NCT05184803,Evaluation of R0 resection rate in patients who underwent prior chemotherapy as a clinical trial.,,2022-03-23,RECRUITING,INTERVENTIONAL,['PHASE2'],
2318,NCT00137449,Number of Participants With Clinical Benefit Response (CBR) According to RECIST,Score of EQ-5D (Euro Quality of Life-5 Dimension) Weighted Health Index,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
2319,NCT05839951,Cohort R-T or Cohort T-R: Descriptive analysis of biomarker Kirsten rat sarcoma 2 viral oncogene homolog (KRAS),Cohort R-T or Cohort T-R: Overall survival of patients with Regorafenib followed by TAS-102 and vice versa in 3rd line treatment and 4th line treatment,2023-04-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
2320,NCT04700410,Boston Bowel Preparation scale (BBPS)-score after cleaning with the Pure-Vu system.,Number of adverse events after study intervention,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],
2321,NCT01434485,Number of Adverse Drug Reactions,,2011-09,COMPLETED,OBSERVATIONAL,['NA'],
2322,NCT03930888,Progression of the self sufficiency,Effect of tumor localization,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],
2323,NCT05051423,"Correlations with statistical significance between time-intensity curve analysis parameters, immunohistochemical markers of angiogenesis and clinico-pathological parameters.",,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
2324,NCT05208372,Expression of ctDNA,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
2325,NCT04224896,SPECIFICITY OF THE TWO DIAGNOSTIC STRATEGIES,,2011-03-01,COMPLETED,OBSERVATIONAL,['NA'],
2326,NCT01304602,Maximum tolerated dose,Biological half life of BKM120,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
2327,NCT06172647,Proportion and abundance of bacterial taxa (defined as total percentage of bacterial DNA sequences),,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],
2328,NCT02488577,Overall percent of postoperative complications.,Recurrence.,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],
2329,NCT02650427,Safety (Number of adverse events. Toxicity grade > 3),Infiltration of leucocytes in tumor tissue,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
2330,NCT00747136,"Determine sensitivity/specificity to identify dysplasia/cancer in the esophagus WavSTAT System alone, endoscopist alone/combination of WavSTAT and endoscopist. Sensitivity of the endoscopist will be compared to combination of endoscopist and WavSTAT.",,2008-08,TERMINATED,OBSERVATIONAL,['NA'],
2331,NCT02325999,DFS,,2013-12,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
2332,NCT02465736,Toxicities of neo-adjuvant chemoradiotherapy,Health Related Quality of Life,2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
2333,NCT00002828,,,1995-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
2334,NCT01306799,Volumetric bone mineral density as measured by pQCT,measure vitamin B12 levels at each study visit,2010-01,COMPLETED,OBSERVATIONAL,['NA'],
2335,NCT05894694,PFS,1-year PFS rate,2023-06-11,RECRUITING,INTERVENTIONAL,['PHASE4'],
2336,NCT04865601,Correlation of DNA adduct and DNA repair products,Correlation of DNA adducts with CRC causes,2021-02-15,RECRUITING,OBSERVATIONAL,['NA'],
2337,NCT00193882,Relief of dysphagia,Time to achieving a complete response i.e. dysphagia score of 0.,2003-07-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
2338,NCT05861336,Resectability rate,Quality of life questionnaire (QLQ),2023-06-14,RECRUITING,INTERVENTIONAL,['PHASE2'],
2339,NCT01921673,Progression-free survival,Biomarker,2013-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2340,NCT03053999,Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Genome Sequencing,Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Data Review,2012-10-09,UNKNOWN,OBSERVATIONAL,['NA'],
2341,NCT00259922,To compare alvimopan with placebo for efficacy in the treatment of OBD,"Safety and tolerability, quality of life, pharmacogenetics (dependent on results from other data)",2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2342,NCT03330028,Dose Limiting Toxicity (DLT) of Paclitaxel via Intraperitoneal Route Combined with Fixed Doses of Mitomycin and Cisplatin during Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC),,2017-10-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
2343,NCT00001165,,,1978-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
2344,NCT00019591,Response rate every 3 months for up to a year after completion of study treatment,,1999-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2345,NCT03984578,Immune T-cell infiltration before and after treatment,Percentage of cell viability and cell death at fixed time points (e.g. 24 or 48 hours),2019-06-12,RECRUITING,INTERVENTIONAL,['PHASE2'],
2346,NCT04241523,Resection rate,Exploratory serum biomarker research,2020-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2347,NCT00785785,Time to Progression Free Survival (PFS),,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
2348,NCT00324428,"Pain (visual analog scale, CGI,PGA); Medication use (medication diary)",Safety (cognitive assessment - neuropsychological battery),2006-05,COMPLETED,INTERVENTIONAL,['NA'],
2349,NCT06289712,Correlate 3D numerical simulations of the IRE electric field with patient imaging follow-up,Develop software solutions potentially usable in real-time and tailored for clinical use.,2023-11-23,RECRUITING,OBSERVATIONAL,['NA'],
2350,NCT02500004,Brown adipose tissue (BAT) activity measured by PET(-MRI),"Lean tissue mass measured by MRI, DXA, and doubly labeled water",2015-06,COMPLETED,INTERVENTIONAL,['NA'],
2351,NCT04389957,Provider Screening Adenoma detection rate (Screening colonoscopies only),Bowel Preparation Quality (provider level),2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],
2352,NCT02595086,"Incidence of Dumping syndrome, assessed by Sigstad score (≥7)",Gross and microscopic changes measured by gastroscopy (composite),2015-07,UNKNOWN,INTERVENTIONAL,['NA'],
2353,NCT05421689,Anterior tongue pressure measured from Iowa Oral Performance Instrument (IOPI),Patient-reported dysphagia symptoms based on Eating Assessment Tool EAT10 score,2022-05-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Patient-reported Quality of Life based on FACT-HN score
2354,NCT00710710,Best Objective Response Evaluated According to the RECIST Criteria by Independent Review,Number of Participants With Incidence and Intensity of Adverse Events Graded According to Common Terminology Criteria for Adverse Events (CTCAE),2006-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2355,NCT04684095,Changes of quality of life (QoL) at 1 year after randomization compared with baseline,Patient satisfaction,2021-05-26,RECRUITING,INTERVENTIONAL,['NA'],Economic assessment for ePRO compared to regular follow-up
2356,NCT02406508,Progression free survival in months of patients receiving Melphalan/HDS treatment followed by Sorafenib,,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Quality of life questionnaires
2357,NCT00605800,To determine qualitatively and quantitatively whether bone marrow derived liver associated stem cells are mobilized from the bone marrow in patients undergoing major liver resections (3 or more liver segments).,To determine whether a difference exist in the baseline levels of bone marrow derived liver associated stem cells between normal healthy subjects/ volunteers and cancer patients prior to liver surgery.,2006-03,WITHDRAWN,OBSERVATIONAL,['NA'],
2358,NCT00182130,Hospital rate of local recurrence,Quality of life,2002-05,UNKNOWN,INTERVENTIONAL,['NA'],
2359,NCT00003368,,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
2360,NCT00033306,"Determine the clinical activity of BMS-247550, as measured by the tumor response rate, in patients with metastatic colorectal cancer previously treated with a fluoropyrimidine and irinotecan.","Determine the response duration, time to progression, and survival in patients treated with this drug.",2002-02,TERMINATED,INTERVENTIONAL,['PHASE2'],
2361,NCT05242757,The size (tumor diameter) and number (tumor recurrence lesions) of PHC tumors were examined by enhanced abdominal CT,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
2362,NCT03167125,Increased colorectal cancer screening rates,,2017-09-05,COMPLETED,INTERVENTIONAL,['NA'],
2363,NCT02252926,Reduction of oral and pharyngeal pain measured on Visual Analogue Scale (VAS),Safety: Peak plasma concentrations of bupivacaine,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
2364,NCT00005981,Determine the response rate of patients with metastatic colorectal carcinoma treated with O6-benzylguanine and carmustine.,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2365,NCT01105806,To document advance directive (AD)completion,To longitudinally follow discussions about ADs and nature of hospitalizations,2010-04,COMPLETED,OBSERVATIONAL,['NA'],
2366,NCT02743065,Progress-free-survival (PFS),Objective Response Rates,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],
2367,NCT05279677,ORR,Adverse events,2022-08-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2368,NCT00327457,Medical record verified flexible sigmoidoscopy or colonoscopy,,2002-06,COMPLETED,INTERVENTIONAL,['NA'],
2369,NCT00957424,Number of Participants Willing to Continue With Preferred HRP,,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
2370,NCT00320320,Response rate after FOLFIRI reintroduction,Overall survival,2005-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
2371,NCT04547153,hematological response rate (HeRR),quality of life assessed by EORTC QOL C-30 and STO-22 (QoL),2021-01-15,COMPLETED,INTERVENTIONAL,['PHASE2'],
2372,NCT00265356,proportion of patients who have a change in management resulting from PET,prognostic ability of the PET standard uptake value (SUV) in predicting 3-year overall survival,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
2373,NCT05189730,Incidence of adverse events,Overall Survival,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2374,NCT00487409,this study will evaluate the surgical approach using the Ligasure device at six weeks post operative.,Will evaluate the surgical approach using electrocautery with surgical clips and staples,2006-12,COMPLETED,INTERVENTIONAL,['NA'],
2375,NCT02077868,Overall survival,Quality of life (QoL),2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2376,NCT00608595,Change of gene and protein expression pattern from pre- to post-treatment levels,,2002-07,TERMINATED,INTERVENTIONAL,['NA'],
2377,NCT02127541,Measuring the accuracy of the Tumour-Localisation of 68-DOTA-Exendin-4 PET/CT and 111 In-DOTA-exendin-4 SPECT/CT.,Comparison of the angiogenesis markers with the those of breast carcinoma patients,2014-01-06,COMPLETED,INTERVENTIONAL,['NA'],
2378,NCT02506803,Number of participants with toxicity of NAC-GEMABR therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,The R0 resection rate of NAC-GEMABR therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2379,NCT02511821,Percentage of patients who are able to wear the wristband device for at least 1 week post-operatively,"Suggestions for items that were not covered but should be added, as measured by responses from Satisfaction Tool",2015-07-22,COMPLETED,INTERVENTIONAL,['NA'],
2380,NCT00187109,To evaluate whether recombinant human thrombopoietin will reduce the time necessary for platelet counts to recover following chemotherapy.,,2000-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2381,NCT05149807,Phase III : Event-free Survival (EFS),30-day postoperative mortality.,2022-01-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2382,NCT00003571,disease free survival,determine the prognostic and predictive values for response to this therapy,1998-08,COMPLETED,OBSERVATIONAL,['NA'],
2383,NCT01187641,"The primary endpoint will be the accuracy of MRI and CT in determining T stage using histology as the gold standard, on a per patient basis.","We will also compare the accuracy of 1.5T against 3.0T MRI scans, and T2 weighted against T1 weighted images",2010-08-18,COMPLETED,OBSERVATIONAL,['NA'],
2384,NCT00797732,Treatment Compliance Rate,MDADI Scores,2008-12,COMPLETED,INTERVENTIONAL,['NA'],
2385,NCT02601079,Highest proportion (number) of representative biopsies for diagnostic purposes from the tumor tissue.,Number of fusion genes in tissue harvested from esophageal neoplasms prior to neoadjuvant oncological treatment.,2016-09,TERMINATED,INTERVENTIONAL,['NA'],
2386,NCT01959061,Progression-free survivial,,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2387,NCT02710812,Rate of organ preservation,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],
2388,NCT05347745,therascreen® KRAS RGQ PCR Kit,,2022-01-07,UNKNOWN,INTERVENTIONAL,['NA'],
2389,NCT03766295,Overall Survival (median),Progression Free Survival,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
2390,NCT03022734,complete resection (R0) rate for rectal and liver lesions,Response rate (RECIST V1.1),2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2391,NCT02552745,Pain scores,Hospital Stay,2014-10,COMPLETED,OBSERVATIONAL,['NA'],
2392,NCT03638206,"Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0",CAR-T cells testing,2018-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2393,NCT01271192,5-year disease free survival,"Side effect of chemo radiotherapy, postoperative complications, recurrent rate, distant metastatic rate,biomarkers, quality of life, toxic profile, convenience",2010-12,UNKNOWN,INTERVENTIONAL,['NA'],
2394,NCT00031837,Quality of life as measured by FACT-Hep version 4 every 4 weeks,Safety as measured by the occurrence of bleeding complications,2002-10,TERMINATED,INTERVENTIONAL,['PHASE3'],
2395,NCT00526786,The eradication of LGD and HGD within BE at 24 months after the final treatment. The primary safety endpoint is the incidence of all adverse events.,1.Eradication of all BE by 24 months after the final treatment. 2.The proportion of lesions that decreased in length by the 24-month follow-up. 3.The proportion of lesions where severity was downgraded by the 24-month follow-up.,2007-09,TERMINATED,INTERVENTIONAL,['PHASE4'],
2396,NCT05872295,Objective Response Rate (Part 2),Evaluation of the immunogenicity of IKS014 (Part 1 and 2),2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE1'],
2397,NCT02579278,To determine if there is a link between EMVI status and ctDNA,To investigate the effect of ctDNA status on patient survival outcomes,2015-11,RECRUITING,OBSERVATIONAL,['NA'],
2398,NCT00006245,,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
2399,NCT06057350,CRC recurrence or sign of lymph nodes or distant metastases,Health related quality of life and functional outcomes after 30 days and one year,2023-10-27,RECRUITING,INTERVENTIONAL,['NA'],Cost-effectiveness
2400,NCT05101265,Total plasma dose-normalized AUC0-∞,Pharmacogenetics,2021-03-09,RECRUITING,INTERVENTIONAL,['PHASE1'],
2401,NCT05355662,Recurrence of the primary disease after surgery,Post-operative complications in patients who underwent liver transplantation,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],
2402,NCT00629759,"To determine the maximum tolerable dose (MTD) and/or the maximum feasible dose (MFD), as well as to evaluate the safety of JX-594 injected within unresectable solid tumor(s) within the liver","Secondary objectives include determination of JX-594 pharmacokinetics, replication and shedding, immune response, and injection site tumor responses.",2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
2403,NCT01409499,Overall survival (OS),cost of treatments,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2404,NCT04560270,Correlation of the ctDNA level to the response to chemotherapy,Progression free survival,2016-04-25,COMPLETED,INTERVENTIONAL,['NA'],
2405,NCT05990543,Progression free survival,Overall survival,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2406,NCT02211443,Number of participants with SCT200-related adverse events,Area Under the plasma concentration versus time curve (AUC) of SCT200,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Time to Disease Progression (TTP) of SCT200
2407,NCT06050707,Change in locoregional failure (LRF) at Year 2,Quality of life (QOL),2023-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],
2408,NCT01794793,Incidence of adverse events to evaluate long term safety data,Percentage of patients with clinical benefit as assessed by the investigator,2013-06-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
2409,NCT05754229,False negative findings: Adenomas (histopathologically verified) characterized as non-adenomas by the AI system,,2022-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2410,NCT05978882,Detection rate of Sentinel lymph nodes,5 year recurrence free survival rate,2023-08-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2411,NCT01890213,Number of participants with adverse events,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
2412,NCT06316466,OS,PFS,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],
2413,NCT02490111,Proportion of patient developing gallstone at 12 month after gastrectomy,Time to gallstone formation,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
2414,NCT02194387,Change in waist circumference (Pilot II),,2014-09-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2415,NCT02985801,Change in Body Weight,Change in Body Weight Composition,2016-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2416,NCT00812175,The safety of Nexavar in all patients with unresectable HCC who are candidates for systemic therapy and in whom a decision to treat with Nexavar has been made under real-life practice conditions,Reports of adverse events,2009-01,COMPLETED,OBSERVATIONAL,['NA'],
2417,NCT02404909,to investigate the influence of the liver resection on hemodynamic status in terms of hemodynamic indexes changes,,2005-01,COMPLETED,OBSERVATIONAL,['NA'],
2418,NCT06186609,Progression-free survival,Overall Survival,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
2419,NCT06013657,Mortality,Length of stay,2021-12-01,COMPLETED,OBSERVATIONAL,['NA'],
2420,NCT00007618,,,1998-01,COMPLETED,OBSERVATIONAL,['NA'],
2421,NCT04231929,Tumor response,Best overall response,2020-05,WITHDRAWN,INTERVENTIONAL,['NA'],
2422,NCT00655499,Objective Response Rate (ORR) During the Combination Therapy Phase,Overall Survival (OS),2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2423,NCT05256381,Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1),Number of Participants with Anti-drug Antibodies (ADAs),2022-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2424,NCT04943406,Prognostic impact of ctDNA positivity,Prognostic impact of ctDNA positivity in peritoneal lavage and peripheral blood on the risk of peritoneal and distant metastases,2020-05-08,RECRUITING,OBSERVATIONAL,['NA'],
2425,NCT05038098,Safety of endoscopic peritumoral gastric injection of FerroTrace,,2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
2426,NCT00225784,Objective Response of Tumor by RECIST 1.0 Criteria,Pattern of Failure After Therapy,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2427,NCT04753879,Progression-free Survival (PFS) after 6 months according to IRECIST criteria.,Number of participants experiencing grade 3 or above drug-related toxicities,2021-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],
2428,NCT01764802,"Sexual pain graded using the International Pelvic Pain Society Pelvic Pain Assessment, patient/physician version",Body change stress graded according to the Impact of Treatment Scale (ITS),2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2429,NCT03768531,Number of participants experiencing study drug-related toxicities,Disease free survival (DFS),2019-06-14,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
2430,NCT00132041,Proportion of Participants With Successful Control of Disease at 18 Months,Remote Tumor Occurrence Rates,2005-12,COMPLETED,INTERVENTIONAL,['NA'],
2431,NCT03189914,Number of Participants With Progression Free Survival (PFS) and/or Objective Clinical Response (Phase 2),Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 15,2017-10-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of Life (QOL) (Phase 1 and 2)
2432,NCT00775073,Time to Progression,Overall Survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2433,NCT04825574,Safety as assessed by the number of serious adverse events and adverse events of special interest,,2021-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
2434,NCT01559844,Number of Participants Who Died,Proportion of Participants With Virologic Failure Prior to Transplant,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
2435,NCT03153332,The primary outcomes was the precise allocation of hepatic disease,Time spent to judge tumor location,2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],
2436,NCT00484211,Antitumour activity defined as progression free survival (PFS),Experimental imaging study (DCE-MRI),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
2437,NCT01703585,Patient recruitment for paired core and fine needle biopsy greater than or equal to 50% of those screened or approached.,Actionable genomic result analysis of fresh core needle biopsy samples and fresh fine needle biopsy samples greater than or equal to 30%,2012-10-04,COMPLETED,OBSERVATIONAL,['NA'],
2438,NCT02051868,Best overall response rate by 24 weeks post treatment,Identification of potential tumour biomarker,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2439,NCT02282722,Number of Patients With Accurate Understanding of Chemotherapy Benefits,Patient-Reported Prognostic Understanding in Median Years,2015-06-10,COMPLETED,INTERVENTIONAL,['NA'],
2440,NCT03044743,Number of participants with Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients,Th1/Th2 change in the peripheral blood,2017-04-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2441,NCT00238212,Response probability (confirmed complete and confirmed partial responses),Time to progression,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2442,NCT01460888,Maximum Tolerated Dose (MTD) of olaparib in combination with radical radiotherapy in patients with oesophageal cancer,Exploration of blood and tissue borne pharmacodynamic markers to establish the biological efficacy of the addition of Olaparib to radiotherapy.,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2443,NCT00260559,Change from baseline in SF36 Quality of Life Questionnaire at 36 month,,1999-05,RECRUITING,OBSERVATIONAL,['NA'],
2444,NCT04174079,Disease-free survival,overall survival,2019-12-11,RECRUITING,INTERVENTIONAL,['NA'],
2445,NCT02276768,Mean visceral pain intensity score following dosing with GIC-1001 375 mg TID,"Standard laboratory measures (biochemistry, hematology, urinalysis)",2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
2446,NCT00305877,Proportion of Patients With Specific Protocol Defined Adverse Event at Conclusion of All Therapy,Two-year Disease-free Survival (DFS),2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2447,NCT04638959,differences in abundance of gut microbiota,evidence of gastric carcinoma,2019-09-30,UNKNOWN,OBSERVATIONAL,['NA'],Basic information of patients with different clinical outcomes
2448,NCT00590239,Pathologic and Clinical Outcomes,Efficacy of endoscopic detection of early esophageal lesions,2007-05-15,RECRUITING,OBSERVATIONAL,['NA'],
2449,NCT06323382,Progression-Free-Survival (PFS),Adverse events,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],
2450,NCT06051695,Phase 2: The Overall Response Rate (ORR) for patients,Cytokine analysis,2024-04-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2451,NCT04203641,Adverse events (as per CTCAE v. 5.0),Proportion of patients expressing anti-L-DOS47 antibodies,2019-12-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2452,NCT04446793,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],
2453,NCT04689347,"To evaluate the safety and to determine the recommended phase 2 dose of the combination of FLIRT- bevacizumab in patients with MGMT silenced and MSS mCRC, previously untreated for advanced disease",Quality of life as assessed using the Euro Quality of Life 5 Dimensions Questionnaire (EQ-5D-5L),2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],OS of FLIRT bevacizumab
2454,NCT02069704,AUC at Steady State (AUCss) of BEVZ92 and Avastin®,Volume of Distribution (Vd) of BEVZ92 and Avastin®,2014-10-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
2455,NCT02256514,Effect of hepcortespenlisimut-L (V5) immunotherapy on tumor size or clearance,Effect of hepcortespenlisimut-L (V5) immunotherapy on patients' performance,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2456,NCT01364805,Determine safety of combined gemcitabine chemotherapy with IV ascorbate.,Assess pharmacokinetic and pharmacodynamic interactions when adding IV AA to front-line gemcitabine chemotherapy in the treatment of locally advanced or metastatic pancreatic cancer not eligible for surgical resection.,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
2457,NCT05829057,Number of participants with physical examinations,changes of cytokines relative to the baseline,2023-05-23,RECRUITING,INTERVENTIONAL,['PHASE1'],
2458,NCT02664077,"Disease-free survival (DFS) - time from randomization until first colon cancer recurrence, second primary colon cancer, or death due to any cause.",Compare the symptoms experienced by patients receiving regorafenib to patients receiving placebo during treatment as measured by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE),2016-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
2459,NCT05059717,Magnetic Resonance Displacement Encoding with Stimulated Echo (MR DENSE) imaging data of patients treated with chemotherapy prior to resection of metastases to explore its utility in detecting sinusoidal liver injury.,,2018-07-12,WITHDRAWN,INTERVENTIONAL,['NA'],
2460,NCT04152889,DFS,,2020-04-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2461,NCT01659424,Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy (BT) Improve Compliance,4) Quality of Life,2011-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
2462,NCT05594914,AE,OS,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2463,NCT02837263,Recurrence rate at 1 year,Overall survival estimated using the Kaplan-Meier method,2016-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Expression levels of PDL1
2464,NCT00971126,"Terms of efficacy assessment: objective tumor response, overall survival, progression-free survival. Terms of safety assessment: adverse effects, laboratory values.",,2009-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2465,NCT01853319,Progression-Free Survival (PFS),,2013-07-24,COMPLETED,INTERVENTIONAL,['PHASE3'],
2466,NCT02140463,feasibility,response rate,2014-02,COMPLETED,OBSERVATIONAL,['NA'],
2467,NCT02714374,Number of participants with treatment-related adverse events as defined by CTCAE v4.03.,Amount of lymphocyte infiltration in pre-treatment biopsy and post-treatment resected tumor tissue,2016-03-25,TERMINATED,INTERVENTIONAL,['PHASE1'],
2468,NCT01521104,,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],
2469,NCT01802203,Collect efficacy and outcome data related to the use of trūFreeze® spray cryotherapy for treatment of unwanted tissue in the pulmonary and gastrointestinal settings.,Collect safety data related to the use of trūFreeze® spray cryotherapy for treatment in the pulmonary and gastrointestinal settings.,2013-04,COMPLETED,OBSERVATIONAL,['NA'],
2470,NCT01505972,Participation rate,Response rate in FOUR&TWO group,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
2471,NCT05613621,clinical outcomes of MAFLD vs. non-MAFLD.,,2022-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2472,NCT05641896,Positive predictive value will be determined on a per-lesion basis for all lesions with tissue available for FAP analysis.,Further characterize the safety profile of [18F]FAPI-74 in subjects utilizing Common Terminology Criteria for Adverse Events (CTCAE v5),2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2'],
2473,NCT03841799,Characterization of colorectal tissue microenvironment of patients with locally colorectal neoplasia.,Identification of potential molecular abnormalities in cancer cells from colorectal tissue and from blood samples.,2019-05-02,RECRUITING,OBSERVATIONAL,['NA'],
2474,NCT06054308,pathologic response,Disease free and overall survival,2024-02-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2475,NCT04454476,Safety of Trametinib treatment: adverse events,,2022-11-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
2476,NCT03111823,Total number of minutes exercised per week with >80% total weekly minutes (48/60 minutes) completed,Change in QOL,2016-07-07,TERMINATED,INTERVENTIONAL,['NA'],Change in endothelial function
2477,NCT04195373,Determine MTD and dose for phase II,Efficacy of therapy assessed by changes in tumor marker level,2020-11-23,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
2478,NCT01915225,"Collection of biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors for the purpose of identifying novel molecular and biologic therapeutic targets","Collection of detailed history, demographic, treatment data, and perioperative outcomes data related to surgical quality and safety in order to categorize and track the specific procedures.",2013-07-21,RECRUITING,OBSERVATIONAL,['NA'],
2479,NCT05156788,R0 resection rate,RFS,2021-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2480,NCT02350166,30-day complications,C-reactive protein,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2481,NCT05718882,Progression free survival,Safety endpoint,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],
2482,NCT03757455,Days until discharge from university hospital,Readmission frequency,2020-09-01,TERMINATED,INTERVENTIONAL,['NA'],
2483,NCT05449847,Relation between MicroRNA and HCV,,2021-05-13,COMPLETED,OBSERVATIONAL,['NA'],
2484,NCT04727151,Phase 2: Evaluate Progression-Free survival (PFS) or Time to progression (TTP),Phase 1 and Phase 2: Cytokine level detection,2021-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2485,NCT04397601,Overall Survival (OS).,Progression-free survival (PFS).,2020-05-11,RECRUITING,OBSERVATIONAL,['NA'],Serum level of PlGF (Placental Growth Factor).
2486,NCT02012699,Development and implementation of a web-based Cancer Collaborative Registry at the University of Nebraska Medical Center (UNMC)/Nebraska Medical Center (NMC),Procurement and banking of excess biological material for future analysis,2013-11-01,RECRUITING,OBSERVATIONAL,['NA'],"Collection and banking of blood, DNA, and urine samples for future analysis that will be proposed in future studies"
2487,NCT04294160,Dose intensity,Tmax derived from Serum/plasma concentration of individual investigational drugs within combination treatments,2020-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
2488,NCT01047293,"Evaluate Safety of the Combination at a Daily Dosing of 2.5mg RAD001, 5 mg RAD001 or 10 mg RAD001 (Phase 1 Part)",,2010-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2489,NCT02384759,Radiological progression-free survival according to the investigator,progression-free survival,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2490,NCT03099564,Progression free survival (PFS),Estimate overall survival (OS),2017-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
2491,NCT00626639,Pharmacokinetics of Palifermin,Overall Survival,2005-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2492,NCT04151394,Overall survival,,2019-01-31,COMPLETED,OBSERVATIONAL,['NA'],
2493,NCT01402089,Steady-state partial area-under the plasma concentration-time curve over 24 hours (AUC24h) of sunitinib and erlotinib and CYP3A4/1A2-phenotype activity as defined in the protocol,"Concentrations of Sunitinib, Erlotinib and probe drugs (Midazolam, Caffeine) in whole blood, sampled from patient's dried blood spots (DBS)",2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2494,NCT01611506,Dose limiting toxicity,"Toxicity (according to NCI-CTCAE, Version 4.0)",2012-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2495,NCT02836535,Number of complications,,2016-07,COMPLETED,OBSERVATIONAL,['NA'],
2496,NCT00033319,,,1997-05,UNKNOWN,INTERVENTIONAL,['NA'],
2497,NCT02630004,Number (percentage) of patients who develop severe oral mucositis (grade 3-4 according to the RTOG scale),Pharmacokinetics evaluation [Clearance],2015-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number (percentage) of patients with progression disease using the RECIST 1.1 criteria
2498,NCT05732389,Complete clinical response,Change in Quality of life (EORCT QLQ-CR29),2023-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
2499,NCT04171141,Objective Response - Number of Participants With Objective Response for Dose Expansion (Part 2),Change from baseline of immune cells from tumor biopsies,2019-11-19,TERMINATED,INTERVENTIONAL,['PHASE1'],
2500,NCT02364154,metabolic phenotype of colorectal cancer,tumor stage,2014-12,COMPLETED,OBSERVATIONAL,['NA'],
2501,NCT05989789,Procedure-Safety (No residual source of radiation),Number of patients without side effects,2020-06-15,COMPLETED,INTERVENTIONAL,['NA'],
2502,NCT00168155,disease free survival,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2503,NCT05293041,Blood loss,I-FABP (change in organ damage markers),2022-03-27,RECRUITING,INTERVENTIONAL,['PHASE4'],
2504,NCT01574677,Performance characteristics of the Septin 9 biomarker among patients who have a positive FIT result,Concordance and discordance (Kappa scores) between Septin 9 test results and colonoscopy findings associated with specific medication use practices.,2012-06,WITHDRAWN,OBSERVATIONAL,['NA'],
2505,NCT02587689,Phase I: Adverse events attributed to the administration of the anti-MUC1 CAR T cells,,2015-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2506,NCT05528952,objective response rate (ORR),disease control rate (DCR),2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE2'],
2507,NCT04242199,Number of treatment-emergent adverse events,Vz/F of INCB099280,2020-09-04,RECRUITING,INTERVENTIONAL,['PHASE1'],
2508,NCT00427713,Disease-free survival at 3 years,Toxicity,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
2509,NCT03039322,Golgi protein correlated with presence of HCC,,2014-12-22,COMPLETED,OBSERVATIONAL,['NA'],
2510,NCT05644249,Objective tumor response according to RECIST v 1.1 after second PIPAC,Adverse events of chemotherapy drugs,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],
2511,NCT05340569,Unexpected abortion,Early distant recurrence,2022-03-28,RECRUITING,INTERVENTIONAL,['NA'],
2512,NCT03368131,The pathological complete response rate(pCR),Adverse events,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2513,NCT04484311,Residual neoplasia,,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
2514,NCT05427227,Tumor associated proteins expression level of exosomes,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],
2515,NCT00002711,,,1995-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
2516,NCT05132244,Frequency of glucose levels maintained within range in Arm 1 compared to Arm 2,Overall survival (OS) in each study arm from the initiation of FOLFIRINOX,2024-04-16,RECRUITING,INTERVENTIONAL,['NA'],"Amount of circulating biomarkers, measured in molar, for participants in each study arm from screening until the end of study visit"
2517,NCT00910143,"Local recurrence, recurrence-free survival, overall survival",Percentage of patients undergoing transcatheter arterial embolisation,1993-01,COMPLETED,OBSERVATIONAL,['NA'],
2518,NCT05953961,Disease Progression,Duration of Response,2023-08-08,RECRUITING,INTERVENTIONAL,['NA'],
2519,NCT00004547,Number of Participants With Adverse Events,Signal Transduction Pathways in Tumor Tissue Versus Normal Tissue,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2520,NCT03550885,Change in the mucosal abundance of bacterial genes associated with sulfur and bile acid metabolism,Change in colonocyte proliferation,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2521,NCT05845268,cCR rate,immune-related adverse event rate,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
2522,NCT01329809,Delivery to and replication within tumors,Toxicity: Grade I-IV Adverse Events (according to CTCAE),2011-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
2523,NCT03361150,Oxygen consumption (VO2),Hospital Anxiety and Depression Scale (HADS) score,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
2524,NCT01198392,Time to progression,Response rate,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2525,NCT05417230,ORR,AEs,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],ctDNA
2526,NCT02591082,Survival,Tumor response,2015-12,COMPLETED,OBSERVATIONAL,['NA'],
2527,NCT02694536,Percentage of Participants With Adverse Events (AEs),Progression-Free Survival (PFS) According to RECIST,2006-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2528,NCT01863862,The final three-year rate of local and distant recurrences taking into consideration results of rescue surgery for pelvic recurrence.,Multivariable analysis of prognostic factors associated with clinical complete response.,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],
2529,NCT02278133,Overall response rate in phase II,Number of participants with dose interruptions and dose reductions (phase Ib/II),2014-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2530,NCT06316401,Safety of ESD under SA,Median ESD duration,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],
2531,NCT02117466,Clinical Benefit Rate,Quality of life (QoL) and health related QoL,2014-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2532,NCT04194775,Overall survival (OS),"Time to deterioration (TTD), defined as the time from randomization to the first deterioration of European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) scale",2019-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
2533,NCT05692037,Progression Free Survival Rate of Liver Target Lesions,Disease control rate (DCR),2022-12-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2534,NCT04518579,anti tumour immunity,change in pain intensity,2018-04-15,COMPLETED,INTERVENTIONAL,['NA'],
2535,NCT00014079,Determine the clinical and pathologic significance of unstable DNA elements,Determine the clinical and pathologic significance of loss of heterozygosity,1997-09,COMPLETED,OBSERVATIONAL,['NA'],
2536,NCT06310902,Bioinformatics analysis of single-cell sequencing results,,2024-03-01,RECRUITING,OBSERVATIONAL,['NA'],
2537,NCT00499395,Sensitivity and specificity of fludeoxyglucose F 18 (FDG)-PET imaging in early diagnosis of residual disease,Findings on day 7 after RFA using FDG-PET imaging,2005-07,COMPLETED,INTERVENTIONAL,['NA'],
2538,NCT03740360,Mutations in pancreatic cystic neoplasm,Relation between pancreatic fluid and serum molecular analysis,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],
2539,NCT03116945,"Uptake of positron emitting radiotracer, 68Gallium Citrate will be measured in the lesions of hepatocellular carcinoma.",,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2540,NCT01385956,Number of Participants With Serious Adverse Events,Number of Participants With Overall Survival (OS),2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
2541,NCT02527772,Progression-Free-Survival,Time-to-Progression,2015-09,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2542,NCT04466254,Best of Response (BOR),Deepness of Response (DpR),2020-12-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2543,NCT06223230,Median progression-free survival time,Duration of Response,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],
2544,NCT04408859,Quality of life index,,2018-04-17,UNKNOWN,OBSERVATIONAL,['NA'],
2545,NCT00973609,Time to failure of maintenance and reinduction treatment strategy measured from randomization,"TFS, Toxicity, QoL, PFS 1, PFS 2, ORR (first induction), ORR (reind. treatm.), Treatment free interval/duration of maintenance therapy, second. Resection rate, Reasons for discontinuation, OS, Translational research.",2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2546,NCT04021056,Evaluate the recurrence free survival rate of HCC patients after curative treatments,,2011-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
2547,NCT02817308,correlation of CA19-9 levels in urine and saliva with those in the serum,Number of participants needed to standardize the measurements in urine and saliva according to those measured in the serum.,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],
2548,NCT01006577,Side-to-end anastomosis is not inferior not colon J pouch in terms of fecal incontinence. fecal incontinence (Wexner score),cancer related deaths,2010-06,UNKNOWN,INTERVENTIONAL,['NA'],
2549,NCT03801876,"Incidence of specific grade 3+ cardiopulmonary adverse events (AEs) that are definitely, probably, or possibly related to protocol treatment",Cost-benefit economic analysis of treatment,2019-03-15,RECRUITING,INTERVENTIONAL,['PHASE3'],
2550,NCT03375320,Progression-free survival (PFS),Radiographic response rate,2018-10-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
2551,NCT04028375,MSCT and MRI staging in Gastric Cancer.,MSCT and MRI prediction of prognosis in gastric cancer,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA'],
2552,NCT00769106,Time to recurrence (TTR),AEs and SAEs,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2553,NCT00271011,Percentage of Patients With an Objective Response,Proportion of Patients Experiencing Hematologic and Non-hematologic Adverse Events,2005-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
2554,NCT00318903,The determination of pathologic response in patients who undergo surgical resection.,To assess the toxicities associated with this treatment and any impact on surgery.,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2555,NCT02751606,Sensitivity and specificity of 7 Tesla MRI in combination with ferumoxtran-10 on nodal level.,Comparison of 7 Tesla and 3 Tesla MRI,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2556,NCT02623153,response rate,adverse events,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2557,NCT01801163,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Time from start of treatment until death from any cause or date of last patient contact.,2012-02,WITHDRAWN,INTERVENTIONAL,['PHASE1'],"3.2.4 To evaluate biologic markers such as VEGF, eNOS and HIF1-alpha, VEGF-R2 genetic polymorphisms as well as serum VEGF and soluble VEGFR2 levels and correlate with efficacy outcomes."
2558,NCT05241899,Progression free survival (PFS),"Safety and tolerance evaluated by incidence, severity and outcomes of AEs",2022-05-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2559,NCT03602703,Pattern of immunity in patients with de novo HCC develped after treatment with DAAs,,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],
2560,NCT05718232,Overall Survival (OS),Time to Progression （TTP）,2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
2561,NCT05628194,MSM awareness of strategies to decrease anal cancer risk,,2023-06-08,RECRUITING,OBSERVATIONAL,['NA'],
2562,NCT01188876,Best Overall Response,Area Under the Plasma Drug Concentration-Time Curve (AUC),2010-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2563,NCT05620537,postoperative overall survival,,2022-11-10,COMPLETED,OBSERVATIONAL,['NA'],
2564,NCT02135757,The pharmacoeconomic impact of panitumumab for the treatment of metastatic colorectal cancer in a real-life setting,Identification of blood biomarkers that confer significant improvement in progression-free survival in patients treated with panitumumab.,2014-08,COMPLETED,OBSERVATIONAL,['NA'],
2565,NCT02269904,DFS (Disease Free Survival),adverse event,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2566,NCT04747600,the incidence of the pancreatic fistula,recurrence rate in percentage,2014-06-01,COMPLETED,OBSERVATIONAL,['NA'],
2567,NCT01995396,Rates ot postoperative surgical complications within 30 days.,Other postop complications,2014-02,TERMINATED,INTERVENTIONAL,['NA'],Late complications after surgery
2568,NCT01843400,Number of patients with serious adverse events(SAEs) from the first administration of regorafenib.,Tumor response assessed by RECIST or physicians own evaluation,2013-04-22,COMPLETED,OBSERVATIONAL,['NA'],
2569,NCT04140552,Overall Survival,,2008-01-01,RECRUITING,OBSERVATIONAL,['NA'],
2570,NCT02702401,Overall Survival (OS),Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE),2016-05-26,COMPLETED,INTERVENTIONAL,['PHASE3'],
2571,NCT00562380,Pharmacokinetic profile,Circulating levels of IGF-1R and IGF-BP3,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
2572,NCT03244787,Percentage of patients in intervention and control groups who completed any colorectal cancer screening during the six-month study period,Number of polys found in intervention polyps (histology),2017-01,COMPLETED,INTERVENTIONAL,['NA'],
2573,NCT01783171,MTD of dinaciclib in combination with Akt inhibitor MK2206 defined as the highest dose at which 0 or 1 dose-limiting toxicities are observed in six patients,Progression-free survival,2013-01-15,COMPLETED,INTERVENTIONAL,['PHASE1'],Protein expression in serum as measured by fluorescence activated cell sorting (FACS)
2574,NCT00869570,Pathological near complete or complete tumor response (Dworak grade 3 and 4) (Phase II),Adverse events as assessed by NCI CTCAE v3.0,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2575,NCT03955224,Rate of patients who didn't need a dose increase or introduction of new analgesics for mouth pain during the study compared to baseline,Frequency of adverse events related to the LLLT using the National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI CTCAE) version 5.0,2021-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
2576,NCT01483014,Objective response using the RECIST criteria,Overall survival,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2577,NCT06241079,Overall survival,,2003-03-31,COMPLETED,OBSERVATIONAL,['NA'],
2578,NCT03388047,Level of confidence in delineating the area of interest by multispectral imaging,Correlation with molecular biomarkers,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
2579,NCT05003700,Objective response rate (ORR),Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2021-04-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
2580,NCT05195502,Evaluation of metabolic profile,Colonic biofilm,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
2581,NCT06048458,Change in myocardial blood flow from baseline with adenosine stress assessed by quantitative perfusion cardiac MRI,Change in retinal vessel density,2022-05-18,RECRUITING,OBSERVATIONAL,['NA'],
2582,NCT04354662,Pathological complete response rate (pCR),5-year Survival Rate,2019-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],
2583,NCT04044313,Progression free survival rate at 6 months,Adverse events,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2584,NCT06320301,the effectiveness of first-line treatment with Adebrelimab and a tyrosine kinase inhibitor (TKI) in combination with gemcitabine and oxaliplatin (GEMOX) in patients with advanced BTC,To evaluate the overall survival (OS).,2024-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],The DoR based on an immunomodified RECIST (imRECIST）
2585,NCT00625625,Disease-free survival,,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2586,NCT00999882,Evaluate the pharmacokinetics of AZD8055 following both single and multiple dosing,To collect and store DNA for future exploratory research that may influence response to AZD8055,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
2587,NCT03419481,Response rate (RR) according to RECIST1.1,Overall survival (OS),2018-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2588,NCT05083247,R0 Resection rate,Technical and quality success rate of EUS-delivered fiducials.,2023-03-24,RECRUITING,INTERVENTIONAL,['PHASE2'],
2589,NCT06151223,Collection of radiology images and videos,,2021-07-13,RECRUITING,OBSERVATIONAL,['NA'],
2590,NCT06328101,Standardized incidence ratio (SIR) of first invasive cancer,Risk factor associated with cancer diagnosis.,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2591,NCT02025842,risk for hepatocellular carcinoma,survival,2000-01,COMPLETED,OBSERVATIONAL,['NA'],
2592,NCT01236300,NPV (Negative Predictive Value),Overall Complication Rate,2010-07,COMPLETED,INTERVENTIONAL,['NA'],
2593,NCT04241835,"To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, fu: unbound fraction of drug in plasma",To evaluate the number of participants with adverse events (AEs) as assessed by CTCAE v5.0,2020-01-28,RECRUITING,INTERVENTIONAL,['PHASE1'],
2594,NCT06024980,Swallowing ability to four different textures,The time in weeks of nasogastric feeding,2023-01-03,RECRUITING,INTERVENTIONAL,['NA'],
2595,NCT01718873,Objective Response Rate,Toxic Effects,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
2596,NCT04003181,Serum concentration of FGF19,Quality of life after treatment with antibiotics or bile acid binder,2017-09-28,COMPLETED,INTERVENTIONAL,['NA'],
2597,NCT00084773,Safety profile,Activity in terms of pathological complete response rate,2004-03,COMPLETED,INTERVENTIONAL,['NA'],
2598,NCT05364918,Acute radiotherapy-induced oral mucositis,Oral pain,2020-08-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
2599,NCT00055250,6-month survival,PK,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2600,NCT05135364,Progression-free survival (according to mRECIST),Disease control rate (according to mRECIST and RECIST 1.1),2021-11-05,RECRUITING,INTERVENTIONAL,['PHASE2'],
2601,NCT01927016,To identify predictors of recurrence after esophageal cancer surgery,"Impact of patient preconditioning (such as nutritional support, esophageal prosthesis, mini-invasive approach…) on outcomes",2012-07,COMPLETED,OBSERVATIONAL,['NA'],
2602,NCT03045497,Ability of contrast-enhanced ultrasound to predict response to transarterial chemoembolization with drug eluting beads,Changes in contrast fill time,2012-12-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
2603,NCT00891332,Overall Response Rate (ORR),Pharmacokinetics,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2604,NCT01150916,diagnostic accuracy of BNP for the diagnosis of ascites due to heart failure,,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
2605,NCT03449030,Recommended Phase 2 Dose (RP2D) of TAK-164,Number of Participants With Positive Antidrug Antibody (ADA) Levels in Serum,2018-04-23,TERMINATED,INTERVENTIONAL,['PHASE1'],
2606,NCT01048580,"Safety and tolerability of the combination of perifosine and capecitabine (i.e., dose limiting toxicity)",Pharmacokinetic (PK) data for the combination of perifosine and capecitabine,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
2607,NCT02534142,Variables related to non-completion of colonoscopy following a positive fecal occult blood test,,2015-10,COMPLETED,OBSERVATIONAL,['NA'],
2608,NCT02117674,polyp detection rate,patients' satisfaction,2014-04,COMPLETED,INTERVENTIONAL,['NA'],
2609,NCT01372527,Cancer completion for all eligible cancers,TopCare system measures (intervention practices),2011-06,COMPLETED,INTERVENTIONAL,['NA'],
2610,NCT01549795,Time to recurrence after liver transplant,Complication rate due to radiotherapy (Hepatic artery thrombosis and Portal vein thrombosis),2012-01,UNKNOWN,INTERVENTIONAL,['NA'],
2611,NCT06321913,vital signs,Overall Survival (OS),2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],CLDN18.2 expression level
2612,NCT04239261,Development of Oral Mucositis during ChemoRadiation Treatment,Change in Bowel Movements,2020-01-17,TERMINATED,INTERVENTIONAL,['PHASE2'],
2613,NCT00001332,,,1992-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
2614,NCT03135652,Disease free survival,Toxicities,2017-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
2615,NCT05458791,Quantification of Parameters for Intra-arterial Perfusion,Impact of low dose radiation technique on intra-arterial perfusion parameters,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],
2616,NCT01539824,Disease stabilisation rate,Tumour Markers,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2617,NCT02981719,Safety (number of adverse effects),Technical success of ablation,2016-10-01,COMPLETED,INTERVENTIONAL,['NA'],
2618,NCT00956241,Primary endpoint was the function of the neo-rectum as assessed by a validated functional outcome questionnaire at 4 months.,Quality of life,2002-04,COMPLETED,INTERVENTIONAL,['NA'],
2619,NCT04721470,AFP variation rate,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],
2620,NCT00594529,Curative resection rates of liver metastases,Completion rates of neoadjuvant chemotherapy,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2621,NCT05964361,Safety of IL15/IL15Ra/WT1 DC vaccine administration: total (S)AEs (grade),Evaluation of changes in quality of life: How patient-reported quality of life evolves over time,2023-12-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2622,NCT03817866,Disease Progression,,2019-01-29,COMPLETED,OBSERVATIONAL,['NA'],
2623,NCT04072224,Description of volume of in vivo ablation,liver response,2018-10-23,COMPLETED,OBSERVATIONAL,['NA'],
2624,NCT01161316,progression-free survival,Adverse events,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
2625,NCT03985891,ORR,OS,2020-12-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2626,NCT05517239,Progression free survival,Overall survival,2015-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2627,NCT00530010,Patient Completion,,2004-12,COMPLETED,OBSERVATIONAL,['NA'],
2628,NCT05589480,Recurrence-free survival,,2022-08-01,COMPLETED,OBSERVATIONAL,['NA'],
2629,NCT03387982,Difference in pain quality 4 weeks post-procedure for subjects receiving Balloon Cryotherapy or Radiofrequency Ablation via the Pain Quality Assessment Scale (PQAS),,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],
2630,NCT01285557,Overall Survival (OS),Time to Tumor Response (TTR),2011-04-14,TERMINATED,INTERVENTIONAL,['PHASE3'],
2631,NCT02751736,Low Anterior Resection Syndrome score,Postoperative complication,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],
2632,NCT06278883,Uptake of genetic testing recommendations by the provider,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2633,NCT00054262,,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
2634,NCT06199895,Objective Response Rate,Incidence of adverse events,2023-11-28,RECRUITING,INTERVENTIONAL,['PHASE2'],
2635,NCT02006030,Determine time to tumor progression (TTP),Tumor response rates,2014-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],
2636,NCT00746317,Determine the safety and tolerability of escalating doses of GC33,Perform a preliminary assessment of anti-tumor activity of GC33,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
2637,NCT02910960,Total area of procured tissue between the two FNB needles,Diagnostic adequacy between the two FNB needles,2016-12,COMPLETED,INTERVENTIONAL,['NA'],
2638,NCT00420394,Feasibility of the study regimen.,Overall and progression free survival following the study treatment plan,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2639,NCT04673968,Body composition,Mitochondria functionality,2020-02-25,RECRUITING,INTERVENTIONAL,['NA'],
2640,NCT04597294,Peritoneal recurrence rate,Treatment-related quality of life assessed by Quality of Life Questionnaire-Stomach (STO22),2021-08-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
2641,NCT02902484,Maximum Tolerated Dose (MTD),,2017-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2642,NCT05625893,Incidence of adverse event assessed according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0),Local tumor progression rate,2022-09-16,RECRUITING,INTERVENTIONAL,['PHASE2'],
2643,NCT03693807,% frequency liver toxicity,progression free survival,2018-10-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2644,NCT01526200,new colorectal liver metastases detected at contrast-enhanced intraoperative ultrasonography,new colorectal liver metastases detected during 6-month postoperative follow-up,2007-10,COMPLETED,OBSERVATIONAL,['NA'],
2645,NCT05291338,Interleukin 28 B (IL28B) rs12979860.,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],
2646,NCT05965817,To assess the feasibility of simultaneous use of ICG and SGM-101 for intraoperative imaging of colorectal liver metastases.,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2647,NCT01472419,Overall Survival,,2012-03,COMPLETED,OBSERVATIONAL,['NA'],
2648,NCT03100409,Changes in food intake,Change in quality of life for cervical cancer patients: (European Organization for Research and Treatment of Cancer Cervical cancer module- EORTC QLQ-CX 24),2017-02-01,TERMINATED,INTERVENTIONAL,['NA'],
2649,NCT05424692,The difference of 3-year disease-free survival rate of patients in both group,The difference of OS of patients in both group,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],
2650,NCT05988645,Number of mural injuries.,Perception of difficulty.,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],
2651,NCT00019019,,,1994-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
2652,NCT00660426,"To define the maximum tolerated dose of oxaliplatin, gemcitabine and capecitabine in the treatment of patients with advanced gastrointestinal malignancies and other solid tumors.",To perform correlative pharmacogenomic and pharmacokinetic tests for this novel regimen.,2005-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
2653,NCT03500068,Developing organoids from advanced pancreatic cancer patients that predict non response or response,Functional studies will be done with the patient derived organoids to find biomarkers that correlate with response in organoids and patients.,2017-09-04,UNKNOWN,INTERVENTIONAL,['NA'],
2654,NCT03520790,Overall survival,Progression free survival,2018-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2655,NCT05628857,Objective Response Rate (ORR),Terminal elimination half life,2022-11-11,RECRUITING,INTERVENTIONAL,['PHASE2'],
2656,NCT02728596,Incidence of Febrile Neutropenia Among Intermediate Risk Participants,Overall Survival (OS),2016-10-07,COMPLETED,INTERVENTIONAL,['NA'],Differences Among Cohort Components and Intervention and Usual Care Components
2657,NCT00995202,Overall survival rate,Disease-free survival rate,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2658,NCT02453464,Maximum Tolerated Dose (MTD),Overall Survival (OS),2015-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2659,NCT04223141,Mortality,Medical complications,2020-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2660,NCT03374293,Local control,Overall survival,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2661,NCT00019760,,,1999-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
2662,NCT01798251,Progression Free Survival (PFS),adverse events (AE),2012-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],K-ras gene type
2663,NCT00002984,Number of subjects experiencing adverse events,Efficacy of treatment,1997-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2664,NCT03314532,disease-progression-free period,overall survival period,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],
2665,NCT02879227,Feasibility of treatment: Number of patients with completed treatment,Quality of life,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2666,NCT03469258,Effect of Pancreatic Enzyme Replacement Therapy on the Completion Rate of Adjuvant Chemotherapy and Radiation After Surgery for Early Stage Pancreatic Cancer,Measure Grip Strength Before and After Surgery and Adjuvant Treatment for Early-stage Pancreatic Cancer,2018-04-13,TERMINATED,INTERVENTIONAL,['PHASE2'],
2667,NCT02541149,"serum Annexin A2 in patients with hepatocellular carcinoma, chronic liver disease and healthy subjects",,2014-06,COMPLETED,OBSERVATIONAL,['NA'],
2668,NCT04882423,Hydroxylated PhlP profile with both cruciferous and apiaceous vegetables,,2013-09-19,TERMINATED,INTERVENTIONAL,['NA'],
2669,NCT01047475,The Primary Efficacy Endpoint of This Study is the Best Overall Response (Complete Response + Partial Response),,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2670,NCT04105062,Phase II only: Ability of LS301 to predict presence of positive margins,,2021-12-31,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2671,NCT00123318,The percentage of major radiotherapy protocol violations,Median survival and overall survival at 3 years,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
2672,NCT01625702,circulating tumor cells in blood,,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
2673,NCT05257057,Lynch Syndrome Screen Positive Rate,,2019-05-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
2674,NCT06314971,Recurrence-free Survival,,2023-03-15,RECRUITING,OBSERVATIONAL,['NA'],
2675,NCT01160367,family decision-making self-efficacy,"family psychological outcomes (depression, caregiver burden, decision making distress)",2010-08-26,COMPLETED,INTERVENTIONAL,['NA'],
2676,NCT05828381,The pathological complete response rate,The disease free survival rate,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2677,NCT05034627,Incidence of dose-limiting toxicities (DLTs),Mean plasma asparaginase activity,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],Therapy induced changes in the tumor and tumor ecosystem
2678,NCT00414492,,,2006-12,COMPLETED,OBSERVATIONAL,['NA'],
2679,NCT02261714,Patients' Immune Response,Clinical Efficacy,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Relationship Between (KRAS) Status and Clinical Efficacy
2680,NCT01293942,conversion to resectability during downsizing therapy with IXO+A patients with initially unresectable liver-only metastases associated with colorectal cancer,"R0, R1, R2 resection rate after up to 8 cycles of downsizing therapy with IXO+A",2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
2681,NCT00905047,patients preference after randomization and cross-over,safety of each treatment,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2682,NCT05263336,Anastomotic leak,Postsurgical Ileus,2021-01-03,RECRUITING,INTERVENTIONAL,['NA'],
2683,NCT05641129,Primary outcome,Secondary outcome 9,2023-01-16,COMPLETED,OBSERVATIONAL,['NA'],
2684,NCT04389632,Number of participants with dose-limiting toxicities (DLTs),Number of participants with antidrug antibodies (ADAs),2020-06-08,RECRUITING,INTERVENTIONAL,['PHASE1'],
2685,NCT04813861,Lesion Response,Delayed Lesion Response,2010-01-04,COMPLETED,OBSERVATIONAL,['NA'],
2686,NCT02340975,Progression Free Survival at 6 (PFS-6) Month in Phase 2,Percentage of Participants With Objective Response in Phase 2 by Programmed Death-ligand (PD-L1) Status,2015-03-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2687,NCT04823715,Disease-free survival of the patient after start of treatment,,2020-10-15,COMPLETED,OBSERVATIONAL,['NA'],
2688,NCT05810714,Number of Participants to Return Fecal Immunochemical Test (FIT),,2021-11-20,COMPLETED,INTERVENTIONAL,['NA'],
2689,NCT04242342,local control at 2 years,,2020-01-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2690,NCT01862562,Early complication rate,Health-related QOL score,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2691,NCT00516230,,,2006-01,UNKNOWN,OBSERVATIONAL,['NA'],
2692,NCT05402124,Measurement of Adverse Events,"Factors related to uptake, in-study adherence and post-study maintenance using measurement of chemoprevention knowledge",2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2693,NCT00190385,Incidence of small hepatocellular carcinoma (HCC),Clinical value of serum alfa-fetoprotein assay,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
2694,NCT00003344,,,1998-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2695,NCT02503696,Sensitivity and Specificity of the Exact CRC diagnostic screening test.,,2014-09,COMPLETED,OBSERVATIONAL,['NA'],
2696,NCT04210115,Overall Survival (OS),Number of participants discontinuing study treatment due to an adverse event (AE),2020-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
2697,NCT04120701,3-year Disease-Free Survival in ctDNA positive patients,,2020-01-17,RECRUITING,INTERVENTIONAL,['PHASE3'],
2698,NCT00349336,Weekly Steady-state Exposure of Bevacizumab,Terminal Half-life of Bevacizumab,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2699,NCT00573131,Overall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT,,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
2700,NCT02424838,Proportion of diagnostic cell block specimens obtained according to needle size and the use of suction.,Rate of complications,2014-07-28,COMPLETED,INTERVENTIONAL,['NA'],
2701,NCT03173729,Sensitivity and specificity of a point of care device to diagnose colorectal cancer and polyps,Cost per patient of point of care urine test for diagnosing patients with colorectal cancer and polyps.,2017-02-11,COMPLETED,OBSERVATIONAL,['NA'],
2702,NCT05572684,Define a recommended Phase 2 dose (RP2D) of NC410 when combined with standard dose Pembrolizumab,Progression-free Survival (PFS) per RECIST,2022-10-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2703,NCT00587067,Number of Patients With Treatment Related Toxicity,Median Survival,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2704,NCT05340231,PFS,Pathological response rate (PCR+MPR),2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2705,NCT00049322,Neovessel Formation as Measured by Angiogram at 14 Weeks,Measure (Vascular Endothelial Growth Factor)VEGF Before and After TACE With and Without Bevacizumab,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2706,NCT06328361,Disease-free survival,Complication rates,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2707,NCT04683731,"Decision Quality assessed using the multi-dimensional measure of informed consent (MMIC) which incorporates knowledge, intent, and behavior.",Number of providers who open their provider notification,2021-01-19,COMPLETED,INTERVENTIONAL,['NA'],
2708,NCT05585814,Tumor regression grade (TRG),Quality of life score (QoL score),2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2709,NCT06248879,Body Mass Index,Feeding amount,2024-02-28,WITHDRAWN,INTERVENTIONAL,['NA'],
2710,NCT05200611,The efficacy of fecal immunochemical test to detect advanced adenoma,The efficacy of fecal immunochemical test to detect colorectal neoplasms,2022-01-04,UNKNOWN,OBSERVATIONAL,['NA'],
2711,NCT03191604,Altered chosen treatment modality due to NBI,Differences in pathology identification between subgroups,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],
2712,NCT06293014,Time to treatment failure (TTF),European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30),2024-02-23,RECRUITING,INTERVENTIONAL,['PHASE2'],
2713,NCT03263663,Progression-free-survival,,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],
2714,NCT02138422,Response Rate,,2014-07-31,COMPLETED,INTERVENTIONAL,['PHASE3'],
2715,NCT06071507,Clinical Success,Nutritional status,2024-04-15,RECRUITING,OBSERVATIONAL,['NA'],Overall Survival
2716,NCT03206866,serum regucalcin in HCC patients,,2016-12-30,UNKNOWN,OBSERVATIONAL,['NA'],
2717,NCT02112162,Radiosensitivity index,,2014-06,TERMINATED,INTERVENTIONAL,['PHASE1'],
2718,NCT00005910,,,2000-06,COMPLETED,INTERVENTIONAL,['NA'],
2719,NCT00790569,CO-confirmed 7-day Abstinence,Change in Cigarettes Per Day,2008-09,COMPLETED,INTERVENTIONAL,['NA'],
2720,NCT03458949,variation of the rate of participation in colorectal cancer screening,,2018-06-18,UNKNOWN,INTERVENTIONAL,['NA'],
2721,NCT00006468,,,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2722,NCT02581059,Subject Fatigue Assessment,Evaluate Overall Survival (OS),2016-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
2723,NCT05363007,12W-PFS,,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
2724,NCT05245474,pCR rate,quality of life score,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
2725,NCT01831531,3-yr local control rate,Overall survival,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
2726,NCT02870582,Overall Survival (OS),Safety variables will be summarized using descriptive statistics based on adverse events collection,2016-12-28,COMPLETED,INTERVENTIONAL,['PHASE3'],
2727,NCT03355612,Disease Free Survival(DFS),Percentage of Participants With Adverse Events,2017-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
2728,NCT05450484,2) Incidence of (severe) adverse events (SAE/AEs) related to administration of durvalumab-680LT assessed by CTCAE,,2023-04-05,RECRUITING,INTERVENTIONAL,['PHASE1'],
2729,NCT04835402,Serious adverse reaction (SAR) rate according to CTCAE v5,"Adverse event rate (CTCAEv5, all grades)",2021-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2730,NCT01806649,disease control rate,overall survival,2013-07-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
2731,NCT00272051,Clinical evaluation of peripheral sensory neuropathy using the Oxaliplatin specific scale for dose adjustment : Q2W ; response rate using RECIST criteria : Q8W,Safety : Q2W ; Nerve conduction studies : Baseline + cycle 12 ; Progression Free Survival : Q8W ; Survival,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
2732,NCT03958032,Postoperative complications,Major complication,2016-12-03,COMPLETED,OBSERVATIONAL,['NA'],
2733,NCT01488045,Patient Satisfaction Scores (Absolute Value),Physician Perceptions (Absolute Value),2011-06,COMPLETED,INTERVENTIONAL,['NA'],
2734,NCT00135005,To determine the MTD which will be the Phase II dose of AMN107 when given in combination with Imatinib. The MTD is defined to be the highest dose of AMN107 in combination with Imatinib given for at least 21 days in the first treatment cycle,patients showing progression of disease on Imatinib. The patient will be followed-up for at least 4 cycles (28 days for one cycle),2005-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
2735,NCT05785325,Objective Response Rate,Overal survival,2023-08-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
2736,NCT01874665,Clinical Benefit Rate (CBR) in Cohort A,"Cmax, SS: Maximum Observed Plasma Concentration at Steady State for Ponatinib",2013-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2737,NCT04768686,Overall response rate in subjects treated with FLX475 in combination with pembrolizumab,,2021-05-18,COMPLETED,INTERVENTIONAL,['PHASE2'],
2738,NCT05870969,Early diagnosis rate of HCC patients,The 3-year cumulative incidence of liver cancer in each subject category according to the risk stratification at the time of initial diagnosis,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],The compliance rate of each risk group defined at the initial risk stratification
2739,NCT05366881,Detection of cancer,Clinical outcomes,2022-05-03,RECRUITING,OBSERVATIONAL,['NA'],
2740,NCT02800005,postoperative complications,Change of the postoperative AFA,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],
2741,NCT05111860,Peri-operative complications,Overall survival,2022-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2742,NCT00692770,Recurrence Free Survival (RFS) by Independent Assessment,Overall Survival (OS),2008-08-15,COMPLETED,INTERVENTIONAL,['PHASE3'],The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - MET
2743,NCT02360605,Repeat Screening,,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
2744,NCT04066894,Sacral Nerve Stimulation (SNS) Success,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal 29,2019-04-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
2745,NCT03708705,relapse rate of tumor,,2018-11-20,UNKNOWN,OBSERVATIONAL,['NA'],
2746,NCT00025129,,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
2747,NCT04086888,OS (overall survival),progression-free survival (PFS),2016-12-12,UNKNOWN,OBSERVATIONAL,['NA'],
2748,NCT00091286,Number of patients with an immune response to the peptides,Immunogenicity of the peptide mixture measured in the peripheral blood,2003-03-24,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],
2749,NCT00698451,The Primary Efficacy End Point is the Number of Patients With an Objective Response.,The Secondary Efficacy Endpoints is Duration of Objective Response.,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
2750,NCT02828865,Tumor response,Assess for presence of adverse events,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
2751,NCT04062058,PCR rate,R0 resection rate,2019-11-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2752,NCT00207298,Change in management based on PET procedure,Safety of 18F-FDG,2005-06,COMPLETED,OBSERVATIONAL,['NA'],
2753,NCT02544737,"The proportion of patients with response (CR, PR, SD and PD based on RECIST version 1.0) assessed at 5-6 weeks after the initiation of treatment.","The proportion of patients alive (overall survival rate) from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study.",2015-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2754,NCT03448757,non-invasive hemodynamic parameter measurements during exposure AM RF EMF,Hemodynamic alteration´s comparison among advanced cancer patients and healthy controls,2018-02-15,RECRUITING,INTERVENTIONAL,['NA'],Searching for cancer-specific frequency modulation
2755,NCT00331786,Effects of nitric oxide-releasing acetylsalicyclic acid (NCX 4016) on aberrant cryptic foci (ACF) multiplicity after the second dose at 6 months,Safety and tolerability of long-term oral administration of NCX 4016 as measured by NCI CTCAE v3.0,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
2756,NCT02753465,disease-free survival rate,30-day mortality rate,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],
2757,NCT04318756,Syntactic and semantic equivalence of Cancer worry scale' items between English and Italian language and vice versa,Exploratory comparison between Patients Health Questionnaire and Irritability Depression Anxiety Scale and cancer worry scale,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA'],
2758,NCT05420064,Comparison of participant perceived quality of care,,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],
2759,NCT00767377,Time to progression,Toxicity,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],PET Scan response
2760,NCT01686971,,,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],
2761,NCT03040180,Histopathologic tumor regression following electrochemotherapy,Tumor Immunologic response following electrochemotherapy,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2762,NCT00955019,,,2007-10,COMPLETED,OBSERVATIONAL,['NA'],
2763,NCT02374255,Number of Patients Perception of Improved Goals of Care Discussions,Communication Skills Training,2016-03-15,COMPLETED,INTERVENTIONAL,['NA'],
2764,NCT01392131,Number of patients who have prolonged survival after receiving Oncoxin,Reduction in serum alpha-fetoprotein level and decrease in tumor size,2011-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2765,NCT00742729,Receipt of a colorectal cancer screening test,Knowledge and attitudes regarding CRC screening.,2004-09,COMPLETED,INTERVENTIONAL,['NA'],
2766,NCT01301417,Rate of anastomotic leakage,Rate of other device related complications and measures during hospitalization and post procedure:,2011-02,COMPLETED,OBSERVATIONAL,['NA'],
2767,NCT02168608,survival rate,complications,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],
2768,NCT02015754,"Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer",One-year Survival Percentage,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory Endpoint - Angiogenesis
2769,NCT01609231,Assessment of Progression-free Survival (PFS),Percentage of Participants With Objective Response Rate (ORR),2012-07-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
2770,NCT00897819,Correlation of MSI and LOH to outcome and response,,2007-01-03,COMPLETED,OBSERVATIONAL,['NA'],
2771,NCT02087878,Collection of Samples,,2014-03-31,WITHDRAWN,OBSERVATIONAL,['NA'],
2772,NCT05808712,Rate of supportive care needs in cancer,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],
2773,NCT02728804,Cumulative Incidence Rate of Treatment-related Major Financial Hardship,"Financial Stress (Patient, Caregiver, or Bereaved Caregiver)",2016-06-22,COMPLETED,OBSERVATIONAL,['NA'],
2774,NCT05465512,AUC for BNCISS,disease free survival,2022-01-04,COMPLETED,OBSERVATIONAL,['NA'],
2775,NCT06307080,Safety and efficacy assessment,Survival benefit,2023-10-08,RECRUITING,INTERVENTIONAL,['NA'],The application of medical-mechanical combination therapy mode
2776,NCT01308840,The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy naïve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response Evaluation Criteria In Solid Tumors (RECIST) Criteria.,The Number of Participants Who Experience an Adverse Event,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
2777,NCT04391348,Demonstrate that the identification of new tumour lesions by an experimental procedure combining PET-TDMs with 18F-FDG and 18F-Fluorocholine in patients with HCC modifies the initially planned therapeutic strategy,Number of patients who had an additional examination proposed by the MCM (multidisciplinary consultation meeting) following the PET-TDMs performed,2020-07-17,COMPLETED,INTERVENTIONAL,['NA'],
2778,NCT05720910,Quality of life assessed by the EORTC quality of life questionnaire (EORTC QLQ-C30 ),GERONTE patient-centered system implementation and usage,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2779,NCT02562976,Number of patients with severe gastric atrophy and/or intestinal metaplasia in early gastric cancer and non-early gastric cancer,"correlations between Helicobacter pylori infection and moderate-to-severe EGA classification, OLGA stage III-IV, OLGIM stage III-IV",2013-05,COMPLETED,OBSERVATIONAL,['NA'],
2780,NCT01927965,To establish the dose of Minnelide™ recommended for future phase 2 protocol,To determine pharmacodynamic effect of Minnelide™ on HSP70 levels. And to explore pharmacodynamics effect of Minnelide™ on PET Scans and using Choi criteria on the CT scans.,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
2781,NCT03950102,Rate of transplant complication,Rate of dropout from transplant waitlist,2015-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
2782,NCT01704651,Postoperative Length of Hospital Stay,Postoperative Ileus Incidence,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2783,NCT00006467,overall survival at 6 months,response rate,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2784,NCT05518201,Number of subjects with Severe adverse events (SAE),The immunogenicity of subjects receiving 3 doses of vaccination was assessed by IgG antibodies and neutralizing antibodies,2022-09-23,COMPLETED,INTERVENTIONAL,['PHASE1'],
2785,NCT00281736,Efficacy,Response,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2786,NCT05529615,3-year disease-free survival rate,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],
2787,NCT01238042,Optimal Light Dose,Resolve Barrett's mucosa,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
2788,NCT03034473,Number of patients with histopathologically confirmed complete remission (pCR) (ypT0N0 R0) after preoperative RCTx related to pretherapeutically determined gene expression signature predicting tumor response to RCTx.,Wexner-Score-Questionnaire,2011-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2789,NCT00293124,Time to Disease Progression,Overall Survival,2004-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
2790,NCT00176813,"To determine the overall survival time in patients with metastatic pancreatic cancer treated with the combination of gemcitabine, cisplatin and celecoxib.",To determine the influence of therapy on the blood levels of prostaglandins and angiogenesis,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
2791,NCT04995354,WHO grade of mucositis,,2022-06-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2792,NCT01098344,Adverse event and severity according to NCI CTCAE Version 4.02,Plasma concentrations of MK0752,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
2793,NCT02837679,Change in Quality of life,Length of hospital stay,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],Health costs per patient
2794,NCT04069455,CR29 scores,Overall survival,2019-10-01,RECRUITING,INTERVENTIONAL,['NA'],
2795,NCT00655655,"Efficacy outcomes in patients with metastatic kidney cancer, neuroendocrine carcinoma, non-small cell lung cancer, or melanoma (Cohort II)",,2004-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
2796,NCT04361227,Closure time after ESD,Clips used post-ESD,2020-07-02,COMPLETED,OBSERVATIONAL,['NA'],
2797,NCT06243393,Progression Free Survival (PFS),Overall Survival (OS),2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2798,NCT00655785,toxicities as assessed by NCI-CACAE ver3),Survival,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2799,NCT03175679,Incidence of Treatment-Emergent Adverse Events [Safety],Biological activity of infused iNKT cells,2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Disease Control Rate (DCR)
2800,NCT02127645,incidence of local and distant recurrence,anorectal function,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2801,NCT04264962,Recurrance rate,quality of life (QOL) questionnaire,2017-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
2802,NCT05313191,To determine the cumulative rate of CTCAE v5.0 Grade ≥3 acute and late treatment related adverse events within 1 year of definitive reirradiation completion using proton therapy for recurrent or second primary tumor.,To characterize patient reported outcomes within 1 year of reirradiation using the MDASI SP form for spinal tumors.,2022-01-24,RECRUITING,INTERVENTIONAL,['NA'],
2803,NCT05276037,Survival,FDG PET-CT value in Milan-in patients,2019-01-01,RECRUITING,OBSERVATIONAL,['NA'],
2804,NCT03101475,Best overall immune response rate (iBOR) of lesions not treated by ablation/radiotherapy including the extrahepatic lesions according to iRECIST (with response confirmation),Safety: Safety analyses will be performed on the Safety population. The worst toxicity grade per patient over the treatment period according to the CTCAE criteria version 4.0 will be displayed.,2018-11-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
2805,NCT06069778,Phase 2 - Disease-free survival (DFS),Phase 2 - Occurrence of abnormal laboratory parameters,2024-03-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2806,NCT02969096,Rate of complete tumor ablation,Adverse Events,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2807,NCT02582970,Percentage of Participants With Adverse Events,Mean Direct Medical Cost for Cancer Related Medical Care Utilization,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
2808,NCT00217555,Quality of life,Overall survival,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
2809,NCT01668017,Number of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT),Percentage of Subjects With Disease Control,2012-09-30,TERMINATED,INTERVENTIONAL,['PHASE1'],
2810,NCT05055323,Incidence of dose limited toxicity (DLT),Fatty tissue accumulation of PP,2021-07-29,RECRUITING,INTERVENTIONAL,['PHASE1'],
2811,NCT01187212,Progression-free survival,Biomarker for sorafenib,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
2812,NCT02146703,Objective reponse rate,"Progression free survival, median overall survival, disease control rate, and over grade 3 hematologic toxicities (neutropenia, thrombocytopenia, and febrile neutropenia)",2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
2813,NCT00919282,overall survival,safety of treatment,1997-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
2814,NCT05378919,disease-free survival,Overall survival,2015-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
2815,NCT03500380,Progression-free Survival (PFS) as Assessed by an IRC,Overall Survival,2018-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2816,NCT05203549,Establishment of patient-derived organoids,Correlation between results of the drug sensitivity tests in patient-derived organoid models and clinical outcomes,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],
2817,NCT04753203,Progression Free Survival,Duration of response,2021-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2818,NCT03678883,Part 3 Arm B,,2019-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2819,NCT04382079,oral mucositis,"IL-1, IL-6, IL-10,TNF",2020-04-08,UNKNOWN,INTERVENTIONAL,['NA'],
2820,NCT05760599,DCR per RECIST 1.1,Biomarkers such as PD-L1 expression,2023-02-27,RECRUITING,INTERVENTIONAL,['PHASE2'],
2821,NCT03320733,Negative predicative value,Parameters optimization keV,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],
2822,NCT00016900,,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
2823,NCT03941093,Overall Survival (OS),"Best Overall Objective Response Rate (ORR), as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",2019-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
2824,NCT03028311,Incidence of adverse event assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,,2017-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
2825,NCT06002425,Influence Rate of ChatGPT on Treatment Plans,3-year Progression-Free Survival (PFS) Rate,2023-08-29,RECRUITING,INTERVENTIONAL,['NA'],5-year Overall Survival (OS) Rate
2826,NCT01587534,the change in body weight at eight weeks after the randomisation,Frequency of bowel movements per day,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2827,NCT03395938,The proportion of siblings that contacted the study team within 4 weeks from point of engagement by the index colorectal cancer patient.,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],
2828,NCT01093755,Change in Esophageal Inflammation Biomarker COX-2 Gene Expression,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
2829,NCT00787787,Median Progression-free Survival,Median Overall Survival,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
2830,NCT04560712,Retention,Satisfaction of pain control,2020-08-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Postoperative length of stay
2831,NCT05711433,incidence of postoperative pancreatic fistula,,2014-07-01,COMPLETED,OBSERVATIONAL,['NA'],
2832,NCT00467194,Maximum tolerated dose,Change in DCE-CT scan assessment of angiogenesis,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
2833,NCT03687853,Death,,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
2834,NCT05375370,Change in tcDNA dosage between baseline and 3 Months,Survival at 2 years,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2835,NCT02333721,3-year disease free survival rate,Technical performance,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],
2836,NCT00001241,,,1989-01-27,COMPLETED,OBSERVATIONAL,['NA'],
2837,NCT03853772,Demographic and clinical data obtained via chart review and questionnaires,,2019-04-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
2838,NCT04254939,Phase II: ORR based on mRESIST 1.1,,2019-08-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2839,NCT05603039,Objective remission rate (ORR),Duration of remission (DOR) Duration of remission (DOR) Duration of remission (DOR) Duration of remission (DOR),2021-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS)
2840,NCT05104567,Objective Response Rate (ORR),Cend of infusion of cetuximab,2021-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2841,NCT01661270,Progression-free Survival (PFS),Percentage of Participants With Objective Response,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
2842,NCT01273493,Pharmacokinetics of trabectedin,Evaluate survival data,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
2843,NCT03787537,Change in nutritional status,length of hospital stay,2017-08-01,COMPLETED,OBSERVATIONAL,['NA'],
2844,NCT02525380,The rate of Time to progression of hepatocellular carcinoma 30 patients.,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2845,NCT01333631,Number of the patients with side effects,Number of the patients survived,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2846,NCT00544193,Measurement of biochemical parameters in tumors that may correlate with the effectiveness of therapy,,1997-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
2847,NCT05070247,Dose Expansion: Overall Response Rate (ORR),Dose Expansion: Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations,2022-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2848,NCT05177484,"the feasibility of running the study, to see if it could be run as a large multi-centre study",postoperative allogenic red blood cell transfusion rates,2022-05-30,RECRUITING,INTERVENTIONAL,['PHASE3'],
2849,NCT01441336,3 year recurrence free survival,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
2850,NCT00066677,Progression-free Survival,Number of Participants With Thromboembolic Events,2003-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
2851,NCT02862015,European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ)-C30 score change,Adverse effect,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2852,NCT05497271,diagnostic accuracy by cystic fluid analysis,DNA mutation profile of cystic fluid,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],
2853,NCT00474994,Overall Objective Response,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
2854,NCT03259763,Rate of gastric outlet obstruction recurrence,Duration of stent patency,2020-10-26,RECRUITING,INTERVENTIONAL,['NA'],
2855,NCT01373047,Determine the safety of modified T cells delivered into the hepatic artery by documenting the type and severity of any side effects and establishing the Maximum Tolerated Dose (MTD).,Designer T cell survival and phenotype following infusion,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
2856,NCT04185454,Osteocalcin ratio,Lipid profil 2,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],
2857,NCT03370432,Incidence of colorectal cancer in the DCH cohort,,1993-12,COMPLETED,OBSERVATIONAL,['NA'],
2858,NCT04647045,Serum cytokine level,Constipation related symptoms,2017-05-02,COMPLETED,INTERVENTIONAL,['NA'],
2859,NCT02325453,Compare the three treatment arms in terms of tumor recurrence after treatment. (Disease-free survival),"Verify whether robotic gastrectomy, compared with laparoscopic or open techniques, is capable of improving postoperative surgical stress. (Granulocyte-to-lymphocyte ratio.)",2015-05,UNKNOWN,OBSERVATIONAL,['NA'],
2860,NCT01843725,To determine the maximum tolerated dose and the recommended phase II dose of capecitabine in association with aflibercept,"The secondary endpoint is preliminary data on efficacy, and this will be evaluated using CT scan or MRI using RECIST (Response Evaluation Criteria in Solid Tumors) v1.1",2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
2861,NCT05545293,Postoperative nutritional status and quality of life,Postoperative intestinal function recovery time,2022-09-14,RECRUITING,OBSERVATIONAL,['NA'],
2862,NCT02919878,Estimate the rate of pathological complete response following neoadjuvant combined-modality therapy using weekly Gemcitabine and radiation therapy in rectal cancer.,R0 resection rate,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2863,NCT05098197,Overall Survival (OS),Change in Quality of Life,2021-09-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
2864,NCT05178043,The Objective Response Rate (ORR) (confirmed) as evaluated by an Independent Review Committee (IRC) according to RECIST v1.1,Presence of Anti-Drug Antibodies (ADAs) to GT90001 and Nivolumab during the study relative to the presence of ADAs at baseline,2021-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2865,NCT02841436,Tumor response,Assess for presence of adverse event,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
2866,NCT00768937,Safety of Sorafenib in combination with TACE,,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2867,NCT02748304,Overall survival,Number of patients with treatment-related bleedings who use aspirin,2016-04,TERMINATED,INTERVENTIONAL,['NA'],
2868,NCT05520840,Number of patient with presence of best isolated serum biomarkers selected from different candidates,Number of patient with presence of other isolated serum biomarkers selected from different candidates,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2869,NCT04024358,PNI and VI correlation with DFS,Correlation of neurotoxicity with PNI,2015-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
2870,NCT02332213,VOCs differentiating the study groups,Groups of gastrointestinal microbiota correlating to VOCs,2014-01,COMPLETED,OBSERVATIONAL,['NA'],Gastrointestinal microbiome in cancer patients
2871,NCT00685828,Progression-free survival,Toxicity as assessed by NCI CTC v2.0,2001-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2872,NCT01697943,Change in QOL (Quality of Life),Nutritional status of patients,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2873,NCT02291289,Progression-Free Survival (PFS),Percentage of Participants With Improvement and/or Stayed the Same on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score,2015-04-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
2874,NCT06248554,Disease-free survival,Adverse effects,2019-12-01,RECRUITING,INTERVENTIONAL,['NA'],
2875,NCT03192735,Radical surgical resection rate,adverse event,2017-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2876,NCT00865189,Percentage of Participants With Tumor Sterilization Defined by ypT0-N0,Percentage of Participants With Surgery,2007-10-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
2877,NCT02697084,time of disease-free survival,best treatment response criterion: complete or partial metabolic response according to EORTC or PERCIST criteria,2014-11,UNKNOWN,OBSERVATIONAL,['NA'],
2878,NCT03475680,Postoperative 30-day surgical site infection (SSI).,Date of adjuvant chemotherapy beginning,2018-08-08,TERMINATED,INTERVENTIONAL,['PHASE3'],
2879,NCT05336539,Application value of polygene methylation detection in colorectal cancer in community population,,2022-04-01,RECRUITING,OBSERVATIONAL,['NA'],
2880,NCT06001567,Proportion of patients with PLT >75×10^9/L or doubling from baseline,Adverse events (AEs),2023-08-14,RECRUITING,INTERVENTIONAL,['PHASE2'],
2881,NCT02037399,present pain intensity (PPI),,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],
2882,NCT04709055,Percentage of patients with postoperative complications of grade II or higher in the Clavien-Dindo,Patient and professionals experience (ancillary study using semi-directive interviews),2021-01-14,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2883,NCT05220046,Retention Rate,Change in Demoralization Scale (D-II) total score from Baseline to 1 week post-dose,2023-04-10,RECRUITING,INTERVENTIONAL,['PHASE1'],
2884,NCT05855291,Overall survival,,2018-01-22,COMPLETED,INTERVENTIONAL,['NA'],
2885,NCT05385250,Rate of PIFs,Quality of Life measures (EORTC),2021-08-23,RECRUITING,INTERVENTIONAL,['NA'],
2886,NCT04527861,3-year disease free survival rate,5-year overall survival rate,2021-04-08,RECRUITING,INTERVENTIONAL,['NA'],
2887,NCT05913674,Feasibility of mEPIC,Satisfaction of care team,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2888,NCT04880811,Objective response rate,Overall survival,2021-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2889,NCT05606848,Change in serum prealbumin,Energy intake in kcal / kg BW,2022-11-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
2890,NCT04227886,Toxicities,pCR,2019-12-01,UNKNOWN,OBSERVATIONAL,['NA'],
2891,NCT06192719,Gallbladder Cancer/Dysplasia development,,2019-12-01,RECRUITING,OBSERVATIONAL,['NA'],
2892,NCT04717765,"Treatment of osteonecrosis of the jaws with LLL phototherapy, evaluation using Notani scale - grade 1 to 3 - Radiotherapy",Pain assessed by EVA - score 0 to 10 - all patients,2021-02-10,COMPLETED,INTERVENTIONAL,['NA'],
2893,NCT01356264,six minute walk test,Fatigue,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
2894,NCT00655876,Overall Survival (24-month Rate Reported),"Quality-adjusted Survival (Using EQ-5D), Only if Primary Hypothesis is Supported",2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2895,NCT02292745,overall survival,predictive value of a set of biological markers for treatment response,2014-12-02,COMPLETED,INTERVENTIONAL,['NA'],
2896,NCT04191551,Progression of intestinal metaplasia,,2018-07-30,RECRUITING,OBSERVATIONAL,['NA'],
2897,NCT00844883,Safety Will be Assessed by Grading Toxicities Reported at Intervals Throughout the Study. Higher Grade Toxicities Will be Assessed for Their Degree of Relatedness to the Study Treatment.,Efficacy - Factors Associated With Overall Survival (OS) After Combination Treatment With Sorafenib and TACE,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Overall Survival OS Stratified by BCLC Criteria
2898,NCT04592289,Incisional surgical site infection (SSI) rate,Bowel preparation compliance,2020-10-30,RECRUITING,INTERVENTIONAL,['NA'],
2899,NCT00561418,Safety and Tolerability of Vorinostat (SAHA) After Autologous Stem Cell Transplantation,Time to Progression,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
2900,NCT02425059,Number of participants with Adverse events,Percentage of lesions that show no sign of recurrence 12 months after IRE,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Overall survival (OS)
2901,NCT06300463,"Mean CD8:Treg ratio, as determined by flow cytometry of tumor tissue, at time of surgical resection in each treatment arm",Number of Participants Per Arm with ctDNA Clearance,2024-03-26,RECRUITING,INTERVENTIONAL,['PHASE2'],
2902,NCT00941655,Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm II,Patterns of Disease Recurrence Between the Two Therapeutic Approaches and Their Clinical Implications,2009-07-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
2903,NCT04025567,To evaluate the effect of oral vancomycin therapy in the relative CXCR6 gene expression levels in the liver,,2020-03-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
2904,NCT05184283,Change in mean muscle fat,Delta HOMA-IR,2022-06-16,TERMINATED,OBSERVATIONAL,['NA'],
2905,NCT02412683,Oxaliplatin-Specific Neurotoxicity Scale,Sense of Coherence scale (SOC-scale),2014-01,COMPLETED,OBSERVATIONAL,['NA'],
2906,NCT05546619,RFS,OS,2022-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2907,NCT01032044,"Number of Barrett's Esophagus (BE) Participants With a Composite Outcome of ""Optimally Treated""",,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
2908,NCT02005484,Percentage of Participants With a Response by Response Evaluation Criteria In Solid Tumors (RECIST) Category,Time to Progression,2004-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
2909,NCT06084884,"1. Incidence of participants with dose-limiting toxicities (DLTs), adverse events (AEs), including adverse events of special interest (AESI) and serious adverse events (SAEs). Determination of the recommended dose of AZD5851 for expansion phase",12. Pharmacokinetics - Exposure of AZD5851,2023-11-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2910,NCT02534389,Check effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on Glasgow Prognostic Score (GPS).,Check for effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on pathological response.,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
2911,NCT03638193,Safety of CART-meso infusion: number of adverse events,CAR-T cell detection,2018-07-11,UNKNOWN,INTERVENTIONAL,['NA'],
2912,NCT03322267,1-year relapse-free survival (RFS) rate.,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),2018-10-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Blood-based biomarkers
2913,NCT02385604,Disease-free survival,Histopathologic response,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
2914,NCT03958747,Tibial Nerve Cross-Sectional Area Comparison,Reduction of Intraepidermal Nerve Fiber Density,2019-12-17,RECRUITING,INTERVENTIONAL,['NA'],
2915,NCT03236649,Overall survival (OS),Assessment on Quality of life 2,2017-09-20,TERMINATED,INTERVENTIONAL,['PHASE3'],"Genome level (DNA, mRNA, miRNA) biomarker analysis"
2916,NCT05472896,Progression-free survival (PFS) by Independent Review Committee,2 year survival rate,2022-06-09,RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse event/ serious adverse event
2917,NCT05810805,Concentrations of different gas in digestive tract,The correlation between the severity of gastrointestinal symptoms and gas concentrations in various parts of the digestive tract.,2023-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2918,NCT01998347,median overall survival,median progression free survival,2013-11,WITHDRAWN,INTERVENTIONAL,['PHASE3'],time to progression
2919,NCT01755767,Overall Survival (OS) Rate At Different Time Points Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy,Treatment-Emergent Adverse Events Reported (>20% in Tivantinib Cohort) Following Treatment With Tivantinib Compared With Placebo in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy,2012-12-27,COMPLETED,INTERVENTIONAL,['PHASE3'],
2920,NCT06161233,Change in health-related QoL outcomes in RCC patients,User experience of the CAPABLE system in other cancer types patients,2023-05-16,COMPLETED,INTERVENTIONAL,['NA'],
2921,NCT00790322,Compare the proportion of patients in the two arms who develop severe oral mucositis,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
2922,NCT06313567,Disease-free survival,Side effects,2024-03-10,RECRUITING,INTERVENTIONAL,['PHASE3'],
2923,NCT03133650,Maximum tolerated laser fluence rate,,2017-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
2924,NCT02024087,Number of Participants With Adverse Events as a Measure of Safety and Tolerability.,Disease Control Rate (DCR),2014-08-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2925,NCT00241020,Overall Survival,· Safety,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2926,NCT00743678,To evaluate overall R0 resection rates following neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis,"Correlative analyses between pretreatment EGFR, KRAS mutation and response rate/survival",2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2927,NCT01397747,"Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer.",,2011-06,COMPLETED,OBSERVATIONAL,['NA'],
2928,NCT04328740,Determine recommended Ph2 dose (RP2D) of TP-1454,Determine antitumor activity of TP-1454.,2020-07-08,RECRUITING,INTERVENTIONAL,['PHASE1'],
2929,NCT04479436,Objective Response Rate (ORR) As Assessed By Blinded Independent Central Review (BICR) Following Administration of U3-1402 In Participants with Advanced or Metastatic Colorectal Cancer,Pharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) and During Dosing Interval (AUCtau) of analytes of U3-1402 Following Administration In Participants with Advanced or Metastatic Colorectal Cancer,2020-09-14,TERMINATED,INTERVENTIONAL,['PHASE2'],
2930,NCT04749303,Adenoma Detection Rate (ADR),Severe adverse events,2020-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
2931,NCT00085163,"Disease-free survival as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter","Toxicity as measured by CTC AE version 2.0 every 3 months in year 1, every 6 months in years 2-3, and annually thereafter",2004-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
2932,NCT02952859,Time from diagnosis to death for any reason,,2017-01,TERMINATED,OBSERVATIONAL,['NA'],
2933,NCT04227041,Progression-free survival (PFS),Incidence of Treatment-Emergent Adverse Events [Safety],2020-01-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2934,NCT03978702,"Measurement of immune effectors (Tcells, NK) levels after pancreatectomy",,2021-02-24,UNKNOWN,INTERVENTIONAL,['NA'],
2935,NCT03697239,Disease Control Rate,Changes in patient's self-reported pain levels,2019-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2936,NCT03579784,Disease control rate,Safety and tolerability as measured by number and grade of toxicity events,2018-11-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2937,NCT01621217,To establish maximum tolerable dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab and radiotherapy in patients with locally advanced cancer in the anal region,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
2938,NCT04665687,Indentify prognostic biomarkers for predicting recurrence of early gastric cancer and precancerous adenoma lesion.,"Change in the tumor's molecular profile on serial biopsies at the time of initial treatment, 2 months after treatment, 1 year after treatment, or recurrence.",2020-12-17,UNKNOWN,OBSERVATIONAL,['NA'],
2939,NCT05647122,Proportion of patients with radiological response (ORR),Immunogenicity of AZD9592: Anti-Drug Antibodies (ADA),2022-12-22,RECRUITING,INTERVENTIONAL,['PHASE1'],
2940,NCT00393822,Incidence of Grade ≥ 2 (WHO scale) oral mucositis,Incidence of grade ≥ 2 (WHO scale) oral mucositis,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2941,NCT04612504,The response rate of patients with HCC receiving SynOV1.1,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2022-06-23,RECRUITING,INTERVENTIONAL,['PHASE1'],
2942,NCT05438836,"Early Rate of Common Terminology Criteria for Adverse Events (CTCAE) Gastrointestinal Toxicity grade 2 or more (scale from 0-5, 5 being the highest)",Treatment Related Hospitalization,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],
2943,NCT03863236,Postoperative complications,Hospital stay,2019-04-01,RECRUITING,INTERVENTIONAL,['NA'],
2944,NCT06172049,Survival,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],
2945,NCT05731336,"Overall Survival, OS","Adverse events, AEs",2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],
2946,NCT00577902,"To study baseline antioxidant capacity (ORAC), selected biomarkers of nutritional status and nutritional risk of patients beginning therapy for head and neck cancers.","To assess antioxidant capacity, nutritional biomarkers and nutritional risk of patients during and after concurrent radiation and chemotherapy.",2005-06,COMPLETED,OBSERVATIONAL,['NA'],
2947,NCT02301143,Kaplan-Meier Estimates for Time to Treatment Failure (TTF),Participants With Treatment Emergent Adverse Events (TEAEs),2015-04-21,COMPLETED,INTERVENTIONAL,['PHASE2'],
2948,NCT04907591,"Change of body composition (weight, kg)","Muscle mass (lumbar 2,㎠)",2021-05-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2949,NCT00411151,Objective Response Rate (ORR),Safety and Tolerability: Adverse Events in ≥10% of Patients,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
2950,NCT06083974,OS and DFS of patients with metastatic colorectal cancer patients received anti_EGFR targeted therapy,Response rate (RR) in patients received chemotherapy only or with combination with targeted therapy.,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],
2951,NCT03699761,Grade III-IV complications,Treatment cost,2020-09-01,RECRUITING,INTERVENTIONAL,['NA'],
2952,NCT05170282,The diagnostic accuracy of infantile liver tumors with deep learning algorithm,The diagnostic negative predictive value of infantile liver tumors with deep learning algorithm,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
2953,NCT05277766,Maximally tolerated dose (MTD) of Nal-IRI,Overall treatment response,2022-11-21,RECRUITING,INTERVENTIONAL,['PHASE1'],Exploratory outcome: Expression of human carboxylesterase 2 (hCE2)
2954,NCT04460066,major pathologic response rate,adverse events rate,2020-11-18,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2955,NCT02248805,Characterize dose limiting toxicity and establish a maximum tolerated dose and schedule,Describe any evidence of anti-tumor activity,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
2956,NCT01570582,24month progression free survival,Toxicity Profile,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2957,NCT01175447,Maximum tolerated dose (MTD) of s-1 in combination with thoracic radiotherapy in elderly patients (> 70 years old) with esophageal Cancer,"Objective response rate (e.g. complete response [CR], partial response [PR], stable disease [SD], or progressive disease [PD]).",2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
2958,NCT05571956,simultaneous establishment of pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts,,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],
2959,NCT03027427,Clinical and laboratory evaluation and molecular profiling of tumor tissue,,2017-02-01,RECRUITING,OBSERVATIONAL,['NA'],
2960,NCT02090153,Overall Response Rate (ORR),Adverse Events (AEs),2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
2961,NCT00433550,Confirmed Tumor Response Rate (Proportion of Participants With Complete Response),Time to Treatment Failure,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2962,NCT05189171,MOS generation,,2022-10-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
2963,NCT00514228,Progression-free survival,Serum alpha fetoprotein level,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
2964,NCT01830582,determine the best MR imaging schedule,Determine if the best imaging schedule for DCE is the same as for DWI,2013-04-09,COMPLETED,INTERVENTIONAL,['NA'],
2965,NCT02405416,Normalized transection-related blood loss,Postoperative mortality,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],
2966,NCT03553004,Objective Response Rate (ORR),Proportion of participants with adverse events (AEs),2019-01-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2967,NCT03837782,overall survival,,2019-02-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
2968,NCT00036959,,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
2969,NCT05179889,Disease free survival (DFS),Incidence of treatment-related adverse events,2021-07-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2970,NCT03565354,Preoperative change in serum ferritin (mcg/L),Days (alive and) at home within 30 days of surgery (DAH30),2018-07-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Median waiting time to surgery (days)
2971,NCT05101889,Severe oral mucositis graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 criteria,overall survival (OS),2013-01-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
2972,NCT00253617,,,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
2973,NCT01676922,Treatment duration in patients receiving chemotherapy with Avastin as first-line therapy in daily clinical practice,Correlation between Comprehensive Geriatric Assessment (CGA) scores and initial treatment,2011-08,COMPLETED,OBSERVATIONAL,['NA'],
2974,NCT01801852,Occurrence of study related adverse events,Anti-tumor responses to NKT cells infusions,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],
2975,NCT04246970,Progression in the activities of daily life (ADL),Change in Quality of life,2021-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
2976,NCT02675946,Number of participants with adverse events and/or abnormal laboratory values that are related to treatment,CGX1321 half-life,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2977,NCT01841294,Dosage of NKs activity after surgery,Major adverses events,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2978,NCT05678257,Number of patients achieving progress-free survival (PFS),Number of patients reporting treatment-emergent adverse events (TEAEs),2023-04-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2979,NCT06282575,Progression Free Survival (PFS) in participants with Immunohistochemistry (IHC) 3+ tumors,"TDD for all participants in patient-reported symptoms scores as measured by the EORTC QLQ-BIL21 (Pain, Jaundice, Abdominal Pain, and Pruritis)",2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE3'],
2980,NCT05606523,Body weight changes in mice after fecal material transplantation.,GALT function and systemic inflammation,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],
2981,NCT05655949,Incidence of Grade 3 or Higher Treatment-Related Toxicity,Disease Control Rate (DCR),2024-02-13,RECRUITING,INTERVENTIONAL,['PHASE2'],
2982,NCT03838029,Biomarkers in blood samples,Fatigue,2019-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
2983,NCT02977702,overall survival,,2015-12,COMPLETED,OBSERVATIONAL,['NA'],
2984,NCT04442984,Progression-Free Survival,Treatment associated toxicities,2019-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],
2985,NCT00032123,,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2986,NCT06021015,Disease control rate (DCR) of target lesions 1 month after the last TACE treatment,Equipment performance evaluation,2023-09-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2987,NCT03281369,For Arm 1L-A : Percentage of Participants with Serious and Non-serious Treatment-related AEs,Percentage of Participants With ADA to BL-8040,2017-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2988,NCT00901901,Overall Survival,Health-related Quality of Life and Utility Values as Measured by EQ-5D - VAS,2009-05-21,COMPLETED,INTERVENTIONAL,['PHASE3'],Tumor Response
2989,NCT06089330,Incidence and severity of adverse events (AE) and serious adverse events (SAE),Overall Survival (OS),2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2990,NCT04393220,OS,,2020-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
2991,NCT00459901,To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer,To determine the qualitative and quantitative toxicity of this combination and sequence of drug administration,2004-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
2992,NCT04901741,Go/no-go decision for a randomized expansion study,Time-to-next-anticancer-treatment (TTNT),2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
2993,NCT00242190,Occurrence of dose limiting toxicity up to three weeks following the second cycle of chemotherapy.,"Characterize pattern of responses, progression free survival, and survival after treatment",2004-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2994,NCT03426371,Progression Free Survival (PFS) Time,quality of life score,2018-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2995,NCT00289003,"To assess actual grade of mucositis upon completion of radiotherapy or chemoradiotherapy and after prophylactic treatment with soluble beta-1,3/1,6-glucan or placebo.",To assess the safety of the investigational product,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2996,NCT01802684,Progression free survival at 6 months,Curative salvage surgery,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2997,NCT05939661,Pathological complete response (pCR),,2023-05-25,RECRUITING,INTERVENTIONAL,['PHASE2'],
2998,NCT05085548,Determine Recommended Phase 2 Dose (RP2D),Assess serum tumor marker CA19-9 or appropriate tumor specific marker.,2021-10-29,RECRUITING,INTERVENTIONAL,['PHASE1'],
2999,NCT00520013,Consolidation Treatment-related Toxicity Rate,Consolidation Objective Response Rate,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
3000,NCT02967107,Number of participants with residual or recurrent adenoma as assessed at surveillance endoscopy,Number of participants with pain after EMR as assessed by VAS score and telephone interview at 2 weeks,2016-06,COMPLETED,INTERVENTIONAL,['NA'],
3001,NCT05788744,Sub-study 2 eccDNA,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],
3002,NCT06253897,Qualitative interview: patients' injection experiences and satisfaction with the Ipsen lanreotide syringe and with the Pharmathen lanreotide syringe;,Qualitative interview: experiences that are unique to patients between disease indications,2024-03-26,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3003,NCT06256328,Progression-free survival (PFS) (site investigator assessment),Adverse event (AE),2023-12-06,RECRUITING,INTERVENTIONAL,['PHASE2'],
3004,NCT02727179,Overall survival,Morbidity,2005-02,COMPLETED,INTERVENTIONAL,['NA'],
3005,NCT00608361,Pharmacokinetic parameters of dasatinib,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Liver dysfunction data
3006,NCT00103545,The primary endpoint is drop-out due to toxicity as the overall measure of feasibility,Duration and strength of the immune response induced by ACA 125 vaccination,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3007,NCT04179305,Change in Prognostic Understanding,Patient Performance Status,2020-10-25,COMPLETED,INTERVENTIONAL,['NA'],
3008,NCT02115542,Overall Survival (OS) at 6 Months,Progression Free Survival (PFS),2014-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
3009,NCT04503902,Objective response rate（ORR） as determined by the Invertigator using RECIST V1.1,Progression free survival (PFS),2020-10-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3010,NCT03774134,Risk of recurrence,Mesocolic lymph nodes yield,2008-06-01,UNKNOWN,OBSERVATIONAL,['NA'],
3011,NCT02074124,Change in arterial flow during adenosine vasodilation test (CT perfusion parameter),Change in Permeability (CT perfusion parameter) during adenosine vasodilation test.,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
3012,NCT04729205,Evaluate Disease Control Rate,Plasma MLP level after Promitil infusion,2021-01-13,TERMINATED,INTERVENTIONAL,['PHASE1'],
3013,NCT00172757,,,2002-01,UNKNOWN,OBSERVATIONAL,['NA'],
3014,NCT01051284,To demonstrate that radiation treatments can be reproduced as determined by evaluation of the prescription isodose curves,The feasibility of measuring pancreatic cancer stem cell populations by analysis of fine needle aspirate specimens,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
3015,NCT06044506,Optimal treatment dosage,Progression-free survival,2022-08-29,RECRUITING,INTERVENTIONAL,['PHASE1'],
3016,NCT02915432,Objective response rate (ORR) evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1),Apparent volume of distribution of steady state (Vss) after multiple dose injection of Anti-PD-1 mAb,2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Correlation of the changes of TBNK lymphocytes subgroup in patients receiving chemotherapy combined with JS001 and its correlation with the anti-tumor activity
3017,NCT00431925,,,na,UNKNOWN,OBSERVATIONAL,['NA'],
3018,NCT01075113,Determine the appropriate Doses for the combination of sorafenib tosylate and vorinostat appropriate for phase II study in hepatocellular carcinoma (HCC).,Anti-tumor effects of the combination of sorafenib tosylate and vorinostat,2010-08-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
3019,NCT04969874,patient attendance at monthly remote monitoring,felt swallowing,2024-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3020,NCT04434508,the number of lymph nodes (LNs) harvested among both groups,post-operative complications,2017-07-01,COMPLETED,INTERVENTIONAL,['NA'],
3021,NCT03098108,local control rate at 3-year,Colonrectum Quality of life (QOL-CR) assessment,2017-02-09,UNKNOWN,INTERVENTIONAL,['NA'],
3022,NCT03698825,Maximum Tolerated Dose (MTD),pharmacokinetics of TEW-7197,2018-08-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",pSMAD as a pharmacodynamic marker
3023,NCT06008288,Objective response rate (ORR) by independent central radiological review (IRC) according to RECIST 1.1.,Number of participants with adverse events,2023-10-27,RECRUITING,INTERVENTIONAL,['PHASE2'],
3024,NCT00137878,,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],
3025,NCT06018142,Perfusion ratio,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],
3026,NCT02413853,Progression free survival (PFS),Survivin mRNA expression levels,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Intratumoral gene expression of Wnt related biomarkers
3027,NCT04443478,The number of lower mediastinal lymph nodes retrieved,Overall survival in 3 years,2020-08-01,RECRUITING,OBSERVATIONAL,['NA'],Number of patients that can be screened and successfully recruited
3028,NCT01079533,Colorectal Cancer Screening,,2008-07,COMPLETED,INTERVENTIONAL,['NA'],
3029,NCT02628665,Partial remission rate,The recent incidence of adverse reactions,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3030,NCT04435197,Pathologic complete response,Overall Survival (OS),2020-08-11,RECRUITING,INTERVENTIONAL,['PHASE2'],
3031,NCT01862198,The stent patency rate,Complication rate related to the hybrid stents,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
3032,NCT04809870,Long-term survival,Pulmonary complications,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],
3033,NCT04459468,Predictive accuracy of Proteomic biomarker(s) measured with bead-based X-aptamer library for overall survival in hepatocellular carcinoma patients,Predictive accuracy of Proteomic biomarker(s) measured with bead-based X-aptamer library for Progression free survival in Hepatocellular carcinoma patients.,2022-11-04,RECRUITING,OBSERVATIONAL,['NA'],
3034,NCT04746469,Overall colorectal cancer screening uptake (any modality),Colorectal cancer screening uptake by modality,2020-09-02,COMPLETED,INTERVENTIONAL,['NA'],
3035,NCT01387932,Median Overall Survival,Objective Response Rates (ORR),2011-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Number of TACE-Related Adverse Events in Subjects Treated With HepaSphere/QuadraSphere vs Subjects Treated With Conventional TACE.
3036,NCT01924819,Overall survival,Surgical complete resection rate (R0),2009-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3037,NCT00458809,Maximum tolerated dose,Change in the phenotypic expression of proteins involved in the apoptotic and heat-stress inducible pathways,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
3038,NCT01908504,The number of subjects with benefit from an intra-treatment PET-CT,Measure late toxicities,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
3039,NCT05542030,Lesions recurrence in a three-month follow-up after EMR,Recurrence risk after EMR,2022-09-12,RECRUITING,INTERVENTIONAL,['NA'],
3040,NCT05610332,Objective response rate,"The prediction performance of Exosome contents (including proteins, nucleic acids)",2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
3041,NCT06243757,Appetite level score according to the MDASI-GI,,2024-01-08,RECRUITING,OBSERVATIONAL,['NA'],
3042,NCT00848952,Report of proportion of the positives truths and the positive wrong for an examination,,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],
3043,NCT01035437,Determine the toxicity of sequential PDT and chemoradiation in obstructing esophageal cancer,Evaluate the efficacy of PDT in palliation of dysphagia,2009-12,WITHDRAWN,INTERVENTIONAL,['NA'],
3044,NCT03097848,Disease free survival,mortality,2017-05-04,UNKNOWN,INTERVENTIONAL,['NA'],
3045,NCT06204523,"Investigate pathways of interest at a deeper level, as well as identify other potential pathways/functions impacting clinical outcomes.",,2018-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3046,NCT03790553,Overall survival in ITT population,Questionnaire EORTC-QLQ-OES18,2018-10-15,RECRUITING,INTERVENTIONAL,['PHASE3'],
3047,NCT03102047,Median modified Neoadjuvant Rectal (mNAR) Score,Frequency of adverse events assessed by CTCAE 4.0,2018-05-14,COMPLETED,INTERVENTIONAL,['PHASE2'],
3048,NCT05238831,Proportion of participants who receive an ACT therapy based an ACT Tumor Board recommendation.,Overall survival,2023-01-30,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],
3049,NCT06152978,Event-free survival (EFS),adverse events,2023-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
3050,NCT05497453,Duration of Response (DOR) (for Part 1 and Part 2 expansion),,2022-08-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3051,NCT02140021,Sensitivity and specificity of the combination of anal pap testing + anal HPV testing to diagnose anal dysplasia,,2014-10-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3052,NCT02106910,Mean Procedure Preference Rating,Cytosponge™ Operating Characteristics,2014-10-27,COMPLETED,INTERVENTIONAL,['NA'],
3053,NCT00577109,Progression-free survival,"AEs, laboratory parameters.",2007-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
3054,NCT01411189,The proportion of patients had no or mild peristalsis during the therapeutic procedures,Adverse events and adverse drug reactions,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
3055,NCT06030934,Objective Response Rate (ORR),Adverse Events (AEs),2022-10-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],
3056,NCT02282059,Percentage of Participants With Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs),Progression-free survival by clinical judgment,2014-12-12,COMPLETED,OBSERVATIONAL,['NA'],
3057,NCT03295084,Maximal Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT) of oral Irinotecan based on incidence of Treatment-Emergent Adverse Events,Objective tumor response to treatment based on RECIST 1.1 criteria,2015-07-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
3058,NCT01123811,objective response rate,Progression-free survival,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
3059,NCT01519232,Changes in hepatobiliary single photon emission tomography (SPECT) after radiation therapy,"measuring values between regional radiation dose and local hepatic function as measured by hepatobiliary SPECT, in normal liver parenchyma",2008-08,COMPLETED,OBSERVATIONAL,['NA'],
3060,NCT04183478,overall survival,QOL,2017-09-26,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Hematology Index
3061,NCT04652947,"compare diagnostic MRI performance of gadoteric acid, gadoxetic acid and P03277 for suspected CHC nodules",,2016-12-07,COMPLETED,OBSERVATIONAL,['NA'],
3062,NCT00303628,5-year Overall Survival Rate,Proportion of Patients Who Completed 12 Cycles of Treatment,2006-05-11,TERMINATED,INTERVENTIONAL,['PHASE3'],Change in Oxaliplatin-related Neurotoxicity Between Baseline and 12 Months
3063,NCT04584996,circRNAs for diagnosis,Bioinformatics,2020-10-04,UNKNOWN,OBSERVATIONAL,['NA'],
3064,NCT01530503,Progression Free Survival (PFS),Overall Survival (OS),2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
3065,NCT01575730,Area under the plasma concentration versus time curve (AUC) of platinum,Tissue Concentration (Cmax) of Platinum,2012-05-21,COMPLETED,INTERVENTIONAL,['PHASE2'],
3066,NCT03699410,Negative Prognostic Value (NPV),,2018-08-28,TERMINATED,OBSERVATIONAL,['NA'],
3067,NCT05187182,Expansion dose of CA-4948 in combination with FOLFOX/PD-1 inhibitor with/without trastuzumab,Overall survival (OS),2023-06-02,RECRUITING,INTERVENTIONAL,['PHASE1'],
3068,NCT04027543,Overall survival (OS),30-day postoperative or in-hospital mortality,2018-11-14,COMPLETED,OBSERVATIONAL,['NA'],
3069,NCT01322633,Incidence Rate of Gastric Cancer,Incidence Rate of Overall Cancer,2004-07,COMPLETED,OBSERVATIONAL,['NA'],
3070,NCT04084249,FCI,CE,2020-01-01,RECRUITING,INTERVENTIONAL,['NA'],
3071,NCT06301399,ORR,DCR,2024-03-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
3072,NCT01839500,"Cohort III, V: Disease-Free Survival (DFS), as Assessed by the Investigator Using RECIST V1.1 Criteria",Cohort II: Percentage of Participants Who Decline to the Recommendation Categorized by Reasons,2013-04-25,COMPLETED,OBSERVATIONAL,['NA'],
3073,NCT06096623,Electronic patient-reported outcome (ePRO) confirming treatment initiation,Time to treatment in days,2023-11-06,RECRUITING,INTERVENTIONAL,['NA'],
3074,NCT06236633,Safety of endovascular inferior mesenteric artery embolisation prior to surgical resection of the rectum in patients with tumours of the lower and middle rectum.,Markers of epithelial-mesenchymal transition : transcription factors,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Operative data
3075,NCT04710758,Overall survival,Postoperative recovery course,2021-01-20,RECRUITING,INTERVENTIONAL,['NA'],
3076,NCT03042611,Overall Survival (OS),Number of Participants Per QOL Dimension Response as Measured by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire,2017-03-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
3077,NCT05772546,Response Rate of CIT Treatment in Placebo Group,Rate of Serious Treatment-Emergent Adverse Events (TEAEs) in Placebo Group,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
3078,NCT05675059,Malnutrition: Low Skeletal Muscle Mass,,2022-12-21,RECRUITING,INTERVENTIONAL,['NA'],
3079,NCT04996355,"The accuracy, specificity and sensitivity of organoids-on-chip for drug sreening",,2021-05-31,RECRUITING,OBSERVATIONAL,['NA'],
3080,NCT02249650,Dose limiting toxicities (DLTs),,2017-07-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
3081,NCT01834742,Primary Variable,Safety profile,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3082,NCT06326619,Survival,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],
3083,NCT05101772,The acquisition rate of the core tissue sample,the incidence of adverse events and the incidence of device defects,2021-09-24,UNKNOWN,OBSERVATIONAL,['NA'],
3084,NCT01199250,"Role of FGFR2 mutations in low, intermediate and high risk endometrial cancers (Project 1)",,2100-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3085,NCT04177810,Objective Response Rate (ORR) Using Immune RECIST (iRECIST) Criteria,Number of Participants Experiencing Grade 3 or Above Drug-related Toxicities,2020-11-16,COMPLETED,INTERVENTIONAL,['PHASE2'],
3086,NCT00714701,This clinical study will assess the diagnostic yield of a clinical screening program for early pancreatic neoplasia in high risk individuals.,,2008-06,COMPLETED,OBSERVATIONAL,['NA'],
3087,NCT01670851,Perineal wound healing,Incidence of parastomal hernia,2013-03,COMPLETED,OBSERVATIONAL,['NA'],
3088,NCT00026130,Overall Survival,Toxicity,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3089,NCT04594655,MPI and major morbidity,Prediction of complication,2017-10-01,COMPLETED,OBSERVATIONAL,['NA'],
3090,NCT04187352,Overall survival (OS),Duration of response (DoR) assessed by BICR and investigators according to RECIST v1.1,2019-12-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
3091,NCT02519348,Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events,Overall Survival (OS),2015-10-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
3092,NCT03222557,GI-2 recovery,Adverse events related to EA/SA,2017-11,UNKNOWN,INTERVENTIONAL,['NA'],
3093,NCT02387203,Overall survival,"Progression-free survival measured by no evidence of disease progression, i.e. tumor markers within normal limits, no radiographical evidence of disease",2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Analyze number of live bacteria in PMP tumor and mucin
3094,NCT03984214,Standardized area under the curve of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 symptom summary score over the on-treatment period.,Overall survival (OS),2019-12-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
3095,NCT00159432,Median Time for Progression Free Survival,Number of Participants With Grade 3 or Higher Toxicity,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
3096,NCT02521649,Measurable Antibody Titer,Injection Site Reaction,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3097,NCT05311176,Objective Response Rate of HER-Vaxx in combination with chemotherapy or pembrolizumab,Duration of Response,2022-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Exploratory Outcome: Associations between clinical outcome and HER2/neu, PD-L1 expression"
3098,NCT00209729,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,Determine the OS(Overall Survival) and DFS(Disease Free Survival).,2005-04,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3099,NCT01073384,Preliminary Efficacy,,2009-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3100,NCT02200055,Bioimpedance Assessment,Amount of Intraoperative Fluids,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
3101,NCT02385552,Adenoma detection rate,Colonoscopy quality indicators,2011-03,UNKNOWN,OBSERVATIONAL,['NA'],
3102,NCT05516641,Gut Flora modulation,Immune Profile,2022-07-25,RECRUITING,INTERVENTIONAL,['NA'],
3103,NCT02772965,Percent of Participants Experiencing Treatment Failure,Percent of Patients With Positive Anti-TNF Antibody,2016-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
3104,NCT02041312,Cholesterol level in paitents with and withoutgastric neoplasm,Degree of decresed serum cholesterol levels in paitents with gastric neoplasm,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],
3105,NCT05635149,Progression-Free Survival (PFS),Gut microbiome analysis,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],Exploratory endpoint
3106,NCT00636610,Progression-free Survival (PFS),Progression-free Survival (PFS) in Patients With Various Degrees of Hedgehog Antigen Tumor Expression,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
3107,NCT02378389,The maximum-tolerated dose (MTD) of Pyrotinib and that of Pyrotinib with Docetaxel in patients with HER2 positive advanced gastric cancer,preliminary antitumor activity for the regimen,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3108,NCT03196232,Progression-free Survival (PFS),Treatment Delay or Reduction,2017-09-13,COMPLETED,INTERVENTIONAL,['PHASE2'],
3109,NCT01554969,Tumor response and disease progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST).,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
3110,NCT02833363,Difference of Gastric Microbiota in the Process of Correa's Model.,Difference of Gastric Microbiota in the Process of Correa's Model.,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],
3111,NCT03888638,Survival,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],
3112,NCT00657371,Number Polyps Detected With the Standard Colonoscope and Third Eye Retroscope (TER),Number Participants With Polyps Who Would Have Incorrectly Been Classified as Polyp-free Had the Third Eye Retroscope Not Been Used.,2008-03,COMPLETED,INTERVENTIONAL,['NA'],
3113,NCT00709462,"To establish the safety and tolerability profile of CDX-1307 in patients with incurable breast, colorectal, pancreatic, ovarian or bladder cancer, alone and in combination with adjuvants.","To evaluate dose-limiting toxicities, immune response, and clinical activity (tumor response and time to progression)",2004-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
3114,NCT00997022,Maximum tolerated dose of daily sorafenib,Duration of progression free survival,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
3115,NCT04585516,Presence of upper GI pathology,patient characteristics of colorectal cancer 7,2020-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Patients characteristics in patients < 50 years who were admitted for a gastroscopy 9
3116,NCT00718055,,,2006-11,WITHDRAWN,OBSERVATIONAL,['NA'],
3117,NCT05785780,Up-to-date CRC screening,Rate of CRC Screening Uptake by Glucose Control (Controlled vs. Uncontrolled) Among Participants with Type 2 Diabetes,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],Implementation Fidelity
3118,NCT01975454,Progression-free survival(PFS),Adverse events,2012-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3119,NCT06212700,Acceptability of the virtual multimodal hub.,Implementation Outcome: Maintenance,2024-02-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3120,NCT05669482,To determine the efficacy of the RP2D identified in Part A,Number of abnormal laboratory values,2023-03-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3121,NCT05188586,Specificity,Stage Shift,2022-12-06,RECRUITING,INTERVENTIONAL,['NA'],
3122,NCT00716209,,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],
3123,NCT00476970,Percentage of Eligible Patients In Study and Control Groups Who Undergo CRC Screening,Number of Polyps and Cancers per 100 Patients in the Study vs Control Group,2007-09,COMPLETED,INTERVENTIONAL,['NA'],
3124,NCT03010722,"disease control rate (DCR), measured in months",Median values of volume transfer constant (Ktrans) and enhancing fraction (EF) and their product KEF (product of summarised median values of Ktrans x EF/100) will be compared at baseline and on day 15,2015-01,COMPLETED,OBSERVATIONAL,['NA'],
3125,NCT02946138,Progression-free survival of all patients,Objective responses rate,2016-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
3126,NCT01471743,Number of participants with post-op Infections,,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
3127,NCT02181075,Patients Demonstrating >Two-fold Increase in the Amount of Intratumoural Doxorubicin Before and After Focused Ultrasound,Patients With Significant (Grade 3-5) Adverse Event(s) Deemed Related to FUS Procedure,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
3128,NCT04855331,Postoperative complications,The 90 days mortality rate after operation,2021-04-15,RECRUITING,INTERVENTIONAL,['NA'],Postoperative quality of life
3129,NCT04523467,Progression-free survival (PFS),Adverse events,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],Conversion rate
3130,NCT04415385,ORR,Incidence of Adverse Events (AEs) in the treatment of Camrelizumab in combination with apatinib,2020-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3131,NCT04342910,Overall Survival (OS) in PD-L1 Positive Participants.,Plasma concentration of apatinib,2020-09-21,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3132,NCT00725335,Disease free survival,"overall survival,morbidity,postoperative mortality;blood loss,Liver function test,etc",2008-09,COMPLETED,INTERVENTIONAL,['NA'],
3133,NCT06325410,type of resected tumor,,2013-01,COMPLETED,OBSERVATIONAL,['NA'],
3134,NCT04222114,Overall survival (OS),Tendency of theperipheral blood lymphocyte counts change associated with the intra-peritoneal infusion of catumaxomab,2020-10-06,RECRUITING,INTERVENTIONAL,['PHASE3'],
3135,NCT06123494,Overall survival (OS),Serum concentrations of SHR-A1811 toxin-binding antibodies and free toxin SHR169265,2024-01-09,RECRUITING,INTERVENTIONAL,['PHASE3'],
3136,NCT03520088,Changes in sexual dysfunction pre- and post-Total Mesorectal Excision,,2018-09-03,UNKNOWN,INTERVENTIONAL,['NA'],
3137,NCT02970916,FOLFIRI+aflibercept efficacy in terms of Progression-free survival (PFS) with or without ACE polymorphisms.,Number of participants with adverse events as assessed by CTCAE v4.0.,2016-11,COMPLETED,INTERVENTIONAL,['PHASE2'],"Other biomarkers in serum and tumour tissue associated with cell and tumour growth and/or involved in the mechanism of action of FOLFIRI+aflibercept and their correlation with tumour-efficacy parameters (ORR, PFS and OS)"
3138,NCT01628913,Progression Free Survival (PFS),Time to Treatment Failure (TTF),2012-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
3139,NCT02724267,Overall Survival,Time to Progression,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
3140,NCT05412355,long-term survival,Postoperative complications,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],
3141,NCT03456206,CID diagnosis,,2018-11-10,UNKNOWN,OBSERVATIONAL,['NA'],
3142,NCT01831037,Hepatocellular carcinoma,Profile with lowest risk for hepatocellular carcinoma,2015-07,WITHDRAWN,OBSERVATIONAL,['NA'],Regression of liver fibrosis
3143,NCT00260884,We expect to enter 50 patients per year and finish accrual of patient within 2.5 years.,,1993-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
3144,NCT02729298,Incidence of dose-limiting toxicities (DLTs) and treatment emergent adverse events,Objective response rate using RECIST v1.1 and iRECIST,2016-12-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
3145,NCT04298008,disease control rate (DCR) of AZD6738 and Durvalumab combination,quality of life measurement,2020-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],
3146,NCT05345054,A database linking socioecological determinants of health with nationally validated surgical outcomes.,,2022-08-01,COMPLETED,OBSERVATIONAL,['NA'],
3147,NCT04843644,oral mucositis,Microbiota,2021-04-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3148,NCT05265221,Resection speed,Complication rate,2022-03-01,COMPLETED,OBSERVATIONAL,['NA'],
3149,NCT00006039,,,1999-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
3150,NCT01580410,"The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments",Quality of Life as Assessed by Functional Assessment of Cancer Therapy: General (FACT-G),2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
3151,NCT00020826,psychometric validity of the STO22 module,debriefing questionnaire information,2001-04,COMPLETED,OBSERVATIONAL,['NA'],correlation between QLQ-C30 and STO22 scores
3152,NCT02620228,Difference in mean between measured bioimpedance spectra from tumorous and nontumorous tissue,,2016-06-09,COMPLETED,INTERVENTIONAL,['NA'],
3153,NCT04977882,Tolerance to solid diet,C-Reactive Proteine,2020-10-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
3154,NCT00321828,Major Morbidity Related to the Intact Primary Tumor,Overall Survival as Measured by Death From Any Cause,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3155,NCT00103103,Response rate as measured by RECIST every 8 weeks,Molecular correlates on and off study treatment,2005-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
3156,NCT06134024,Rate of safety of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of double pigtail plastic stents introduced through the LAMS.,Rate of long-term success of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of double pigtail plastic stents introduced through the LAMS.,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3157,NCT02000180,Difference Between Progressive and High-Fidelity Groups on Clinical Colonoscopy Peformance (JAG/DOPS),"Colonoscopy Specific Performance, Communication Skills, and Global Performance on an Integrated Scenario",2013-06,COMPLETED,INTERVENTIONAL,['NA'],
3158,NCT00433602,"Incidence of symptomatic pulmonary embolism as assessed by ventilation/perfusion lung scan, pulmonary angiogram, or CT lung scan within 72 hours of detection of symptoms or during autopsy (during the 3-month observation period)",,2006-11,COMPLETED,OBSERVATIONAL,['NA'],
3159,NCT01839877,Progression-free survival rate at 9 months,Overall survival,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
3160,NCT00294476,"and Serum tumor markers as appropriate CEA, PSA. Additionally, ECOG performance status is evaluated before each treatment cycle",Safety assessments include Adverse events and laboratory values which are measured and evaluated before every treatment cycle,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3161,NCT01060501,overall survival,Toxicity (WHO),1992-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
3162,NCT05841134,Percentage of Participants With Pathological Complete Response (pCR),Incidence of adverse events during the treatment and follow-up (safety),2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
3163,NCT04500171,ColoCARE Completion Efficacy,,2020-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3164,NCT00636298,Progression-free survival,Response rate,2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
3165,NCT05984602,Number of patients who proceeded to surgical resection,Number of changes in outcome of surgery that is attributed to study drug,2023-07-14,RECRUITING,INTERVENTIONAL,['PHASE1'],
3166,NCT06063941,Visual analogue scale scores at 30 minutes after chromoendoscopy,Associated factors for visual analogue scale scores,2023-10-10,RECRUITING,INTERVENTIONAL,['NA'],
3167,NCT01804166,Number of Samples Collected for the Identification of Biomarkers for Early Evaluation of Risk of Developing Hepatosplenic T-cell Lymphoma (HSTCL),,2013-03-21,COMPLETED,INTERVENTIONAL,['PHASE4'],
3168,NCT06335420,Number and size of polyps found at the one-year follow up colonoscopy,Acceptability of treatment,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3169,NCT02625623,Overall Survival (OS),Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22) Questionnaire Scores at End of Treatment (EOT),2015-12-28,COMPLETED,INTERVENTIONAL,['PHASE3'],
3170,NCT00280176,Dose-limiting toxicity,Gene expression pattern of tumors as assessed by cDNA microarray analysis pre- and post-treatment,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3171,NCT00778830,Percentage of Subjects With Best Overall Confirmed Response Rate (BORR),"Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (SAEs), TEAEs Leading to Discontinuation and TEAEs Leading to Death",2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3172,NCT03345563,Functional Assessment of Chronic Illness (FACIT)-Fatigue Scale,Consensus Sleep Diary,2019-07-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3173,NCT05575635,pCR,TRAEs,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
3174,NCT02469480,Rise or normalization of hemoglobin,Overall survival,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3175,NCT00325494,"Safety and Tolerability as a measure of physical examinations, vital signs, and ECGs",Objective Tumor Response Rate Assessed by Investigator,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
3176,NCT06305169,Measurement of the specificity and negative predictive value of serum biomarkers in gastric cancer,Creating a scoring system for patients that warrant urgent endoscopy on the cancer pathway,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3177,NCT00606983,Re-insertion rate of urinary catheter after removal,Scores of IPSS (International Prostatic Symptom Score) and the results of uroflowmetry,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
3178,NCT03702998,Incidence of HCC,Mortality due to HCC or liver-related conditions,2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],
3179,NCT00160875,pathological complete response,PET scan parameters (radiological),2009-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3180,NCT05410197,Objective Response Rate (ORR),Incidence of Adverse Events (AE),2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],
3181,NCT04906044,The incidence of serious adverse events,Wexner score,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
3182,NCT01980238,"anastomotic leakage, reoperation and mortality rate",ileus rate,2011-01,UNKNOWN,INTERVENTIONAL,['NA'],hospital stays and costs
3183,NCT03323866,Disease specific quality of life questionnaire,Endoscopic evaluation of the nasal cavities,2017-05-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
3184,NCT04913662,Recommended dose,,2021-04-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3185,NCT01662869,OS in the Intent-To-Treat (ITT) Population,European Quality of Life-5 Dimensions (EQ-5D) Questionnaire Score,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3186,NCT00601627,One Year Survival Rate,Time to Treatment Failure,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3187,NCT02665702,Progression Free Survival,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3188,NCT01308086,Relapse Free Survival,Safety Profil according to NCI-CTAE v 3.0,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3189,NCT04401800,Overall Response Rate (ORR) as assessed by Central Imaging Facility based on RECIST v1.1,Progression-Free Survival (PFS),2020-09-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3190,NCT00238407,Proportion of patients without local failure measured 6 months after completion of study treatment,Dysphagia as measured 6 months after completion of study treatment,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3191,NCT03210298,Overall survival,Quality of life according to QLQ-30 of EORTC,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],
3192,NCT05984511,Overall survival (OS),Adverse events (AEs),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3193,NCT01641783,progression free survival,biomarkers,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3194,NCT03648632,Resection rate for all patients starting SBRT,Mortality,2018-08-22,COMPLETED,INTERVENTIONAL,['NA'],
3195,NCT05275530,Overall completion of any Colorectal Cancer Screening test,Colorectal cancer screening uptake by modality,2022-02-21,COMPLETED,INTERVENTIONAL,['NA'],
3196,NCT02226107,Colonoscopy Completion,,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
3197,NCT06264921,Objective Response Rate (ORR),Accumulation ratio (AR),2024-02-23,RECRUITING,INTERVENTIONAL,['PHASE1'],
3198,NCT04937647,neoplasia detection rate,Endoscopist neoplasia detection rate,2021-06-16,RECRUITING,OBSERVATIONAL,['NA'],
3199,NCT05507112,Pathological complete response (pCR) rates,Patient reported outcome: Functional outcome according to Wexner score,2022-09-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
3200,NCT05866172,overall survival,Adverse Events,2023-05-10,RECRUITING,INTERVENTIONAL,['PHASE3'],
3201,NCT00717756,Response Rate by Recist Criteria,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
3202,NCT04651634,Incidence of severe OM,Analgesic use for OM,2021-06-21,RECRUITING,INTERVENTIONAL,['PHASE2'],
3203,NCT00220142,,,2003-11,COMPLETED,OBSERVATIONAL,['NA'],
3204,NCT04773626,Evaluate the relationship between tumor deposits and prognosis of colorectal cancer patient.,,2021-06,UNKNOWN,OBSERVATIONAL,['NA'],
3205,NCT04598984,The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients with Rectal Cancer,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],
3206,NCT00247676,Objective Response (CR or PR),Plasma Concentration of Soluble KIT (sKIT),2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
3207,NCT01847495,Number of participants with adverse events related to toxicities from concurrent SBRT and irinotecan,Overall survival,2013-10,WITHDRAWN,INTERVENTIONAL,['NA'],
3208,NCT02608879,Oral Mucositis Severity - NCI Scale,Change in Quality of Life as Measured by the Composite Score of the EORTC,2014-03,COMPLETED,INTERVENTIONAL,['NA'],
3209,NCT02443324,Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs),Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab,2015-07-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
3210,NCT02298010,Topographic pattern of metastasis to regional lymph node stations,recurrence pattern,2016-01,COMPLETED,OBSERVATIONAL,['NA'],
3211,NCT03749005,Impact on operation strategy of three dimensional visualization technique,1-year disease free survival rate,2017-04-18,UNKNOWN,OBSERVATIONAL,['NA'],
3212,NCT05506696,25OHD level,,2012-09-24,COMPLETED,INTERVENTIONAL,['NA'],
3213,NCT06152289,Develop an artificial intelligence solution to help with diagnosis in VCE,Evaluation of the diagnostic performance of the A.I. solution in terms of quality of preparation of the various segments of the digestive tract,2023-02-10,RECRUITING,OBSERVATIONAL,['NA'],
3214,NCT05035108,The incidence of adverse events (safety and tolerability).,Electrolyte level,2020-11-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
3215,NCT04338685,Number of Participants with Adverse Events (AEs) According To NCI CTCAE v5.0,Overall Survival (OS),2020-07-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
3216,NCT05631015,The accuracy of recommentions for different disease with deep learning algorithm,The F-score of gastric diseases with deep learning algorithm,2012-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3217,NCT00335595,Determine the free time to disease progression,Prognostic factor of the K-Ras gene mutation,2006-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
3218,NCT03051464,TME-free survival,Overall Quality of life,2017-04-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3219,NCT00338039,Median Overall Survival,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3220,NCT02339116,Progression Free Survival 2 (PFS2),Toxicity Rate,2015-02-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3221,NCT01655641,Primary objective of the study is to compare transfusion requirements and Mortality in patients receiving Tranexamic acid (Cyklokapron®) and those not receiving it.,Secondary outcome measure,2012-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3222,NCT03078348,Rate of Fecal Immunochemical Test (FIT) Kit Return Per Study Arm,Rate of Diagnostic Colonoscopy,2011-12-05,COMPLETED,INTERVENTIONAL,['NA'],
3223,NCT00178698,Survival,Quality of Life,2002-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3224,NCT05883644,Objective response rate (ORR),Change from baseline in HRQoL as assessed by EORTC QLQ-HCC18,2023-06-27,RECRUITING,INTERVENTIONAL,['PHASE3'],
3225,NCT05356039,Resection,Quality of Life at 24 months after inclusion,2022-04-19,RECRUITING,OBSERVATIONAL,['NA'],
3226,NCT04743479,Hazard ratio (HR),Diagnostic yield,2020-12-01,RECRUITING,OBSERVATIONAL,['NA'],
3227,NCT01443377,Histopathological complete response rate (pCR),overall survival,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
3228,NCT03150628,Mortality,Readmissions,2017-08-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
3229,NCT03041662,death,biliary dysplasia,2011-10-31,COMPLETED,OBSERVATIONAL,['NA'],
3230,NCT00792285,colorectal cancer screening,colonoscopy screening,2005-03,COMPLETED,INTERVENTIONAL,['NA'],
3231,NCT06092112,The objective response rate based on mRECIST,Overall Survival,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],The impact of CD-801 treatment on immune cell profiling in serum after treatment.
3232,NCT02644408,Quality of Life (QoF),adverse events,2014-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
3233,NCT00691691,Response rate to SBRT,Treatment Related Toxicity,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3234,NCT03487484,Change in quality of life specific for the gastrointestinal tract,Change in faecal Incontinence,2018-03-22,TERMINATED,OBSERVATIONAL,['NA'],
3235,NCT00593866,The Maximum Tolerated Radiation Dose,The Percentage of Participants Free From Local Progression at 2 Years,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3236,NCT04161755,Drug related toxicity,,2019-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
3237,NCT03563651,"Detection rates of Kras, Braf, or PI3K tumor DNA extracted from urine in patients without pre-existing mutations",,2014-02-06,COMPLETED,OBSERVATIONAL,['NA'],
3238,NCT06056908,"Provide education on the diagnosis, medical management, and treatment of SDS/SDS-Like conditions for patients, families, and the medical/scientific community.",,2016-01-19,RECRUITING,OBSERVATIONAL,['NA'],
3239,NCT04456933,Percentage of anastomotic leak (AL),Rate of Re-interventions,2020-06-29,UNKNOWN,OBSERVATIONAL,['NA'],
3240,NCT01860742,Progression Free Survival (PFS),"Tumor 18FDG PET/CT and 68Ga-octreotate PET/CT uptake at baseline, at mid and end of treatment",2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
3241,NCT00190801,Response rate according to RECIST criteria,The quantitative and qualitative toxicity of pemetrexed plus cisplatin in this patient population,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3242,NCT02541461,Change in body composition (changes in lean tissue mass and fatty tissue mass Using DEXA machine produced by Hologic),Changes in lipid profile,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
3243,NCT02291744,"TFS time of failure of strategy (the second progression time after induction therapy, or time to the use of second line strategy (if no reapplication of induction therapy) or time to no further treatment)",,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3244,NCT06065891,Prevalence of paraaortic lymph nodes in pancreatic cancer in patients submitted to a tentative curative resection,To address the question of how to optimize the frozen section analyses (lgll station 16) as related to the final pathology report?,2023-09-05,RECRUITING,INTERVENTIONAL,['NA'],
3245,NCT01681472,Concentration of [6S]-5-formyl-THF in Adjacent Mucosa Tissue,Number of AEs Per Severity,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3246,NCT02038283,Direct Health Care Costs for each CRC screening strategy,Factors Associated with HRQOL,2009-10,COMPLETED,OBSERVATIONAL,['NA'],
3247,NCT00470340,Survival without recurrence at 2 years,Morbidity and mortality following adjuvant treatment,2007-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
3248,NCT05107661,: Colorectal Screening Strategies in the High Risk Medically Underserved Population in a Hospital-based Community Outreach Program,Colorectal Screening Strategies in the High Risk Medically Underserved Population in a Hospital-based Community Outreach Program,2021-09-26,TERMINATED,OBSERVATIONAL,['NA'],
3249,NCT00577031,PFS: Time to Event,European Quality of Life 5 Dimension (EQ-5D) Raw-Index Score,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
3250,NCT03997162,Rate and type of post-operative complications,QoL after stomach cancer surgery,2018-10-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Overall survival of enrolled patients
3251,NCT01236053,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,,2010-06,COMPLETED,OBSERVATIONAL,['NA'],
3252,NCT01883297,Number of occurrences and severity of side effects,Number of patients with an immunity and no immunity to the study treatment,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
3253,NCT00826579,To assess the extent of upstaging due to the SLN procedure for colon cancer.,To evaluate the accuracy of the SLN procedure for colon cancer. To identify factors influencing the success of the procedure. To correlate SLN results with the presence of colon cancer cell in bone marrow aspirates. To assess OS and DFS.,2000-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3254,NCT02858778,The difference in the percentage of patients with a completed advance directive (AD) in Ig vs.Cg,Time to consultation in Ig vs. Cg groups,2016-06,UNKNOWN,INTERVENTIONAL,['NA'],
3255,NCT00098527,Radiographic response rate (complete response & partial response),Change in plasma and urine TGFB levels,2004-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
3256,NCT00003365,,,1996-08,TERMINATED,INTERVENTIONAL,['NA'],
3257,NCT05066048,Species composition of fecal microbial,age in year,2021-04-30,UNKNOWN,OBSERVATIONAL,['NA'],
3258,NCT02391662,Efficacy of treatment through 3-months deterioration free rate,CA 19.9 biomarker response,2015-06-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
3259,NCT05853172,R0 surgical conversion rate,Adverse event (AE),2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE2'],
3260,NCT01170754,Boston Prep Scale,Phosphorus Level in mg/dl,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],Boston Prep Scale (Per Protocol Analysis)
3261,NCT04025840,2-year overall survival,2-year progression-free survival,2019-09-11,RECRUITING,INTERVENTIONAL,['PHASE4'],Time to oral intake after surgery.
3262,NCT01924897,postoperative morbidity,Admission to HDU/ITU,na,UNKNOWN,INTERVENTIONAL,['NA'],Feasibility outcomes for exercise training
3263,NCT02685046,Effects of treatment on the mesenchymal gene expression profile,Number of participants with treatment-related adverse events as assessed by CTCAEv4.02,2016-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
3264,NCT02419586,Time to first flatus,Length of stay,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
3265,NCT00098787,Objective Response Rate,Overall Survival (OS),2005-09-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
3266,NCT02277548,Average/Cumulative Opioid Dose,,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
3267,NCT00537823,All-cause Mortality,Change in Tumor Size From Pretreatment to Preoperative CT Scan,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
3268,NCT04188158,Disease-free survival (SLE) at 2 years,To compare the postoperative morbidity and mortality of the neoadjuvant treatment in relation to the standard treatment,2017-03-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3269,NCT01340105,Complete ablation rate,Hospital stay,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
3270,NCT01387503,For Phase III - Overall Survival,Validation of the Metroticket model for the prognosis of survival after liver transplantation in patients exceeding Milan Criteria,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
3271,NCT01668134,Stereotactic radiation therapy (either photon or proton) can be delivered to the liver with a less than 10% 3-month incidence of Grade 4 study related toxicity.,Measure the response rates associated with using SBRT in patients with resectable HCC and IHC,2009-12-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
3272,NCT02705118,Registration accuracy,Registration time,2015-12,COMPLETED,INTERVENTIONAL,['NA'],
3273,NCT03256084,Evaluation of CTC features,,2017-07-17,RECRUITING,INTERVENTIONAL,['NA'],
3274,NCT02441153,Disease-free survival,,2016-03,COMPLETED,OBSERVATIONAL,['NA'],
3275,NCT03396926,Overall response rate (ORR) (Expansion Cohort),Progression-free survival (PFS) (Expansion Cohort),2018-04-18,COMPLETED,INTERVENTIONAL,['PHASE2'],
3276,NCT00154726,Response rate,overall survival,1997-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3277,NCT01322815,Number of Participants Alive and Free of Progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients),,2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
3278,NCT04106167,Overall Survival (OS) post-Infusion,,2019-06-11,TERMINATED,OBSERVATIONAL,['NA'],
3279,NCT03340844,Patient survival,Morbidity,2017-12-15,UNKNOWN,INTERVENTIONAL,['NA'],
3280,NCT01316679,,,2011-03,COMPLETED,OBSERVATIONAL,['NA'],
3281,NCT02488707,Hospital stay,,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3282,NCT00968604,Dose-Limiting Toxicity (DLT),,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
3283,NCT05804331,Long term outcomes: recurrent and residual disease,Patient interviews/questionnaires,2023-03-14,RECRUITING,OBSERVATIONAL,['NA'],
3284,NCT04671862,Rate of occurence of radiation mucositis,Radiation dermatitis,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],
3285,NCT01394120,Overall Survival,,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3286,NCT01494155,Progression-free survival,Measure utilization of health services,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3287,NCT05117957,Safety (Adverse events),Disease control rate (DCR),2022-02-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],
3288,NCT02498041,Endoscopic Diagnostic Accuracy for Barrett's esophagus,Adverse events,2009-04,COMPLETED,INTERVENTIONAL,['NA'],
3289,NCT01916447,"Safety monitoring including adverse events, vital signs, and laboratory assessments",Document any preliminary antitumor activity of TAS-102 administered in combination with CPT-11 and in combination with CPT-11 and Bevacizumab.,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
3290,NCT06024343,Incidence of Clinically Relevant Postoperative Pancreatic Fistula,Recurrence-free survival (RFS),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3291,NCT00061932,True Response Rate Evaluated for the Combination of Irinotecan and PS341 by Response Evaluation Criteria in Solid Tumors (RECIST),Change in Patterns of Gene Expression Pre- and Post-treatment Performed by GeneChip Analysis,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3292,NCT05493033,Anastomotic leak,Incision herniation,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3293,NCT00019331,,,1997-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
3294,NCT01667198,Screening centre leader's adenoma detection rate,Screening centre leader's withdrawal technique,2012-07,COMPLETED,INTERVENTIONAL,['NA'],
3295,NCT00252161,overall survival,adverse events,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3296,NCT00701857,The maximum tolerated dose (MTD) of pemetrexed,"Response (complete response, partial response, progressive disease, and stable disease) as measured by RECIST criteria",2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
3297,NCT03482609,The incidence of postoperative referred pain in the left shoulder within 1 month,inflammatory and immune response,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA'],
3298,NCT03976960,Number of biological risk factors for colorectal cancer,,2018-09-19,RECRUITING,INTERVENTIONAL,['NA'],
3299,NCT00039208,Peak delivery time for CPT11 tolerability over the first 3 courses of treatment in patients who started therapy,Overall survival,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
3300,NCT03008980,Outcomes of patients undergoing WATS sampling. Specifically incremental yield for Barrett's Esophagus and Esophageal Dysplasia due to WATS sampling above that noted from routine forceps biopsies in various clinical settings.,,2014-05,COMPLETED,OBSERVATIONAL,['NA'],
3301,NCT02250638,A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients with Pancreatic Cancer,,2014-05,COMPLETED,OBSERVATIONAL,['NA'],
3302,NCT03606785,reduction in blood loss,,2018-08-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
3303,NCT03977077,Progression free survival (PFS),Overall survival,2019-06-01,UNKNOWN,INTERVENTIONAL,['NA'],
3304,NCT02391207,the safety of HV-sparing surgery in terms of operative mortality and morbidity,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],
3305,NCT01733719,Recruitment rate and retention,Quality of life,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
3306,NCT02685553,Number of hypervascular pancreatic neoplasms detected intraoperatively by NIR,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
3307,NCT00541047,Freedom from distant metastases (any distance metastases or prostate cancer death) (RADICALS-RT),Freedom from biochemical progression (RADICALS-RT),2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3308,NCT05780684,Proportion of patients that receive dose intensified infusional 5-FU in Cycle 6 of the FOX regimen,5-FU drug exposure,2023-07-14,RECRUITING,INTERVENTIONAL,['NA'],
3309,NCT02607332,Disease control rate,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
3310,NCT04616196,Objective Response Rate (ORR) by RECIST 1.1 of NKTR-255 in combination with Cetuximab in R/R metastatic HNSCC or CRC for Phase 2 Dose Expansion,The development of anti-drug antibodies (ADA) against NKTR-255 and cetuximab,2020-10-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3311,NCT05137782,Operationalization as measured by the creation of a manual of operating procedures and web-based data collection forms,Acceptability as measured by willingness to recommend study participation to others.,2023-01-03,COMPLETED,INTERVENTIONAL,['NA'],
3312,NCT00955188,Adherence to colorectal cancer screening at 12 months post-intervention,Intention to get screened,2004-08,COMPLETED,OBSERVATIONAL,['NA'],
3313,NCT01072851,Comparison of the acceptance of colorectal cancer screening by patients who view print or multimedia educational tools,Comparative knowledge of colorectal cancer screening by patients who view the print or multi-media educational tools.,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
3314,NCT03607643,Response rate,Quality-of-life assessment in patients using clinician-reported outcomes (ClinRO) data.,2019-01-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3315,NCT00828048,Identify clinical and morphological predictors of cancer or high grade dysplasia in patients with IPMN. Identify predictors of progression to cancer or high grade dysplasia among patients who are followed in surveillance programs.,,2008-03,COMPLETED,OBSERVATIONAL,['NA'],
3316,NCT06260150,Incidence rate of DVT,Amount of bleeding during surgery,2023-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3317,NCT04000737,Progression free survival (PFS),Effects of YIV-906 on mean t½ (Hr) of sorafenib in blood,2020-01-10,RECRUITING,INTERVENTIONAL,['PHASE2'],
3318,NCT04616131,Number of patients with circulating tumor DNA (ctDNA) levels as not detectable in their blood compared to number of patients with ctDNA detected.,"Investigators will look for statistically significant correlations of ctDNA blood levels with clinical treatment responses of tumor grades, CA 19-9 units/milliliter blood level, and radiologic response by RECIST categories of complete response.",2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
3319,NCT01220063,tumor response accoording to recist criteria,,2007-10-19,COMPLETED,INTERVENTIONAL,['PHASE2'],
3320,NCT01872988,overall survival,time to liver decompensation,2012-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
3321,NCT03076957,Maximum Tolerated Dose(MTD),"Number of participants with toxicity as assessed by CTCAE v4.03 through study completion, an average of 1 year",2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3322,NCT03635021,Progression-free survival rate at 35 months,Incidence and severity of AEs CTCAE v4.03 criteria,2018-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],clinical impact of clonal dynamics by longitudinal analysis of circulating tumour deoxyribonucleic acid (ctDNA) in plasma
3323,NCT01397019,2 year survival rate,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3324,NCT00238199,Time to progression,Change in pancreatic cancer-induced pain,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3325,NCT05369117,Three-year disease-free survival rate,operative mortality,2022-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3326,NCT00112580,Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR),,2005-07-31,COMPLETED,INTERVENTIONAL,['PHASE2'],
3327,NCT04959617,Specificity of quantitative FIT,,2019-01-06,UNKNOWN,OBSERVATIONAL,['NA'],
3328,NCT02518373,Change in plasma gastrin level.,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3329,NCT02833506,Incidence of adverse events defined by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03,Time to disease progression as documented by Response Evaluation Criteria in Solid Tumors version 1.1,2017-12-08,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
3330,NCT00152906,Phase II: To determine with more confidence the rate and spectrum of all toxicities that occur at the maximally tolerated dose of radiation.,To determine whether serum cytokines and P-III-P can help predict RILD.,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3331,NCT05429190,Increased sensitivity for HCC detection,Cost-effectiveness analysis of SMS protocol,2023-11-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Patients acceptance of the SMS protocol (through a questionnaire)
3332,NCT04134104,Sexual Dysfunction,,2014-12,COMPLETED,OBSERVATIONAL,['NA'],
3333,NCT05610592,5-year event-free survival rate,Local recurrence,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],
3334,NCT01434459,The maximum tolerated dose of gemcitabine when given in combination with therasphere,The progression free of patients treated on the trial,2011-09,TERMINATED,INTERVENTIONAL,['PHASE1'],
3335,NCT05964621,VTE incidence in primary pancreatic cancer resection,,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],
3336,NCT05411432,SUV of organs,radioactivity of blood sample,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
3337,NCT04622176,Accuracy of lymph node diagnosis compared to MRI,,2021-06-17,RECRUITING,OBSERVATIONAL,['NA'],
3338,NCT04523818,Incidence of adverse events,Overall survival (OS),2020-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
3339,NCT06094140,The proportion of patients receiving at least 80% of planned neoadjuvant treatment.,Objective response rate.,2022-05-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Analysis of tumour tissue (baseline and surgical resection) for molecular changes and gene expression profile.
3340,NCT02221700,"Completion Rates of Two Massage Treatment Protocols for Patients With Chronic, Oxaliplatin-Induced Peripheral Neuropathy",Baseline treatment expectations,2015-04-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3341,NCT03427346,Eradication rate of neoplastic Barrett's Esophagus,Intervention time,2016-12,RECRUITING,INTERVENTIONAL,['NA'],
3342,NCT00004189,,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
3343,NCT00963794,"Electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.",,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
3344,NCT04524702,Change from baseline tumor size as measured by cross sectional imaging at 8 weeks.(every 8 weeks),Overall survival,2020-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in selected biomarkers in tumor microenvironment and circulation
3345,NCT05417386,R0 Resection Rate,Resection rate,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],
3346,NCT04044326,the efficacy of microwave ablation for the treatment of primary or secondary liver cancers: modified RECIST criteria,safety and local tumor recurrences,2019-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],
3347,NCT06222255,The LARS (Low Anterior Resection Syndrome) Score with Night symptoms,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - CR29,2023-12-06,RECRUITING,INTERVENTIONAL,['NA'],
3348,NCT01149642,The rate of grade 3 and 4 acute mucosal toxicity,overall survival rates,2009-11,COMPLETED,INTERVENTIONAL,['NA'],
3349,NCT02078362,Percentage of cell lysis,,2013-09,UNKNOWN,OBSERVATIONAL,['NA'],
3350,NCT02332863,Procedure Duration Required for Placing the Fiducial Markers,Number of Fiducials Placed,2016-08-03,COMPLETED,INTERVENTIONAL,['NA'],
3351,NCT06191120,Tumor-level CMS4 status as assessed by the current RNA-sequencing based CMS4 status reference standard performed on fresh-frozen tissue samples following surgery.,10-120 minutes post-injection dynamic [18F]-ALF-FAPI-74 uptake levels in tumor lesions and reference organs,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],RNA-sequencing derived gene-expression levels per tumor lesion
3352,NCT01270178,The survival rate and recurrence rate between patients receiving ETV therapy and those in historical control,"HBV reactivation, incidence of ALT normalization, reduction of serum HBV DNA level, HBsAg loss and HBsAg seroconversion to anti-HBsAb, emergence of resistance.",2011-01,UNKNOWN,OBSERVATIONAL,['NA'],
3353,NCT05007106,PFS per RECIST 1.1 as Assessed by Investigator at 12 months,Number of Participants Who Discontinued Study Intervention Due to an AE,2021-09-16,RECRUITING,INTERVENTIONAL,['PHASE2'],
3354,NCT04646772,Postoperative mortality,Disease Free Survival,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
3355,NCT03941561,DFS,OS,2019-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Side effects
3356,NCT02687113,RFA feasibility rates on planning USG with/without fusion CT/MR and US,Number of patients with safety access route on planning USG with/without fusion technique,2013-03,COMPLETED,INTERVENTIONAL,['NA'],Anticipated number of overlapping of RFA electrodes on planning USG with/without fusion technique
3357,NCT03864640,Content validity of Mediterranean Colorectal Cancer Registry: answering multiple-choice items,Face validity of Mediterranean Colorectal Cancer Registry: the major reason behind the negative response,2019-02-27,COMPLETED,OBSERVATIONAL,['NA'],
3358,NCT02678832,Social norms and cognitions toward self-management strategies of cancer patients as assessed by the variables of the theory of planned behavior (TPB),Physical activity as assessed with SQUASH,2015-12,COMPLETED,OBSERVATIONAL,['NA'],
3359,NCT01972503,3 years disease-free survival,3 years overall survival and metastasis-free survival,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3360,NCT04766736,Netrin-1 expression patterns in HCC samples,,2019-07-01,UNKNOWN,OBSERVATIONAL,['NA'],
3361,NCT01861483,R0 resection rate,,2013-03,COMPLETED,OBSERVATIONAL,['NA'],
3362,NCT02102646,Change in hepatic fat content,Correlation between Hepatic fat content and baseline androgen status,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
3363,NCT01964430,Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee,The Number of Participants With Clinical Chemistry Laboratory-Detected Abnormalities (Grade 3-4),2014-03-28,COMPLETED,INTERVENTIONAL,['PHASE3'],
3364,NCT04755543,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Serum concentration of the antibody against LP002 within 1 hour prior to each administration,2019-06-17,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3365,NCT02312167,"The number of participants with adverse events, their type and severity",The ease of manipulation of the robotized probe (grade 1 to 5),2014-10,COMPLETED,INTERVENTIONAL,['NA'],"number of interpretable images per organ, per contrast agent and per pathology"
3366,NCT01206218,Progression-free Survival,Response Rate,2010-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3367,NCT00598975,Number of Patients With Dose Limiting Toxicities,Number of Patients With Overall Response,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
3368,NCT00380588,Percentage of Patients Alive at 1 Year (1-Year Survival Rate),Progression Free Survival,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Survival Time
3369,NCT01132534,"To compare the detection rate of premalignant lesions(intestinal metaplasia, gastric atrophy, dysplasia) and early neoplasia of stomach between combined AFI/NBI endoscopy versus standard endoscopy",To assess the diagnostic accuracy AFI and NBI imaging,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
3370,NCT03208335,progress-free survival(PFS),Quality of life (QOL),2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3371,NCT02783261,liver hypertrophy,,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],
3372,NCT05486572,Hepatocellular Carcinoma Mortality,Overall Survival,2023-11-03,RECRUITING,INTERVENTIONAL,['NA'],
3373,NCT05578430,Major Pathological Response Rate (MPR rate),Incidence of Adverse Events (AE),2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
3374,NCT01361035,"Change in cervical, breast and colorectal cancer screening rates",Change in standardized patient ratings of physician communication behaviors,2008-06,COMPLETED,INTERVENTIONAL,['NA'],
3375,NCT02399059,Global survival,Disease free survival,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
3376,NCT03380052,The evaluation of OLGA and OLGIM stage systems with serum pepsinogen for prediction of gastric cancer risk,,2006-02,COMPLETED,OBSERVATIONAL,['NA'],
3377,NCT00077389,Rate of complete remission after completion of study therapy,Event-free survival,2004-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3378,NCT05214222,Objective Response Rate (ORR),The 3-year OS rate,2022-09-02,RECRUITING,INTERVENTIONAL,['PHASE2'],
3379,NCT04151030,Technical success of endoscopic vs radiographic Push-PEG placement in patients who are not candidates for a Pull-PEG placement,Procedure duration between endoscopic push PEG placement and IR guided push PEG placement,2019-06-28,COMPLETED,INTERVENTIONAL,['NA'],
3380,NCT05830890,Accuracy,Sensitivity,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3381,NCT00003594,time to progression,quality of life,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
3382,NCT00903565,To validate the performance of ColoPrint in estimating the 3-year relapse rate in patients with stage II colorectal cancer.,• Compare the ColoPrint results from fresh RNARetain colorectal tumor specimens to the matched formalin-fixed paraffin-embedded tissue (FFPE) colon tumor specimens for concordance.,2008-09,UNKNOWN,OBSERVATIONAL,['NA'],
3383,NCT04307654,Postoperative complications,,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
3384,NCT02954094,"Establish a longitudinal observational cohort to understand the natural history and management of HCC, including the safety and outcomes of HCC treatment interventions utilized in usual clinical practice",Establish a Biorepository Specimen Bank (BSB),2016-12,RECRUITING,OBSERVATIONAL,['NA'],
3385,NCT02021422,The Number of Participants with SAEs and AEs.,Gather preliminary information on the immune modulation and clinical activity of this therapy,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3386,NCT02739698,"The Grouped Miller and Payne (MP) System for Pathological Response: G1 (Minimal Changes and < 30% Cells Tumour Reduction That Includes MP G1-G2), G3 (Microscopic Foci, Cells Tumour Reduction up to >90% That Includes MP G3-G4) and G5 (no Residual Tumour)",,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
3387,NCT00505024,"To study the effectiveness of the interactive voice response system (IVRS), which is designed to send a report to a patient's doctor about severe symptoms they are experiencing.","To study if systematic symptom assessment (by the use of IVRS) is another way to report symptoms rather than the usual method, which is calling the doctor when there is a problem.",2006-07,COMPLETED,INTERVENTIONAL,['NA'],
3388,NCT00720512,Progression-free survival,Safety,2008-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
3389,NCT05729230,Perception of prognosis and treatment side effects,Evaluation of patient satisfaction with the information received during the consultation,2021-04-05,COMPLETED,OBSERVATIONAL,['NA'],
3390,NCT03937440,Difference of stress responses between deep block and moderate block,,2019-07-03,COMPLETED,INTERVENTIONAL,['NA'],
3391,NCT02215642,Disease-specific survival,Overall survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],Disease-free survival
3392,NCT05228587,To identify IGT PDR cut-off level below which the liver graft is not to be used for solid organ transplantation,To identify IGT PDR cut-off level(s) below which post-LT organ recovery is impaired (early allograft dysfunction).,2022-02-01,RECRUITING,INTERVENTIONAL,['NA'],
3393,NCT03117556,Daily Narcotic Requirements,Use of Anti-emetics,2017-08-31,WITHDRAWN,INTERVENTIONAL,['NA'],
3394,NCT03851887,ORR,DCR,2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3395,NCT00684801,Caregiver's satisfaction with end-of-life care,,2007-08,COMPLETED,OBSERVATIONAL,['NA'],
3396,NCT03825861,Pathologic Complete Response (pCR),Rate of Disease Progression,2017-02-23,RECRUITING,INTERVENTIONAL,['PHASE2'],
3397,NCT01637194,Number of patients with dose limiting toxicity,Pharmacodynamic effects of this regimen on post-therapy tumor and/or skin specimens,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
3398,NCT05198856,progression-free survival (PFS),Percentage of Participants With Adverse Events (AEs),2022-03-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3399,NCT04931654,Preliminary anti-tumour activity of AZD7789,Preliminary anti-tumour activity of AZD7789: Changes in circulating tumor DNA (ctDNA),2021-09-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3400,NCT03052335,Negative predictive value (NPV) of the CCE2 for large polyps (≥ 10 mm),Cost-effectiveness analyses: cost reduction of preventive colonoscopies spared,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],
3401,NCT02205463,Maximum Tolerated Dose (MTD),Pharmacokinetics of KD019,2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
3402,NCT02130427,Tumor Volume,,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
3403,NCT01898091,Maximum Change in Mean Mouth and Throat Soreness (MTS) Score From Baseline Through Weeks of Radiation Therapy Using the MTS Question of the Modified Oral Mucositis Daily Questionnaire*.,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
3404,NCT03988712,Diagnostic yield of colorectal cancer,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],
3405,NCT02843581,Relief degree,Overall survival（OS）,2016-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3406,NCT00820339,Overall survival,"Blood transfusion ,hepatic function of patients after surgery, the incidence rate of complications",2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3407,NCT05239546,Major Clinical Response (MCR) Rate,Overall Response Rate (ORR),2023-03-24,RECRUITING,INTERVENTIONAL,['PHASE2'],
3408,NCT00122187,Percent of Patients Receiving GI Consult Plus Anatomic Workup for FOBT+ Results,,2005-08,COMPLETED,INTERVENTIONAL,['NA'],
3409,NCT01909830,Objective Response Rate (ORR),Overall Survival (OS),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
3410,NCT05792735,Pathological Complete Response Rate,Number of participants with treatment-related adverse events (TRAE) as assessed by CTCAE v5.0,2023-04-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life (QoL)
3411,NCT03998644,"Gut microbiota structure and function difference between colorectal cancer, precancer and healthy controls","Metabolic difference of blood samples between colorectal cancer, precancer and healthy controls",2015-12,RECRUITING,OBSERVATIONAL,['NA'],
3412,NCT01919463,Mean Intubation Time (MIT),Polyp Detection Rate (PDR),2015-03,UNKNOWN,INTERVENTIONAL,['NA'],
3413,NCT02046356,Technical success,IDR-free survival,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],RFA complications
3414,NCT02775227,Comprehensive Complication Index,Readmissions,2016-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Disease specific survival
3415,NCT01586416,Number of participants who withdraw from study after enrollment,Proportion of each chemotherapy component administered during the treatment regimen relative to the total planned amount,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],
3416,NCT05381038,CURATE.AI applicability: percentage of participants in whom the investigators successfully apply CURATE.AI profile.,Clinically significant dose changes,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",ctDNA Analysis
3417,NCT02657330,Maximum tolerated dose of SBP-101,Plasma drug half-life,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3418,NCT01695863,Bowel Prep Efficacy - Boston Bowel Preparation Scale (BBPS),Renal Function Pre and Post Bowel Prep - Continued (mmol/L),2012-02,COMPLETED,INTERVENTIONAL,['PHASE4'],Non-Serious Adverse Events on Self Report Scale
3419,NCT00267696,Determine the Antitumor Activity of Gemcitabine/Carboplatin/Bevacizumab Regimen as Measured by the Probability of Surviving Progression-free for at Least 6 Months or Responding.,Overall Survival for Patients Treated With the Regimen.,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
3420,NCT04949737,Estimation of the prevalence of Helicobacter pylori,,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3421,NCT00192114,Percentage of Participants With Progression Free Survival (PFS) at 6 Months,Change From Baseline in Carcinoembryonic Antigen (CEA) Response at Each Cycle,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline in Vascular Endothelial Growth Factor (VEGF) to Cycle 2 and Cycle 3
3422,NCT04697186,Helicobacter pylori eradication,adverse events,2021-01-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
3423,NCT01292330,postoperative complications,hospitalization expenses and length of stay,2010-01,UNKNOWN,INTERVENTIONAL,['NA'],
3424,NCT02023021,Recurrence-free survival at one year after curative resection,CA199 level after curative resection,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
3425,NCT01739439,MTD defined as the dose level in which 1 out of 6 patients observes dose-limiting toxicity (DLT) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE1'],
3426,NCT04207489,The imaging effect of indocyanine green,,2020-04-15,UNKNOWN,OBSERVATIONAL,['NA'],
3427,NCT01150630,Event-free survival at 1 year (phase II),Lymph node status,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
3428,NCT00006010,six-month overall survival,time to progression,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3429,NCT03667495,Colorectal cancer or adenoma recurred,,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
3430,NCT00946153,Phase 2: Time to Progression (TTP) by Independent Review Assessment,Phase 2: Overall Survival (OS),2009-07-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3431,NCT03420443,Action of synbiotics on irradiated GI mucosa in rectal cancer treatment,,2008-11,COMPLETED,INTERVENTIONAL,['NA'],
3432,NCT00005860,,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3433,NCT00746655,To evaluate the Health Related Quality of Life (HRQL) associated with combined therapy.,To determine if SBRT and TACE will be able to bridge patients to transplant that were initially ineligible.,2009-07,WITHDRAWN,INTERVENTIONAL,['NA'],
3434,NCT05797077,5-years Progression Free Survival,Complication,2023-02-20,RECRUITING,INTERVENTIONAL,['PHASE3'],
3435,NCT04990895,Assessment of the Quality of Life of Colorectal Cancer Patients Using EORTC-QLQ CR29 Questionnaire,Patient self-efficacy,2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE3'],
3436,NCT05976568,Overall Survival (OS) (Phase III),Time to progression (TTP),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3437,NCT04792801,Rate of patients reclassified for lymph node fixation (N +) and / or extrahepatic extension (M +) after PET TDM FDG-Choline,Binding intensity (SUV) of PET TDM FDG-Choline and the last aFP value before transplantation or WL dropout.,2021-06-22,RECRUITING,OBSERVATIONAL,['NA'],
3438,NCT06293625,DFS (disease Free Survival),,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
3439,NCT02720666,The maximum-tolerated dose (MTD) of K-001,Clinical efficacy of K-001 assessed by disease control rate (DCR) according to RECIST V 1.0 criteria,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3440,NCT01560260,Number of Participants With Complete Response or Partial Response Using Response Evaluation Criteria in Solid Tumors Guideline Version 1.1,"Correlations Between Glucose, Insulin, Tumor Tissue and Blood Biomarkers With FDG-PET Metabolic Response.",2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Determine the Number of Participants With Tumor Metabolic Response Correlating With Anatomic Response and Clinical Benefit.
3441,NCT01426074,Pathologic Complete Response (pCR),,2011-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
3442,NCT02007954,Collection of Adverse Events Related to Study Device as a Measure of Safety,AFP Tumor Marker Pre- and Post-treatment,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory Endpoint - Tmax of Doxorubicin and Doxorubicinol Post DEBDOX-M1 TACE
3443,NCT03626922,Objective Response Rate to pembrolizumab and pemetrexed plus oxaliplatin,Overall Survival,2019-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
3444,NCT03924349,Success rate of localization,Number of Participants with Complication,2019-07-08,COMPLETED,INTERVENTIONAL,['NA'],
3445,NCT00274872,Pharmaco-economic evaluation,,2004-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3446,NCT06011330,overall survival (OS),progress-free survival (PFS),2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],Treatment-Related Adverse Events (TRAE)
3447,NCT01591590,Mortality,Tumour Progression,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
3448,NCT04644315,"Confirmed Objective Response Rate (ORR) as Determined by the Investigator Per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",OS in Participants With Primary CNS Tumors,2021-05-24,TERMINATED,INTERVENTIONAL,['PHASE2'],
3449,NCT05815290,complete response rate,pCR rate,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],
3450,NCT03205735,progression free survival,toxicities evaluation,2017-06-29,UNKNOWN,OBSERVATIONAL,['NA'],
3451,NCT04525833,The incidence of a new diagnosis of any event of liver cirrhosis complications,,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
3452,NCT05933785,anal preservation rate,incidence of positive distal resection margin,2018-01-02,COMPLETED,OBSERVATIONAL,['NA'],
3453,NCT02960061,Number of survival participants will be assessed according to the data collected by the followed up office.,Progression Free Survival,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3454,NCT01853774,Primary Outcome is Clinic Attendance,The Secondary Outcome is Participant Completion of a CRC Screening Test.,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
3455,NCT03851471,Overall Survival,10cm-VAS of the pain,2019-04-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
3456,NCT03947775,The proportion of participants in each arm with biopsy-proven HGAIN (AIN-2/3).,"The geometric mean titres (GMT) of antibody to each vaccine type above a pre-specified, validated cut-off. F",2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in anal carriage of vaccine HPV types. Repeated detection of anal HPV will indicate the duration of carriage. This will be compared between the early and delayed vaccine groups.
3457,NCT00732836,Maximum Tolerated Dose (MTD) of HAI Abraxane,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
3458,NCT00005085,,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
3459,NCT00440310,Overall Survival,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
3460,NCT06192680,Progression free Survival,Incidence of adverse events,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
3461,NCT04195438,Measure the extent of HO-1 induction by measuring endogenous CO production in relationship to the extent of hepatic resection,Measure the relationship between HO-1 induction and the quality of post-hepatectomy liver regeneration,2014-05-07,RECRUITING,INTERVENTIONAL,['NA'],
3462,NCT04645797,Primary Outcome Measure,Secondary Outcome,2021-01-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
3463,NCT06035250,Accuracy of TRG prediction by the AI model,Overall Survival (OS) at 5 years,2023-09-10,RECRUITING,OBSERVATIONAL,['NA'],
3464,NCT01584336,The incidence of postoperative morbidity and mortality,the surgical outcomes according to the method of reconstruction,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3465,NCT02594150,Increase in return rate of completed FIT,,2015-12,COMPLETED,INTERVENTIONAL,['NA'],
3466,NCT04174339,Objective response rate(ORR),Disease control rate(DCR),2019-12-10,UNKNOWN,INTERVENTIONAL,['NA'],
3467,NCT03377400,Progression-free survival,,2017-12-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3468,NCT05461248,Incidence of low anterior resection syndrome,Quality of life score,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3469,NCT00314678,Recurrence-Free Interval,Examine the toxicity of therapy and to develop suitable strategies for dose modification.,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3470,NCT03141437,Patients' decisional conflict (Part 2),Patients' decision-making process (Part 2),2017-04-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Feasibility of the multicomponent DS intervention and research methods (Part 2)
3471,NCT04455737,retrieved lymph nodes,survival,2013-10,COMPLETED,OBSERVATIONAL,['NA'],
3472,NCT01299493,Practice-level colon cancer screening rate,,2012-06-19,COMPLETED,INTERVENTIONAL,['NA'],
3473,NCT01034670,Detection of neoplasia,,2009-06,RECRUITING,INTERVENTIONAL,['NA'],
3474,NCT00409292,To Assess Progression-free Survival of RAD001 at Two Months in Patients With Metastatic Pancreatic Cancer Whose Disease Has Progressed on Gemcitabine Chemotherapy.,to Assess Overall Survival Associated With RAD001 in This Patient Population.,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
3475,NCT00093444,"Pharmacokinetics and pharmacodynamics of heat-activated doxorubicin HCL liposome at 15, 30, 45, 60, 75, and 90 minutes; 2, 3, 4, 6, 24, and 46 hours; and 4 and 8 days following infusion",Effects of ablative therapy on tumor blood flow and tumor vascular density as measured by MRI at 28 days following study completion,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
3476,NCT01451632,To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s): Cetuximab and Irinotecan,Immunogenicity,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
3477,NCT03060720,"We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool",Number of patients who disclose genetic testing results to relatives,2017-02-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3478,NCT04543695,The rate of tumor down-staging,Incidence of surgical complications,2020-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
3479,NCT00640913,Reversal of defunctioning loop stoma on postoperative day 14 following low anterior resection of the rectum for cancer with or without preoperative adjuvant treatment,Postoperative 30 day morbidity. Postoperative ano-rectal function at 1 and 6 months.,2008-02,UNKNOWN,OBSERVATIONAL,['NA'],
3480,NCT04929028,Incidence of adverse events (High-risk stratum),Change in combination antiretroviral therapy (cART) adherence,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Impact of reduced intensity CRT on quality of life
3481,NCT01595243,12-Item Short Form Survey,,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
3482,NCT00764621,Primary variable is the proportion of patients in each of the three treatment groups for whom further imaging is required after initial imaging to come to a therapy decision.,"Proportion of patients with intra-operatively modified surgical plans based on initial imaging with either Primovist-, ECCM-MRI or CE-CT",2008-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
3483,NCT01210313,feasibility of physical activity,gen- and metabolic signs,2010-10,COMPLETED,OBSERVATIONAL,['NA'],
3484,NCT02567331,"Response rate, ie, percentage of participants with complete, partial, and overall response",Pharmacoeconomic analysis: Treatment-related and AE-related spending/savings\n,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
3485,NCT01359410,Clinically Significant Postoperative Pancreatic Leak at Any Time as Defined by the ISGPF Pancreatic Leak Grading System,Number of Non-pancreatic Adverse Events,2007-06,TERMINATED,INTERVENTIONAL,['NA'],
3486,NCT03481920,To assess the safety of this combination in patients with PDAC.,"Changes in CA 19,9 leves",2018-01-10,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Immune infiltrate.
3487,NCT01078415,Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.,Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
3488,NCT05689918,Level of awareness of esophageal cancer risk factors and alarm symptoms,Beliefs about esophageal cancer,2022-12-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3489,NCT06148155,Complete PET imaging,,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],
3490,NCT04435652,Overall survival（OS）（stage 2）,Immunogenicity（stage 1 and 2）,2020-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3491,NCT02504099,Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12),Percentage of Participants With Recurrent HCV Infection Post Liver Transplant,2015-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
3492,NCT01380600,Determine the safety of JX-594 administered by biweekly IV infusion,Determine the anti-tumoral response of JX-594,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
3493,NCT01279681,Progression-Free Survival,Number of Participants With Grade 3 Adverse Events At Least Possibly Related to Treatment,2011-01,TERMINATED,INTERVENTIONAL,['PHASE3'],Prognostic Single-nucleotide Polymorphisms (SNPs) for Grade 3+ Hypertension
3494,NCT05130684,rate of completion of protocol treatment,,2021-02-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3495,NCT02232620,Disease Control Rate (DCR),Pharmacodynamics (biomarkers) of BBI503 when tumor biopsy is possible,2017-03-13,TERMINATED,INTERVENTIONAL,['PHASE2'],
3496,NCT04258813,Diversity supplement primary outcome: 90-day postoperative cardiovascular complications,Provider-reported care coordination,2021-06-14,RECRUITING,INTERVENTIONAL,['NA'],PCP-reported care coordination
3497,NCT06013228,Fatigue,,2023-08-30,RECRUITING,OBSERVATIONAL,['NA'],
3498,NCT04257955,Patient's Compliance,,2020-09-15,COMPLETED,OBSERVATIONAL,['NA'],
3499,NCT05513742,Overall Response Rate,Exposure Response by Pharmacokinetic (PK) Sampling,2022-12-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
3500,NCT05235607,Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0,Number of participants with Overall survival as assessed by RECIST1.1,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3501,NCT03290209,3-year disease specific survival rate,operation time,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3502,NCT04288284,early postoperative morbidity after curative resection of colorectal cancer,Overall survival,2015-01,COMPLETED,OBSERVATIONAL,['NA'],
3503,NCT05500248,Positive Predictive Value (PPV),Adenoma Detection Rate (ADR) in the rectosigmoid tract.,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],
3504,NCT01384864,to determine whether tissue is neoplastic or non-neoplastic,,2011-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
3505,NCT04183712,3-year DFS,3-year OS,2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],sensitivity and specificity of ctDNA
3506,NCT01315990,Progression-free survival,Development of acneiforme follicular exanthema >= grade2,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3507,NCT05636150,Progression free survival (PFS),Disease control rate (DCR),2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE2'],
3508,NCT06042816,analgesic efficacy of free-opioid anesthesia,Adverse effects of free-opioid anesthesia,2019-12-30,COMPLETED,INTERVENTIONAL,['NA'],
3509,NCT01088815,Safety of Combination Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas as Assessed by Number of Grade 3 or 4 Adverse Events,Efficacy of Combination of GDC-0449 With Gemcitabine and Nab-Paclitaxel as Assessed by Hedgehog Signaling Pathway Downregulation,2010-09-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
3510,NCT01480817,Time to Progression (Efficacy),Alpha feto protein (AFP) responsiveness,2012-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
3511,NCT05406206,Progression-Free Survival (PFS),Overall Survival (OS),2022-02-25,RECRUITING,INTERVENTIONAL,['PHASE2'],
3512,NCT03705897,Proportion of patients achieving appropriate screening regimen.,,2013-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3513,NCT00138177,"Grade 3, 4, or 5 adverse events graded using the NCI CTCAE version 4.0",DPD activity,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
3514,NCT00259844,"To evaluate the safety, toxicity and tolerability of the TroVax vaccine in this setting.",To monitor and collect data on clinical outcomes (time to progression/relapse/death).,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3515,NCT01033682,"The percentage of patients who are able to achieve a bladder volume within +/- 30% of planning volume, on all treatment CBCT (cone beam computed tomography) scans",The correlation between bladder volume and small bowel volume planning target volume,2009-05,UNKNOWN,OBSERVATIONAL,['NA'],
3516,NCT05739045,pathological complete response rate (pCR),3-year DFS,2022-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],
3517,NCT05899985,Surgical quality,SLN Ultra-staging Overall Survival,2024-03-21,RECRUITING,INTERVENTIONAL,['NA'],FerroTrace enhanced MRI Response
3518,NCT03737591,Specificity,,2010-05-01,COMPLETED,OBSERVATIONAL,['NA'],
3519,NCT05806333,Diagnostic performance of FAPI PET,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],
3520,NCT05809661,stoma compliance,life quality,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],
3521,NCT00055705,,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3522,NCT00247728,Tumour Non-recurrence Rate,Survival Rate,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3523,NCT02095236,Three-dimensional intra- and interfractional measurement of fiducial marker or transponder motion,,na,WITHDRAWN,INTERVENTIONAL,['NA'],
3524,NCT00874263,Endoscopic Confocal microscopy may help distinguish small adenomatous polyps with malignant potential from non-neoplastic (hyperplastic) polyps in real- time enabling immediate diagnosis and removal of only polyps with truly malignant potential.,"Endoscopic Confocal microscopy has the potential to fundamentally change the way endoscopy and pathology interact by allowing near histological-quality imaging in vivo, without the need, risk, and cost of tissue removal.",2008-03,COMPLETED,OBSERVATIONAL,['NA'],
3525,NCT04160832,Prevalence of germline pathogenic/likely pathogenic variants in cancer predisposition genes in patients with advanced colorectal polyps,Risk factors for germline pathogenic/likely pathogenic variants in patients with advanced colorectal polyps,2019-10-24,RECRUITING,OBSERVATIONAL,['NA'],
3526,NCT04989153,Risk factors for GC,,2016-03-05,UNKNOWN,OBSERVATIONAL,['NA'],
3527,NCT01577511,Ability to maintain the cells isolated from colorectal tumors in culture or 3D collagen matrices and then infect these cells to make them express reporter genes: yes/no.,Number of circulating cancer cells per ml blood,2012-06-12,COMPLETED,OBSERVATIONAL,['NA'],
3528,NCT01807546,Overall response rate,Number of Adverse Events,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3529,NCT02320448,Number of Patients with Adverse Events.,Feasibility: Completion of procedure in 28:35,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3530,NCT02626195,postoperative complication,postoperative cost( + nutritional support cost),2013-10,COMPLETED,INTERVENTIONAL,['NA'],immunologic change(CD4/CD8) after nutritional support
3531,NCT00862342,Progression free survival,Toxicity profiles,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
3532,NCT03778710,The correlation of lymph node ratio and prognosis of recurrence of gastric cancer patients,The correlation of total of lymph node retrieved less than 15 and more than 15 nodes and survival of gastric cancer patients,2018-12-18,COMPLETED,OBSERVATIONAL,['NA'],
3533,NCT02121405,Disease-free survival,Overall survival,2015-10,SUSPENDED,INTERVENTIONAL,['PHASE3'],
3534,NCT04842006,Postoperative ctDNA,Treatment response by patient-derived organoid (PDO) therapy response,2021-12-20,RECRUITING,INTERVENTIONAL,['NA'],
3535,NCT00969124,Detection Rates for All Polyps,Time Spent During Withdrawal Phase and Total Procedure,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
3536,NCT03061058,Progression-free Survival (PFS),Adverse Events,2013-04-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3537,NCT01760616,Time to significant progression after surgery and postoperative survival period.,Alpha-fetoprotein quantitation and related biochemical indicators,2011-11-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
3538,NCT00004860,,,2000-10-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3539,NCT02650635,Change in pharmacodynamics after TLR8 agonist VTX-2337 alone vs TLR8 agonist VTX-2337+cyclophosphamide,PFS as measured by serial imaging studies and assessed by irRECIST,2016-02-05,TERMINATED,INTERVENTIONAL,['PHASE1'],Changes in immunomodulation
3540,NCT05528614,Postoperative morbidity and mortality of simultaneous pancreatic and hepatic resectio,,2022-01-13,COMPLETED,OBSERVATIONAL,['NA'],
3541,NCT01210495,"Overall Survival (OS) - Stratified Analysis, Randomized Portion",Number of Participants With Treatment-Related Adverse Events (AEs) in Randomized Portion,2010-12-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3542,NCT00832299,Pathologic Complete Response,"Observation of Overall Pathologic Response Rate, Correlation of Pathologic Staging With Pre-op Ultrasound and Pelvic MRI Staging Observed Toxicities Patterns of Disease Relapse Disease-free Survival Overall Survival",2009-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
3543,NCT03082586,Number of Dose Limiting Toxicities (DLTs) Occurring in Participants,Local Failure,2016-11-20,COMPLETED,INTERVENTIONAL,['NA'],
3544,NCT05914597,Feasibility of home delivery of CCE service,assessing the patient's acceptability of home delivery of CCE service,2022-12-12,RECRUITING,INTERVENTIONAL,['NA'],
3545,NCT05129605,Diagnosis of prostate cancer,Positive predictive value of multiparametric MRI for detection of prostate cancer,2020-02-12,RECRUITING,OBSERVATIONAL,['NA'],
3546,NCT04505553,Severity of chemotherapy-induced peripheral neuropathy (CIPN),"Incidence of pain, fatigue, nausea, and anxiety",2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
3547,NCT04778566,Evaluate the feasibility of the Cologuard test for Lynch Syndrome,Evaluate bowel preparation tolerability,2021-11,WITHDRAWN,OBSERVATIONAL,['NA'],
3548,NCT05327400,High expression of IGHD is independent risk factors for poor prognosis in patients with pancreatic cancer.,,2022-05-01,UNKNOWN,OBSERVATIONAL,['NA'],
3549,NCT01582178,Cecal Intubation Time,Patient Comfort During Insertion Phase of the Colonoscopy,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
3550,NCT05327751,The change in HFS-specific QOL questionnaire (HFS-14).,The change in serum levels of malondialdehyde (MDA).,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
3551,NCT00034619,,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],
3552,NCT05913141,Objective response rate (ORR),12-month survival rate,2023-06,RECRUITING,OBSERVATIONAL,['NA'],
3553,NCT01754987,Number of Participants That Experience Serious Adverse Events.,Number of Participants That Are Alive After 15 Weeks of Treatment.,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3554,NCT04969887,Determine the proportion of participants with progression free survival at 6 months,Quantification of treatment related toxicities to ipi/nivo according to CTCAE V5.0,2021-08-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
3555,NCT02096666,Phase 2- Overall Response Rate (per RECIST v1.1) in subjects with MET amplified measurable gastric/gastroesophageal junction/esophageal adenocarcinoma (cohort 1),Phase 1- Overall Survival,2014-04-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3556,NCT02809716,"HD-SCA solid tumor biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles","HD-SCA biosignatures in pre-resection liquid biopsy samples assessed by cell morphology, protein expression, and whole genome CNV profiles",2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],
3557,NCT04394572,"Diagnostic performances of markers derived from circulating tumor exosomes in the context of colorectal cancer, focusing on metallo proteases",,2021-01-07,COMPLETED,OBSERVATIONAL,['NA'],
3558,NCT02194959,Colonoscopy completion,,2011-07,COMPLETED,INTERVENTIONAL,['NA'],
3559,NCT03679039,The sensitivity and specificity of the model to predict the drug resistance,,2018-09-20,UNKNOWN,OBSERVATIONAL,['NA'],
3560,NCT00399750,To evaluate the safety and efficacy of three oxaliplatin-fluoropyrimidine regimens when combined with bevacizumab as therapy for previously untreated metastatic colorectal cancer (TREE 2),Patients enrolled prior to the initiation of Amendment 3 (TREE1) will not be eligible to receive Avastin as a component of their treatment regimen.,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
3561,NCT01996059,Body Mass Index,Onodera Prognosis Nutritional Index,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Visick rates
3562,NCT03546127,Delay time to send a validated exome sequencing report from sample receipt,The rate of patients with bioinformatic analysis available for interpretation for whom results has been discussed by MTB,2017-05-23,COMPLETED,OBSERVATIONAL,['NA'],
3563,NCT01711242,disease free survival,5 year Overall Survival,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of participants with adverse events as a measure of safety and tolerability
3564,NCT05757336,Safety：the incidence of adverse events and serious adverse events,Proportion of acceptable radical resection of primary lesions,2022-12-22,RECRUITING,INTERVENTIONAL,['PHASE2'],
3565,NCT01764438,"incidence of change of BCLC stage after add-on Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.","Sensitivity, specificity, false positive predictive value, false negative predictive value, and accuracy of Primovist-enhanced MRI",2012-08,UNKNOWN,OBSERVATIONAL,['NA'],
3566,NCT04835896,Phase 2: Progression-free survival in subjects with M7824 and paclitaxel combination treatment,"Safety and Tolerability, in terms of the number, severity, and duration of treatment-emergent adverse events as assessed by CTCAE v5.0",2021-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3567,NCT02567045,Proportion of patients who participate in each screening arm,Costs measure: cost (euros) of the procedures associated with each screening strategy and treatment of advanced neoplastic lesions,2016-02-25,COMPLETED,INTERVENTIONAL,['NA'],
3568,NCT00619242,Ki-67,,2006-06,TERMINATED,INTERVENTIONAL,['NA'],
3569,NCT05667181,Incidence of anastomotic complications,,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],
3570,NCT03890926,Local control time,Incidence of adverse events,2015-12,COMPLETED,OBSERVATIONAL,['NA'],
3571,NCT00909987,"Efficacy of XELOX/BVZ neoadjuvant therapy with selective radiotherapy use in patients with locally advanced tumors of the rectum, measured in terms of the proportion of responders (PCR + CCR), according to RECIST criteria",Complete Phatologic Response (pCR),2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3572,NCT01545687,The AUC of the MTS score,DFS at 12 months after treatment,2012-04,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
3573,NCT01713387,Maximum tolerated dose,Number of Participants with dose limiting toxicity,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3574,NCT04514341,Time to completion of diagnostic colonoscopy,Navigation Services Provided,2022-03-01,RECRUITING,OBSERVATIONAL,['NA'],
3575,NCT00555334,Overall survivals,Recurrence rates,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3576,NCT05508126,Diagnostic performance of DECT and mpMRI in tumor restaging assessment,Contrast-to-noise Ratio (CNR),2021-11-01,RECRUITING,OBSERVATIONAL,['NA'],
3577,NCT01453153,Recommended Phase 2 Dose (RP2D),Change From Baseline in CA19-9 in Participants Classified as Responders and Non-responders,2011-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3578,NCT01339832,Progression-free Survival,Incidence of Adverse Event (AE) and Serious Adverse Event (SAE),2010-08,COMPLETED,OBSERVATIONAL,['NA'],
3579,NCT01294085,One year survival rate,Progression free survival,2010-11,COMPLETED,OBSERVATIONAL,['NA'],
3580,NCT00313859,overall response rate,duration of response,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3581,NCT03784677,Change of the treatment regimen such as dose delay and dose reduction over time by dose level due to treatment-related adverse events,Predictive biomarkers,2019-07-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
3582,NCT04851119,Area under the drug concentration curve of tegavivint,Antitumor effects of tegavivint in patients with solid tumors,2021-11-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3583,NCT06015971,Functionality,C-RP,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],
3584,NCT00834860,"Efficacy: sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.",Safety: adverse event rate and profile.,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3585,NCT05935189,Creation of a registry,,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],
3586,NCT01653301,Pathological major downstaging,survival,2005-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3587,NCT00048529,,,2002-09,SUSPENDED,INTERVENTIONAL,['PHASE2'],
3588,NCT04232176,Precision in polyps sizing the pathologist,Rate of polyps' recurrence at the end of the follow-up.,2019-12-22,COMPLETED,OBSERVATIONAL,['NA'],
3589,NCT03785938,Cost-benefit evaluation of the study,Evaluate responsible guardian/participants experience of the MaCROS study,2019-01-20,UNKNOWN,INTERVENTIONAL,['NA'],
3590,NCT01349075,Response to Treatment,Survival Time,2007-10,COMPLETED,OBSERVATIONAL,['NA'],
3591,NCT01618253,Maximum Tolerated Dose,Health Related Quality of Life,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
3592,NCT05552755,Percent change from baseline in polyp burden,"Assess the pharmacodynamic (PD) effect of REC-4881, and correlation between PD and clinical outcome",2023-07-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3593,NCT00965172,"Incidence/Severity of Oral Mucositis WHO Grades 1, 2, 3, and 4",,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3594,NCT03849469,"Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03.",,2019-05-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
3595,NCT04962958,2-year cumulative recurrence-free survival rate,Adverse Events,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
3596,NCT03910634,Overall objective response rate,Incidence of toxic and side effects above 3 degrees,2019-04-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3597,NCT00370513,Adverse events (AEs) and changes in vital signs and laboratory values. A dose regimen where no more than 1 out of 6 subjects experience a dose-limiting toxicity (DLT) will define the maximum tolerated dose (MTD).,Various pharmacokinetic parametersAlpha-fetoprotein (AFP) measurements and scans,2006-12-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
3598,NCT03823846,pain at rest (Numerical rating scale),adverse events during rehabilitation,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],
3599,NCT02578602,"Precision in tumor measurement for each type of image (CT vs. MRI), for each phase ( 4 for CT and 5 for MRI), and for each method of measuring ""size"" (1-,2-, and 3-dimensional), assessed by low inter- and intra-reader variability",Changes in apparent diffusion coefficient (ADC) values within lesions and within normal liver before and after administration of Gadoxetate,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
3600,NCT00293397,Efficacy - Overall Survival,,2005-11,COMPLETED,INTERVENTIONAL,['NA'],
3601,NCT02887365,3-year disease-free survival Safety profile of tegafur-uracil,5-year overall survival,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3602,NCT04726800,Frequency of positive ctDNA preoperative converted to negative postoperatively.,,2020-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3603,NCT00259363,Phase II : Response and resectability rate.,,2002-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3604,NCT06194461,Incidence of specific AEs,"Kinetics parameters that indicate persistence (eg, Clast and Tlast)",2024-06-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3605,NCT04681248,,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],
3606,NCT04281667,Comprehensive Complication Index,Adjuvant therapy,2020-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Bowel microbiota
3607,NCT00814359,The severity of patient-reported symptoms of mucositis as determined by the change in Oral Mucositis Weekly Questionnaire - Head and Neck Cancer (OMWQ-HN) score from baseline to 6 weeks.,Incidence of WHO Grade 3 or 4 oral mucositis after 4 weeks of radiotherapy.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
3608,NCT04101747,Number of intestinal flora,,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
3609,NCT05160753,Disease-free survival (DFS) at three years,,2022-01-10,RECRUITING,INTERVENTIONAL,['NA'],
3610,NCT00222079,,,2004-11,TERMINATED,INTERVENTIONAL,['NA'],
3611,NCT03981848,tumor recurrent status,,2019-07,UNKNOWN,OBSERVATIONAL,['NA'],
3612,NCT03594448,Correlation between presence of MSI present in circulating tumor DNA versus in primary tumor specimens,,2018-09-05,RECRUITING,OBSERVATIONAL,['NA'],
3613,NCT04817826,Primary outcome of Cohort 2: 2-year complete response rate,Post gastrectomy complications,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
3614,NCT01403064,Number of Participants With All Grades of OM at a Radiation Dose of 55 Gy,Mean Change From Baseline in C-reactive Protein (CRP) Values at Varying Weeks,2011-07,TERMINATED,INTERVENTIONAL,['PHASE2'],
3615,NCT03518632,Change of Oxgen consumption at anaerobic threshold :,Changes in Fatigue :,2018-03-27,COMPLETED,INTERVENTIONAL,['NA'],
3616,NCT02004769,PFS(Progression-free survival ),Safety,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
3617,NCT03302403,Number of participants with CRA T-related adverse events as assessed by CTCAE v4.03,Engraftment,2017-12-29,UNKNOWN,INTERVENTIONAL,['NA'],Changes of cell subsets for CAR T cells against T cells
3618,NCT03773367,To determine the rate of histopathological response according to Becker criteria.,,2018-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
3619,NCT04078828,The rate of general complications,"White blood cells(WBC) ,C-reactive protein (CRP) and procalcitonin (PCT) count in the blood sample",2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],
3620,NCT00892242,Evaluate whether treatment with perioperative zoledronic acid prolongs overall survival or disease free survival.,Determine the pharmacodynamics of neoadjuvant zoledronic acid therapy on selected immune cell subgroups in the hepatic metastatic niche by flow cytometric analysis of pancreatic tumor samples,2009-12,TERMINATED,INTERVENTIONAL,['PHASE1'],
3621,NCT02856126,Overall survival,Number of of Patients developed Adverse Events,2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
3622,NCT06203821,Determining if NP137 can shift the primary tumor MAK's Signature Epithelial-to-Mesenchymal Transition (EMT) Mean Score towards a more epithelial phenotype,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]),2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
3623,NCT01086059,Major malformations,Infant follow-up,2003-11,COMPLETED,OBSERVATIONAL,['NA'],
3624,NCT04729738,"correlation between the development of a postoperative complication within 30 days from surgery and patient-related characteristics (comorbidity, frailty, malnutrition and sarcopenia)","relatedness between the average density sarcopenia indices, HUAC, PI, TPA and the distance between the anterior-superior iliac spines and the size of the psoas muscles (RPSI)",2012-06-01,COMPLETED,OBSERVATIONAL,['NA'],
3625,NCT02776527,disease free survival,overall survival,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3626,NCT01556490,Overall Survival (OS) Per Protocol (PP) Population,Tumor Response,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
3627,NCT05432492,Objective Response Rate (ORR) Per mRECIST,Overall survival (OS),2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Percentage of participants who obtain a pathologic complete response (pCR)
3628,NCT00493025,Pathologic Complete Response Rate to the Neoadjuvant Regimen,Correlation Between EGFR Pathway Component Expression and Activation With Pathologic Complete Response and Survival,2005-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
3629,NCT03228407,Correlation between the time from intravenous injection of fluorescein to visualization of fluorescein on probe based confocal endomicroscopy (pCLE) with esophageal permeability (i.e. - epithelial barrier function).,Correlation between the Ussing's chamber findings (esophageal permeability) and Mucosal impedance findings of patients with symptoms of refractory GERD and controls,2017-04-28,UNKNOWN,INTERVENTIONAL,['NA'],
3630,NCT02894801,death due to recurrence,,2013-01,COMPLETED,OBSERVATIONAL,['NA'],
3631,NCT03214991,Overall survival rate,"Overall survival rate (K-ras mutation type, EUS-FNA)",2017-05-12,UNKNOWN,OBSERVATIONAL,['NA'],
3632,NCT04973475,False negative rate,The variation of C-reactive protein,2021-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
3633,NCT04909671,Mean number of adenomas per colonoscopy,Subjective endoscopist measures,2021-09-13,UNKNOWN,INTERVENTIONAL,['NA'],
3634,NCT01974661,Registration of adverse events as a measure of safety and tolerability,To study overall survival (OS),2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],"Local tissue changes in injected/non-injected tumor and surrounding tissue, assessed by MRI"
3635,NCT03435588,Final diagnosis of benign pancreatic mass,Rate of procedure-related adverse events,2018-02-14,COMPLETED,INTERVENTIONAL,['NA'],
3636,NCT02146508,Complete resolution of advanced esophageal squamous dysplasia,Safety of endoscopic interventions,2013-06,SUSPENDED,INTERVENTIONAL,['NA'],
3637,NCT00093548,,,na,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3638,NCT05792254,1-year progression-free survival rate,the Rates of AE and SAE,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3639,NCT02726360,study-specific coding structure,,2015-12-14,COMPLETED,OBSERVATIONAL,['NA'],
3640,NCT04444544,Health-related Quality of Life,Health-related Quality of Life,2020-09-05,RECRUITING,OBSERVATIONAL,['NA'],
3641,NCT01854749,Progression Free Survival,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
3642,NCT05891730,Number of colorectal cancer patients who remain in clinical trial until completion.,,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3643,NCT05300789,Metachronous peritoneal carcinomatosis,Time to metachronous peritoneal carcinomatosis diagnosis,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],
3644,NCT01961791,Prognostic performance,,2000-01,COMPLETED,OBSERVATIONAL,['NA'],
3645,NCT02458664,Recurrence free survival and Recurrence free survival after resection of the colon cancer,Overall survival,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],
3646,NCT04230642,Evaluation of the feasibility of the Quantum Surgical device: Number of targets reached,Evaluation of the safety not related to the procedure,2020-05-25,COMPLETED,INTERVENTIONAL,['NA'],
3647,NCT00436137,Performance of colonoscopy,,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
3648,NCT00773097,Number of Participants With Anti Muc-1 Antibody,Number of Participants With Adverse Events Associated With the Study Agent,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
3649,NCT06102278,overall survival,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],
3650,NCT03856437,Intention to Vaccinate Free of Cost,Intention to Vaccinate With Cost,2021-01-22,COMPLETED,INTERVENTIONAL,['NA'],
3651,NCT00006198,,,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3652,NCT02586610,Pathological Complete Response (pCR) Rate,Overall Survival (OS),2016-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
3653,NCT00019630,,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
3654,NCT01937780,Disease-free survival,Pain relief of palliative radiotherapy,2013-10-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Overall survival
3655,NCT05563441,perioperative complications,disease free survival,2015-01-20,COMPLETED,OBSERVATIONAL,['NA'],
3656,NCT02222844,Randomised Phase: To measure the difference in treatment stratification policy caused by the difference in staging on CT and MRI.,To compare permanent defunctioning stoma rates in patients staged by CT and MRI according to predicted prognostic risk.,2014-08,RECRUITING,INTERVENTIONAL,['NA'],
3657,NCT02582541,Stent patency rate,Change from Baseline in Bile Duct Stricture Diameter,2014-02,UNKNOWN,INTERVENTIONAL,['NA'],
3658,NCT00847119,Pathologic complete response rate. % patients with pathologic complete response (absence of tumoral cells in the resected piece),To determine the angiogenic profile changes in tumour.,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3659,NCT02748811,Number of patients completing planned treatment without dose reductions,Quality of Life prior,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
3660,NCT03130790,Overall Survival (OS) - Phase 3 part,European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Gastric Cancer 22 items (EORTC QLQ STO22) measuring patients general cancer symptoms and functioning - Phase 3 part,2017-08-31,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3661,NCT03797209,Removal success,,2019-01-15,COMPLETED,OBSERVATIONAL,['NA'],
3662,NCT04449679,Post-intervention evaluation,,2020-04-15,COMPLETED,INTERVENTIONAL,['NA'],
3663,NCT02949596,Evaluate quality of sexual life validated questionnaire (IIEF) among patients treated for anal cancer with concurrent chemoradiotherapy who are men who have sex with other men,Evaluate quality of life among patients who are HIV positive in this cohort with the use of questionnaire HAT-QoL,2015-10,COMPLETED,OBSERVATIONAL,['NA'],
3664,NCT05809999,Proportion of persons with ≥ 1 neoplastic lesion detected,CRC incidence over five years following study colonoscopy (obtained through patient linkage to provincial cancer registries five years following trial completion),2022-09-23,RECRUITING,INTERVENTIONAL,['NA'],
3665,NCT05674422,ctDNA from liquid biopsy,TNT compliance,2023-05-26,RECRUITING,OBSERVATIONAL,['NA'],
3666,NCT02416466,Safety of CAR-T cell hepatic artery infusions in combination with Sir-Spheres as Measured by Number of Participants with Adverse Events,"CAR-T detection in liver tumors, normal liver, and extrahepatic sites",2015-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3667,NCT00509444,"The primary outcome variable will be difference between the two intervention groups in the time to initiation of therapy, beginning on the date of randomization.","The proportion receiving recommended screenings for breast, cervix, colon/rectum and prostate cancer.",2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
3668,NCT04898842,"Symptoms of sub-acute bowel obstruction: abdominal pain, feeling bloated, feeling full-up quickly, nausea and / or vomiting",Weight,2021-03-02,COMPLETED,INTERVENTIONAL,['NA'],
3669,NCT01468623,Overall response rate (ORR),Progression-free survival (PFS),2011-09,TERMINATED,INTERVENTIONAL,['PHASE4'],
3670,NCT05773105,Desease control rate (DCR),Adverse Events (AEs),2023-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3671,NCT04338542,Change of RAS mutant clones in the metastatic lesion,Molecular patterns other than RAS,2020-04-08,COMPLETED,OBSERVATIONAL,['NA'],
3672,NCT06168825,Acceptability of the MOM intervention,Number of participants who reported MOM intervention as linguistically appropriate,2024-01-17,RECRUITING,OBSERVATIONAL,['NA'],
3673,NCT01296763,Number of Participants Who Experienced a Dose Limiting Toxicity to Determine the Maximum Tolerated Dose (MTD),"Number of Years From Cycle 1, Day 1 On-Study to Date of Death",2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3674,NCT03081637,Rate of expression of Filamin A (FLNA) in HCC specimens from patients resected for HCC.,,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],
3675,NCT00031681,Side effect profile of 7-hydroxystaurosporine in combination with irinotecan hydrochloride in triple negative recurrent breast cancer (Part II),In vivo mechanistic basis for 7-hydroxystaurosporine activity,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
3676,NCT02379520,Number of patients with dose limiting toxicity (DLT),Overall response rate,2015-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
3677,NCT00769535,Clinical relevance,Clinical relevance,2006-01,COMPLETED,INTERVENTIONAL,['NA'],
3678,NCT02322736,To describe the pattern of use of Vectibix® in combination with chemotherapy in 1st line or in 2nd line mCRC treatments as per approved Vectibix® indication.,"To investigate the rate of objective response (ORR, defined as either a Complete Response or a Partial Response) and the rate of stable disease as best response in 1st line or in 2nd line chemotherapy regimens of mCRC including Vectibix®.",2014-11-21,COMPLETED,OBSERVATIONAL,['NA'],"Frequency of primary tumor resection, of metastatic lesion resection, of BRAF testing in the entire number of the study participants and frequency of BRAF mutation in the unselected Greek patient population with WT RAS mCRC included in the study."
3679,NCT01770431,Incidence of Recurrence and Metastasis After Hepatectomy,Postoperative Survival Period,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
3680,NCT02365896,postoperative early anastomotic morbidity,Nutrition,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],
3681,NCT00342641,,,2005-06-08,COMPLETED,OBSERVATIONAL,['NA'],
3682,NCT05894369,Tumor diameter,Overall survival,2023-05-04,RECRUITING,OBSERVATIONAL,['NA'],
3683,NCT02850536,Safety of CAR-T cell hepatic artery infusions delivered using the Surefire Infusion System (SIS) as Measured by Number of Participants with Adverse Events,Safety of Direct Intrapancreatic CAR-T Retrograde Venous Infusions (RVI) Delivered Using the Surefire Infusion System (SIS),2017-02-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3684,NCT01392274,Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious l,Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious l,2012-04,COMPLETED,OBSERVATIONAL,['NA'],
3685,NCT04629677,Bleeding risk (Cohort A and B),,2019-04-02,RECRUITING,OBSERVATIONAL,['NA'],
3686,NCT00002608,,,1994-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
3687,NCT05526443,Proportion of patients with locally advanced inoperable and/or metastatic PDAC undergoing palliative second line therapy after progression on first line chemotherapy,To analyze the mutational landscape of advanced pancreatic cancer and its impact on treatment decision making and clinical outcome,2023-01-13,RECRUITING,OBSERVATIONAL,['NA'],
3688,NCT04764084,Dose limiting toxicity (DLT) and maximum tolerated dose (MTD),Progression-free survival (PFS),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3689,NCT05130021,progress free survival(PFS)[Part 2],Safety and tolerability assessed by incidence and severity of adverse events,2022-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3690,NCT01791309,objective response rate (ORR),efficacy,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3691,NCT04494022,Compared diagnostic performance of Gd-EOB-MRI alone and Gd-EOB-MRI with CEUS.,Comparing image characters between two types of ultrasound contrast media,2020-06-08,UNKNOWN,INTERVENTIONAL,['NA'],
3692,NCT02562924,Change in Lund-Kennedy Endoscopic Scores,Change in SNOT-22 Nasal Symptom Scores,2015-11,COMPLETED,INTERVENTIONAL,['NA'],
3693,NCT03480256,Maximum Tolerated Dose (MTD),Area Under the Curve,2018-07-27,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3694,NCT03224221,One-year survival rate,Quality of life using EORTC QLQ C30 - scale,2017-03-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3695,NCT04985084,Acceptability outcome: participants' satisfaction and perspectives of the intervention,Dietary behavior self-efficacy,2021-07-12,UNKNOWN,INTERVENTIONAL,['NA'],
3696,NCT06106568,Descriptive summary of healthcare costs in EOB-MRI and non-EOB-MRI group,Descriptive summary of the likelihood of open-close laparotomy in patients with confirmed diagnosis of pancreatic cancer who is intended the surgical intervention between those in the EOB-MRI group and non-EOB-MRI group,2023-11-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3697,NCT05740137,Adenoma detection rate (ADR),Polyps per positive patient (PPP),2022-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3698,NCT01920113,A comparison of safety during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil,A comparison of efficacy during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil,2012-10,COMPLETED,INTERVENTIONAL,['NA'],"A comparison of gastric motility, easiness for procedure, operator's satisfaction during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil"
3699,NCT02774161,Spectral slope,,2016-05,COMPLETED,INTERVENTIONAL,['NA'],
3700,NCT00919659,nutritional status presented by phase angle,"quantity of port infections, quantity of oedema, quantity of diarrhea",2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
3701,NCT04993261,Sensitivity and specificity of dual energy computed tomography in detecting primary gastrointestinal carcinoid tumors,,2015-09-23,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
3702,NCT03996031,Patient activation,Patient satisfaction,2019-08-19,COMPLETED,OBSERVATIONAL,['NA'],
3703,NCT02289300,Change from baseline in liver stiffness measurement (kPa) assessed by Fibroscan® at Final visit,"Changes from baseline to post-treatment visits in vital signs, laboratory examination, and physical examinations results",2020-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
3704,NCT03454035,Overall Survival,Cancer Antigen 19-9 (CA19-9) response,2018-01-30,RECRUITING,INTERVENTIONAL,['PHASE1'],
3705,NCT03434379,PFS-IRF Per RECIST v1.1 in the China Population,Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the China Population,2018-03-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
3706,NCT03803891,Technical Success,Histologically confirmed full-thickness resection,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],
3707,NCT03300843,Percentage of Patients Who Had a Clinical Response (Complete Response (CR) + Partial Response (PR)) to Treatment,Number of Participants With Serious and Non-serious Adverse Events,2018-04-11,TERMINATED,INTERVENTIONAL,['PHASE2'],
3708,NCT01294072,Concentration of curcumin in normal and cancerous tissue,measurement of curcumin mixed with plant exosomes on metabolic characteristics of normal colon mucosa and colon tumors,2011-01,RECRUITING,INTERVENTIONAL,['NA'],
3709,NCT04635423,Percentage of participants with ≥1 serious adverse events (SAEs),Geometric mean titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58,2020-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
3710,NCT02138370,Time to disease recurrence,overall survival,2015-04,UNKNOWN,OBSERVATIONAL,['NA'],
3711,NCT06130280,Local control rate CRC liver metastasis,,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],
3712,NCT05626985,GAMAD,circulating tumor DNA methylation,2022-10-19,RECRUITING,OBSERVATIONAL,['NA'],
3713,NCT04727541,Major Pathologic Response (MPR) measured in the surgically resected tumor,Adverse Events of Special Interest,2021-07-08,TERMINATED,INTERVENTIONAL,['PHASE2'],
3714,NCT06139926,Changes in perioperative HADS scale scores.,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
3715,NCT01339000,Evaluate and Quantify the Impact of Interleukin-7 (CYT107) Therapy on Specific Immune Responses to Vaccines (in Particular to Neo Antigens) in Older Subjects Following Chemotherapy,Number of Participants With Adverse Events,2011-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
3716,NCT05957289,Fear of Progression Questionaire-Short Form (FoP-Q-SF),Semi-structured interviews,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3717,NCT03578874,Resectability,Overall survival,2016-06-20,COMPLETED,INTERVENTIONAL,['PHASE2'],
3718,NCT00614393,Percentage of Participants Who Experience an AE of Infusion Site Reaction,Overall Response Rate (ORR) of Dalotuzumab in Combination With Cetuximab + Irinotecan Versus ORR of Cetuximab + Irinotecan Alone in Participants With Wild Type of Colorectal Cancer,2007-12-24,COMPLETED,INTERVENTIONAL,['PHASE2'],
3719,NCT02008929,"Disease free survival, DFS","Overall survival, OS",2014-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
3720,NCT00994721,The primary end-point is recurrence-free survival.,"The secondary end-points are overall survival; local and distant control rate, and the quality of life.",2009-02,COMPLETED,OBSERVATIONAL,['NA'],
3721,NCT00568971,"Response rate, overall survival",Side effects,2007-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
3722,NCT03799380,ED visits,Missed days of radiation +/- chemotherapy/immunotherapy treatment,2019-11-05,COMPLETED,INTERVENTIONAL,['NA'],
3723,NCT01086332,Dose limiting toxicities,Surgical resection rate,2009-05,TERMINATED,INTERVENTIONAL,['PHASE1'],
3724,NCT00019825,,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
3725,NCT02963831,Progression-free Survival (PFS) at Week 24 as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),Median Overall Survival (OS) as Estimated Using the Kaplan-Meier Method,2017-09-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3726,NCT01853241,Comparison of the depth of insertion into the small bowel of SBE compared with SE from the pylorus.,A comparison of the mean adjusted diagnostic procedure time,2010-05,TERMINATED,OBSERVATIONAL,['NA'],
3727,NCT01634685,dose-limiting toxicities (DLT),maximally tolerated dose (MTD),2012-08-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
3728,NCT02820194,Control of local disease,Incidence of acute and late complications,2016-06,TERMINATED,INTERVENTIONAL,['NA'],
3729,NCT00079027,Overall survival,Proteomic and immunological analysis,2004-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3730,NCT01485679,"Specificity of TEP-CT to point out malignant lesions in pancreas, the gold standard being the anatomopathological analysis of the piece of pancreas removed during the surgery.",Number of patients for which metastasis will be detected through TEP-CT and confirmed by biopsy and/or conventional specific device,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
3731,NCT05911425,ORR,OS,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
3732,NCT06106308,Objective Response Rate (ORR),Safety: Exposure Response Evaluation of Onvansertib,2024-02-27,RECRUITING,INTERVENTIONAL,['PHASE2'],
3733,NCT02709070,recurrence free survival,overall survival,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3734,NCT01647828,Phase 2: Median OS by Notch 3 Percentile (ITT Population),,2012-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3735,NCT03520946,Overall survival,Quality of life II (QoL),2019-01-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Explorative: Progression-free survival (PFS)
3736,NCT03730545,Change from baseline serum concentration of immune markers to postoperative day 5,"Change among baseline, postoperative day 3 and 5 serum nutritional markers",2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],
3737,NCT04242901,Number of participants who yield sequential FIT results in divergent strata used for clinical decision making,"Calculation of Odds Ratios for age, gender, family history of CRC, hypertension, obesity, smoking status, excessive alcohol intake, right sided tumour, stage 1 cancer",2020-10-20,COMPLETED,OBSERVATIONAL,['NA'],
3738,NCT01613430,"Completing at least one recommended cancer screenings (colorectal, breast, cervical)","Time to completion of cancer screenings, and the effect of comorbid conditions, health literacy, patient satisfaction,and health care costs on cancer screening",2012-06,COMPLETED,INTERVENTIONAL,['NA'],
3739,NCT04866862,Objective response rate(ORR),Tumor Mutation Burden (TMB),2021-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],immunocytes and cell factor
3740,NCT04471480,overall survival (OS),progression-free survival(PFS),2020-09-01,UNKNOWN,INTERVENTIONAL,['NA'],
3741,NCT00096330,•Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
3742,NCT01279837,Clinical swallowing Ability,Swallowing Quality of Life,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3743,NCT05475054,Major complications,Red blood cell transfusion,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],
3744,NCT06037902,absolute mean heart radiation dose,movement of tumor in cm,2023-08-21,RECRUITING,INTERVENTIONAL,['NA'],
3745,NCT03329664,Time to progression (TTP),Patient quality of life,2020-02-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3746,NCT01877018,Patient's status participation to colorectal cancer screening program,,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
3747,NCT05609448,Feasibility of performing intraprocedural treatment planning,Dosimetry optimization,2023-05-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
3748,NCT00888888,Short-term survival,Long-term survival,2009-04,COMPLETED,OBSERVATIONAL,['NA'],
3749,NCT06118047,Remission rate of EGFR inhibitor-related acneiform eruption,Quality of life（EORTC QLQ-C30),2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
3750,NCT06023004,ctDNA analysis,Cost-effectiveness of treatment,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],
3751,NCT04889859,diabetes remission rate (%),changes in gut microbiota,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],
3752,NCT02464930,Sensitivity and specificity of tissue and serum microRNA expression by digital polymerase chain reaction for diagnosis of BE neoplasia,"Differences in the microRNA expression of biliary exosomes between GERD, Barrett's esophagus and Cancer",2015-04,UNKNOWN,OBSERVATIONAL,['NA'],
3753,NCT00023751,disease-free survival,colostomy-free survival,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
3754,NCT01337492,Adverse events associated with technical aspects of the operation,Waiting Time,2010-09,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],
3755,NCT05344339,Reflux esophagistis,6th month reflux esophagistis,2022-10-08,RECRUITING,INTERVENTIONAL,['NA'],
3756,NCT06327568,Sensitivity and specificity of BD Onclarity HPV assay for HPV detection and genotyping in case/control patients.,,2022-06-17,RECRUITING,OBSERVATIONAL,['NA'],
3757,NCT00642239,tumour local control rate,survival rate,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3758,NCT00499265,"Safety, in terms of vital signs, ECG, biochemistry, hematology (including coagulation), and adverse events",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3759,NCT01614522,The percentage of patients demonstrating clear evidence of inhibition of receptor auto-phosphorylation in HER-1 and HER-2 co-expressing patients on Day 29.,Objective Response Rate,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3760,NCT03859869,Change in Stool Fat From Baseline (Day 1) to Week 1 (Day 8) Among Participants With Resected Pancreatic Cancer,Change in the Total EPI Symptoms Score From Baseline to Week 1 Among Participants With Resected Pancreatic Cancer,2020-02-25,TERMINATED,INTERVENTIONAL,['PHASE4'],
3761,NCT04536220,Status of survival,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],
3762,NCT04012645,Anastomotic leakage,the change of surgical precedure,2023-11-16,RECRUITING,INTERVENTIONAL,['NA'],
3763,NCT04947956,The incidence of treatment-emergent adverse events (TEAE),Time to progression,2021-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3764,NCT00621725,"To assess the single dose pharmacokinetics (PK) of Cediranib, in patients with cancer with various degrees of hepatic dysfunction (defined by bilirubin levels).",Safety/tolerability of Cediranib (single and multiple dose PK),2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3765,NCT01926197,Progression-free Survival (PFS),Grade 2 or Greater Gastrointestinal (GI) Toxicity,2013-08-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
3766,NCT00833859,Number of Participants With Resectability,Number of Participants With Overall Survival,2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
3767,NCT01986738,Distance traveled by the pancreatic tumor between radiation treatments using Computed Tomography (CT) Scans and an Active Breathing Control (ABC) Device,Assess the impact of the determined treatment margins on the radiation dose to normal tissues and the ability to escalate dose to the tumor using Intensity-Modulated Radiation Therapy (IMRT),2012-01,COMPLETED,OBSERVATIONAL,['NA'],
3768,NCT05003895,"To determine the safety and feasibility of T-cells, expressing a novel humanized anti-GPC3 chimeric antigen receptor, in patients with advanced HCC, expressing GPC3","To determine the best overall response (BOR) rate according to Response Evaluation Criteria (by RECIST v 1.1) of treatment with T-cells, expressing a novel humanized anti-GPC3 chimeric antigen receptor in participants with advanced HCC, expressi...",2021-12-08,RECRUITING,INTERVENTIONAL,['PHASE1'],
3769,NCT02273713,Progression Free survival,Overall survival,2014-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3770,NCT04974281,Resection rate,Progression free survival (PFS),2021-01-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
3771,NCT02311712,Death from all causes,Change in Quality of life,2016-12,UNKNOWN,INTERVENTIONAL,['NA'],
3772,NCT05729737,Evaluate if the time to peak (TP) is predictive of response to chemotherapy therapy measured by comparison of TP at CEUS imaging prior to the start of first-line chemotherapy and TP at imaging performed after 2 cycles chemotherapy,Assessment of overall survival,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],
3773,NCT02482701,"Successful endoscopic resection defined as complete resection of the delineated area, including all delineation markings, in a single procedure.",Histopathology,2015-08,COMPLETED,OBSERVATIONAL,['NA'],
3774,NCT02461836,disease-free survival (DFS),safety as assessed according to NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) Ver. 4,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3775,NCT00582257,"Create registry of families w/ early onset & familial gastric cancer for analysis of risk factors, family history and unidentified susceptibility genes. Create cohorts of pts w/ low genetic risk for the development of gastric cancer",To determine the gastric pathology evident from a single baseline endoscopic screen of unaffected first-degree relatives of a patient with EOGC or FGC.,2005-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3776,NCT02501980,5-year HCC specific mortality rate,Identification of early diagnosis markers of HCC,2012-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3777,NCT02335619,Total symptom distress score,"Details of death (survival time from first oncology appointment at BC Cancer location of death (home, hospice, Cancer Centre)",2015-02,COMPLETED,INTERVENTIONAL,['NA'],
3778,NCT05960955,Pathological complete response (pCR) rates,ADA,2023-11-13,RECRUITING,INTERVENTIONAL,['PHASE2'],
3779,NCT05067413,Rate of anastomotic leakage,3-year disease-free survival,2020-12-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
3780,NCT05062317,To establish the 1-year recurrence-free survival rate following liver resection of CLM with curative intent among ctDNA-negative patients who receive risk-stratified postoperative chemotherapy,,2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],
3781,NCT00251485,"To assess the response rate, progression-free survival, and overall safety profile of a modified FOLFOX 6 plus cetuximab regimen in the first-line treatment of patients with metastatic colorectal cancer.",To assess overall survival of patients with metastatic colorectal cancer who receive first-line therapy with a modified FOLFOX 6 + cetuximab regimen,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3782,NCT03880617,"Change in Background, Disease and Treatment Information Form (BDTIF)",,2015-03-25,COMPLETED,OBSERVATIONAL,['NA'],
3783,NCT02056015,Human organ and whole body absorbed dose values from organ kinetic quantification of [68Ga]MLN6907 uptake and clearance,"Correlate tumor uptake of [68Ga]MLN6907 measured by PET and the level of guanylyl cyclase C (GCC) expression in tumor lesions from surgical specimens , for tumors in individual patients and for aggregated liver tumors across patients",2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
3784,NCT04943484,Surgical conduct,Clinical variables associated with change of the surgical conduct,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],
3785,NCT01679327,Overall response rate,Number of Participants with Adverse Events,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3786,NCT05706779,To assess the rate of significant tumour regression (TRG 0 to 2 according to Ryan's modified score of the AJCC 2010),,2023-02-13,RECRUITING,INTERVENTIONAL,['PHASE2'],
3787,NCT03552458,Quality of Life post Radiation,Oral Bacteria Analysis and Gene Expression Analysis,2018-06-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3788,NCT03923400,Location,,2016-11-01,COMPLETED,OBSERVATIONAL,['NA'],
3789,NCT02171429,"Percentage of Participants in Remission at Week 10 With Etrolizumab Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28949 Population","Number and Percentage of Participants With Anti-Drug Antibodies (ADAs) to Etrolizumab at Baseline and Anytime Post-Baseline, GA28949 Population",2014-11-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
3790,NCT02324868,Self-reported autonomy score regarding bathing activities,Laboratory-Confirmed Bloodstream Infection,2016-01,TERMINATED,INTERVENTIONAL,['NA'],Catheter/Huber needle status
3791,NCT04053998,Morbidity assessed according to the Comprehensive Complications Index® (CCI®),Disease free survival rate,2019-08-09,COMPLETED,OBSERVATIONAL,['NA'],
3792,NCT04331535,Time-to-new diagnosis of common complex disease,Medication adherence,2020-07-17,RECRUITING,INTERVENTIONAL,['NA'],Health status and quality of life
3793,NCT03397199,Progression-free Survival (PFS),Overall survival(OS),2018-01-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3794,NCT00900094,Potential markers for early detection of cancer,,2000-06,COMPLETED,OBSERVATIONAL,['NA'],
3795,NCT04994548,technical success of early esophageal cancer resection,preemptive methods to the risk of bleeding,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],
3796,NCT01040000,Efficacy OS,Pharmacokinetics and select immune responses to the antibody will be assessed.,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3797,NCT02823678,Percent resected volume of pancreas and diabetes development,Blood glucose control,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],
3798,NCT03828396,Assay sensitivity and specificity for colorectal cancer and advanced adenoma,,2018-10-26,UNKNOWN,OBSERVATIONAL,['NA'],
3799,NCT06169410,pCR,total response time,2023-12-30,RECRUITING,INTERVENTIONAL,['PHASE4'],
3800,NCT02666976,Changes of symptoms,changes of inflammatory biomarkers,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
3801,NCT06204094,Complete response,Validation of the Wexner score,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
3802,NCT00693173,The Genital Drop Technique (IMRT-GD) decreased the radiation dose to the testicles scrotal skin and penile shaft compared to standard prone technique.,Dosimetry comparison details.,2007-07,COMPLETED,OBSERVATIONAL,['NA'],
3803,NCT03746392,Documentation of goals of care,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],
